Unnamed: 0,datetime,title,source,link
0.0,4/16/2013 11:30:40 PM,Amgen to pay $25 million to settle kickback allegations,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/JHplK3C4_S0/story01.htm
1.0,5/29/2013 6:45:47 AM,"Amgen to make move into Japan, takes on Astellas as partner",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/aPObQi_Ex5g/story01.htm
2.0,6/17/2013 1:01:20 AM,"Amgen share buybacks, drugs may fuel more stock gains - Barron's",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/2W0E2dIIdpA/story01.htm
3.0,6/30/2013 6:33:33 PM,Onyx Pharma rejects buyout offer from Amgen,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/5jcZCYfK54U/story01.htm
4.0,7/1/2013 2:15:23 AM,Onyx explores possible sale after rejecting Amgen offer,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/LYPpUduf9eI/story01.htm
5.0,7/2/2013 12:00:11 AM,"Pfizer, Novartis may join Amgen in bidding for Onyx-sources",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/v0ZTgxHa898/story01.htm
6.0,8/7/2013 6:40:51 PM,"Amgen close to Onyx takeover, deal possible within week-sources",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/7tFl0Drawd4/story01.htm
7.0,8/15/2013 10:00:23 PM,Amgen seeks drug trial data before finalizing Onyx deal: sources,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/3SiuKQhMf1Q/story01.htm
8.0,8/24/2013 11:08:59 PM,Amgen close to buying Onyx for $125 per share,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/3d_nso6Wn3I/story01.htm
9.0,8/26/2013 12:07:48 AM,Amgen to buy Onyx for more than $10 billion,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ub8oVciVua8/story01.htm
10.0,8/26/2013 2:27:01 AM,Amgen seeks to bolster drug pipeline with $10.4 billion Onyx buy,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/6RFFhaXbcRU/story01.htm
11.0,8/27/2013 1:14:01 AM,Bradway's patient dealmaking brings Onyx to Amgen,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/Rs9hKGkPCTk/story01.htm
12.0,10/27/2014 9:36:21 PM,Amgen profit tops Wall Street expectations; raises 2014 outlook,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/kPRLqT4HWdw/story01.htm
13.0,1/27/2015 10:13:47 PM,"Amgen profit tops expectations on Enbrel sales, tax credit",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/q1GoiIENMsA/story01.htm
14.0,7/30/2015 10:14:29 PM,"Amgen profit tops Street view, boosts full-year forecast",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/gIk_W8oIPDY/story01.htm
15.0,1/28/2016 10:40:34 PM,Amgen fourth quarter profit tops Street; raises 2016 forecast,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/Szge5NMidcc/story01.htm
16.0,9/26/2016 9:20:25 AM,U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira (AMGN),Reuters,/news/stocks/u-s-fda-approves-amgens-cheaper-copy-of-arthritis-drug-humira-amgn-1001416536
17.0,9/26/2016 12:00:24 PM,"BRIEF-U.S. FDA approves Amjevita, a biosimilar to Humira (AMGN)",Reuters,/news/stocks/brief-u-s-fda-approves-amjevita-a-biosimilar-to-humira-amgn-1001416566
18.0,9/26/2016 12:30:21 PM,UPDATE 1-U.S. FDA approves Amgen's copy of AbbVie arthritis drug Humira (AMGN),Reuters,/news/stocks/update-1-u-s-fda-approves-amgens-copy-of-abbvie-arthritis-drug-humira-amgn-1001416564
19.0,9/26/2016 12:40:21 PM,BRIEF-FDA approves Amgen's Amjevita (Adalimumab-Atto) (AMGN),Reuters,/news/stocks/brief-fda-approves-amgens-amjevita-adalimumab-atto-amgn-1001416590
20.0,9/27/2016 5:10:22 AM,"BRIEF-Amgen and UCB say FDA accepts biologics license application for romosozumab (UCB, AMGN)",Reuters,/news/stocks/brief-amgen-and-ucb-say-fda-accepts-biologics-license-application-for-romosozumab-ucb-amgn-1001419559
21.0,9/27/2016 11:00:23 AM,BRIEF-Amgen says opens nomination process for LabCentral residency (AMGN),Reuters,/news/stocks/brief-amgen-says-opens-nomination-process-for-labcentral-residency-amgn-1001419594
22.0,9/27/2016 2:10:27 PM,BRIEF-Amgen says phase 3 study of Carfilzomib did not meet primary endpoint (AMGN),Reuters,/news/stocks/brief-amgen-says-phase-3-study-of-carfilzomib-did-not-meet-primary-endpoint-amgn-1001420405
23.0,9/27/2016 2:20:25 PM,"Amgen's multiple myeloma drug falls short in late stage study (4502, AMGN)",Reuters,/news/stocks/amgens-multiple-myeloma-drug-falls-short-in-late-stage-study-4502-amgn-1001420494
24.0,9/27/2016 3:40:24 PM,"UPDATE 1-Amgen's Krypolis fails newly diagnosed multiple myeloma study (4502, AMGN)",Reuters,/news/stocks/update-1-amgens-krypolis-fails-newly-diagnosed-multiple-myeloma-study-4502-amgn-1001420870
25.0,9/29/2016 9:10:27 AM,BRIEF-Amgen says erenumab significantly reduces monthly migraine days in patients with episodic migraine in first phase 3 study (AMGN),Reuters,/news/stocks/brief-amgen-says-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-episodic-migraine-in-first-phase-3-study-amgn-1001425074
26.0,9/29/2016 3:40:28 PM,"Amgen and Arrowhead to develop gene-therapies for heart disease (ALNY, AMGN, ARWR)",Reuters,/news/stocks/amgen-and-arrowhead-to-develop-gene-therapies-for-heart-disease-alny-amgn-arwr-1001426636
27.0,9/29/2016 6:50:23 PM,"UPDATE 1-Amgen, Arrowhead team up on gene-therapies for heart disease (ALNY, AMGN, ARWR)",Reuters,/news/stocks/update-1-amgen-arrowhead-team-up-on-gene-therapies-for-heart-disease-alny-amgn-arwr-1001427171
28.0,10/3/2016 10:10:21 AM,"Novartis psoriasis drug maintains efficacy after 4 years - study (JNJ, AMGN)",Reuters,/news/stocks/novartis-psoriasis-drug-maintains-efficacy-after-4-years-study-jnj-amgn-1001431486
29.0,10/3/2016 12:10:22 PM,"Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001431817
30.0,10/3/2016 1:50:22 PM,"AstraZeneca licenses inflammatory disease candidate to Allergan (AZN, AGN, AMGN)",Reuters,/news/stocks/astrazeneca-licenses-inflammatory-disease-candidate-to-allergan-azn-agn-amgn-1001432383
31.0,10/3/2016 2:20:21 PM,"RPT-Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/rpt-big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001432682
32.0,10/4/2016 1:50:20 PM,BRIEF-Nuevolution: strategic collaboration with Amgen in oncology and neuroscience (AMGN),Reuters,/news/stocks/brief-nuevolution-strategic-collaboration-with-amgen-in-oncology-and-neuroscience-amgn-1001434624
33.0,10/5/2016 10:30:23 PM,"Support for California drug spending limits stokes industry fears (MRK, PFE, AMGN)",Reuters,/news/stocks/support-for-california-drug-spending-limits-stokes-industry-fears-mrk-pfe-amgn-1001439072
34.0,10/6/2016 12:20:22 AM,BRIEF-Amgen says new data in melanoma and metastatic colorectal cancer to be presented at ESMO 2016 congress (AMGN),Reuters,/news/stocks/brief-amgen-says-new-data-in-melanoma-and-metastatic-colorectal-cancer-to-be-presented-at-esmo-2016-congress-amgn-1001439311
35.0,10/10/2016 10:50:20 PM,BRIEF-Amgen says new retrospective analyses confirm Vectibix treatment provided survival benefit over chemotherapy with or without Bevacizumab (AMGN),Reuters,/news/stocks/brief-amgen-says-new-retrospective-analyses-confirm-vectibix-treatment-provided-survival-benefit-over-chemotherapy-with-or-without-bevacizumab-amgn-1001447007
36.0,10/14/2016 11:30:23 PM,"BRIEF-Boeing board elects Amgen CEO Robert Bradway as new director (BA, AMGN)",Reuters,/news/stocks/brief-boeing-board-elects-amgen-ceo-robert-bradway-as-new-director-ba-amgn-1001457788
37.0,10/16/2016 6:00:23 PM,BRIEF-Amgen announces appointment of Ellen Kullman to board (AMGN),Reuters,/news/stocks/brief-amgen-announces-appointment-of-ellen-kullman-to-board-amgn-1001458009
38.0,10/21/2016 12:12:20 AM,BRIEF-Amgen announces positive top-line results from Xgeva (Denosumab) Phase 3 trial (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-announces-positive-top-line-results-from-xgeva-denosumab-phase-3-trial-2016-10
39.0,10/24/2016 3:48:20 AM,"Sanders urges Californians to approve drug price ballot measure (MYL, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-sanders-urges-californians-to-approve-drug-price-ballot-measure-2016-10
40.0,10/24/2016 3:18:20 PM,"BRIEF-Unilife Corp implemented cost reduction measures (UNIS, AMGN)",Reuters,http://www.businessinsider.com/r-brief-unilife-corp-implemented-cost-reduction-measures-2016-10
41.0,10/25/2016 12:44:23 PM,BRIEF-Amgen to invest in israel-based ehealth ventures (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-to-invest-in-israel-based-ehealth-ventures-2016-10
42.0,10/27/2016 10:40:20 PM,Amgen 3rd-quarter profit tops expectations on cost cutting (AMGN),Reuters,http://www.businessinsider.com/r-amgen-3rd-quarter-profit-tops-expectations-on-cost-cutting-2016-10
43.0,10/27/2016 10:56:25 PM,UPDATE 1-Amgen 3rd-quarter profit tops expectations on cost cutting (AMGN),Reuters,http://www.businessinsider.com/r-update-1-amgen-3rd-quarter-profit-tops-expectations-on-cost-cutting-2016-10
44.0,10/27/2016 11:50:20 PM,BRIEF-Amgen Inc Q3 Non-GAAP EPS $3.02 (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-inc-q3-non-gaap-eps-302-2016-10
45.0,11/3/2016 4:12:20 PM,BRIEF-Amgen unlikely to launch Humira biosimilar in 2017 (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-unlikely-to-launch-humira-biosimilar-in-2017-2016-10
46.0,11/7/2016 5:58:20 AM,BRIEF-FDA approves expanded use of ENBREL to treat children with chronic moderate-to-severe plaque psoriasis (AMGN),Reuters,http://www.businessinsider.com/r-brief-fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis-2016-11
47.0,11/9/2016 1:16:18 PM,"California drug pricing initiative headed for defeat (XLV, IBB, MRK, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-california-drug-pricing-initiative-headed-for-defeat-2016-11
48.0,11/9/2016 6:28:14 PM,"Drug stocks rip higher after Trump's upset victory signals easing pressure on prices (MRK, PFE, AMGN, JNJ, AGN, ABBV, SNY, NVS, AZN, GSK, IBB)",Business Insider,http://www.businessinsider.com/drug-company-stocks-morning-after-election-2016-11
49.0,11/9/2016 9:50:20 PM,"UPDATE 1-California voters turn down drug pricing initiative (XLV, IBB, MRK, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-california-voters-turn-down-drug-pricing-initiative-2016-11
50.0,11/10/2016 5:06:17 PM,"BRIEF-Genmab says combination of drugs from J&J, Amgen will be tested in study (GEN, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-brief-genmab-says-combination-of-drugs-from-jj-amgen-will-be-tested-in-study-2016-11
51.0,11/10/2016 5:40:18 PM,"BRIEF-Janssen reports clinical trial collaboration and supply agreement with Amgen to evaluate Daratumumab in combination with Carfilzomib (AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-brief-janssen-reports-clinical-trial-collaboration-and-supply-agreement-with-amgen-to-evaluate-daratumumab-in-combination-with-carfilzomib-2016-11
52.0,11/13/2016 10:44:18 PM,BRIEF-European Commission approves Parsabiv for adults on hemodialysis (AMGN),Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-parsabiv-for-adults-on-hemodialysis-2016-11
53.0,11/15/2016 10:10:17 PM,"Amgen cholesterol drug reduces artery-clogging plaque in study (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-amgen-cholesterol-drug-reduces-artery-clogging-plaque-in-study-2016-11
54.0,11/15/2016 11:20:19 PM,"BRIEF-Amgen, Allergan submit biosimilar biologics license application for ABP 215 to U.S. FDA (AGN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-allergan-submit-biosimilar-biologics-license-application-for-abp-215-to-us-fda-2016-11
55.0,11/17/2016 12:16:24 AM,BRIEF-Amgen announces Erenumab significantly reduces monthly migraine days in patients with episodic migraine in second phase 3 study (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-announces-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-episodic-migraine-in-second-phase-3-study-2016-11
56.0,11/17/2016 6:34:18 AM,Amgen's migraine drug succeeds in late-stage trial (AMGN),Reuters,http://www.businessinsider.com/r-amgens-migraine-drug-succeeds-in-late-stage-trial-2016-11
57.0,11/17/2016 1:04:18 PM,"UPDATE 1-Amgen, Novartis aim for big, crowded migraine market after new drug data (AGN, LLY, TEVA, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-amgen-novartis-aim-for-big-crowded-migraine-market-after-new-drug-data-2016-11
58.0,11/17/2016 1:16:18 PM,"No early win for Sanofi, Regeneron cholesterol drug in study",Reuters,http://www.businessinsider.com/r-no-early-win-for-sanofi-regeneron-cholesterol-drug-in-study-2016-11
59.0,12/1/2016 9:06:04 AM,"BRIEF-Amgen and Cytokinetics say Lancet published results from Phase 2 clinical trial evaluating omecamtiv mecarbil (CYTK, AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-and-cytokinetics-say-lancet-published-results-from-phase-2-clinical-trial-evaluating-omecamtiv-mecarbil-2016-11
60.0,12/1/2016 3:16:05 PM,"BRIEF-Cytokinetics starts phase 3 clinical trial of omecamtiv mecarbil (CYTK, AMGN)",Reuters,http://www.businessinsider.com/r-brief-cytokinetics-starts-phase-3-clinical-trial-of-omecamtiv-mecarbil-2016-12
61.0,12/2/2016 5:16:05 PM,"BRIEF-Amgen and Allergan submit biosimilar marketing authorization (AGN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-and-allergan-submit-biosimilar-marketing-authorization-2016-12
62.0,12/2/2016 5:40:08 PM,"Amgen, Allergan apply for European nod for Avastin biosimilar",Reuters,http://www.businessinsider.com/r-amgen-allergan-apply-for-european-nod-for-avastin-biosimilar-2016-12
63.0,12/6/2016 12:00:07 PM,"DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12
64.0,12/6/2016 2:02:03 PM,"RPT-DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-rpt-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12
65.0,12/12/2016 6:44:03 PM,U.S. Supreme Court declines to hear biologic drug patent fight,Reuters,http://www.businessinsider.com/r-us-supreme-court-declines-to-hear-biologic-drug-patent-fight-2016-12
66.0,12/12/2016 7:16:03 PM,UPDATE 1-U.S. Supreme Court declines to hear biologic drug patent fight (AMGN),Reuters,http://www.businessinsider.com/r-update-1-us-supreme-court-declines-to-hear-biologic-drug-patent-fight-2016-12
67.0,12/16/2016 3:42:03 PM,BRIEF-Amgen receives positive response from EMA for its single-dose delivery injection Repatha (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-receives-positive-response-from-ema-for-its-single-dose-delivery-injection-repatha-2016-12
68.0,12/23/2016 8:42:05 PM,Migraine drugs may repeat rheumatoid arthritis success,Reuters,http://www.businessinsider.com/r-migraine-drugs-may-repeat-rheumatoid-arthritis-success-2016-12
69.0,1/6/2017 5:42:05 AM,BRIEF-Court grants permanent injunction for infringement of Amgen's Repatha patents (AMGN),Reuters,http://www.businessinsider.com/r-brief-court-grants-permanent-injunction-for-infringement-of-amgens-repatha-patents-2017-1
70.0,1/6/2017 7:00:04 AM,"PRESS DIGEST - Wall Street Journal - Jan 6 (7203, AAPL, SHLD, YHOO, VZ, WMT, 005930, SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---jan-6-2017-1
71.0,1/6/2017 5:11:54 PM,"2 drugmakers just got banned from selling their cholesterol drug — and their rival's stock is jumping (AMGN, REGN, SNYNF)",Reuters,http://www.businessinsider.com/r-judge-blocks-sanofi-regeneron-from-selling-cholesterol-drug-2017-1
72.0,1/9/2017 10:52:10 AM,"BRIEF-Amgen, Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies (AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-immatics-enter-strategic-collaboration-to-develop-novel-bispecific-cancer-immunotherapies-2017-1
73.0,1/9/2017 1:04:05 PM,"BRIEF-Amgen and Davita enter into new sourcing and supply agreement (AMGN, DVA)",Reuters,http://www.businessinsider.com/r-brief-amgen-and-davita-enter-into-new-sourcing-and-supply-agreement-2017-1
74.0,1/10/2017 12:10:08 AM,BRIEF-Amgen does not expect Repatha outcomes data in label until 2018 (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-does-not-expect-repatha-outcomes-data-in-label-until-2018-2017-1
75.0,1/10/2017 2:16:08 AM,"Regeneron CEO says Amgen not putting patients first in patent dispute (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-regeneron-ceo-says-amgen-not-putting-patients-first-in-patent-dispute-2017-1
76.0,1/10/2017 3:14:03 AM,"BRIEF-Amgen comments on Delaware court's ruling on PCSK9 patent litigation (AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-amgen-comments-on-delaware-courts-ruling-on-pcsk9-patent-litigation-2017-1
77.0,1/10/2017 5:38:05 AM,"UPDATE 1-Regeneron CEO says Amgen not putting patients first in patent dispute (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-ceo-says-amgen-not-putting-patients-first-in-patent-dispute-2017-1
78.0,1/25/2017 2:48:05 PM,Novartis says court battle will delay its Enbrel copy until 2018 at least,Reuters,http://www.businessinsider.com/r-novartis-says-court-battle-will-delay-its-enbrel-copy-until-2018-at-least-2017-1
79.0,1/27/2017 2:04:05 PM,"BRIEF-EMA recommends approval of two biosimilars from Amgen (AMGN, LLY, GSK)",Reuters,http://www.businessinsider.com/r-brief-ema-recommends-approval-of-two-biosimilars-from-amgen-2017-1
80.0,1/31/2017 4:10:07 PM,"Trump meets with drugmakers, seeks lower prices, U.S. production (MRK, JNJ, CELG, LLY, AMGN)",Reuters,http://www.businessinsider.com/r-trump-meets-with-drugmakers-seeks-lower-prices-us-production-2017-1
81.0,1/31/2017 7:06:07 PM,"UPDATE 3-Trump pushes drugmakers for lower prices, more U.S. production (JNJ, MRK, LLY, AMGN, CELG)",Reuters,http://www.businessinsider.com/r-update-3-trump-pushes-drugmakers-for-lower-prices-more-us-production-2017-1
82.0,1/31/2017 9:30:07 PM,"UPDATE 4-Trump pushes drugmakers for lower prices, more U.S. production (JNJ, MRK, LLY, AMGN, CELG)",Reuters,http://www.businessinsider.com/r-update-4-trump-pushes-drugmakers-for-lower-prices-more-us-production-2017-1
83.0,2/2/2017 2:14:12 PM,"BRIEF-Cytokinetics and Royalty Pharma announce $100 million transaction for Omecamtiv Mecarbil (CYTK, AMGN)",Reuters,http://www.businessinsider.com/r-brief-cytokinetics-and-royalty-pharma-announce-100-million-transaction-for-omecamtiv-mecarbil-2017-2
84.0,2/2/2017 10:10:07 PM,BRIEF-Amgen announces Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-announces-repatha-significantly-reduced-the-risk-of-cardiovascular-events-in-fourier-outcomes-study-2017-2
85.0,2/2/2017 10:26:07 PM,Amgen cholesterol drug succeeds in cutting serious heart problems -study (AMGN),Reuters,http://www.businessinsider.com/r-amgen-cholesterol-drug-succeeds-in-cutting-serious-heart-problems--study-2017-2
86.0,2/2/2017 10:30:30 PM,Amgen Inc. Q4 Earnings Rise 9%,RTTNews,/news/stocks/amgen-inc-q4-earnings-rise-9-1001719618
87.0,2/2/2017 10:32:08 PM,BRIEF-Amgen reports Q4 EPS $2.59 (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-reports-q4-eps-259-2017-2
88.0,2/2/2017 10:39:20 PM,"Amgen fourth quarter profit tops Street view, cholesterol news lifts shares",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/MIu8iS8Gc7M/us-amgen-results-idUSKBN15H2TE
89.0,2/2/2017 10:46:07 PM,"Amgen 4th-qtr profit tops Street view, but 2017 outlook light (AMGN)",Reuters,http://www.businessinsider.com/r-amgen-4th-qtr-profit-tops-street-view-but-2017-outlook-light-2017-2
90.0,2/2/2017 11:02:51 PM,Amgen Issues FY17 Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-issues-fy17-guidance-quick-facts-1001719774
91.0,2/2/2017 11:07:30 PM,Amgen: FOURIER Trial On Repatha Meets Its Primary Composite Endpoints ,RTTNews,/news/stocks/amgen-fourier-trial-on-repatha-meets-its-primary-composite-endpoints-1001719788
92.0,2/2/2017 11:08:07 PM,"UPDATE 1-Amgen 4th qtr profit tops Street view, but 2017 outlook light (AMGN)",Reuters,http://www.businessinsider.com/r-update-1-amgen-4th-qtr-profit-tops-street-view-but-2017-outlook-light-2017-2
93.0,2/3/2017 12:30:10 AM,BRIEF-Amgen CEO expects to see U.S. tax reform (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-ceo-expects-to-see-us-tax-reform-2017-2
94.0,2/3/2017 10:44:08 PM,BRIEF-Amgen appoints Charles Holley Jr. to board of directors (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-appoints-charles-holley-jr-to-board-of-directors-2017-2
95.0,2/6/2017 6:43:23 AM,"ESPR, MDCO Riding High, New Uses For MRK's Old Drug, DBVT In Full Smile(e) ",RTTNews,/news/stocks/espr-mdco-riding-high-new-uses-for-mrk-s-old-drug-dbvt-in-full-smile-e-1001723805
96.0,2/6/2017 7:14:08 PM,"Priced like an automaker, sputtering Gilead shares lure value bets",Reuters,http://www.businessinsider.com/r-priced-like-an-automaker-sputtering-gilead-shares-lure-value-bets-2017-2
97.0,2/8/2017 12:28:11 AM,U.S. FDA approves Amgen drug for secondary hyperparathyroidism (AMGN),Reuters,http://www.businessinsider.com/r-us-fda-approves-amgen-drug-for-secondary-hyperparathyroidism-2017-2
98.0,2/8/2017 12:36:09 AM,"BRIEF-FDA approves Amgen's Parsabiv, first new treatment in more than a decade for secondary hyperparathyroidism in adult patients on hemodialysis (AMGN)",Reuters,http://www.businessinsider.com/r-brief-fda-approves-amgens-parsabiv-first-new-treatment-in-more-than-a-decade-for-secondary-hyperparathyroidism-in-adult-patients-on-hemodialysis-2017-2
99.0,2/8/2017 9:36:33 AM,"FLXN Gets FDA Date, KTOV In Crosshairs, It's A Thumbs Up For AMGN ",RTTNews,/news/stocks/flxn-gets-fda-date-ktov-in-crosshairs-it-s-a-thumbs-up-for-amgn-1001732032
100.0,2/8/2017 10:06:11 AM,"UPDATE 1-Drugmaker Sanofi sees weak 2017 earnings, not in hurry for M&A (SAN, JNJ, REGN, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-drugmaker-sanofi-sees-weak-2017-earnings-not-in-hurry-for-ma-2017-2
101.0,2/8/2017 11:50:11 PM,"BRIEF-Regeneron pharmaceuticals says appeals court grants stay of permanent injunction for praluent (REGN, SAN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-says-appeals-court-grants-stay-of-permanent-injunction-for-praluent-2017-2
102.0,2/9/2017 2:31:52 AM,Sanofi Says Appeals Court Grants Stay Of Permanent Injunction For Praluent ,RTTNews,/news/stocks/sanofi-says-appeals-court-grants-stay-of-permanent-injunction-for-praluent-1001735367
103.0,2/9/2017 1:10:11 PM,"UPDATE 1-Regeneron profit edges past estimates (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-profit-edges-past-estimates-2017-2
104.0,2/9/2017 4:00:09 PM,"BRIEF-Regeneron says price increases unrelated from innovation will be pushed back on (AMGN, BAYN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-says-price-increases-unrelated-from-innovation-will-be-pushed-back-on-2017-2
105.0,2/14/2017 3:22:57 PM,Amgen Submits SBLA For Blincyto - Quick Facts ,RTTNews,/news/stocks/amgen-submits-sbla-for-blincyto-quick-facts-1001749159
106.0,2/14/2017 3:34:10 PM,BRIEF-Amgen submits supplemental biologics license application for BLINCYTO (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-submits-supplemental-biologics-license-application-for-blincyto-2017-2
107.0,2/21/2017 10:36:12 PM,BRIEF-Repatha receives European commission approval for new 420 mg single-dose delivery option (AMGN),Reuters,http://www.businessinsider.com/r-brief-repatha-receives-european-commission-approval-for-new-420-mg-single-dose-delivery-option-2017-2
108.0,2/22/2017 6:42:12 PM,"Genmab and J&J's cancer drug set for blockbuster sales this year (GEN, JNJ, GILD, AMGN)",Reuters,http://www.businessinsider.com/r-genmab-and-jjs-cancer-drug-set-for-blockbuster-sales-this-year-2017-2
109.0,2/22/2017 9:28:12 PM,"UPDATE 1-Genmab and J&J's cancer drug set for blockbuster sales this year (GEN, JNJ, GILD, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-genmab-and-jjs-cancer-drug-set-for-blockbuster-sales-this-year-2017-2
110.0,2/27/2017 11:43:16 AM,Biotech Stocks Facing FDA Decision In March ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-1001785169
111.0,2/27/2017 11:26:13 PM,BRIEF-Amgen says Perrigo CFO to join company late April (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-says-perrigo-cfo-to-join-company-late-april-2017-2
112.0,2/28/2017 3:00:00 PM,Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients,PR Newswire,/news/stocks/phase-3-head-to-head-trial-showed-kyprolis-carfilzomib-significantly-improved-overall-survival-compared-to-velcade-bortezomib-in-relapsed-or-refractory-multiple-myeloma-patients-1001790438
113.0,2/28/2017 3:10:13 PM,"Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study (AMGN, 4502)",Reuters,http://www.businessinsider.com/r-longer-survival-seen-with-amgens-kyprolis-vs-velcade-in-myeloma-study-2017-2
114.0,2/28/2017 3:20:41 PM,"The quest to find new drugs to treat Alzheimer's just suffered another blow (MRK, LLY, BIIB, AMGN)",Reuters,http://www.businessinsider.com/r-acceras-alzheimers-trial-fails-in-yet-another-setback-for-disease-2017-2
115.0,2/28/2017 3:26:53 PM,Amgen: Phase 3 Trial Results Confirm Superiority Of KYPROLIS Over Velcade ,RTTNews,/news/stocks/amgen-phase-3-trial-results-confirm-superiority-of-kyprolis-over-velcade-1001790674
116.0,3/1/2017 12:34:13 AM,BRIEF-Amgen announces positive results from planned overall survival analysis of phase 3 head-to-head ENDEAVOR trial (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-announces-positive-results-from-planned-overall-survival-analysis-of-phase-3-head-to-head-endeavor-trial-2017-2
117.0,3/1/2017 10:00:00 PM,Amgen To Present New KYPROLIS® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop,PR Newswire,/news/stocks/amgen-to-present-new-kyprolis-carfilzomib-and-xgeva-denosumab-data-at-the-16th-international-myeloma-workshop-1001796594
118.0,3/1/2017 11:09:00 PM,BLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy,PR Newswire,/news/stocks/blincyto-blinatumomab-significantly-improved-overall-survival-in-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-compared-to-chemotherapy-1001796885
119.0,3/2/2017 10:00:00 PM,Amgen To Present At The Cowen And Company 37th Annual Health Care Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-cowen-and-company-37th-annual-health-care-conference-1001800865
120.0,3/3/2017 10:00:00 PM,Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop,PR Newswire,/news/stocks/amgen-presents-overall-survival-data-from-kyprolis-carfilzomib-phase-3-endeavor-trial-at-16th-international-myeloma-workshop-1001804127
121.0,3/6/2017 1:34:23 PM,"BRIEF-Coherus Biosciences says Amgen files trade secret action against company (CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-brief-coherus-biosciences-says-amgen-files-trade-secret-action-against-company-2017-3
122.0,3/6/2017 10:00:00 PM,Amgen Highlights Landmark Repatha® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17,PR Newswire,/news/stocks/amgen-highlights-landmark-repatha-evolocumab-cardiovascular-outcomes-study-amongst-data-to-be-presented-at-acc-17-1001808401
123.0,3/7/2017 12:22:06 AM,BRIEF-Amgen highlights Landmark Repatha (evolocumab) cardiovascular outcomes study (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-highlights-landmark-repatha-evolocumab-cardiovascular-outcomes-study-2017-3
124.0,3/7/2017 2:05:00 PM,NICE Recommends Amgen's Vectibix® (panitumumab) for Metastatic Colorectal Cancer for Previously Untreated Patients,PR Newswire,/news/stocks/nice-recommends-amgen-s-vectibix-panitumumab-for-metastatic-colorectal-cancer-for-previously-untreated-patients-1001811069
125.0,3/7/2017 3:26:21 PM,"Drugmaker shares slip as Trump tweets about pricing system (PFE, MRK, AMGN, GILD)",Reuters,http://www.businessinsider.com/r-drugmaker-shares-slip-as-trump-tweets-about-pricing-system-2017-3
126.0,3/7/2017 4:50:21 PM,"UPDATE 1-Drugmaker shares slip as Trump tweets about pricing system (PFE, MRK, AMGN, THC, CYH, HCA, UNH, GILD)",Reuters,http://www.businessinsider.com/r-update-1-drugmaker-shares-slip-as-trump-tweets-about-pricing-system-2017-3
127.0,3/7/2017 5:50:21 PM,"UPDATE 2-Trump backs House Republican healthcare plan, aims to cut drug prices (PFE, MRK, AMGN, UNH, AET, HUM, THC, CYH)",Reuters,http://www.businessinsider.com/r-update-2-trump-backs-house-republican-healthcare-plan-aims-to-cut-drug-prices-2017-3
128.0,3/7/2017 6:14:21 PM,"GLOBAL MARKETS-Wall Street slips, U.S. dollar firm on Fed outlook (PFE, MRK, AMGN)",Reuters,http://www.businessinsider.com/r-global-markets-wall-street-slips-us-dollar-firm-on-fed-outlook-2017-3
129.0,3/7/2017 10:00:00 PM,Amgen Announces 2017 Second Quarter Dividend,PR Newswire,/news/stocks/amgen-announces-2017-second-quarter-dividend-1001813039
130.0,3/7/2017 10:14:21 PM,BRIEF-Amgen sets quarterly dividend of $1.15 per share (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-sets-quarterly-dividend-of-115-per-share-2017-3
131.0,3/7/2017 11:28:24 PM,"GLOBAL MARKETS-Stocks slip, U.S. dollar firm on Fed outlook (PFE, AMGN)",Reuters,http://www.businessinsider.com/r-global-markets-stocks-slip-us-dollar-firm-on-fed-outlook-2017-3
132.0,3/8/2017 5:42:22 PM,"INSIGHT-'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks (JNJ, MRK, LLY, CELG, AMGN, GM, F, CPB, TGT, LUV, UAL, DAL)",Reuters,http://www.businessinsider.com/r-insight-its-like-kumbaya-trumps-genial-private-meetings-with-ceos-jar-with-public-attacks-2017-3
133.0,3/13/2017 6:48:23 AM,"Data on heart benefits of Amgen drug is key to unlocking sales (AMGN, REGN, SAN, ESRX)",Reuters,http://www.businessinsider.com/r-data-on-heart-benefits-of-amgen-drug-is-key-to-unlocking-sales-2017-3
134.0,3/13/2017 11:16:26 AM,"RPT-Data on heart benefits of Amgen drug is key to unlocking sales (AMGN, REGN, SAN, ESRX)",Reuters,http://www.businessinsider.com/r-rpt-data-on-heart-benefits-of-amgen-drug-is-key-to-unlocking-sales-2017-3
135.0,3/13/2017 2:00:00 PM,Repatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study,PR Newswire,/news/stocks/repatha-evolocumab-demonstrates-reduced-need-for-apheresis-in-patients-with-high-ldl-cholesterol-in-phase-3-study-1001829230
136.0,3/13/2017 2:12:54 PM,Amgen Reports Positive Top-line Results From Repatha Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/amgen-reports-positive-top-line-results-from-repatha-phase-3-study-quick-facts-1001829329
137.0,3/13/2017 2:28:23 PM,"Amgen's Repatha lowers need for cholesterol-lowering procedure (AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-amgens-repatha-lowers-need-for-cholesterol-lowering-procedure-2017-3
138.0,3/13/2017 2:46:28 PM,BRIEF-Repatha demonstrates reduced need for apheresis in patients with high LDL cholesterol (AMGN),Reuters,http://www.businessinsider.com/r-brief-repatha-demonstrates-reduced-need-for-apheresis-in-patients-with-high-ldl-cholesterol-2017-3
139.0,3/14/2017 9:00:00 PM,Amgen To Webcast Investor Meeting At Upcoming American College Of Cardiology Scientific Sessions,PR Newswire,/news/stocks/amgen-to-webcast-investor-meeting-at-upcoming-american-college-of-cardiology-scientific-sessions-1001835135
140.0,3/14/2017 9:15:00 PM,Repatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology',PR Newswire,/news/stocks/repatha-evolocumab-four-year-open-label-follow-up-study-published-in-jama-cardiology-1001835181
141.0,3/14/2017 9:44:26 PM,BRIEF-Amgen Inc reports four-year follow-up results from Repatha Osler-1 study (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-inc-reports-four-year-follow-up-results-from-repatha-osler-1-study-2017-3
142.0,3/16/2017 1:00:00 PM,The Most Promising Biotech Innovation of 2017,PR Newswire,/news/stocks/the-most-promising-biotech-innovation-of-2017-1001841725
143.0,3/16/2017 9:00:00 PM,Amgen To Present At The Oppenheimer Global Health Care Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-oppenheimer-global-health-care-conference-1001843811
144.0,3/17/2017 2:00:00 PM,Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues,PR Newswire,/news/stocks/landmark-outcomes-study-shows-that-repatha-evolocumab-decreases-ldl-c-to-unprecedented-low-levels-and-reduces-risk-of-cardiovascular-events-with-no-new-safety-issues-1001846030
145.0,3/17/2017 2:11:36 PM,Amgen Says Repatha Reduces Risk Of Hard Major Adverse Cardiovascular Events ,RTTNews,/news/stocks/amgen-says-repatha-reduces-risk-of-hard-major-adverse-cardiovascular-events-1001846081
146.0,3/17/2017 2:34:43 PM,"RPT-Amgen cholesterol drug cuts heart attack, stroke risk more than 20 pct-study (AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-rpt-amgen-cholesterol-drug-cuts-heart-attack-stroke-risk-more-than-20-pct-study-2017-3
147.0,3/17/2017 3:04:33 PM,"Amgen is getting whacked after disappointing study results for its $14,000 heart drug (AMGN)",Reuters,http://www.businessinsider.com/r-amgen-cholesterol-drug-cuts-heart-attack-stroke-risk-more-than-20-percent-study-2017-3
148.0,3/17/2017 3:18:43 PM,"US STOCKS-Wall St little changed as healthcare stocks weigh (AMGN, ADBE, TIF)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-little-changed-as-healthcare-stocks-weigh-2017-3
149.0,3/17/2017 4:46:43 PM,"Express Scripts says Amgen data opens door to patients (ESRX, AMGN, SAN, REGN)",Reuters,http://www.businessinsider.com/r-express-scripts-says-amgen-data-opens-door-to-patients-2017-3
150.0,3/17/2017 5:14:44 PM,"US STOCKS-Wall St edges lower as financial stocks drag (WFC, BAC, ADBE, AMGN, TIF)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-edges-lower-as-financial-stocks-drag-2017-3
151.0,3/17/2017 5:22:45 PM,"GLOBAL MARKETS-World stocks hover near peaks, dollar extends slide (AMGN)",Reuters,http://www.businessinsider.com/r-global-markets-world-stocks-hover-near-peaks-dollar-extends-slide-2017-3
152.0,3/17/2017 6:28:43 PM,"CVS Health says Amgen data may increase eligible patients by millions (CVS, SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-cvs-health-says-amgen-data-may-increase-eligible-patients-by-millions-2017-3
153.0,3/17/2017 6:28:43 PM,"US STOCKS-Wall St flat as tech gains offset weakness in banks (WFC, BAC, ADBE, AMGN, TIF)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-flat-as-tech-gains-offset-weakness-in-banks-2017-3
154.0,3/17/2017 6:29:41 PM,"Amgen cholesterol drug cuts heart attack, stroke risk but shares fall",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/QdYCWoao2fs/heart-amgen-cholesterol-idINKBN16O1OO
155.0,3/17/2017 7:16:45 PM,"GLOBAL MARKETS-World stocks at record highs, dollar slide deepens (ADBE, AMGN)",Reuters,http://www.businessinsider.com/r-global-markets-world-stocks-at-record-highs-dollar-slide-deepens-2017-3
156.0,3/17/2017 9:32:06 PM,"US STOCKS-Wall St flat as banks, Amgen weigh; Adobe rallies (AMGN, ADBE, TIF)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-flat-as-banks-amgen-weigh-adobe-rallies-2017-3
157.0,3/17/2017 10:04:45 PM,"Amgen discounts cholesterol drug, but payers want more (AMGN, CVS, ESRX, REGN, SAN, PFE)",Reuters,http://www.businessinsider.com/r-amgen-discounts-cholesterol-drug-but-payers-want-more-2017-3
158.0,3/18/2017 7:00:46 AM,"UPDATE 1-Amgen discounts cholesterol drug, but payers want more (AMGN, CVS, ESRX, REGN, SAN, PFE, MDCO)",Reuters,http://www.businessinsider.com/r-update-1-amgen-discounts-cholesterol-drug-but-payers-want-more-2017-3
159.0,3/18/2017 1:00:00 PM,Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study,PR Newswire,/news/stocks/lowering-ldl-levels-with-repatha-evolocumab-did-not-adversely-affect-cognitive-function-in-landmark-phase-3-study-1001847704
160.0,3/19/2017 2:44:59 AM,Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study ,RTTNews,/news/stocks/amgen-low-ldl-levels-with-repatha-did-not-affect-cognitive-function-in-study-1001847924
161.0,3/19/2017 7:00:00 PM,Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients,PR Newswire,/news/stocks/analyses-of-pcsk9-inhibitor-prescription-rejection-rates-demonstrate-significant-access-barriers-for-appropriate-patients-1001848217
162.0,3/20/2017 5:37:35 AM,"AMGN On Watch, GALE Reports Positive Data, EBS Secures BARDA Contract ",RTTNews,/news/stocks/amgn-on-watch-gale-reports-positive-data-ebs-secures-barda-contract-1001848399
163.0,3/20/2017 8:28:00 AM,Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues,PR Newswire,/news/stocks/landmark-outcomes-study-shows-that-repatha-r-evolocumab-decreases-ldl-c-to-unprecedented-low-levels-and-reduces-risk-of-cardiovascular-events-with-no-new-safety-issues-1001848729
164.0,3/20/2017 9:55:00 AM,Lowering LDL Levels with Repatha(R) (evolocumab) Did Not Adversely Affect Cognitive Function in Landmark Phase 3 Study,PR Newswire,/news/stocks/lowering-ldl-levels-with-repatha-r-evolocumab-did-not-adversely-affect-cognitive-function-in-landmark-phase-3-study-1001849012
165.0,3/21/2017 6:04:45 PM,"Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims",Reuters,http://www.businessinsider.com/r-sanofi-regeneron-sue-amgen-to-protect-eczema-drug-from-patent-claims-2017-3
166.0,3/21/2017 6:28:44 PM,"UPDATE 1-Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-regeneron-sue-amgen-to-protect-eczema-drug-from-patent-claims-2017-3
167.0,3/23/2017 12:46:45 PM,"Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency (SAN, GSK, REGN, AMGN, MYL, HIK, VEC)",Reuters,http://www.businessinsider.com/r-crunch-week-looms-for-sanofi-roche-and-gsk-at-us-drugs-agency-2017-3
168.0,3/23/2017 9:00:00 PM,European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases,PR Newswire,/news/stocks/european-commission-approves-amgevita-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases-500710
169.0,3/23/2017 9:56:48 PM,BRIEF-European Commission approves Amgevita for treatment of certain inflammatory diseases (AMGN),Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-amgevita-for-treatment-of-certain-inflammatory-diseases-2017-3
170.0,3/24/2017 6:11:00 AM,"FDA Approves First-ever Merkel Cell Carcinoma Drug, HTGM Riding High, FLXN Soars ",RTTNews,/news/stocks/fda-approves-first-ever-merkel-cell-carcinoma-drug-htgm-riding-high-flxn-soars-1001864425
171.0,3/28/2017 3:00:00 PM,Amgen Awards Three Golden Tickets for LabCentral Residency,PR Newswire,/news/stocks/amgen-awards-three-golden-tickets-for-labcentral-residency-1001873948
172.0,3/29/2017 2:20:48 PM,BRIEF-Amgen enters into agreement with Inovalon and Avalere (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-enters-into-agreement-with-inovalon-and-avalere-2017-3
173.0,3/29/2017 10:03:00 PM,Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia,PR Newswire,/news/stocks/journal-of-clinical-oncology-publishes-data-on-blincyto-blinatumomab-in-high-risk-patients-with-philadelphia-chromosome-positive-b-cell-precursor-acute-lymphoblastic-leukemia-1001879467
174.0,3/29/2017 10:07:00 PM,FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application,PR Newswire,/news/stocks/fda-grants-priority-review-for-amgen-s-blincyto-blinatumomab-supplemental-biologics-license-application-1001879476
175.0,3/29/2017 10:30:50 PM,BRIEF-FDA grants priority review for Amgen's Blincyto supplemental biologics license application (AMGN),Reuters,http://www.businessinsider.com/r-brief-fda-grants-priority-review-for-amgens-blincyto-supplemental-biologics-license-application-2017-3
176.0,3/30/2017 8:24:46 AM,"FDA Snubs MYL, Roche Wins FDA Panel Vote Hands Down, TNXP Falls After-hours ",RTTNews,/news/stocks/fda-snubs-myl-roche-wins-fda-panel-vote-hands-down-tnxp-falls-after-hours-1001880367
177.0,3/31/2017 3:00:00 PM,Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting,PR Newswire,/news/stocks/amgen-to-highlight-new-preclinical-data-at-the-american-association-for-cancer-research-aacr-annual-meeting-1001886113
178.0,4/1/2017 5:30:00 PM,Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab),PR Newswire,/news/stocks/amgen-and-ucb-report-new-data-at-endo-2017-examining-the-option-of-a-second-course-of-treatment-with-evenity-romosozumab-1001887854
179.0,4/4/2017 3:16:49 PM,BRIEF-Amgen submits applications in the U.S. and Europe to expand current indication for xgeva (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-submits-applications-in-the-us-and-europe-to-expand-current-indication-for-xgeva-2017-4
180.0,4/4/2017 3:20:37 PM,"Amgen Submits Applications In US, Europe To Expand Current Indication For XGEVA ",RTTNews,/news/stocks/amgen-submits-applications-in-us-europe-to-expand-current-indication-for-xgeva-1001894691
181.0,4/6/2017 7:30:41 PM,New drugs could save the US billions of dollars — but there's something holding them back,Business Insider,http://www.businessinsider.com/how-well-biosimilars-are-saving-money-2017-4
182.0,4/6/2017 10:50:53 PM,BRIEF-Amgen says CEO Robert Bradway's total compensation for 2016 was $16.9 mln vs $16.1 mln in 2015 - SEC filing (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-says-ceo-robert-bradways-total-compensation-for-2016-was-169-mln-vs-161-mln-in-2015---sec-filing-2017-4
183.0,4/18/2017 10:00:00 PM,Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES,PR Newswire,/news/stocks/amgen-launches-neulasta-pegfilgrastim-onpro-narratives-1001928411
184.0,4/21/2017 3:15:05 PM,"UPDATE 1-Valeant prices psoriasis treatment at $3,500 per month (VRX, LLY, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-update-1-valeant-prices-psoriasis-treatment-at-3500-per-month-2017-4
185.0,4/22/2017 2:51:04 AM,"U.S. FDA approves Samsung Bioepis' copy of J&J's Remicade -company (JNJ, AMGN, MRK, PFE, 068270)",Reuters,http://www.businessinsider.com/r-us-fda-approves-samsung-bioepis-copy-of-jjs-remicade--company-2017-4
186.0,4/24/2017 10:30:00 PM,Amgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine,PR Newswire,/news/stocks/amgen-announces-expanded-commercial-collaboration-with-novartis-for-erenumab-in-migraine-1001943677
187.0,4/24/2017 11:05:05 PM,BRIEF-Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-announces-expanded-commercial-collaboration-with-novartis-for-erenumab-in-migraine-2017-4
188.0,4/25/2017 7:01:12 AM,"Swiss stocks - Factors to watch on April 25 (AMGN, BEAT, SCHP, KUD, AMS)",Reuters,http://www.businessinsider.com/r-swiss-stocks---factors-to-watch-on-april-25-2017-4
189.0,4/25/2017 2:47:10 PM,"BRIEF-Coherus Biosciences completes formalities with amgen for Coherus' CHS-1701 (AMGN, CHRS)",Reuters,http://www.businessinsider.com/r-brief-coherus-biosciences-completes-formalities-with-amgen-for-coherus-chs-1701-2017-4
190.0,4/26/2017 1:39:06 PM,"US STOCKS-Futures flat as Trump tax plan awaited (UTX, NDAQ, NOC, BA, AMGN, WYNN, X)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-flat-as-trump-tax-plan-awaited-2017-4
191.0,4/26/2017 8:35:11 PM,"The Supreme Court just heard a case that could determine how quickly patients can access cheaper medications (AMGN, NVS)",Reuters,http://www.businessinsider.com/r-us-top-court-debates-making-copycat-biologics-available-sooner-2017-4
192.0,4/26/2017 9:05:09 PM,UPDATE 1-U.S. top court grapples over making copycat biologics available sooner (AMGN),Reuters,http://www.businessinsider.com/r-update-1-us-top-court-grapples-over-making-copycat-biologics-available-sooner-2017-4
193.0,4/26/2017 10:01:00 PM,Las Vegas Sands Reports First Quarter 2017 Results,PR Newswire,/news/stocks/las-vegas-sands-reports-first-quarter-2017-results-605616
194.0,4/26/2017 10:04:00 PM,Amgen Reports First Quarter 2017 Financial Results,PR Newswire,/news/stocks/amgen-reports-first-quarter-2017-financial-results-1001953359
195.0,4/26/2017 10:12:48 PM,Amgen first-quarter profit exceeds Street estimates on lower costs,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/0skJU3Fxz1w/us-amgen-results-idUSKBN17S2RF
196.0,4/26/2017 10:15:11 PM,Amgen first-quarter profit exceeds Street estimates on lower costs (AMGN),Reuters,http://www.businessinsider.com/r-amgen-first-quarter-profit-exceeds-street-estimates-on-lower-costs-2017-4
197.0,4/26/2017 11:23:14 PM,Amgen Inc. Reports 6% Gain In Q1 Bottom Line,RTTNews,/news/stocks/amgen-inc-reports-6-gain-in-q1-bottom-line-1001953735
198.0,4/26/2017 11:25:49 PM,Amgen Updates Guidance; Q1 Product Sales Down 1% YoY - Quick Facts ,RTTNews,/news/stocks/amgen-updates-guidance-q1-product-sales-down-1-yoy-quick-facts-1001953734
199.0,4/26/2017 11:42:41 PM,Amgen Inc. Announces 6% Advance In Q1 Bottom Line,RTTNews,/news/stocks/amgen-inc-announces-6-advance-in-q1-bottom-line-1001953776
200.0,4/27/2017 12:41:11 AM,BRIEF-Amgen reports Q1 GAAP earnings per share $2.79 (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-reports-q1-gaap-earnings-per-share-279-2017-4
201.0,4/27/2017 12:41:11 AM,BRIEF-Amgen optimistic for Enbrel sales rebound (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-optimistic-for-enbrel-sales-rebound-2017-4
202.0,4/27/2017 12:33:06 PM,"UPDATE 1-India watchdog orders antitrust probe into Roche cancer drug (BIOCON, MYL, AMGN, AGN)",Reuters,http://www.businessinsider.com/r-update-1-india-watchdog-orders-antitrust-probe-into-roche-cancer-drug-2017-4
203.0,4/27/2017 4:33:00 PM,NICE Recommends Amgen's BLINCYTO® ▼ (Blinatumomab) for Adults With Relapsed or Refractory Philadelphia Chromosome-Negative B-Precursor Acute Lymphoblastic Leukaemia,PR Newswire,/news/stocks/nice-recommends-amgen-s-blincyto-blinatumomab-for-adults-with-relapsed-or-refractory-philadelphia-chromosome-negative-b-precursor-acute-lymphoblastic-leukaemia-1001957683
204.0,4/27/2017 10:00:00 PM,Amgen To Participate In The 2017 World Medical Innovation Forum™ Focused On Cardiovascular Disease,PR Newswire,/news/stocks/amgen-to-participate-in-the-2017-world-medical-innovation-forum-focused-on-cardiovascular-disease-613213
205.0,4/28/2017 12:49:07 PM,"CORRECTED-UPDATE 2-Valeant prices psoriasis treatment at $3,500 per month (April 21) (VRX, LLY, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-corrected-update-2-valeant-prices-psoriasis-treatment-at-3500-per-month-april-21-2017-4
206.0,4/28/2017 11:55:09 PM,FDA approves Radius Health's osteoporosis drug Tymlos (AMGN),Reuters,http://www.businessinsider.com/r-fda-approves-radius-healths-osteoporosis-drug-tymlos-2017-4
207.0,5/2/2017 7:40:05 AM,"Temasek, Yunfeng lead $75 mln funding into China genomics firm (AMGN)",Reuters,http://www.businessinsider.com/r-temasek-yunfeng-lead-75-mln-funding-into-china-genomics-firm-2017-5
208.0,5/2/2017 10:00:00 PM,Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab),PR Newswire,/news/stocks/amgen-and-harvard-pilgrim-agree-to-first-cardiovascular-outcomes-based-refund-contract-for-repatha-evolocumab-627170
209.0,5/2/2017 10:26:02 PM,"BRIEF-Amgen, Harvard Pilgrim agree to contract for repatha (AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-harvard-pilgrim-agree-to-contract-for-repatha-2017-5
210.0,5/3/2017 12:15:00 PM,"Biotech Stocks on Investors' Radar -- Array BioPharma, Celgene, Amgen, and Cerulean Pharma",PR Newswire,/news/stocks/biotech-stocks-on-investors-radar-array-biopharma-celgene-amgen-and-cerulean-pharma-1001973652
211.0,5/8/2017 3:00:09 PM,BRIEF-Amgen files for potential five-part senior notes offering (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-files-for-potential-five-part-senior-notes-offering-2017-5
212.0,5/9/2017 2:44:05 PM,BRIEF-Feldan Therapeutics and Elasmogen announce research agreement with Amgen (AMGN),Reuters,http://www.businessinsider.com/r-brief-feldan-therapeutics-and-elasmogen-announce-research-agreement-with-amgen-2017-5
213.0,5/9/2017 3:01:00 PM,Gamblit Gaming Raises New Growth Capital To Support Ongoing Skill-Based Gaming Launches,PR Newswire,/news/stocks/gamblit-gaming-raises-new-growth-capital-to-support-ongoing-skill-based-gaming-launches-1001656880
214.0,5/18/2017 4:23:04 AM,"Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN... ",RTTNews,/news/stocks/gainers-losers-of-may-17-sndx-pulm-pbyi-cnce-xlrn-1002022955
215.0,5/18/2017 3:46:07 PM,BRIEF-Amgen submits Biologics License Application to the FDA for erenumab (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-submits-biologics-license-application-to-the-fda-for-erenumab-2017-5
216.0,5/19/2017 7:12:03 AM,"Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy (JNJ, AMGN)",Reuters,http://www.businessinsider.com/r-janssen-files-suit-in-us-to-block-sale-of-samsung-bioepis-remicade-copy-2017-5
217.0,5/22/2017 1:46:20 AM,Amgen And UCB Announce Phase 3 Data From Active-Comparator Study Of EVENITY ,RTTNews,/news/stocks/amgen-and-ucb-announce-phase-3-data-from-active-comparator-study-of-evenity-1002030873
218.0,5/22/2017 2:06:07 AM,"Higher rate of heart problems with Amgen osteoporosis drug in trial (AMGN, UCB, MRK)",Reuters,http://www.businessinsider.com/r-higher-rate-of-heart-problems-with-amgen-osteoporosis-drug-in-trial-2017-5
219.0,5/22/2017 3:08:07 AM,"UPDATE 1-Higher rate of heart problems with Amgen osteoporosis drug in trial (AMGN, UCB, MRK)",Reuters,http://www.businessinsider.com/r-update-1-higher-rate-of-heart-problems-with-amgen-osteoporosis-drug-in-trial-2017-5
220.0,5/22/2017 1:58:07 PM,"US STOCKS-Futures flat as rise in oil offsets political concerns (AMGN, UCB, F, HUN)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-flat-as-rise-in-oil-offsets-political-concerns-2017-5
221.0,5/22/2017 8:08:39 PM,Amgen Posting Notable Loss In Afternoon Trading ,RTTNews,/news/stocks/amgen-posting-notable-loss-in-afternoon-trading-1002033690
222.0,5/30/2017 7:43:00 PM,"Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc.",PR Newswire,/news/stocks/lifshitz-miller-llp-announces-investigation-of-akari-therapeutics-plc-alexion-pharmaceuticals-inc-amgen-inc-cel-sci-corp-dick-s-sporting-goods-inc-eco-science-solutions-inc-1002051798
223.0,6/2/2017 10:00:00 PM,"Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge",PR Newswire,/news/stocks/amgen-showcases-a-legacy-of-science-innovation-and-collaboration-in-cambridge-1002064727
224.0,6/3/2017 11:45:00 PM,Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017,PR Newswire,/news/stocks/amgen-presents-new-phase-2-data-on-imlygic-talimogene-laherparepvec-investigational-combination-at-asco-2017-1002065454
225.0,6/4/2017 6:03:43 PM,Amgen Presents Data From Phase 3 XGEVA Study In Patients With Multiple Myeloma ,RTTNews,/news/stocks/amgen-presents-data-from-phase-3-xgeva-study-in-patients-with-multiple-myeloma-1002065889
226.0,6/5/2017 8:42:55 AM,"AMGN Finds New Use For Old Drug, NLNK Disappointed, ECYT Cuts Workforce ",RTTNews,/news/stocks/amgn-finds-new-use-for-old-drug-nlnk-disappointed-ecyt-cuts-workforce-1002066348
227.0,6/5/2017 3:00:00 PM,Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe,PR Newswire,/news/stocks/amgen-submits-regulatory-applications-for-repatha-evolocumab-cardiovascular-outcomes-data-in-us-and-europe-1002067285
228.0,6/5/2017 3:20:08 PM,"BRIEF-Amgen submits regulatory applications for repatha cardiovascular outcomes data in US, Europe (AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-submits-regulatory-applications-for-repatha-cardiovascular-outcomes-data-in-us-europe-2017-6
229.0,6/6/2017 11:48:05 PM,"Regeneron, Sanofi urge court to reverse ban on cholesterol drug (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-regeneron-sanofi-urge-court-to-reverse-ban-on-cholesterol-drug-2017-6
230.0,6/7/2017 2:52:06 PM,"UPDATE 1-AbbVie's rheumatoid arthritis drug succeeds in late-stage trial (AMGN, PFE, LLY, INCY)",Reuters,http://www.businessinsider.com/r-update-1-abbvies-rheumatoid-arthritis-drug-succeeds-in-late-stage-trial-2017-6
231.0,6/7/2017 3:00:00 PM,"Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab",PR Newswire,/news/stocks/amgen-and-allergan-announce-fda-advisory-committee-meeting-to-review-abp-215-a-biosimilar-candidate-to-bevacizumab-1002074491
232.0,6/7/2017 3:11:36 PM,Amgen: FDA Committee To Review Data Supporting BLA For ABP 215 - Quick Facts ,RTTNews,/news/stocks/amgen-fda-committee-to-review-data-supporting-bla-for-abp-215-quick-facts-1002074602
233.0,6/7/2017 4:44:03 PM,"Teva's migraine drug clears another hurdle, aims for launch in 2018 (TEVA, AMGN)",Reuters,http://www.businessinsider.com/r-tevas-migraine-drug-clears-another-hurdle-aims-for-launch-in-2018-2017-6
234.0,6/8/2017 9:46:41 AM,"ABBV Hits A High Note, AGN Opens Wallet, TEVA's HALO Does An Encore ",RTTNews,/news/stocks/abbv-hits-a-high-note-agn-opens-wallet-teva-s-halo-does-an-encore-1002077173
235.0,6/8/2017 10:00:00 PM,Amgen To Present At The Goldman Sachs 38th Annual Global Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference-1002079790
236.0,6/8/2017 10:30:00 PM,Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society,PR Newswire,/news/stocks/amgen-presents-erenumab-data-at-the-59th-annual-scientific-meeting-of-the-american-headache-society-1002079883
237.0,6/12/2017 12:58:03 PM,"FDA rejects Coherus's biosimilar for Amgen's Neulasta (CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-fda-rejects-coheruss-biosimilar-for-amgens-neulasta-2017-6
238.0,6/12/2017 1:28:08 PM,"UPDATE 1-FDA rejects Coherus' biosimilar for Amgen's Neulasta (CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-fda-rejects-coherus-biosimilar-for-amgens-neulasta-2017-6
239.0,6/12/2017 1:44:06 PM,"US STOCKS-Futures down as tech rout continues (AAPL, MSFT, NFLX, QCOM, SWKS, MU, GE, CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-down-as-tech-rout-continues-2017-6
240.0,6/12/2017 3:02:05 PM,"US STOCKS-Wall St set to open lower as tech selloff continues (AAPL, MSFT, NFLX, GE, QCOM, SWKS, MU, CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-lower-as-tech-selloff-continues-2017-6
241.0,6/12/2017 3:42:06 PM,"BRIEF-Coherus to take nearly 6 months to respond to FDA's requests on Neulasta biosmilar (CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-brief-coherus-to-take-nearly-6-months-to-respond-to-fdas-requests-on-neulasta-biosmilar-2017-6
242.0,6/12/2017 4:02:03 PM,"US STOCKS-Tech selloff pulls Wall St lower (AAPL, MSFT, NFLX, GE, CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-selloff-pulls-wall-st-lower-2017-6
243.0,6/12/2017 4:28:05 PM,U.S. high court speeds copycat biologic drugs to market (AMGN),Reuters,http://www.businessinsider.com/r-us-high-court-speeds-copycat-biologic-drugs-to-market-2017-6
244.0,6/12/2017 4:38:08 PM,UPDATE 1-U.S. Supreme Court speeds copycat biologic drugs to market (AMGN),Reuters,http://www.businessinsider.com/r-update-1-us-supreme-court-speeds-copycat-biologic-drugs-to-market-2017-6
245.0,6/12/2017 5:02:03 PM,"RPT-UPDATE 3-FDA rejects Coherus's biosimilar for Neulasta, shares plunge (CHRS, AMGN, MYL, BIOCON)",Reuters,http://www.businessinsider.com/r-rpt-update-3-fda-rejects-coheruss-biosimilar-for-neulasta-shares-plunge-2017-6
246.0,6/12/2017 5:40:10 PM,"US STOCKS-Wall St slips on tech selloff (AAPL, MSFT, NFLX, GE, CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-slips-on-tech-selloff-2017-6
247.0,6/12/2017 7:12:03 PM,"US STOCKS-Tech selloff drags down Wall St (AAPL, MSFT, GE, CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-selloff-drags-down-wall-st-2017-6
248.0,6/12/2017 10:30:06 PM,"There’s a race to treat a condition that affects 38 million Americans — here’s what you need to know (AMGN, TEVA, LLY, ALDR)",Business Insider,http://www.businessinsider.com/new-migraine-prevention-treatments-2017-6
249.0,6/12/2017 10:34:03 PM,"US STOCKS-Wall St falls as Apple drags tech shares lower (GE, NFLX, CHRS, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-falls-as-apple-drags-tech-shares-lower-2017-6
250.0,6/13/2017 1:01:00 AM,"Amgen's Multiple Myeloma Treatment, KYPROLIS® (Carfilzomib), in Combination with Dexamethasone, Receives NICE Recommendation for Use at First Relapse",PR Newswire,/news/stocks/amgen-s-multiple-myeloma-treatment-kyprolis-carfilzomib-in-combination-with-dexamethasone-receives-nice-recommendation-for-use-at-first-relapse-1002087103
251.0,6/13/2017 1:32:05 AM,"BRIEF-Amgen's multiple Myeloma treatment in combination with Dexamethasone, receives NICE recommendation for use at first relapse (AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgens-multiple-myeloma-treatment-in-combination-with-dexamethasone-receives-nice-recommendation-for-use-at-first-relapse-2017-6
252.0,6/13/2017 7:48:07 AM,"Swiss stocks - Factors to watch on June 13 (AMGN, BSLN, CLXN, PWTN)",Reuters,http://www.businessinsider.com/r-swiss-stocks---factors-to-watch-on-june-13-2017-6
253.0,6/13/2017 12:15:00 PM,"Technical Reports on Biotech Equities -- Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ",PR Newswire,/news/stocks/technical-reports-on-biotech-equities-amgen-pulmatrix-argos-therapeutics-and-bioverativ-1002088258
254.0,6/19/2017 3:00:00 PM,FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients,PR Newswire,/news/stocks/fda-accepts-amgen-s-supplemental-biologics-license-application-to-expand-indication-for-xgeva-denosumab-to-include-multiple-myeloma-patients-1002103663
255.0,6/19/2017 3:10:20 PM,Amgen: FDA To Review SBLA To Expand Indication For XGEVA - Quick Facts ,RTTNews,/news/stocks/amgen-fda-to-review-sbla-to-expand-indication-for-xgeva-quick-facts-1002103738
256.0,6/19/2017 3:20:12 PM,BRIEF-Amgen says FDA accepts sBLA to expand indication for XGEVA (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-says-fda-accepts-sbla-to-expand-indication-for-xgeva-2017-6
257.0,6/20/2017 8:08:53 AM,"AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade ",RTTNews,/news/stocks/amgn-s-xgeva-to-face-fda-in-feb-double-treat-for-lpcn-sgen-drops-cascade-1002105856
258.0,6/20/2017 3:58:08 PM,"Worldwide drug sale forecasts fall as pricing pressures mount (AMGN, SAN, PFE)",Reuters,http://www.businessinsider.com/r-worldwide-drug-sale-forecasts-fall-as-pricing-pressures-mount-2017-6
259.0,6/21/2017 7:26:46 AM,Novartis Says EMA Accepts MAA For AMG 334 For Prevention Of Migraine ,RTTNews,/news/stocks/novartis-says-ema-accepts-maa-for-amg-334-for-prevention-of-migraine-1002110220
260.0,6/21/2017 3:00:00 PM,Amgen To Present New Data At 22nd Congress of the European Hematology Association,PR Newswire,/news/stocks/amgen-to-present-new-data-at-22nd-congress-of-the-european-hematology-association-1002112109
261.0,6/21/2017 5:42:03 PM,"US STOCKS-Nasdaq boosted by biotechs; banks weigh on Dow, S&P (CELG, REGN, AMGN, GS, BAC, CAT, GE, ADBE)",Reuters,http://www.businessinsider.com/r-us-stocks-nasdaq-boosted-by-biotechs-banks-weigh-on-dow-sp-2017-6
262.0,6/21/2017 7:26:05 PM,"US STOCKS-Nasdaq boosted by biotechs; energy, banks weigh on Dow, S&P (XOM, CVX, CELG, REGN, AMGN, GS, BAC, CAT, FDX)",Reuters,http://www.businessinsider.com/r-us-stocks-nasdaq-boosted-by-biotechs-energy-banks-weigh-on-dow-sp-2017-6
263.0,6/23/2017 1:58:03 PM,"EU backs second biosimilar copy of Humira, world's top drug (AMGN, BIIB)",Reuters,http://www.businessinsider.com/r-eu-backs-second-biosimilar-copy-of-humira-worlds-top-drug-2017-6
264.0,6/23/2017 2:52:05 PM,"UPDATE 1-EU regulators greenlight U.S. biotech Aveo's kidney cancer drug (AVEO, 4151, 4503, BAYN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-eu-regulators-greenlight-us-biotech-aveos-kidney-cancer-drug-2017-6
265.0,6/23/2017 4:08:05 PM,"US STOCKS-Wall St weighed down by health, consumer shares (UNH, REGN, AMGN, BAC, JPM, WFC, GS, CAT, BBBY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-weighed-down-by-health-consumer-shares-2017-6
266.0,6/23/2017 10:00:00 PM,Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis,PR Newswire,/news/stocks/amgen-receives-positive-chmp-opinion-to-expand-use-of-mimpara-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-certain-children-with-end-stage-renal-disease-on-dialysis-1002120886
267.0,6/23/2017 10:30:03 PM,BRIEF-Amgen receives positive CHMP opinion to expand use of mimpara (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-receives-positive-chmp-opinion-to-expand-use-of-mimpara-2017-6
268.0,6/26/2017 3:02:05 PM,"Medtronic deal with Aetna ties insulin pump payment to patient results (MDT, AET, UNH, AMGN)",Reuters,http://www.businessinsider.com/r-medtronic-deal-with-aetna-ties-insulin-pump-payment-to-patient-results-2017-6
269.0,6/27/2017 7:46:05 AM,Novartis gets European OK for biosimilar of Amgen's Enbrel (AMGN),Reuters,http://www.businessinsider.com/r-novartis-gets-european-ok-for-biosimilar-of-amgens-enbrel-2017-6
270.0,6/27/2017 1:16:05 PM,"Alder's migraine drug meets main goal in late-stage study (AMGN, TEVA)",Reuters,http://www.businessinsider.com/r-alders-migraine-drug-meets-main-goal-in-late-stage-study-2017-6
271.0,6/29/2017 6:48:24 AM,Biotech Stocks Facing FDA Decision In July ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-1002133192
272.0,6/29/2017 1:28:05 PM,"UPDATE 1-Sales hopes for new Novartis, Merck heart drugs under microscope (MRK, AMGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-sales-hopes-for-new-novartis-merck-heart-drugs-under-microscope-2017-6
273.0,6/29/2017 11:30:00 PM,FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer,PR Newswire,/news/stocks/fda-approves-vectibix-panitumumab-for-use-in-wild-type-ras-metastatic-colorectal-cancer-1002136808
274.0,6/29/2017 11:44:03 PM,BRIEF-FDA approves Vectibix for use in wild-type RAS metastatic colorectal cancer (AMGN),Reuters,http://www.businessinsider.com/r-brief-fda-approves-vectibix-for-use-in-wild-type-ras-metastatic-colorectal-cancer-2017-6
275.0,6/30/2017 8:53:25 AM,"CARA In Pain, ALKS Enlightened, FDA Expands Approved Use Of AMGN's Vectibix ",RTTNews,/news/stocks/cara-in-pain-alks-enlightened-fda-expands-approved-use-of-amgn-s-vectibix-1002137520
276.0,7/10/2017 10:46:11 PM,"Here’s how much the 10 largest pharmaceutical companies spend on R&D (PFE, AMGN, NVS, ROG, MRK, SNY, JNJ, GILD, GSK, ABBV)",Business Insider,http://www.businessinsider.com/largest-pharmaceutical-companies-by-prescription-sales-and-rd-2017-7
277.0,7/12/2017 2:06:03 AM,BRIEF-Amgen says FDA grants full approval for Blincyto to treat relapsed or refractory b-cell precursor acute lymphoblastic leukemia (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-says-fda-grants-full-approval-for-blincyto-to-treat-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia-2017-7
278.0,7/12/2017 4:33:17 AM,Amgen Says FDA Approves SBLA For BLINCYTO To Include Overall Survival ,RTTNews,/news/stocks/amgen-says-fda-approves-sbla-for-blincyto-to-include-overall-survival-1002165323
279.0,7/12/2017 10:24:05 PM,BRIEF-Amgen says second phase 3 study shows kyprolis regimen significantly improves overall survival in patients with relapsed multiple myeloma (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-says-second-phase-3-study-shows-kyprolis-regimen-significantly-improves-overall-survival-in-patients-with-relapsed-multiple-myeloma-2017-7
280.0,7/13/2017 8:31:05 AM,"NVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track ",RTTNews,/news/stocks/nvs-gets-thumbs-up-two-biosimilar-candidates-to-face-fda-panel-vktx-on-track-1002169617
281.0,7/13/2017 2:28:06 PM,"BRIEF-Amgen, Allergan to discuss data supporting biologics license application for ABP 215 (AGN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-allergan-to-discuss-data-supporting-biologics-license-application-for-abp-215-2017-7
282.0,7/14/2017 8:31:09 AM,"FDA Panel Backs 2 Biosimilars, ALDR Abuzz, MDXG Q2 Revenue Grows 33% ",RTTNews,/news/stocks/fda-panel-backs-2-biosimilars-aldr-abuzz-mdxg-q2-revenue-grows-33-1002173475
283.0,7/14/2017 1:48:03 PM,"Novartis stocks drug cabinet with ""Big-3"" arthritis blockbusters (AMGN, JNJ, LLY)",Reuters,http://www.businessinsider.com/r-novartis-stocks-drug-cabinet-with-big-3-arthritis-blockbusters-2017-7
284.0,7/14/2017 3:16:44 PM,"Amgen Submits Applications In US, Europe To Include OS Data In KYPROLIS Label ",RTTNews,/news/stocks/amgen-submits-applications-in-us-europe-to-include-os-data-in-kyprolis-label-1002174753
285.0,7/14/2017 3:18:08 PM,"BRIEF-Amgen submits regulatory applications in US, Europe (AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-submits-regulatory-applications-in-us-europe-2017-7
286.0,7/17/2017 12:32:03 AM,"BRIEF-Amgen and UCB provide update on regulatory status of Evenity in U.S. (AMGN, UCB)",Reuters,http://www.businessinsider.com/r-brief-amgen-and-ucb-provide-update-on-regulatory-status-of-evenity-in-us-2017-7
287.0,7/17/2017 12:41:46 AM,Amgen And UCB Say FDA Issues CRL For BLA For EVENITY ,RTTNews,/news/stocks/amgen-and-ucb-say-fda-issues-crl-for-bla-for-evenity-1002176651
288.0,7/17/2017 3:50:42 AM,"FDA Turns Down AMGN's Osteoporosis Drug, EBS Opens Wallet, TROV Plunges ",RTTNews,/news/stocks/fda-turns-down-amgn-s-osteoporosis-drug-ebs-opens-wallet-trov-plunges-1002176721
289.0,7/17/2017 3:32:06 PM,"BRIEF-Ligand enters into commercial license, supply agreement with Amgen (LGND, AMGN)",Reuters,http://www.businessinsider.com/r-brief-ligand-enters-into-commercial-license-supply-agreement-with-amgen-2017-7
290.0,7/18/2017 10:20:08 AM,UPDATE 1-Novartis sees Alcon recovery opening door to spin-off IPO (AMGN),Reuters,http://www.businessinsider.com/r-update-1-novartis-sees-alcon-recovery-opening-door-to-spin-off-ipo-2017-7
291.0,7/18/2017 2:00:00 PM,Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation,PR Newswire,/news/stocks/amgen-and-array-biopharma-announce-preclinical-license-and-collaboration-agreement-in-inflammation-1001861592
292.0,7/18/2017 2:22:05 PM,"BRIEF-Amgen and Array BioPharma announce preclinical license and collaboration agreement (ARRY, AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-and-array-biopharma-announce-preclinical-license-and-collaboration-agreement-2017-7
293.0,7/19/2017 1:00:06 PM,"Poor test results for Roche cloud growth prospects (MERCK, SHP, PFE, 068270, MYL, TEVA, AMGN)",Reuters,http://www.businessinsider.com/r-poor-test-results-for-roche-cloud-growth-prospects-2017-7
294.0,7/20/2017 10:00:00 PM,Amgen Announces Webcast of 2017 Second Quarter Financial Results,PR Newswire,/news/stocks/amgen-announces-webcast-of-2017-second-quarter-financial-results-508459
295.0,7/20/2017 10:38:04 PM,BRIEF-Amgen says FDA accepts biologics license application for Aimovig (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-says-fda-accepts-biologics-license-application-for-aimovig-2017-7
296.0,7/21/2017 5:09:42 AM,Amgen Says FDA Accepts BLA For Aimovig ,RTTNews,/news/stocks/amgen-says-fda-accepts-bla-for-aimovig-1002193458
297.0,7/21/2017 7:22:01 AM,"AEZS Gets Down To Serious Work, APVO Surges, FDA Tentative Nod For MRK ",RTTNews,/news/stocks/aezs-gets-down-to-serious-work-apvo-surges-fda-tentative-nod-for-mrk-1002193692
298.0,7/24/2017 7:04:03 PM,"UPDATE 1-Merck, Samsung Bioepis launch discounted U.S. Remicade alternative (MRK, JNJ, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-merck-samsung-bioepis-launch-discounted-us-remicade-alternative-2017-7
299.0,7/25/2017 10:01:00 PM,Amgen Reports Second Quarter 2017 Financial Results,PR Newswire,/news/stocks/amgen-reports-second-quarter-2017-financial-results-1002203455
300.0,7/25/2017 10:14:10 PM,"Amgen 2nd quarter profit tops Street estimates, raises forecast (AMGN)",Reuters,http://www.businessinsider.com/r-amgen-2nd-quarter-profit-tops-street-estimates-raises-forecast-2017-7
301.0,7/25/2017 10:24:04 PM,BRIEF-Amgen Q2 GAAP shr $2.91 (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-q2-gaap-shr-291-2017-7
302.0,7/25/2017 10:52:28 PM,Amgen Increases 2017 Adj. EPS Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-increases-2017-adj-eps-guidance-quick-facts-1002203697
303.0,7/25/2017 11:03:53 PM,Amgen Inc. Reports 12% Gain In Q2 Bottom Line,RTTNews,/news/stocks/amgen-inc-reports-12-gain-in-q2-bottom-line-1002203744
304.0,7/25/2017 11:04:06 PM,BRIEF-Amgen Q2 GAAP shr $2.91 (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-q2-gaap-shr-291-2017-7
305.0,7/26/2017 1:32:06 PM,"US STOCKS-Futures edge up ahead of Fed decision; earnings in focus (MCD, CAT, GILD, ORLY, KO, T, AMGN, AKAM)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-edge-up-ahead-of-fed-decision-earnings-in-focus-2017-7
306.0,7/26/2017 2:48:08 PM,"US STOCKS-Wall St set to open higher on earnings; Fed in focus (MCD, CAT, GILD, ORLY, KO, BA, F, T, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-higher-on-earnings-fed-in-focus-2017-7
307.0,7/26/2017 4:02:03 PM,"US STOCKS-Wall St opens at record highs on strong earnings (BA, T, GILD, ORLY, KO, F, AMGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-opens-at-record-highs-on-strong-earnings-2017-7
308.0,7/26/2017 5:34:04 PM,"US STOCKS-Boeing, AT&T power Wall St to record; Fed in focus (BA, T, AMGN, GD)",Reuters,http://www.businessinsider.com/r-us-stocks-boeing-att-power-wall-st-to-record-fed-in-focus-2017-7
309.0,7/26/2017 6:54:07 PM,"US STOCKS-Strong earnings power Wall St to record; Fed awaited (BA, T, AMZN, AMGN, GD)",Reuters,http://www.businessinsider.com/r-us-stocks-strong-earnings-power-wall-st-to-record-fed-awaited-2017-7
310.0,7/27/2017 5:22:06 PM,"US STOCKS-Wall St adds to record rally on strong earnings (VZ, AMGN, JNJ, CELG, UPS, AMZN, INTC, SBUX, MAT)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-adds-to-record-rally-on-strong-earnings-2017-7
311.0,7/27/2017 7:14:08 PM,"US STOCKS-Wall St trims gains as tech stocks weigh (AAPL, VZ, AMZN, INTC, AMGN, JNJ, CELG, UPS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-trims-gains-as-tech-stocks-weigh-2017-7
312.0,7/27/2017 11:58:03 PM,BRIEF-FDA grants priority review for Amgen's supplemental biologics license application for Repatha (AMGN),Reuters,http://www.businessinsider.com/r-brief-fda-grants-priority-review-for-amgens-supplemental-biologics-license-application-for-repatha-2017-7
313.0,7/28/2017 12:24:03 AM,"Amgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label (AMGN, PFE, REGN, SAN)",Reuters,http://www.businessinsider.com/r-amgen-gets-fast-us-fda-review-for-adding-heart-benefits-to-cholesterol-drug-label-2017-7
314.0,7/28/2017 6:57:09 AM,"AGRX At FDA Altar Again, AZN Falls As MYSTIC Fails, VBIV Delivers A Good Shot ",RTTNews,/news/stocks/agrx-at-fda-altar-again-azn-falls-as-mystic-fails-vbiv-delivers-a-good-shot-1002213223
315.0,7/28/2017 2:24:06 PM,"UPDATE 1-AbbVie's profit beats on robust Humira demand (AMGN, CHRS, JNJ)",Reuters,http://www.businessinsider.com/r-update-1-abbvies-profit-beats-on-robust-humira-demand-2017-7
316.0,7/28/2017 10:14:03 PM,BRIEF-Amgen sets quarterly dividend of $1.15/shr (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-sets-quarterly-dividend-of-115-shr-2017-7
317.0,7/31/2017 3:07:19 PM,Amgen And Allergan Submit Biosimilar BLA For ABP 980 To FDA ,RTTNews,/news/stocks/amgen-and-allergan-submit-biosimilar-bla-for-abp-980-to-fda-1002218942
318.0,7/31/2017 3:22:05 PM,BRIEF-Amgen submits supplemental biologics license application for Prolia in glucocorticoid-induced osteoporosis (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-submits-supplemental-biologics-license-application-for-prolia-in-glucocorticoid-induced-osteoporosis-2017-7
319.0,7/31/2017 3:28:03 PM,"BRIEF-Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA (AMGN, AGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-980-to-us-fda-2017-7
320.0,7/31/2017 5:12:07 PM,"Express Scripts to cover Mylan's EpiPen, exclude rivals (ESRX, MYL, IPXL, AMGN, TEVA)",Reuters,http://www.businessinsider.com/r-express-scripts-to-cover-mylans-epipen-exclude-rivals-2017-7
321.0,7/31/2017 10:52:05 PM,"UPDATE 1-Express Scripts to cover Mylan's EpiPen, exclude rivals (ESRX, MYL, IPXL, AMGN, TEVA)",Reuters,http://www.businessinsider.com/r-update-1-express-scripts-to-cover-mylans-epipen-exclude-rivals-2017-7
322.0,8/2/2017 1:37:03 PM,"BRIEF-Cytokinetics announces positive results from phase 2 trial of Omecamtiv Mecarbil (CYTK, AMGN)",Reuters,http://www.businessinsider.com/r-brief-cytokinetics-announces-positive-results-from-phase-2-trial-of-omecamtiv-mecarbil-2017-8
323.0,8/4/2017 1:27:07 PM,"UPDATE 1-Lilly's acute migraine drug succeeds in late-stage study (LLY, AMGN, TEVA)",Reuters,http://www.businessinsider.com/r-update-1-lillys-acute-migraine-drug-succeeds-in-late-stage-study-2017-8
324.0,8/8/2017 8:00:00 AM,"Scottish Medicines Consortium Accepts Amgen's Multiple Myeloma Treatment, KYPROLIS® ▼ (carfilzomib), in Combination with Dexamethasone, for use at First Relapse",PR Newswire,/news/stocks/scottish-medicines-consortium-accepts-amgen-s-multiple-myeloma-treatment-kyprolis-carfilzomib-in-combination-with-dexamethasone-for-use-at-first-relapse-1002239027
325.0,8/14/2017 3:07:03 PM,"BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene (JPM, BIIB, CELG, AMGN, RDSA, REGN)",Reuters,http://www.businessinsider.com/r-brief-temasek-holdings-takes-stake-in-jpmorgan-biogen-celgene-2017-8
326.0,8/16/2017 11:10:00 PM,Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine,PR Newswire,/news/stocks/repatha-evolocumab-phase-3-cognitive-function-study-results-published-in-the-new-england-journal-of-medicine-1002263553
327.0,8/17/2017 10:22:20 PM,"BRIEF-Amgen and Humana partner for improved health outcomes (AMGN, HUM)",Reuters,http://www.businessinsider.com/r-brief-amgen-and-humana-partner-for-improved-health-outcomes-2017-8
328.0,8/18/2017 7:11:16 AM,"FDA Nod For PFE, New Use For AZN's Ovarian Cancer Drug, ELGX's LEOPARD Hits Goal ",RTTNews,/news/stocks/fda-nod-for-pfe-new-use-for-azn-s-ovarian-cancer-drug-elgx-s-leopard-hits-goal-1002267418
329.0,8/21/2017 3:00:00 PM,Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017,PR Newswire,/news/stocks/amgen-to-present-new-data-from-the-repatha-evolocumab-cardiovascular-outcomes-study-at-esc-congress-2017-1002272278
330.0,8/21/2017 3:22:11 PM,BRIEF-Amgen to present new data from the Repatha cardiovascular outcomes study (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-to-present-new-data-from-the-repatha-cardiovascular-outcomes-study-2017-8
331.0,8/23/2017 10:00:00 PM,New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology,PR Newswire,/news/stocks/new-economic-analysis-based-on-repatha-evolocumab-outcomes-data-published-in-jama-cardiology-1002279918
332.0,8/24/2017 12:43:00 AM,Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology,PR Newswire,/news/stocks/overall-survival-analysis-from-kyprolis-carfilzomib-phase-3-endeavor-trial-published-in-the-lancet-oncology-1002280205
333.0,8/24/2017 10:00:00 PM,"Amgen Foundation Expands The Amgen Biotech Experience, Bringing Total Program Reach To 900,000 High School Students By 2020",PR Newswire,/news/stocks/amgen-foundation-expands-the-amgen-biotech-experience-bringing-total-program-reach-to-900-000-high-school-students-by-2020-1002283568
334.0,8/24/2017 10:22:16 PM,BRIEF-Amgen Foundation expands Amgen Biotech experience (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-foundation-expands-amgen-biotech-experience-2017-8
335.0,8/25/2017 3:52:03 AM,"Samsung, Biogen version of AbbVie's Humira approved in Europe (BIIB, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-samsung-biogen-version-of-abbvies-humira-approved-in-europe-2017-8
336.0,8/25/2017 7:02:04 AM,"UPDATE 1-Samsung, Biogen version of AbbVie's Humira approved in Europe (BIIB, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-update-1-samsung-biogen-version-of-abbvies-humira-approved-in-europe-2017-8
337.0,8/28/2017 2:00:00 PM,New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels,PR Newswire,/news/stocks/new-repatha-evolocumab-analysis-demonstrates-cardiovascular-outcomes-efficacy-and-safety-of-achieving-very-low-ldl-c-levels-1002288252
338.0,8/28/2017 2:15:42 PM,Amgen Reports New Repatha Analysis - Quick Facts ,RTTNews,/news/stocks/amgen-reports-new-repatha-analysis-quick-facts-1002288351
339.0,8/28/2017 2:52:04 PM,BRIEF-Amgen says new Repatha analysis demonstrates cardiovascular outcomes efficacy (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-says-new-repatha-analysis-demonstrates-cardiovascular-outcomes-efficacy-2017-8
340.0,8/29/2017 2:23:52 PM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1002291346
341.0,8/29/2017 10:00:00 PM,New Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke,PR Newswire,/news/stocks/new-analysis-shows-repatha-evolocumab-reduces-cardiovascular-events-in-patients-with-history-of-stroke-1002292732
342.0,8/29/2017 10:00:00 PM,New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition,PR Newswire,/news/stocks/new-virtual-histology-sub-study-evaluates-impact-of-repatha-evolocumab-on-coronary-artery-plaque-composition-1002292731
343.0,8/29/2017 10:17:05 PM,BRIEF-New analysis shows Repatha reduces risk of cardiovascular events (AMGN),Reuters,http://www.businessinsider.com/r-brief-new-analysis-shows-repatha-reduces-risk-of-cardiovascular-events-2017-8
344.0,8/30/2017 10:00:00 PM,FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS® (Carfilzomib) Label,PR Newswire,/news/stocks/fda-accepts-amgen-s-filing-of-a-supplemental-new-drug-application-to-add-overall-survival-results-to-kyprolis-carfilzomib-label-1002296038
345.0,8/30/2017 10:17:13 PM,BRIEF-FDA accepts Amgen's filing of a supplemental new drug application to add overall survival results to Kyprolis® (carfilzomib) label (AMGN),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-amgens-filing-of-a-supplemental-new-drug-application-to-add-overall-survival-results-to-kyprolis-carfilzomib-label-2017-8
346.0,8/30/2017 10:18:00 PM,Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma,PR Newswire,/news/stocks/long-term-analysis-of-phase-3-head-to-head-study-confirms-kyprolis-carfilzomib-regimen-extends-overall-survival-in-patients-with-relapsed-multiple-myeloma-1001989407
347.0,8/30/2017 10:37:14 PM,BRIEF-Long-Term analysis of phase 3 head-to-head study confirms Kyprolis® (carfilzomib) regimen extends overall survival in patients with relapsed multiple myeloma (AMGN),Reuters,http://www.businessinsider.com/r-brief-long-term-analysis-of-phase-3-head-to-head-study-confirms-kyprolis-carfilzomib-regimen-extends-overall-survival-in-patients-with-relapsed-multiple-myeloma-2017-8
348.0,8/31/2017 8:36:05 AM,"AMGN's Endeavor Awaits Verdict, NVS Scripts History, OTIC Is Not Music To Ears ",RTTNews,/news/stocks/amgn-s-endeavor-awaits-verdict-nvs-scripts-history-otic-is-not-music-to-ears-1002297057
349.0,8/31/2017 2:00:00 PM,Digital Realty to Present at Investor Conferences in September 2017,PR Newswire,/news/stocks/digital-realty-to-present-at-investor-conferences-in-september-2017-624030
350.0,8/31/2017 10:00:00 PM,European Commission Approves Expanded Use Of Mimpara® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis,PR Newswire,/news/stocks/european-commission-approves-expanded-use-of-mimpara-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-children-with-end-stage-renal-disease-on-dialysis-1002299967
351.0,8/31/2017 10:12:06 PM,BRIEF-European Commission approves expanded use of Mimpara for the treatment of secondary hyperparathyroidism in children with end-stage renal disease on dialysis (AMGN),Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-expanded-use-of-mimpara-for-the-treatment-of-secondary-hyperparathyroidism-in-children-with-end-stage-renal-disease-on-dialysis-2017-8
352.0,9/5/2017 2:55:00 PM,"Decline in Pharmacy Customer Satisfaction Driven by Prescription Drug Costs, J.D. Power Finds",PR Newswire,/news/stocks/decline-in-pharmacy-customer-satisfaction-driven-by-prescription-drug-costs-j-d-power-finds-627012
353.0,9/6/2017 11:02:08 PM,"New AstraZeneca, Amgen biotech drug offers broad asthma relief (AZN, AMGN, GSK, TEVA, SAN)",Reuters,http://www.businessinsider.com/r-new-astrazeneca-amgen-biotech-drug-offers-broad-asthma-relief-2017-9
354.0,9/6/2017 11:07:00 PM,Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma,PR Newswire,/news/stocks/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-broad-population-of-patients-with-severe-uncontrolled-asthma-1002347409
355.0,9/7/2017 8:33:39 AM,AstraZeneca Announces Results From PATHWAY Phase IIb Trial Of Tezepelumab ,RTTNews,/news/stocks/astrazeneca-announces-results-from-pathway-phase-iib-trial-of-tezepelumab-1002348206
356.0,9/7/2017 8:37:04 AM,"UK Stocks-Factors to watch on Sept 7 (UKX, RBS, AZN, AMGN, GSK, TCG, ADM, ANTO, BLT, GLEN, LAND, RSA, SHP, MCB, BVS, GOG, ASHM, ENQ, BHP)",Reuters,http://www.businessinsider.com/r-uk-stocks-factors-to-watch-on-sept-7-2017-9
357.0,9/7/2017 9:57:06 AM,"UPDATE 1-UK Stocks-Factors to watch on Sept 7 (UKX, BVS, CPI, ASHM, RBS, AZN, AMGN, GSK, TCG, ADM, ANTO, BLT, GLEN, LAND, RSA, SHP, BHP)",Reuters,http://www.businessinsider.com/r-update-1-uk-stocks-factors-to-watch-on-sept-7-2017-9
358.0,9/7/2017 12:02:03 PM,"UPDATE 1-New AstraZeneca, Amgen drug looks strong rival in severe asthma (AZN, AMGN, GSK, TEVA, SAN)",Reuters,http://www.businessinsider.com/r-update-1-new-astrazeneca-amgen-drug-looks-strong-rival-in-severe-asthma-2017-9
359.0,9/7/2017 12:02:03 PM,"Quest to offer cholesterol testing without fasting requirement (DGX, AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-quest-to-offer-cholesterol-testing-without-fasting-requirement-2017-9
360.0,9/7/2017 5:27:00 PM,CH2M named to Fortune's Top 50 Companies that Change the World,PR Newswire,/news/stocks/ch2m-named-to-fortune-s-top-50-companies-that-change-the-world-1001650842
361.0,9/7/2017 10:00:00 PM,Amgen To Present At The Morgan Stanley Global Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-1002351430
362.0,9/7/2017 10:30:00 PM,New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies,PR Newswire,/news/stocks/new-data-demonstrate-aimovig-erenumab-reduced-monthly-migraine-days-in-patients-who-failed-previous-preventive-therapies-1002351529
363.0,9/8/2017 8:46:56 AM,"Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High ",RTTNews,/news/stocks/christmas-comes-early-for-kura-anth-on-track-abbv-hits-all-time-high-1002352466
364.0,9/9/2017 9:00:00 AM,Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress,PR Newswire,/news/stocks/amgen-and-allergan-present-phase-3-data-on-biosimilar-trastuzumab-candidate-abp-980-at-the-european-society-for-medical-oncology-2017-congress-1002355474
365.0,9/11/2017 10:00:00 PM,EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine,PR Newswire,/news/stocks/evenity-romosozumab-arch-study-results-published-in-the-new-england-journal-of-medicine-657017
366.0,9/11/2017 10:15:00 PM,Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-657016
367.0,9/14/2017 2:00:00 PM,Biotech Sector Looking to Outperform in 2017,PR Newswire,/news/stocks/biotech-sector-looking-to-outperform-in-2017-1002370082
368.0,9/14/2017 6:37:19 PM,U.S. FDA approves biosimilar version of cancer drug Avastin (AMGN),Reuters,http://www.businessinsider.com/r-us-fda-approves-biosimilar-version-of-cancer-drug-avastin-2017-9
369.0,9/14/2017 6:57:13 PM,"The FDA just approved the first direct competitor to a billion-dollar cancer drug (ROG.VX, AMGN)",Business Insider,http://www.businessinsider.com/fda-approves-avastin-biosimilar-to-treat-cancer-2017-9
370.0,9/14/2017 8:12:15 PM,RPT-U.S. FDA approves biosimilar version of cancer drug Avastin (AMGN),Reuters,http://www.businessinsider.com/r-rpt-us-fda-approves-biosimilar-version-of-cancer-drug-avastin-2017-9
371.0,9/14/2017 8:54:00 PM,FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer,PR Newswire,/news/stocks/fda-approves-amgen-and-allergan-s-mvasi-bevacizumab-awwb-for-the-treatment-of-five-types-of-cancer-1002371985
372.0,9/15/2017 10:32:00 AM,New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes,PR Newswire,/news/stocks/new-fourier-analysis-shows-repatha-evolocumab-reduces-cardiovascular-events-in-patients-with-diabetes-672826
373.0,9/15/2017 2:12:03 PM,"Samsung Bioepis wins EU endorsement for first Herceptin copy (MYL, BIOCON, 068270, AMGN, JNJ, 4502)",Reuters,http://www.businessinsider.com/r-samsung-bioepis-wins-eu-endorsement-for-first-herceptin-copy-2017-9
374.0,9/15/2017 3:00:00 PM,"Republic Services, Inc. Sets Date for Third Quarter 2017 Earnings Release and Conference Call",PR Newswire,/news/stocks/republic-services-inc-sets-date-for-third-quarter-2017-earnings-release-and-conference-call-1002009525
375.0,9/21/2017 2:01:00 AM,"AMGEN (AMGN) ALERT: Johnson Fistel Announces Investigation of Amgen Inc.; Investors that Bought Before March 17, 2017, Encouraged to Contact the Firm",PR Newswire,/news/stocks/amgen-amgn-alert-johnson-fistel-announces-investigation-of-amgen-inc-investors-that-bought-before-march-17-2017-encouraged-to-contact-the-firm-1002390935
376.0,9/22/2017 10:53:00 PM,Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts,PR Newswire,/news/stocks/amgen-foundation-pledges-up-to-$5-million-to-hurricane-maria-relief-efforts-706887
377.0,9/25/2017 3:00:00 PM,Amgen Provides Update On Hurricane Maria,PR Newswire,/news/stocks/amgen-provides-update-on-hurricane-maria-1002520117
378.0,9/25/2017 3:07:03 PM,BRIEF-Amgen provides update on Hurricane Maria (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-provides-update-on-hurricane-maria-2017-9
379.0,9/25/2017 3:14:05 PM,Amgen Updates On Hurricane Maria ,RTTNews,/news/stocks/amgen-updates-on-hurricane-maria-1002520516
380.0,9/26/2017 10:00:00 PM,Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China,PR Newswire,/news/stocks/amgen-and-simcere-announce-strategic-collaboration-to-co-develop-and-commercialize-biosimilars-in-china-1002592538
381.0,9/26/2017 10:07:06 PM,BRIEF-Amgen and Simcere announce strategic collaboration to co-develop and commercialize biosimilars in China (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-and-simcere-announce-strategic-collaboration-to-co-develop-and-commercialize-biosimilars-in-china-2017-9
382.0,9/28/2017 2:09:04 PM,"Amgen, AbbVie Settle Litigation Regarding AMGEVITA - Quick Facts ",RTTNews,/news/stocks/amgen-abbvie-settle-litigation-regarding-amgevita-quick-facts-1002732219
383.0,9/28/2017 2:12:03 PM,BRIEF-Amgen and AbbVie agree to settlement allowing commercialization of Amgevita (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-and-abbvie-agree-to-settlement-allowing-commercialization-of-amgevita-2017-9
384.0,9/28/2017 5:42:05 PM,"US STOCKS-McDonald's props up Dow; financial, tech stocks slip (MCD, AAPL, AMGN, ABT, RAD)",Reuters,http://www.businessinsider.com/r-us-stocks-mcdonalds-props-up-dow-financial-tech-stocks-slip-2017-9
385.0,9/28/2017 7:12:07 PM,"US STOCKS-McDonald's lifts Dow; Trump tax trade fades (MCD, AAPL, AMGN, ABT, 6502)",Reuters,http://www.businessinsider.com/r-us-stocks-mcdonalds-lifts-dow-trump-tax-trade-fades-2017-9
386.0,9/28/2017 8:47:13 PM,"US STOCKS-Wall St edges up on healthcare, tax plan hopes (MCD, AMGN, ABT, ALR)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-edges-up-on-healthcare-tax-plan-hopes-2017-9
387.0,9/28/2017 10:17:12 PM,"US STOCKS-S&P ekes out record on healthcare gains, tax plan hopes (MCD, AMGN, ABT, ALR)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-ekes-out-record-on-healthcare-gains-tax-plan-hopes-2017-9
388.0,9/29/2017 5:27:05 PM,"Puerto Rico power outage set to hurt global reinsurers (MAP, QBE, AIG, BMY, LLY, PFE, AMGN, AZN, MMC)",Reuters,http://www.businessinsider.com/r-puerto-rico-power-outage-set-to-hurt-global-reinsurers-2017-9
389.0,10/3/2017 10:05:00 PM,Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology,PR Newswire,/news/stocks/amgen-and-cytomx-therapeutics-announce-strategic-collaboration-in-immuno-oncology-1002957843
390.0,10/4/2017 12:27:11 AM,"BRIEF-Amgen, CytomX therapeutics announce strategic collaboration in Immuno-Oncology (AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-cytomx-therapeutics-announce-strategic-collaboration-in-immuno-oncology-2017-10
391.0,10/5/2017 4:17:03 PM,"U.S. court reverses ban on sales of Sanofi, Regeneron drug Praluent (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-us-court-reverses-ban-on-sales-of-sanofi-regeneron-drug-praluent-2017-10
392.0,10/5/2017 4:32:03 PM,"UPDATE 1-U.S. court reverses ban on sales of Sanofi, Regeneron drug Praluent (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-us-court-reverses-ban-on-sales-of-sanofi-regeneron-drug-praluent-2017-10
393.0,10/5/2017 6:52:03 PM,"BRIEF-U.S. Appellate Court rules Sanofi, Regeneron can continue manufacturing PRALUENT in U.S. (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-us-appellate-court-rules-sanofi-regeneron-can-continue-manufacturing-praluent-in-us-2017-10
394.0,10/5/2017 10:30:00 PM,"First Randomized Study To Evaluate IMLYGIC® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology",PR Newswire,/news/stocks/first-randomized-study-to-evaluate-imlygic-talimogene-laherparepvec-an-oncolytic-viral-therapy-in-combination-with-a-checkpoint-inhibitor-published-in-the-journal-of-clinical-oncology-1003107237
395.0,10/6/2017 10:01:00 PM,Amgen And LabCentral Open Nomination Process For Lab Residency,PR Newswire,/news/stocks/amgen-and-labcentral-open-nomination-process-for-lab-residency-1003210567
396.0,10/9/2017 11:48:57 AM,New Drugs Approved In September ,RTTNews,/news/stocks/new-drugs-approved-in-september-1003503219
397.0,10/9/2017 10:00:00 PM,FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis,PR Newswire,/news/stocks/fda-accepts-supplemental-biologics-license-application-for-prolia-denosumab-in-glucocorticoid-induced-osteoporosis-1003561721
398.0,10/9/2017 10:12:12 PM,BRIEF-FDA accepts supplemental biologics license application for Prolia (AMGN),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-supplemental-biologics-license-application-for-prolia-2017-10
399.0,10/10/2017 4:16:22 AM,Amgen : FDA Accepts SBLA For Prolia ,RTTNews,/news/stocks/amgen-fda-accepts-sbla-for-prolia-1003598617
400.0,10/12/2017 3:00:00 PM,Amgen Foundation Awards Khan Academy $3 Million To Support Development Of Free Comprehensive Biology Lessons,PR Newswire,/news/stocks/amgen-foundation-awards-khan-academy-3-million-to-support-development-of-free-comprehensive-biology-lessons-1003981005
401.0,10/12/2017 4:12:03 PM,"NIH partners 11 drugmakers to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-nih-partners-11-drugmakers-to-accelerate-cancer-therapy-research-2017-10
402.0,10/12/2017 6:27:06 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10
403.0,10/12/2017 10:12:15 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10
404.0,10/16/2017 10:00:00 PM,Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes,PR Newswire,/news/stocks/amgen-and-boston-children-s-hospital-enter-a-collaboration-to-find-new-genes-and-drug-targets-for-severe-pain-syndromes-1004526392
405.0,10/16/2017 10:12:15 PM,BRIEF-Amgen and Boston Children's Hospital enter into neuroscience research collaboration (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-and-boston-childrens-hospital-enter-into-neuroscience-research-collaboration-2017-10
406.0,10/20/2017 10:00:00 PM,Amgen Announces Webcast of 2017 Third Quarter Financial Results,PR Newswire,/news/stocks/amgen-announces-webcast-of-2017-third-quarter-financial-results-1005068300
407.0,10/23/2017 10:00:00 PM,Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients,PR Newswire,/news/stocks/phase-3-a-r-r-o-w-study-of-once-weekly-kyprolis-carfilzomib-regimen-meets-primary-endpoint-of-progression-free-survival-in-relapsed-and-refractory-multiple-myeloma-patients-1005365500
408.0,10/23/2017 10:07:03 PM,BRIEF-Amgen's Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgens-phase-3-arrow-study-of-once-weekly-kyprolis-regimen-meets-primary-endpoint-2017-10
409.0,10/24/2017 2:07:18 PM,"AbbVie bets on Alzheimer's immunotherapy with big biotech deal (MRK, AMGN)",Reuters,http://www.businessinsider.com/r-abbvie-bets-on-alzheimers-immunotherapy-with-big-biotech-deal-2017-10
410.0,10/24/2017 10:00:00 PM,Amgen Announces 2017 Fourth Quarter Dividend,PR Newswire,/news/stocks/amgen-announces-2017-fourth-quarter-dividend-1005487188
411.0,10/24/2017 10:27:08 PM,BRIEF-Amgen ‍board declares $1.15 per share dividend for Q4 (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-board-declares-115-per-share-dividend-for-q4-2017-10
412.0,10/24/2017 10:34:00 PM,Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors,PR Newswire,/news/stocks/amgen-announces-appointment-of-wanda-m-austin-to-board-of-directors-1005490083
413.0,10/24/2017 11:57:11 PM,BRIEF-Amgen appoints Wanda Austin to board of directors (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-appoints-wanda-austin-to-board-of-directors-2017-10
414.0,10/25/2017 2:37:12 PM,"UPDATE 1-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria (BAX, MRK, JNJ, PFE, GSK, MDT, DEPO, AMGN, BMY, LLY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-baxter-expects-70-mln-hit-to-4th-qtr-sales-from-hurricane-maria-2017-10
415.0,10/25/2017 10:01:00 PM,Amgen Reports Third Quarter 2017 Financial Results,PR Newswire,/news/stocks/amgen-reports-third-quarter-2017-financial-results-1005614142
416.0,10/25/2017 10:12:18 PM,Amgen quarterly profit tops expectations despite sales decline,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/RJXqpAlvR78/amgen-quarterly-profit-tops-expectations-despite-sales-decline-idUSKBN1CU2YW
417.0,10/25/2017 10:12:20 PM,Amgen quarterly profit tops expectations despite sales decline (AMGN),Reuters,http://www.businessinsider.com/r-amgen-quarterly-profit-tops-expectations-despite-sales-decline-2017-10
418.0,10/25/2017 10:13:40 PM,EARNINGS SUMMARY: Details of Amgen Inc. Q3 Earnings Report,RTTNews,/news/stocks/earnings-summary-details-of-amgen-inc-q3-earnings-report-1005615135
419.0,10/25/2017 10:20:29 PM,Amgen Increases 2017 Non-GAAP EPS Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-increases-2017-non-gaap-eps-guidance-quick-facts-1005615154
420.0,10/25/2017 10:37:14 PM,UPDATE 1-Amgen quarterly profit tops expectations despite sales decline (AMGN),Reuters,http://www.businessinsider.com/r-update-1-amgen-quarterly-profit-tops-expectations-despite-sales-decline-2017-10
421.0,10/26/2017 1:37:10 PM,"US STOCKS-Futures higher with earnings in focus (AMZN, MSFT, INTC, BWLD, AMGN, F)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-higher-with-earnings-in-focus-2017-10
422.0,10/26/2017 3:02:06 PM,"US STOCKS-Wall St set to open slightly higher amid earnings rush (AMZN, MSFT, INTC, CELG, AMGN, F)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-slightly-higher-amid-earnings-rush-2017-10
423.0,10/26/2017 11:47:16 PM,"UPDATE 1-CEOs suggest Trump tax cut may lift investors more than jobs (HON, AMGN, LMT)",Reuters,http://www.businessinsider.com/r-update-1-ceos-suggest-trump-tax-cut-may-lift-investors-more-than-jobs-2017-10
424.0,10/27/2017 1:42:09 PM,AbbVie says Humira sales will balloon to $21 bln in 2020 (AMGN),Reuters,http://www.businessinsider.com/r-abbvie-says-humira-sales-will-balloon-to-21-bln-in-2020-2017-10
425.0,10/27/2017 2:52:15 PM,"UPDATE 1-AbbVie says Humira sales will balloon to $21 bln in 2020, shares rise (AMGN)",Reuters,http://www.businessinsider.com/r-update-1-abbvie-says-humira-sales-will-balloon-to-21-bln-in-2020-shares-rise-2017-10
426.0,10/30/2017 12:22:25 PM,"BRIEF-‍Kymera Therapeutics announces $30 mln series A financing round​ (AMGN, LLY)",Reuters,http://www.businessinsider.com/r-brief-kymera-therapeutics-announces-30-mln-series-a-financing-round-2017-10
427.0,10/31/2017 7:30:00 AM,Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen,PR Newswire,/news/stocks/kirin-amgen-joint-venture-to-become-wholly-owned-subsidiary-of-amgen-1006267620
428.0,10/31/2017 7:46:00 AM,Kirin-Amgen JV To Become Wholly-owned Subsidiary Of Amgen - Quick Facts ,RTTNews,/news/stocks/kirin-amgen-jv-to-become-wholly-owned-subsidiary-of-amgen-quick-facts-1006268549
429.0,10/31/2017 8:02:16 AM,"BRIEF-Kirin says terminating shareholders' agreement of JV with Amgen (2503, AMGN)",Reuters,http://www.businessinsider.com/r-brief-kirin-says-terminating-shareholders-agreement-of-jv-with-amgen-2017-10
430.0,10/31/2017 8:02:16 AM,"BRIEF-‍Kirin-Amgen joint venture to become wholly-owned subsidiary of Amgen​ (AMGN, 2503)",Reuters,http://www.businessinsider.com/r-brief-kirin-amgen-joint-venture-to-become-wholly-owned-subsidiary-of-amgen-2017-10
431.0,10/31/2017 10:07:15 AM,"Japan's Kirin cashes out of Amgen drug joint venture (2503, AMGN, 4151, 8109)",Reuters,http://www.businessinsider.com/r-japans-kirin-cashes-out-of-amgen-drug-joint-venture-2017-10
432.0,10/31/2017 3:24:00 PM,Amgen Inc. -- Moody's assigns Baa1 to Amgen's notes; stable outlook,Moodys,/news/bonds/amgen-inc-moody-s-assigns-baa1-to-amgen-s-notes-stable-outlook-1006314545
433.0,11/2/2017 9:30:00 PM,Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program,PR Newswire,/news/stocks/amgen-and-novartis-announce-expanded-collaboration-with-banner-alzheimer-s-institute-in-pioneering-prevention-program-1006640881
434.0,11/2/2017 10:17:04 PM,"BRIEF-Amgen, Novartis announce expanded collaboration with Banner Alzheimer's Institute (AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-novartis-announce-expanded-collaboration-with-banner-alzheimers-institute-2017-11
435.0,11/3/2017 2:58:13 AM,"Novartis, Amgen Report Expanded Collaboration With Banner Alzheimer's Institute ",RTTNews,/news/stocks/novartis-amgen-report-expanded-collaboration-with-banner-alzheimer-s-institute-1006672717
436.0,11/6/2017 3:00:00 PM,Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017,PR Newswire,/news/stocks/amgen-announces-new-analyses-of-high-risk-patient-subgroups-from-repatha-evolocumab-cardiovascular-outcomes-study-at-aha-scientific-sessions-2017-1007060767
437.0,11/10/2017 1:27:00 PM,Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer,PR Newswire,/news/stocks/amgen-and-allergan-receive-positive-chmp-opinion-for-abp-215-biosimilar-bevacizumab-for-the-treatment-of-certain-types-of-cancer-1007548843
438.0,11/10/2017 1:29:00 PM,Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura,PR Newswire,/news/stocks/amgen-receives-positive-chmp-opinion-to-expand-use-of-nplate-romiplostim-in-pediatric-patients-with-chronic-immune-thrombocytopenic-purpura-1007548845
439.0,11/10/2017 1:36:44 PM,"Amgen, Allergan Get Positive CHMP Opinion For ABP 215, Biosimilar Bevacizumab ",RTTNews,/news/stocks/amgen-allergan-get-positive-chmp-opinion-for-abp-215-biosimilar-bevacizumab-1007548911
440.0,11/10/2017 1:37:03 PM,"BRIEF-Amgen and Allergan receive positive chmp opinion for ABP 215 (AGN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-and-allergan-receive-positive-chmp-opinion-for-abp-215-2017-11
441.0,11/10/2017 1:43:14 PM,Amgen Gets Positive CHMP Opinion To Expand Use Of Nplate In Pediatric Patients ,RTTNews,/news/stocks/amgen-gets-positive-chmp-opinion-to-expand-use-of-nplate-in-pediatric-patients-1007549730
442.0,11/10/2017 1:47:03 PM,BRIEF-Amgen receives positive CHMP opinion to expand use of Nplate in pediatric patients with chronic immune thrombocytopenic purpura (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-receives-positive-chmp-opinion-to-expand-use-of-nplate-in-pediatric-patients-with-chronic-immune-thrombocytopenic-purpura-2017-11
443.0,11/13/2017 5:07:03 PM,"Nanotech, gene editing used to edit cholesterol gene-US study (REGN, AMGN)",Reuters,http://www.businessinsider.com/r-nanotech-gene-editing-used-to-edit-cholesterol-gene-us-study-2017-11
444.0,11/13/2017 10:00:00 PM,New Analyses Presented At AHA 2017 Show Repatha® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks,PR Newswire,/news/stocks/new-analyses-presented-at-aha-2017-show-repatha-evolocumab-significantly-reduced-cardiovascular-events-in-patients-with-peripheral-artery-disease-and-in-patients-with-a-history-of-heart-attacks-495994
445.0,11/14/2017 1:22:03 PM,"BRIEF-Temasek Holdings takes share stake in Vantiv Inc, raises share stake in Amgen (EMR, AMGN)",Reuters,http://www.businessinsider.com/r-brief-temasek-holdings-takes-share-stake-in-vantiv-inc-raises-share-stake-in-amgen-2017-11
446.0,11/15/2017 10:07:03 AM,"UPDATE 1-AstraZeneca ticks another box as U.S. approves severe asthma drug (AZN, GSK, TEVA, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-ticks-another-box-as-us-approves-severe-asthma-drug-2017-11
447.0,11/17/2017 3:00:00 PM,Amgen Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients,PR Newswire,/news/stocks/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector-that-is-ergonomically-designed-for-patients-1008432684
448.0,11/17/2017 3:37:03 PM,BRIEF-Amgen launches Enbrel Mini with Autotouch in U.S. (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-launches-enbrel-mini-with-autotouch-in-us-2017-11
449.0,11/27/2017 10:00:00 PM,Amgen To Present At The Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-evercore-isi-2017-biopharma-catalyst-deep-dive-conference-1001567203
450.0,11/29/2017 1:09:07 PM,Biotech Stocks Facing FDA Decision In December ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-1009916247
451.0,11/29/2017 11:00:00 PM,"Aimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention",PR Newswire,/news/stocks/aimovig-erenumab-phase-3-strive-data-published-in-the-new-england-journal-of-medicine-demonstrate-significant-sustained-efficacy-in-migraine-prevention-1009972286
452.0,11/29/2017 11:22:03 PM,"BRIEF-Amgen Says Aimovig Phase 3 Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention (AMGN)",Reuters,http://www.businessinsider.com/r-brief-amgen-says-aimovig-phase-3-data-published-in-the-new-england-journal-of-medicine-demonstrate-significant-sustained-efficacy-in-migraine-prevention-2017-11
453.0,12/1/2017 10:00:00 PM,FDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke,PR Newswire,/news/stocks/fda-approves-amgen-s-repatha-evolocumab-to-prevent-heart-attack-and-stroke-1010228361
454.0,12/1/2017 11:02:03 PM,"FDA approves heart protection claims for Amgen cholesterol drug (AMGN, PFE)",Reuters,http://www.businessinsider.com/r-fda-approves-heart-protection-claims-for-amgen-cholesterol-drug-2017-12
455.0,12/4/2017 7:23:16 AM,Biocartis Signs Diagnostic Development Agreement With Amgen For Idylla RAS Tests ,RTTNews,/news/stocks/biocartis-signs-diagnostic-development-agreement-with-amgen-for-idylla-ras-tests-1010316897
456.0,12/4/2017 7:32:03 AM,BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests (AMGN),Reuters,http://www.businessinsider.com/r-brief-biocartis-and-amgen-sign-companion-diagnostic-agreement-for-idyllatm-ras-biomarker-tests-2017-12
457.0,12/5/2017 2:27:08 PM,BRIEF-Xencor Receives Milestone Payment From Amgen (AMGN),Reuters,http://www.businessinsider.com/r-brief-xencor-receives-milestone-payment-from-amgen-2017-12
458.0,12/6/2017 1:22:04 PM,BRIEF-Carmot Enters A Multi-Year Drug Discovery Collaboration With Amgen (AMGN),Reuters,http://www.businessinsider.com/r-brief-carmot-enters-a-multi-year-drug-discovery-collaboration-with-amgen-2017-12
459.0,12/6/2017 10:00:00 PM,Amgen To Webcast Investor Call At ASH 2017,PR Newswire,/news/stocks/amgen-to-webcast-investor-call-at-ash-2017-564520
460.0,12/7/2017 3:00:00 PM,New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers,PR Newswire,/news/stocks/new-data-to-be-presented-at-ash-2017-underscore-amgen-s-commitment-to-improving-lives-and-changing-outcomes-for-patients-with-difficult-to-treat-blood-cancers-1010493075
461.0,12/8/2017 7:17:03 PM,"BRIEF-Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint (AMGN, CHRS)",Reuters,http://www.businessinsider.com/r-brief-coherus-says-judge-issued-under-seal-report--recommendation-in-relation-to-patent-infringement-complaint-2017-12
462.0,12/10/2017 12:15:24 PM,Repatha & Praluent: A Tale Of Two Rivals... ,RTTNews,/news/stocks/repatha-praluent-a-tale-of-two-rivals-1010812436
463.0,12/11/2017 3:00:00 PM,"Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires",PR Newswire,/news/stocks/amgen-foundation-pledges-up-to-500-000-in-relief-to-victims-of-the-southern-california-wildfires-1010945049
464.0,12/11/2017 10:00:00 PM,KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial,PR Newswire,/news/stocks/kyprolis-carfilzomib-extended-overall-survival-in-patients-with-relapsed-or-refractory-multiple-myeloma-in-phase-3-aspire-trial-578869
465.0,12/11/2017 10:17:04 PM,BRIEF-Kyprolis (Carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma (AMGN),Reuters,http://www.businessinsider.com/r-brief-kyprolis-carfilzomib-extended-overall-survival-in-patients-with-relapsed-or-refractory-multiple-myeloma-2017-12
466.0,12/11/2017 10:32:04 PM,Amgen's Kyprolis improves overall survival in blood cancer patients (AMGN),Reuters,http://www.businessinsider.com/r-amgens-kyprolis-improves-overall-survival-in-blood-cancer-patients-2017-12
467.0,12/11/2017 11:37:03 PM,"UPDATE 1-Amgen's Kyprolis improves overall survival in blood cancer patients (AMGN, CELG, 4502)",Reuters,http://www.businessinsider.com/r-update-1-amgens-kyprolis-improves-overall-survival-in-blood-cancer-patients-2017-12
468.0,12/12/2017 10:00:00 PM,Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend,PR Newswire,/news/stocks/amgen-announces-15-percent-increase-in-2018-first-quarter-dividend-1011133138
469.0,12/14/2017 1:02:03 AM,"Bumper crop of new drugs fails to lift big pharma R&D returns (BION, NOVO , PFE, SAN, GSK, JNJ, AZN, MRK, LLY, BMY, 4502, AMGN, BIIB, CELG, GILD)",Reuters,http://www.businessinsider.com/r-bumper-crop-of-new-drugs-fails-to-lift-big-pharma-rd-returns-2017-12
470.0,12/14/2017 3:51:00 PM,Mapp Enables DMLS To On-Board Over 20 Brands And Deliver Over 700 Million Emails In 18 Months,PR Newswire,/news/stocks/mapp-enables-dmls-to-on-board-over-20-brands-and-deliver-over-700-million-emails-in-18-months-1001939221
471.0,12/14/2017 10:00:00 PM,Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral,PR Newswire,/news/stocks/amgen-teams-up-with-cambridge-biotech-community-to-select-two-startups-to-receive-golden-tickets-at-labcentral-1001606942
472.0,12/16/2017 1:23:00 AM,Centene's Washington Subsidiary Reaches agreement with State of Washington,PR Newswire,/news/stocks/centenes-washington-subsidiary-reaches-agreement-with-state-of-washington-1001610837
473.0,12/22/2017 10:27:03 PM,BRIEF-Amgen Expects To Incur GAAP Net Tax Expense Of Between $6 Bln And $6.5 Bln (AMGN),Reuters,http://www.businessinsider.com/r-brief-amgen-expects-to-incur-gaap-net-tax-expense-of-between-6-bln-and-65-bln-2017-12
474.0,12/22/2017 11:07:03 PM,Amgen estimates its U.S. tax bill at over $6 billion as it repatriates cash (AMGN),Reuters,http://www.businessinsider.com/r-amgen-estimates-its-us-tax-bill-at-over-6-billion-as-it-repatriates-cash-2017-12
475.0,12/22/2017 11:10:47 PM,Amgen estimates its U.S. tax bill at over $6 billion as it repatriates cash,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/xMErsE5OBog/amgen-estimates-its-u-s-tax-bill-at-over-6-billion-as-it-repatriates-cash-idUSKBN1EG2CF
476.0,12/29/2017 4:07:03 PM,"RPT-UPDATE 2-Goldman to take one-time $5 bln hit to profit from new tax law (GS, AAPL, AMGN, DAL, BARC, JPM, WFC, MS, BAC, C)",Reuters,http://www.businessinsider.com/r-rpt-update-2-goldman-to-take-one-time-5-bln-hit-to-profit-from-new-tax-law-2017-12
477.0,12/29/2017 4:07:04 PM,Goldman to take one-time $5 billion hit to profit from new tax law,Reuters,http://www.businessinsider.com/r-update-2-goldman-to-take-one-time-5-bln-hit-to-profit-from-new-tax-law-2017-12
478.0,1/2/2018 11:27:06 PM,"Drugmakers raise 2018 U.S. prices, stick to self-imposed limits (AGN, AMGN, TEVA, HZNP)",Reuters,http://www.businessinsider.com/r-drugmakers-raise-2018-us-prices-stick-to-self-imposed-limits-2018-1
479.0,1/5/2018 3:00:00 PM,FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma,PR Newswire,/news/stocks/fda-approves-xgeva-denosumab-for-the-prevention-of-skeletal-related-events-in-patients-with-multiple-myeloma-1012522659
480.0,1/5/2018 3:10:13 PM,Amgen Says FDA Approves SBLA For XGEVA ,RTTNews,/news/stocks/amgen-says-fda-approves-sbla-for-xgeva-1012522706
481.0,1/8/2018 7:00:00 AM,European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab),PR Newswire,/news/stocks/european-medicines-agency-accepts-filing-for-evenity-romosozumab-1002349296
482.0,1/8/2018 7:16:20 AM,Amgen Says EMA Accepts Filing For EVENITY Application ,RTTNews,/news/stocks/amgen-says-ema-accepts-filing-for-evenity-application-1012648101
483.0,1/9/2018 7:14:44 AM,"Belgium's Biocartis, Amgen In Deal To Develop Idylla CDx Biomarker Tests ",RTTNews,/news/stocks/belgium-s-biocartis-amgen-in-deal-to-develop-idylla-cdx-biomarker-tests-1012707167
484.0,1/9/2018 3:00:00 PM,Seek Thermal Debuts First High-Resolution Thermal Imaging Camera Designed for Automotive Aftermarket and Priced Under $999 at CES 2018,PR Newswire,/news/stocks/seek-thermal-debuts-first-high-resolution-thermal-imaging-camera-designed-for-automotive-aftermarket-and-priced-under-$999-at-ces-2018-643646
485.0,1/9/2018 3:11:00 PM,Moody's: US pharmaceutical companies' cash holdings set to decline under new tax law,Moodys,/news/bonds/moody-s-us-pharmaceutical-companies-cash-holdings-set-to-decline-under-new-tax-law-1012731176
486.0,1/9/2018 6:00:00 PM,"Human Longevity, Inc. and AMRA Partner to Provide Advanced Body Composition Profiling to HLI's Health Nucleus Clients",PR Newswire,/news/stocks/human-longevity-inc-and-amra-partner-to-provide-advanced-body-composition-profiling-to-hli-s-health-nucleus-clients-1001653365
487.0,1/17/2018 10:09:00 PM,Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology,PR Newswire,/news/stocks/overall-survival-analysis-from-kyprolis-carfilzomib-phase-3-aspire-trial-published-in-the-journal-of-clinical-oncology-1013176619
488.0,1/17/2018 10:15:00 PM,FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label,PR Newswire,/news/stocks/fda-approves-addition-of-overall-survival-data-to-kyprolis-carfilzomib-label-1013177058
489.0,1/18/2018 2:00:00 PM,"incredibles, Colorado's Compliance-Focused And Patient-Driven Cannabis Brand, Forges Strategic Partnerships With Like-Minded Partners To Deliver Products To Florida, Illinois And Oregon",PR Newswire,/news/stocks/incredibles-colorados-compliance-focused-and-patient-driven-cannabis-brand-forges-strategic-partnerships-with-like-minded-partners-to-deliver-products-to-florida-illinois-and-oregon-676754
490.0,1/18/2018 10:00:00 PM,European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer,PR Newswire,/news/stocks/european-commission-approves-amgen-and-allergan-s-mvasi-biosimilar-bevacizumab-for-the-treatment-of-certain-types-of-cancer-1013249327
491.0,1/19/2018 5:48:26 AM,Amgen And Allergan's MVASI Gets EU Approval To Treat Certain Types Of Cancer ,RTTNews,/news/stocks/amgen-and-allergan-s-mvasi-gets-eu-approval-to-treat-certain-types-of-cancer-1013276962
492.0,1/22/2018 8:58:59 AM,Some Branded Drugs Going Generic In 2018 ,RTTNews,/news/stocks/some-branded-drugs-going-generic-in-2018-1013567302
493.0,1/22/2018 10:30:00 PM,Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments,PR Newswire,/news/stocks/amgen-reports-aimovig-erenumab-met-all-primary-and-secondary-endpoints-in-unique-phase-3b-study-in-episodic-migraine-patients-who-have-failed-multiple-prior-preventive-treatments-1013632771
494.0,1/22/2018 11:03:27 PM,Novartis: Erenumab Meets All Endpoints In LIBERTY Migraine Prevention Trial ,RTTNews,/news/stocks/novartis-erenumab-meets-all-endpoints-in-liberty-migraine-prevention-trial-1013635287
495.0,1/23/2018 6:51:09 AM,"AMGN's LIBERTY Meets Goals, ANTH Yields RESULT, CCXI Up On Cancer Trial Data ",RTTNews,/news/stocks/amgn-s-liberty-meets-goals-anth-yields-result-ccxi-up-on-cancer-trial-data-1013673586
496.0,1/24/2018 6:00:00 PM,MGM Resorts Named One of 'World's Most Admired Companies',PR Newswire,/news/stocks/mgm-resorts-named-one-of-world-s-most-admired-companies-1002030549
497.0,1/29/2018 10:00:00 PM,Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results,PR Newswire,/news/stocks/amgen-announces-webcast-of-2017-fourth-quarter-and-full-year-financial-results-1014477300
498.0,1/30/2018 3:00:00 PM,Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label,PR Newswire,/news/stocks/amgen-receives-chmp-positive-opinion-to-add-updated-overall-survival-data-to-kyprolis-carfilzomib-label-1014559002
499.0,2/1/2018 10:01:00 PM,Amgen Reports Fourth Quarter And Full Year 2017 Financial Results,PR Newswire,/news/stocks/amgen-reports-fourth-quarter-and-full-year-2017-financial-results-1014834707
500.0,2/1/2018 10:08:28 PM,EARNINGS SUMMARY: Details of Amgen Inc. Q4 Earnings Report,RTTNews,/news/stocks/earnings-summary-details-of-amgen-inc-q4-earnings-report-1014834779
501.0,2/2/2018 4:26:00 PM,Amgen Inc. -- Moody's affirms Amgen at Baa1; outlook stable,Moodys,/news/bonds/amgen-inc-moody-s-affirms-amgen-at-baa1-outlook-stable-1014918368
502.0,2/6/2018 6:31:00 PM,"Acclaimed Hollywood Film Director And Arkansas Native, LazRael Lison, Gives Back With Scholarships For Local High School Seniors",PR Newswire,/news/stocks/acclaimed-hollywood-film-director-and-arkansas-native-lazrael-lison-gives-back-with-scholarships-for-local-high-school-seniors-1002065861
503.0,2/8/2018 10:00:00 PM,Amgen To Present At The 7th Annual Leerink Partners Global Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-7th-annual-leerink-partners-global-healthcare-conference-1015150407
504.0,2/9/2018 12:44:00 AM,Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology,PR Newswire,/news/stocks/results-from-phase-3-xgeva-denosumab-study-in-patients-with-multiple-myeloma-published-in-the-lancet-oncology-1015160866
505.0,2/14/2018 10:00:00 PM,Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab),PR Newswire,/news/stocks/amgen-announces-fda-advisory-committee-meeting-to-review-potential-new-use-of-blincyto-blinatumomab-1015807838
506.0,2/23/2018 2:20:00 PM,Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe,PR Newswire,/news/stocks/amgen-receives-positive-opinion-expanding-use-of-xgeva-denosumab-to-cover-prevention-of-skeletal-related-events-in-patients-with-multiple-myeloma-in-europe-1016849348
507.0,2/26/2018 10:00:00 PM,Amgen To Present New Data From Repatha® (evolocumab) Clinical Trials At ACC.18,PR Newswire,/news/stocks/amgen-to-present-new-data-from-repatha-evolocumab-clinical-trials-at-acc-18-1017214513
508.0,2/27/2018 8:41:40 AM,Biotech Stocks Facing FDA Decision In March ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-1017268709
509.0,2/27/2018 3:00:00 PM,Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim),PR Newswire,/news/stocks/amgen-receives-positive-chmp-opinion-for-delivery-system-of-neulasta-pegfilgrastim-1017303647
510.0,3/4/2018 3:19:34 AM,An Ear To The Pharma: 7 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-7-stocks-to-watch-this-week-1017867022
511.0,3/7/2018 10:00:00 PM,Amgen To Present At the Cowen and Company 38th Annual Health Care Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-1018311624
512.0,3/7/2018 10:15:00 PM,Amgen Announces 2018 Second Quarter Dividend,PR Newswire,/news/stocks/amgen-announces-2018-second-quarter-dividend-1018313659
513.0,3/8/2018 3:00:00 PM,Amgen Announces Final Results Of Tender Offer,PR Newswire,/news/stocks/amgen-announces-final-results-of-tender-offer-1018408334
514.0,3/9/2018 3:00:00 PM,New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events,PR Newswire,/news/stocks/new-analyses-show-payer-utilization-management-criteria-deny-access-to-pcsk9-inhibitors-for-patients-at-the-highest-risk-for-subsequent-cardiovascular-events-1018548988
515.0,3/17/2018 3:50:00 AM,"QUANTUM CORPORATION SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Quantum Corporation - QTM",PR Newswire,/news/stocks/quantum-corporation-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-quantum-corporation-qtm-1002174662
516.0,3/23/2018 1:41:00 PM,Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer,PR Newswire,/news/stocks/amgen-and-allergan-receive-positive-chmp-opinion-for-abp-980-biosimilar-herceptin-for-the-treatment-of-three-types-of-cancer-507882
517.0,3/23/2018 1:44:00 PM,Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes,PR Newswire,/news/stocks/amgen-receives-positive-chmp-opinion-recognizing-that-repatha-evolocumab-prevents-heart-attacks-and-strokes-1019156587
518.0,3/23/2018 1:53:00 PM,BRIEF-Amgen And Allergan Receive Positive CHMP Opinion For Abp 980,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/pG3mVEVulfc/brief-amgen-and-allergan-receive-positive-chmp-opinion-for-abp-980-idUSFWN1R50LT
519.0,3/23/2018 1:57:05 PM,"Amgen, Allergan: CHMP Adopts Positive Opinion For ABP 980 - Quick Facts ",RTTNews,/news/stocks/amgen-allergan-chmp-adopts-positive-opinion-for-abp-980-quick-facts-1019156617
520.0,3/23/2018 1:57:55 PM,"BRIEF-EU Medicines Agency Recommends Approval Of Amgen Europe, Sandoz Biosimilar Drugs",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ANCM6h3m_5w/brief-eu-medicines-agency-recommends-approval-of-amgen-europe-sandoz-biosimilar-drugs-idUSFWN1R50LU
521.0,3/25/2018 3:45:52 AM,An Ear To The Pharma: 5 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-5-stocks-to-watch-this-week-1019307244
522.0,3/29/2018 7:36:06 PM,FDA expands use of Amgen leukemia drug Blincyto to patients with relapse risk,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/l-EI8dB0Mhg/fda-expands-use-of-amgen-leukemia-drug-blincyto-to-patients-with-relapse-risk-idUSL1N1RB1JX
523.0,3/29/2018 9:05:06 PM,UPDATE 1-FDA expands use of Amgen leukemia drug Blincyto to patients with relapse risk,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5nNMaW3Ldxw/update-1-fda-expands-use-of-amgen-leukemia-drug-blincyto-to-patients-with-relapse-risk-idUSL1N1RB1NX
524.0,3/29/2018 9:17:00 PM,FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children,PR Newswire,/news/stocks/fda-approves-blincyto-blinatumomab-to-treat-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukemia-in-adults-and-children-1019880656
525.0,3/29/2018 9:54:57 PM,FDA Approves Amgen's Supplemental Biologics License Application For Blincyto ,RTTNews,/news/stocks/fda-approves-amgen-s-supplemental-biologics-license-application-for-blincyto-1019883443
526.0,4/2/2018 3:00:00 PM,Protein-Packed Muuna® Is Now Powered by Popular 2018 Food Trend - Probiotics,PR Newswire,/news/stocks/protein-packed-muuna-is-now-powered-by-popular-2018-food-trend-probiotics-1001894538
527.0,4/3/2018 7:00:00 AM,European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma,PR Newswire,/news/stocks/european-commission-approves-expanded-indication-for-amgens-xgeva-denosumab-for-the-prevention-of-skeletal-related-events-in-patients-with-multiple-myeloma-530550
528.0,4/3/2018 7:12:54 AM,Amgen: European Commission Approves Expanded Indication For XGEVA - Quick Facts ,RTTNews,/news/stocks/amgen-european-commission-approves-expanded-indication-for-xgeva-quick-facts-1020311192
529.0,4/4/2018 3:30:00 PM,Karma Automotive To Debut New TV Spot During CBS Coverage Of The 2018 Masters Golf Tournament®,PR Newswire,/news/stocks/karma-automotive-to-debut-new-tv-spot-during-cbs-coverage-of-the-2018-masters-golf-tournament-1001562763
530.0,4/9/2018 10:00:00 PM,Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018,PR Newswire,/news/stocks/amgen-to-present-new-pre-clinical-data-showcasing-robust-approach-to-evaluating-potential-anti-cancer-therapies-at-aacr-2018-1020981204
531.0,4/10/2018 5:55:22 PM,Rhode Island governor says Amgen will build another plant in state,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SoLxKpCMziM/rhode-island-governor-says-amgen-will-build-another-plant-in-state-idUSL1N1RN17Q
532.0,4/10/2018 6:07:00 PM,Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant,PR Newswire,/news/stocks/amgen-announces-rhode-island-will-be-location-of-first-us-next-generation-biomanufacturing-plant-1021069394
533.0,4/10/2018 6:15:29 PM,UPDATE 1-Rhode Island governor says Amgen will build second plant in state,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/QcFrgzob3HI/update-1-rhode-island-governor-says-amgen-will-build-second-plant-in-state-idUSL1N1RN008
534.0,4/10/2018 7:56:03 PM,BRIEF-Amgen Plans To Build A New Biomanufacturing Plant in Rhode Island,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/UOwCOmR96hI/brief-amgen-plans-to-build-a-new-biomanufacturing-plant-in-rhode-island-idUSFWN1RN0UQ
535.0,4/17/2018 1:03:00 PM,Linguamatics Spring Text Mining Conference 2018 to Feature Speakers from Leading Biomedical Organizations,PR Newswire,/news/stocks/linguamatics-spring-text-mining-conference-2018-to-feature-speakers-from-leading-biomedical-organizations-1002266806
536.0,4/17/2018 10:00:00 PM,Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures,PR Newswire,/news/stocks/amgen-presents-first-of-its-kind-data-at-aan-annual-meeting-reinforcing-robust-and-consistent-efficacy-of-aimovig-erenumab-for-migraine-patients-with-multiple-treatment-failures-1021453910
537.0,4/18/2018 3:10:00 PM,Renovate America Passes Key Job-Creation Milestone,PR Newswire,/news/stocks/renovate-america-passes-key-job-creation-milestone-589583
538.0,4/19/2018 12:16:00 AM,Gaming Laboratories International (GLI®) First Lab Accredited to Test and Certify Skill-Based Amusement Machines (SBAM) in Ohio,PR Newswire,/news/stocks/gaming-laboratories-international-gli-first-lab-accredited-to-test-and-certify-skill-based-amusement-machines-sbam-in-ohio-594590
539.0,4/19/2018 10:26:00 AM,"Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising",Moodys,/news/bonds/moody-s-stable-outlook-for-global-pharmaceuticals-m-a-event-risk-is-rising-1021562771
540.0,4/19/2018 10:00:00 PM,Amgen Announces Webcast Of 2018 First Quarter Financial Results,PR Newswire,/news/stocks/amgen-announces-webcast-of-2018-first-quarter-financial-results-1021609314
541.0,4/24/2018 7:19:44 PM,"FOCUS-Express Scripts targets Amgen, Lilly migraine drugs in pricing shift",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/8K6WF6BYZEY/focus-express-scripts-targets-amgen-lilly-migraine-drugs-in-pricing-shift-idUSL1N1S11CE
542.0,4/24/2018 7:27:34 PM,"Express Scripts targets Amgen, Lilly migraine drugs in pricing shift",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/JQCdNlbJEJU/express-scripts-targets-amgen-lilly-migraine-drugs-in-pricing-shift-idUSKBN1HV2CX
543.0,4/24/2018 10:01:00 PM,Amgen Reports First Quarter 2018 Financial Results,PR Newswire,/news/stocks/amgen-reports-first-quarter-2018-financial-results-1022160608
544.0,4/24/2018 10:07:37 PM,Amgen Inc. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q1-adjusted-earnings-beat-estimates-1022160658
545.0,4/24/2018 10:25:07 PM,Amgen posts higher 1st-quarter profit as sales rise 3 percent,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/noUk7ycyo0g/amgen-posts-higher-1st-quarter-profit-as-sales-rise-3-percent-idUSB8N1HP029
546.0,4/24/2018 10:30:47 PM,Amgen Revises 2018 Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-revises-2018-guidance-quick-facts-1022163725
547.0,4/24/2018 11:15:41 PM,UPDATE 1-Amgen posts higher 1st-quarter profit as sales rise 3 percent,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/LUeH0WYf8Nw/update-1-amgen-posts-higher-1st-quarter-profit-as-sales-rise-3-percent-idUSL1N1S128N
548.0,4/25/2018 12:05:34 AM,UPDATE 2-Amgen posts higher 1st-qtr profit as sales rise 3 pct,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/i7E9no4aXhg/update-2-amgen-posts-higher-1st-qtr-profit-as-sales-rise-3-pct-idUSL1N1S128N
549.0,4/25/2018 3:00:34 AM,UPDATE 3-Amgen expects strong demand for new migraine prevention drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/NLF3bOAn_pw/update-3-amgen-expects-strong-demand-for-new-migraine-prevention-drug-idUSL1N1S128N
550.0,4/25/2018 12:32:16 PM,"BRIEF-Amgen Says In April, Co's Board Increased The Amount Authorized Under Co's Stock Repurchase Program By An Additional $5 Bln - SEC Filing",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/rGdRm4nmMJw/brief-amgen-says-in-april-cos-board-increased-the-amount-authorized-under-cos-stock-repurchase-program-by-an-additional-5-bln-sec-filing-idUSFWN1S20KT
551.0,4/27/2018 3:00:00 PM,Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis,PR Newswire,/news/stocks/amgen-receives-positive-chmp-opinion-to-expand-use-of-prolia-denosumab-to-patients-with-glucocorticoid-induced-osteoporosis-1022545143
552.0,4/27/2018 3:09:16 PM,Amgen Reports Positive CHMP Opinion For Expanded Use Of Prolia - Quick Facts ,RTTNews,/news/stocks/amgen-reports-positive-chmp-opinion-for-expanded-use-of-prolia-quick-facts-1022545213
553.0,4/28/2018 5:35:58 AM,Biotech Stocks Facing FDA Decision In May ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-1022627793
554.0,4/30/2018 3:00:00 PM,Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label,PR Newswire,/news/stocks/amgen-receives-positive-chmp-opinion-to-add-overall-survival-results-from-the-phase-3-aspire-study-to-kyprolis-carfilzomib-label-1022890931
555.0,4/30/2018 3:10:09 PM,BRIEF-Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 Aspire Study To Kyprolis Label,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Sililc-eGao/brief-amgen-receives-positive-chmp-opinion-to-add-overall-survival-results-from-the-phase-3-aspire-study-to-kyprolis-label-idUSFWN1S70RI
556.0,5/2/2018 11:00:00 PM,Noble Corporation plc Reports First Quarter 2018 Results,PR Newswire,/news/stocks/noble-corporation-plc-reports-first-quarter-2018-results-1002353723
557.0,5/10/2018 10:45:00 PM,Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-bank-of-america-merrill-lynch-2018-health-care-conference-1002021071
558.0,5/12/2018 5:44:25 AM,"An Ear To The Pharma: 8 Stocks To Watch (VYGR, BOLD, RXII, CYAD…) ",RTTNews,/news/stocks/an-ear-to-the-pharma-8-stocks-to-watch-vygr-bold-rxii-cyad-1024202578
559.0,5/15/2018 8:07:30 PM,"UPDATE 2-Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/mOOe4s-kCtI/update-2-pfizers-biosimilar-of-amgen-jjs-anemia-treatments-gets-fda-nod-idUSL3N1SM648
560.0,5/16/2018 8:48:18 AM,"LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim ",RTTNews,/news/stocks/lly-gets-headache-relief-xene-abuzz-3rd-time-s-a-charm-for-pfe-s-epogen-biosim-1024665378
561.0,5/16/2018 3:00:00 PM,Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease,PR Newswire,/news/stocks/amgen-receives-european-commission-approval-for-repatha-evolocumab-to-prevent-heart-attack-and-stroke-in-adults-with-established-cardiovascular-disease-1024702112
562.0,5/16/2018 3:12:25 PM,Amgen Receives European Commission Approval For Repatha ,RTTNews,/news/stocks/amgen-receives-european-commission-approval-for-repatha-1024703283
563.0,5/18/2018 1:04:00 AM,"FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention",PR Newswire,/news/stocks/fda-approves-aimovig-erenumab-aooe-a-novel-treatment-developed-specifically-for-migraine-prevention-1024908101
564.0,5/18/2018 1:07:01 AM,"U.S. FDA approves Amgen migraine drug, price set at $6900/yr",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/L5OH7u0ePfk/u-s-fda-approves-amgen-migraine-drug-price-set-at-6900-yr-idUSL2N1SN2IO
565.0,5/18/2018 2:05:28 AM,UPDATE 2-U.S. FDA approves Amgen drug for prevention of migraines,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/7BuTbHic1BM/update-2-u-s-fda-approves-amgen-drug-for-prevention-of-migraines-idUSL2N1SO2I4
566.0,5/18/2018 3:00:36 AM,FDA Approves Amgen's Aimovig For Preventive Treatment Of Migraine In Adults ,RTTNews,/news/stocks/fda-approves-amgen-s-aimovig-for-preventive-treatment-of-migraine-in-adults-1024919155
567.0,5/18/2018 3:42:33 AM,CORRECTED-UPDATE 3-U.S. FDA approves Amgen drug for prevention of migraines,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/WHcUhLAQsSg/corrected-update-3-u-s-fda-approves-amgen-drug-for-prevention-of-migraines-idUSL2N1SO2I4
568.0,5/18/2018 3:59:53 AM,UPDATE 4-U.S. FDA approves Amgen drug for prevention of migraines,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/0HJeKfT85SM/update-4-u-s-fda-approves-amgen-drug-for-prevention-of-migraines-idUSL2N1SP034
569.0,5/18/2018 6:29:00 PM,Novartis AG -- Moody's: Aimovig approval credit positive for Amgen and Novartis,Moodys,/news/bonds/novartis-ag-moody-s-aimovig-approval-credit-positive-for-amgen-and-novartis-1025006144
570.0,5/21/2018 10:00:00 PM,FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis,PR Newswire,/news/stocks/fda-approves-prolia-denosumab-for-glucocorticoid-induced-osteoporosis-1002055729
571.0,5/22/2018 5:11:02 AM,Amgen Says FDA Approves Prolia For Glucocorticoid-Induced Osteoporosis ,RTTNews,/news/stocks/amgen-says-fda-approves-prolia-for-glucocorticoid-induced-osteoporosis-1025076465
572.0,5/22/2018 8:31:46 AM,"It's Raining FDA Approvals, NBRV, SESN Hit Trial Goals But Fail To Make A Mark ",RTTNews,/news/stocks/it-s-raining-fda-approvals-nbrv-sesn-hit-trial-goals-but-fail-to-make-a-mark-1025079420
573.0,5/22/2018 10:45:00 PM,Amgen Announces Voting Results Of Annual Meeting Of Stockholders,PR Newswire,/news/stocks/amgen-announces-voting-results-of-annual-meeting-of-stockholders-1025103724
574.0,5/23/2018 10:00:00 PM,Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment,PR Newswire,/news/stocks/amgen-enters-groundbreaking-collaboration-to-improve-symptom-management-during-cancer-treatment-1002052392
575.0,5/31/2018 10:00:00 PM,"Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers",PR Newswire,/news/stocks/amgen-and-md-anderson-announce-collaboration-to-accelerate-early-stage-treatments-for-leukemia-myelodysplastic-syndromes-multiple-myeloma-small-cell-lung-and-other-small-cell-cancers-1026021167
576.0,6/1/2018 12:15:47 PM,Intelligent Investor - June 1 ,RTTNews,/news/stocks/intelligent-investor-june-1-1026099845
577.0,6/1/2018 2:02:50 PM,Novartis Gets Positive CHMP Opinion For Aimovig For Prevention Of Migraine ,RTTNews,/news/stocks/novartis-gets-positive-chmp-opinion-for-aimovig-for-prevention-of-migraine-1026109851
578.0,6/1/2018 10:00:00 PM,Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients...,PR Newswire,/news/stocks/phase-3-a-r-r-o-w-interim-analysis-shows-once-weekly-70-mg-m2-kyprolis-carfilzomib-regimen-significantly-extended-progression-free-survival-versus-a-twice-weekly-27-mg-m2-regimen-in-patients-1026154761
579.0,6/5/2018 7:18:55 AM,"FDA Approves First Neulasta Biosimilar, HQY Hits New High, TGTX Turns Heads ",RTTNews,/news/stocks/fda-approves-first-neulasta-biosimilar-hqy-hits-new-high-tgtx-turns-heads-1026524068
580.0,6/6/2018 10:00:00 PM,"Amgen, Oklahoma Health Care Authority And University of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes",PR Newswire,/news/stocks/amgen-oklahoma-health-care-authority-and-university-of-oklahoma-s-pharmacy-management-consultants-partner-to-improve-medicaid-outcomes-1026751208
581.0,6/7/2018 10:00:00 PM,Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference-1026787894
582.0,6/8/2018 3:00:00 PM,European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis,PR Newswire,/news/stocks/european-commission-approves-prolia-denosumab-for-patients-with-glucocorticoid-induced-osteoporosis-1001776379
583.0,6/8/2018 3:13:40 PM,Amgen: EC Approves Prolia For Patients With Glucocorticoid-Induced Osteoporosis ,RTTNews,/news/stocks/amgen-ec-approves-prolia-for-patients-with-glucocorticoid-induced-osteoporosis-1026807351
584.0,6/9/2018 2:23:00 AM,/C O R R E C T I O N -- Amgen/,PR Newswire,/news/stocks/c-o-r-r-e-c-t-i-o-n-amgen-1026824528
585.0,6/11/2018 3:00:00 PM,FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label,PR Newswire,/news/stocks/fda-approves-addition-of-positive-overall-survival-data-from-phase-3-aspire-trial-to-kyprolis-carfilzomib-label-1026836369
586.0,6/11/2018 3:18:22 PM,Amgen: FDA Okays Adding Positive OS Data From Phase 3 Aspire Trial To Kyprolis ,RTTNews,/news/stocks/amgen-fda-okays-adding-positive-os-data-from-phase-3-aspire-trial-to-kyprolis-1026836661
587.0,6/13/2018 10:17:00 PM,Natural Grocers expands craft beer and wine offerings to Gresham,PR Newswire,/news/stocks/natural-grocers-expands-craft-beer-and-wine-offerings-to-gresham-451810
588.0,6/19/2018 3:00:00 PM,Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label,PR Newswire,/news/stocks/amgen-receives-european-commission-approval-to-add-overall-survival-data-to-blincyto-blinatumomab-label-1027200359
589.0,6/23/2018 4:09:43 PM,"Amgen: Repatha Significantly Reduces LDL-C, Non-HDL-C In High-risk Patients ",RTTNews,/news/stocks/amgen-repatha-significantly-reduces-ldl-c-non-hdl-c-in-high-risk-patients-1027312365
590.0,6/27/2018 3:19:59 PM,Amgen Reports Top-Line Results From Phase 3 Study Of ABP 710 - Quick Facts ,RTTNews,/news/stocks/amgen-reports-top-line-results-from-phase-3-study-of-abp-710-quick-facts-1027322818
591.0,7/24/2018 3:02:12 PM,Amgen earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/amgen-stock-price-q2-earnings-preview-1027394142
592.0,7/26/2018 10:05:07 PM,Amgen Inc. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q2-adjusted-earnings-beat-estimates-1027404945
593.0,7/26/2018 10:09:13 PM,Amgen quarterly profit beats Wall Street view on new product sales,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/_NUEiS41yA4/amgen-quarterly-profit-beats-wall-street-view-on-new-product-sales-idUSL1N1UJ0OL
594.0,7/26/2018 10:22:20 PM,Amgen Revises Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-revises-guidance-quick-facts-1027405078
595.0,7/26/2018 10:49:24 PM,UPDATE 1-Amgen quarterly profit beats Wall Street view on new product sales,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/zvlqhXNivvk/update-1-amgen-quarterly-profit-beats-wall-street-view-on-new-product-sales-idUSL1N1UM257
596.0,7/26/2018 11:22:37 PM,Amgen CEO says will not raise drug prices again this year,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/uzMJqBeJBW4/amgen-ceo-says-will-not-raise-drug-prices-again-this-year-idUSL1N1UM2B3
597.0,7/26/2018 11:29:05 PM,Amgen CEO says will not raise drug prices again this year,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/CeLedEeo82A/amgen-ceo-says-will-not-raise-drug-prices-again-this-year-idUSKBN1KG316
598.0,7/27/2018 12:30:41 AM,"UPDATE 2-Amgen profit beats Street view, will not raise prices again in 2018",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/z7Luz04SbsY/update-2-amgen-profit-beats-street-view-will-not-raise-prices-again-in-2018-idUSL1N1UM257
599.0,7/27/2018 12:33:53 AM,"Amgen profit beats Street view, will not raise prices again in 2018",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/jWijlUAzWvg/amgen-profit-beats-street-view-will-not-raise-prices-again-in-2018-idUSKBN1KG2WO
600.0,7/30/2018 11:38:29 PM,Novartis Reports EU Approval Of Aimovig - Quick Facts ,RTTNews,/news/stocks/novartis-reports-eu-approval-of-aimovig-quick-facts-1027413475
601.0,8/2/2018 8:09:00 PM,Moody's: US drug makers face heightened pricing pressure as regulatory risks pick up steam,Moodys,/news/bonds/moody-s-us-drug-makers-face-heightened-pricing-pressure-as-regulatory-risks-pick-up-steam-1027427408
602.0,8/27/2018 3:07:12 PM,Amgen Submits SNDA For KYPROLIS - Quick Facts ,RTTNews,/news/stocks/amgen-submits-snda-for-kyprolis-quick-facts-1027486822
603.0,8/29/2018 3:17:45 PM,Amgen Says EC Oks Expanded Indication For BLINCYTO ,RTTNews,/news/stocks/amgen-says-ec-oks-expanded-indication-for-blincyto-1027493895
604.0,8/30/2018 8:35:32 AM,"MESO Awaits Next Catalyst, EC Nod For Blincyto, EOLS, BHC To Face FDA In Feb. ",RTTNews,/news/stocks/meso-awaits-next-catalyst-ec-nod-for-blincyto-eols-bhc-to-face-fda-in-feb-1027495760
605.0,9/7/2018 8:07:16 AM,"AstraZeneca, Amgen Announce Breakthrough Therapy Designation For Tezepelumab ",RTTNews,/news/stocks/astrazeneca-amgen-announce-breakthrough-therapy-designation-for-tezepelumab-1027516159
606.0,9/21/2018 3:38:51 PM,Mylan & Biocon: CHMP Issues Positive Opinion Recommending Approval Of Fulphila ,RTTNews,/news/stocks/mylan-biocon-chmp-issues-positive-opinion-recommending-approval-of-fulphila-1027555010
607.0,9/25/2018 3:26:16 AM,Amgen : Japan Oks Blincyto For Treatment Of Relapsed Or Refractory B-cell ALL ,RTTNews,/news/stocks/amgen-japan-oks-blincyto-for-treatment-of-relapsed-or-refractory-b-cell-all-1027560464
608.0,9/25/2018 7:08:19 AM,"FDA Nod For VSTM, ANAB Breathes Easy, GEMP Trims Workforce By 33% ",RTTNews,/news/stocks/fda-nod-for-vstm-anab-breathes-easy-gemp-trims-workforce-by-33-1027560711
609.0,10/1/2018 3:12:24 PM,Amgen: FDA Approves KYPROLIS Once-Weekly In Combination With Dexamethasone ,RTTNews,/news/stocks/amgen-fda-approves-kyprolis-once-weekly-in-combination-with-dexamethasone-1027579391
610.0,10/4/2018 9:19:00 AM,"Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US",Moodys,/news/bonds/moody-s-biosimilars-a-growing-challenge-biotech-drugs-with-european-market-developing-more-quickly-than-the-us-1027589140
611.0,10/16/2018 6:24:22 AM,Amgen Launches AMGEVIT In Markets Across Europe - Quick Facts ,RTTNews,/news/stocks/amgen-launches-amgevit-in-markets-across-europe-quick-facts-1027618775
612.0,10/16/2018 2:28:50 PM,"Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/D7Uaz3n9gQM/amgen-novartis-kick-off-fight-for-abbvie-blockbuster-drug-in-eu-idUSL8N1WW26J
613.0,10/17/2018 1:11:37 PM,"Exclusive: Express Scripts covers Amgen, Lilly migraine therapies, excludes Teva drug",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/coPHxSBg1aw/exclusive-express-scripts-covers-amgen-lilly-migraine-therapies-excludes-teva-drug-idUSKCN1MR1IT
614.0,10/17/2018 5:24:21 PM,"Exclusive: Express Scripts covers Amgen, Lilly migraine therapies, excludes Teva drug",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/Y3WzXrQEpn8/exclusive-express-scripts-covers-amgen-lilly-migraine-therapies-excludes-teva-drug-idINKCN1MR2BV
615.0,10/17/2018 7:35:53 PM,"UPDATE 1-Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/4tSMtTSKhLs/update-1-express-scripts-covers-amgen-lilly-migraine-drugs-excludes-teva-idUSL2N1WX10K
616.0,10/17/2018 7:38:55 PM,"Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/mLB-xmqEwlw/express-scripts-covers-amgen-lilly-migraine-drugs-excludes-teva-idUSKCN1MR1IT
617.0,10/17/2018 7:46:29 PM,"Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/-O6p6HCPuXA/express-scripts-covers-amgen-lilly-migraine-drugs-excludes-teva-idINKCN1MR2BV
618.0,10/17/2018 7:59:49 PM,"Exclusive: Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/YwseeWhJIPY/exclusive-express-scripts-covers-amgen-lilly-migraine-drugs-excludes-teva-idINKCN1MR2BV
619.0,10/24/2018 10:06:48 PM,Amgen cuts price of cholesterol drug Repatha by 60 percent,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/U-in5QDy9KQ/amgen-cuts-price-of-cholesterol-drug-repatha-by-60-percent-idUSL2N1X41K6
620.0,10/24/2018 10:29:46 PM,Amgen cuts price of cholesterol drug Repatha by 60 percent,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/jP0R5y_KVBs/amgen-cuts-price-of-cholesterol-drug-repatha-by-60-percent-idINKCN1MY2VP
621.0,10/25/2018 12:48:38 AM,UPDATE 1-Amgen cuts U.S. price of cholesterol drug Repatha by 60 percent,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/D6adzqB2EEU/update-1-amgen-cuts-u-s-price-of-cholesterol-drug-repatha-by-60-percent-idUSL2N1X41ZG
622.0,10/25/2018 12:49:31 AM,Amgen cuts U.S. price of cholesterol drug Repatha by 60 percent,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/AbHzgAAIoaM/amgen-cuts-u-s-price-of-cholesterol-drug-repatha-by-60-percent-idINKCN1MY2VP
623.0,10/28/2018 3:02:07 PM,Here's what to expect from Amgen's earnings report,Markets Insider Automation,/news/stocks/amgen-stock-quarter-earnings-preview-q3-1027662252
624.0,10/30/2018 9:04:45 PM,Amgen quarterly net profit falls as expenses increase; EPS rises,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/D_9gNyetB70/amgen-quarterly-net-profit-falls-as-expenses-increase-eps-rises-idUSL2N1XA1ON
625.0,10/30/2018 9:05:14 PM,Amgen Inc. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q3-adjusted-earnings-beat-estimates-1027673071
626.0,10/30/2018 9:30:57 PM,Amgen Raises Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-raises-guidance-quick-facts-1027673170
627.0,10/30/2018 10:28:59 PM,"UPDATE 1-Amgen quarterly EPS rises, income falls as expenses increase",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/79RV5_WHQx4/update-1-amgen-quarterly-eps-rises-income-falls-as-expenses-increase-idUSL2N1XA1VJ
628.0,10/31/2018 12:12:47 AM,"UPDATE 2-Amgen posts higher quarterly EPS, Repatha sales fall short",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/PdyLOsYWz_U/update-2-amgen-posts-higher-quarterly-eps-repatha-sales-fall-short-idUSL2N1XA1VJ
629.0,12/3/2018 6:07:04 AM,"XLRN On Watch, BPMC Makes An Imprint, Osteoporosis Drug Evenity Faces FDA Panel ",RTTNews,/news/stocks/xlrn-on-watch-bpmc-makes-an-imprint-osteoporosis-drug-evenity-faces-fda-panel-1027773491
630.0,12/4/2018 6:20:38 AM,"UPDATE 1-Amgen antibody shows promise in myeloma trial, gets FDA fast track",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/7VhkAmBdBi8/update-1-amgen-antibody-shows-promise-in-myeloma-trial-gets-fda-fast-track-idUSL1N1Y903B
631.0,12/17/2018 3:30:27 PM,Amgen Submits BLA For ABP 710 To FDA - Quick Facts ,RTTNews,/news/stocks/amgen-submits-bla-for-abp-710-to-fda-quick-facts-1027814392
632.0,12/19/2018 5:08:15 AM,Amgen And Molecular Partners Collaborate In Immuno-Oncology ,RTTNews,/news/stocks/amgen-and-molecular-partners-collaborate-in-immuno-oncology-1027819628
633.0,12/19/2018 9:02:14 AM,Molecular Partners agrees cancer immunotherapy deal with Amgen,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Sf7JgvIFYnY/molecular-partners-agrees-cancer-immunotherapy-deal-with-amgen-idUSL8N1YO13Z
634.0,12/24/2018 11:13:44 AM,Biotech Stocks Facing FDA Decision In January 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2019-1027831124
635.0,1/3/2019 2:32:51 AM,"Teva, Amgen Settle Dispute Over Teva's Generic Cinacalet HCl Product ",RTTNews,/news/stocks/teva-amgen-settle-dispute-over-teva-s-generic-cinacalet-hcl-product-1027840419
636.0,1/3/2019 3:25:35 AM,CORRECTED-BRIEF-Teva And Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalcet HCl Product,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/g3oGNHrAU98/idUSFWN1Z2086
637.0,1/3/2019 3:30:58 AM,"Teva, Amgen end dispute over generic Cinacalcet HCl tablets",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Icam4zAakbA/teva-amgen-end-dispute-over-generic-cinacalcet-hcl-tablets-idUSL3N1Z314F
638.0,1/3/2019 3:33:40 AM,"Teva, Amgen end dispute over generic Cinacalcet HCl tablets",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/hLLDPRqNNbQ/teva-amgen-end-dispute-over-generic-cinacalcet-hcl-tablets-idUSKCN1OX05E
639.0,1/7/2019 3:47:12 PM,U.S. Supreme Court rejects Amgen over cholesterol medication patent fight,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/VqP-S04Pvzc/u-s-supreme-court-rejects-amgen-over-cholesterol-medication-patent-fight-idUSW1N1TK00R
640.0,1/7/2019 3:55:18 PM,UPDATE 1-U.S. Supreme Court rejects Amgen over cholesterol medication patent fight,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/O2gbj2W9ENY/update-1-u-s-supreme-court-rejects-amgen-over-cholesterol-medication-patent-fight-idUSL1N1Z70LG
641.0,1/7/2019 4:34:50 PM,UPDATE 2-U.S. top court rejects Amgen over cholesterol medication patent fight,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2lQqE5cHHU0/update-2-u-s-top-court-rejects-amgen-over-cholesterol-medication-patent-fight-idUSL1N1Z70LG
642.0,1/7/2019 4:36:39 PM,U.S. top court rejects Amgen over cholesterol medication patent fight,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/rc687tZk5rw/u-s-top-court-rejects-amgen-over-cholesterol-medication-patent-fight-idUSKCN1P11FT
643.0,1/7/2019 7:26:49 PM,UPDATE 3-U.S. top court rejects Amgen over cholesterol medication patent fight,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SFkU5SZ4IZc/update-3-u-s-top-court-rejects-amgen-over-cholesterol-medication-patent-fight-idUSL1N1Z70LG
644.0,1/7/2019 8:25:21 PM,UPDATE 4-U.S. top court rejects Amgen over cholesterol medication patent fight,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/0k6_qOMWDhM/update-4-u-s-top-court-rejects-amgen-over-cholesterol-medication-patent-fight-idUSL1N1Z70LG
645.0,1/9/2019 8:22:53 AM,Japan Approves Amgen/UCB's Osteoporosis Drug - Will U.S. Follow Suit? ,RTTNews,/news/stocks/japan-approves-amgen-ucb-s-osteoporosis-drug-will-u-s-follow-suit-1027853966
646.0,1/17/2019 7:00:29 AM,"FDA Panel Nod For Osteoporosis Drug, PTIE Gets Research Funding, ALDR On Watch ",RTTNews,/news/stocks/fda-panel-nod-for-osteoporosis-drug-ptie-gets-research-funding-aldr-on-watch-1027874944
647.0,1/24/2019 3:19:26 PM,Amgen : ABP 798 Study Meets Primary Endpoint Of Pharmacokinetic Similarity ,RTTNews,/news/stocks/amgen-abp-798-study-meets-primary-endpoint-of-pharmacokinetic-similarity-1027893594
648.0,1/25/2019 8:31:32 PM,"Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/a-dUHMFdkyU/exclusive-cvs-to-cover-migraine-drugs-from-teva-lilly-excludes-amgen-idUSKCN1PJ2CX
649.0,1/27/2019 3:01:29 PM,Here's what Wall Street expects from Amgen's earnings,Markets Insider Automation,/news/stocks/amgen-stock-price-quarter-earnings-preview-q4-1027898623
650.0,1/29/2019 10:04:22 PM,Amgen Inc. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q4-adjusted-earnings-beat-estimates-1027906547
651.0,1/29/2019 10:05:33 PM,"Amgen quarterly profit tops Street view, 2019 forecast falls short",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/kkw9G7C9gMQ/amgen-quarterly-profit-tops-street-view-2019-forecast-falls-short-idUSKCN1PN2U5
652.0,1/29/2019 10:53:46 PM,"UPDATE 1-Amgen 2019 forecast falls short of expectations, shares dip",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5zWOUnd8dno/update-1-amgen-2019-forecast-falls-short-of-expectations-shares-dip-idUSL1N1ZT1TC
653.0,1/29/2019 10:56:44 PM,"Amgen 2019 forecast falls short of expectations, shares dip",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/-fjkcci_gP4/amgen-2019-forecast-falls-short-of-expectations-shares-dip-idUSKCN1PN2U5
654.0,1/30/2019 12:47:27 AM,"UPDATE 2-Amgen 2019 forecast falls short of expectations, shares dip",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/iwZB3XBLTR0/update-2-amgen-2019-forecast-falls-short-of-expectations-shares-dip-idUSL1N1ZT1TC
655.0,2/7/2019 3:36:00 PM,Moody's -  Accelerating efforts to lower drug prices raise financial risk for drug companies,Moodys,/news/bonds/moody-s-accelerating-efforts-to-lower-drug-prices-raise-financial-risk-for-drug-companies-1027934159
656.0,2/15/2019 10:12:00 PM,Amgen Inc. -- Moody's announces completion of a periodic review of ratings of Amgen Inc.,Moodys,/news/bonds/amgen-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-amgen-inc-1027957878
657.0,2/25/2019 10:23:34 PM,"Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/4yc7T7L3fZA/sanofi-regeneron-lose-u-s-patent-challenge-to-amgen-cholesterol-drug-idUSL1N20K1KF
658.0,2/25/2019 10:36:35 PM,"UPDATE 1-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug -report",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/TIBd1vGxdEs/update-1-sanofi-regeneron-lose-u-s-patent-challenge-to-amgen-cholesterol-drug-report-idUSL1N20K1LT
659.0,2/25/2019 11:13:40 PM,Amgen: Delaware Jury Upholds Validity Of Two Patents Related To PCSK9 Antibodies ,RTTNews,/news/stocks/amgen-delaware-jury-upholds-validity-of-two-patents-related-to-pcsk9-antibodies-1027981762
660.0,2/25/2019 11:25:35 PM,"CORRECTED-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/xI6it7I0qOw/corrected-sanofi-regeneron-lose-u-s-patent-challenge-to-amgen-cholesterol-drug-idUSL1N20K1KF
661.0,2/25/2019 11:28:17 PM,"CORRECTED-UPDATE 1-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug -report",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/so7_N6KgBoA/corrected-update-1-sanofi-regeneron-lose-u-s-patent-challenge-to-amgen-cholesterol-drug-report-idUSL1N20K1LT
662.0,2/25/2019 11:47:33 PM,"UPDATE 2-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/1TtJ0HTMmJg/update-2-sanofi-regeneron-lose-u-s-patent-challenge-to-amgen-cholesterol-drug-idUSL1N20K1UL
663.0,4/4/2019 5:35:40 PM,Novartis sues Amgen over migraine treatment Aimovig,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/a6MEg2Jg1F4/novartis-sues-amgen-over-migraine-treatment-aimovig-idUSL1N21M0TI
664.0,4/4/2019 6:13:14 PM,UPDATE 1-Novartis sues Amgen over migraine treatment Aimovig,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5LO5u1jf0bo/update-1-novartis-sues-amgen-over-migraine-treatment-aimovig-idUSL1N21M0VC
665.0,4/4/2019 8:04:44 PM,UPDATE 2-Novartis sues Amgen over collaboration on migraine treatment Aimovig,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/lX6pM4XhaeA/update-2-novartis-sues-amgen-over-collaboration-on-migraine-treatment-aimovig-idUSL1N21M0VC
666.0,4/4/2019 11:16:55 PM,"UPDATE 3-Novartis, Amgen in dispute over migraine drug partnership",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/x4ZHxR7Y4aI/update-3-novartis-amgen-in-dispute-over-migraine-drug-partnership-idUSL1N21M0VC
667.0,4/10/2019 12:27:18 AM,FDA Approves Amgen's Osteoporosis Drug Evenity ,RTTNews,/news/stocks/fda-approves-amgen-s-osteoporosis-drug-evenity-1028098259
668.0,4/15/2019 10:03:30 PM,"Amgen sets $21,900 annual price for new Evenity bone drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/uEoLr5iYf2M/amgen-sets-21900-annual-price-for-new-evenity-bone-drug-idUSL1N21X0QW
669.0,4/25/2019 3:59:38 PM,"Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/gKZrkG2UZ4k/drugmakers-astellas-amgen-to-pay-125-mln-in-u-s-charity-kickback-probe-idUSL1N2270OV
670.0,4/25/2019 4:04:32 PM,"AbbVie says Humira rivals from Biogen, Amgen most aggressive so far",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/CZwtzCsvXk8/abbvie-says-humira-rivals-from-biogen-amgen-most-aggressive-so-far-idUSKCN1S11TS
671.0,4/25/2019 4:09:20 PM,"UPDATE 1-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/vQl_aqSkA3Q/update-1-drugmakers-astellas-amgen-to-pay-125-mln-in-u-s-charity-kickback-probe-idUSL1N2270PG
672.0,4/25/2019 4:24:36 PM,"Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/zB4qcKnDKlo/drugmakers-astellas-amgen-to-pay-125-million-in-u-s-charity-kickback-probe-idUSKCN1S11TL
673.0,4/25/2019 5:33:53 PM,"UPDATE 2-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/reEdnTroO9U/update-2-drugmakers-astellas-amgen-to-pay-125-mln-in-u-s-charity-kickback-probe-idUSL1N2270PG
674.0,4/25/2019 11:00:08 PM,"UPDATE 3-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/P1y4CO1Shto/update-3-drugmakers-astellas-amgen-to-pay-125-mln-in-u-s-charity-kickback-probe-idUSL1N2270PG
675.0,4/29/2019 3:02:37 PM,Amgen earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/amgen-quarter-earnings-preview-q1-1028148525
676.0,4/30/2019 10:04:44 PM,Amgen Inc. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q1-adjusted-earnings-beat-estimates-1028155664
677.0,4/30/2019 10:05:31 PM,"Amgen revenue flat for first quarter, Aimovig, Repatha fall short of sales expectations",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Hvut3Hz8KL4/amgen-revenue-flat-for-first-quarter-aimovig-repatha-fall-short-of-sales-expectations-idUSL1N22C133
678.0,4/30/2019 10:26:43 PM,Amgen Updates Earnings Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-updates-earnings-guidance-quick-facts-1028155840
679.0,4/30/2019 11:02:32 PM,"UPDATE 1-Amgen revenue flat as migraine, cholesterol drugs miss sales expectations",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wTD3bbc7SNM/update-1-amgen-revenue-flat-as-migraine-cholesterol-drugs-miss-sales-expectations-idUSL1N22C1VR
680.0,5/1/2019 1:25:42 AM,"UPDATE 2-Amgen revenue flat as migraine, cholesterol drugs miss sales expectations",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/cDVdIxRZy9c/update-2-amgen-revenue-flat-as-migraine-cholesterol-drugs-miss-sales-expectations-idUSL1N22C1VR
681.0,5/10/2019 9:10:44 PM,Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wG-noU5OgVE/lillys-new-migraine-drug-pulls-ahead-of-amgen-in-fierce-battle-for-new-prescriptions-idUSL2N22M1D9
682.0,5/10/2019 9:50:27 PM,UPDATE 1-Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-_ZxHTUOHWE/update-1-lillys-new-migraine-drug-pulls-ahead-of-amgen-in-fierce-battle-for-new-prescriptions-idUSL2N22M1NX
683.0,5/22/2019 8:19:03 AM,Amgen Offers To Buy Nuevolution For SEK 32.50/shr In Cash - Quick Facts ,RTTNews,/news/stocks/amgen-offers-to-buy-nuevolution-for-sek-32-50-shr-in-cash-quick-facts-1028220291
684.0,5/22/2019 9:23:41 AM,Amgen offers to buy Copenhagen-based Nuevolution for $167 mln,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/yrDB1383Dp0/amgen-offers-to-buy-copenhagen-based-nuevolution-for-167-mln-idUSL4N22Y1Y2
685.0,6/3/2019 3:28:27 PM,Amgen drug shows high response rate in small lung and colon cancer trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/TlWgNxBZ7Ig/amgen-drug-shows-high-response-rate-in-small-lung-and-colon-cancer-trial-idUSL2N2371CM
686.0,6/3/2019 3:28:36 PM,Amgen Reports Positive Data From AMG 510 Early Phase 1 Study - Quick Facts ,RTTNews,/news/stocks/amgen-reports-positive-data-from-amg-510-early-phase-1-study-quick-facts-1028249094
687.0,6/3/2019 5:11:27 PM,UPDATE 1-Amgen drug shows high response rate in small lung and colon cancer trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5Idjv93SMuY/update-1-amgen-drug-shows-high-response-rate-in-small-lung-and-colon-cancer-trial-idUSL2N23A0ND
688.0,6/4/2019 5:50:15 PM,Sanofi loses German patent case against Amgen over cholesterol drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ITV9REphZvc/sanofi-loses-german-patent-case-against-amgen-over-cholesterol-drug-idUSL8N23B1RV
689.0,6/5/2019 8:13:00 PM,10 Stocks to Buy That Could Be Takeover Targets,InvestorPlace,/news/stocks/10-stocks-to-buy-that-could-be-takeover-targets-1028258474
690.0,6/6/2019 7:13:05 PM,5 Healthcare Stocks to Pick Up From the Wreckage,InvestorPlace,/news/stocks/5-healthcare-stocks-to-pick-up-from-the-wreckage-1028262327
691.0,6/13/2019 9:22:00 AM,"Moody's – Acquisitions to continue in global pharmaceutical industry, with acquirers having good M&A capacity",Moodys,/news/bonds/moody-s-acquisitions-to-continue-in-global-pharmaceutical-industry-with-acquirers-having-good-m-a-capacity-1028275877
692.0,6/14/2019 5:01:00 AM,"FDA Okays Amgen And Allergan's Kanjinti, Biosimilar To Herceptin ",RTTNews,/news/stocks/fda-okays-amgen-and-allergan-s-kanjinti-biosimilar-to-herceptin-1028278969
693.0,6/16/2019 3:54:45 PM,Amgen Presents BLINCYTO Five-Year Overall Survival Data ,RTTNews,/news/stocks/amgen-presents-blincyto-five-year-overall-survival-data-1028282032
694.0,6/19/2019 3:49:28 PM,3 Large-Cap Biotech Stocks to Buy for Massive Gains,InvestorPlace,/news/stocks/3-large-cap-biotech-stocks-to-buy-for-massive-gains-1028293605
695.0,6/28/2019 7:21:03 AM,Amgen Receives Negative CHMP Opinion For EVENITY To Treat Severe Osteoporosis ,RTTNews,/news/stocks/amgen-receives-negative-chmp-opinion-for-evenity-to-treat-severe-osteoporosis-1028315959
696.0,7/12/2019 4:17:50 AM,"Novartis, Amgen Abandon Alzheimer's Prevention Study ",RTTNews,/news/stocks/novartis-amgen-abandon-alzheimer-s-prevention-study-1028347825
697.0,7/28/2019 3:01:56 PM,Amgen earnings: here's what to expect,Markets Insider Automation,/news/stocks/amgen-stock-price-quarter-earnings-preview-q2-1028391015
698.0,7/30/2019 10:05:08 PM,Amgen quarterly revenue dips 3% but profit tops Street expectations,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/v0fKyEapvqg/amgen-quarterly-revenue-dips-3-but-profit-tops-street-expectations-idUSL2N24R17O
699.0,7/30/2019 10:05:12 PM,Amgen Inc. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q2-adjusted-earnings-beat-estimates-1028400326
700.0,7/30/2019 10:37:38 PM,"UPDATE 1-Amgen quarterly results beat estimates, but revenue dips 3%",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/NRpiEEsZSew/update-1-amgen-quarterly-results-beat-estimates-but-revenue-dips-3-idUSL2N24V1BD
701.0,7/30/2019 11:05:12 PM,"Amgen quarterly results beat estimates, but revenue dips 3%",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/sa2TAtl3DQA/amgen-quarterly-results-beat-estimates-but-revenue-dips-3-idUSKCN1UP2F0
702.0,7/30/2019 11:51:27 PM,"UPDATE 2-Amgen results beat estimates, cancer drug shows wider activity",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/T7xPh97KBhk/update-2-amgen-results-beat-estimates-cancer-drug-shows-wider-activity-idUSL2N24V1BD
703.0,7/30/2019 11:54:33 PM,"Amgen results beat estimates, cancer drug shows wider activity",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/CieMmwqR4uU/amgen-results-beat-estimates-cancer-drug-shows-wider-activity-idUSKCN1UP2F0
704.0,7/31/2019 1:02:17 AM,"UPDATE 3-Amgen results beat estimates, lung cancer trial planned",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/jiQrXaDT5yw/update-3-amgen-results-beat-estimates-lung-cancer-trial-planned-idUSL2N24V1BD
705.0,7/31/2019 1:12:43 AM,"Amgen results beat estimates, lung cancer trial planned",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/4PpMfMqUW6U/amgen-results-beat-estimates-lung-cancer-trial-planned-idUSKCN1UP2F0
706.0,8/5/2019 9:59:25 PM,9 Catalysts That Will Drive Chinese Biotech Stocks Much Higher,InvestorPlace,/news/stocks/9-catalysts-chinese-biotech-stocks-1028419250
707.0,8/7/2019 4:36:00 PM,"Moody's – Latest proposals to reduce drug prices extend social, financial risk for US drug industry",Moodys,/news/bonds/moody-s-latest-proposals-to-reduce-drug-prices-extend-social-financial-risk-for-us-drug-industry-1028427249
708.0,8/12/2019 5:08:10 AM,Sandoz To Appeal U.S. Court Ruling In Biosimilar Erelzi U.S. Patent Case ,RTTNews,/news/stocks/sandoz-to-appeal-u-s-court-ruling-in-biosimilar-erelzi-u-s-patent-case-1028436450
709.0,8/14/2019 1:36:23 PM,"Wednesday’s Vital Data: Amgen, American Airlines and Apple",InvestorPlace,/news/stocks/wednesdays-vital-data-amgen-american-airlines-and-apple-1028447976
710.0,8/22/2019 3:23:39 PM,Amgen: ABP 798 Shows Clinical Equivalence To Rituxan In Clinical Study ,RTTNews,/news/stocks/amgen-abp-798-shows-clinical-equivalence-to-rituxan-in-clinical-study-1028466712
711.0,8/23/2019 9:08:35 AM,"ALXN & Takeover Rumors, AMGN's JASMINE Blooms, CLSD Sees The Writing On The Wall ",RTTNews,/news/stocks/alxn-takeover-rumors-amgn-s-jasmine-blooms-clsd-sees-the-writing-on-the-wall-1028468788
712.0,8/26/2019 12:46:25 PM,Amgen to buy Celgene's psoriasis drug Otezla for $13.4 billion in cash,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/8ma6CvRKqxA/amgen-to-buy-celgenes-psoriasis-drug-otezla-for-13-4-billion-in-cash-idUSKCN1VG102
713.0,8/26/2019 1:04:31 PM,Amgen To Acquire Otezla For $13.4 Billion In Cash - Quick Facts ,RTTNews,/news/stocks/amgen-to-acquire-otezla-for-13-4-billion-in-cash-quick-facts-1028472744
714.0,8/26/2019 1:11:15 PM,Celgene to sell psoriasis drug Otezla for $13.4 billion to Amgen,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/t_TjqGFKNDE/celgene-to-sell-psoriasis-drug-otezla-for-13-4-billion-to-amgen-idUSKCN1VG102
715.0,8/26/2019 2:16:22 PM,Amgen to buy Celgene's psoriasis drug Otezla for $13.4 billion in cash,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/rOZ4-4HZUV0/amgen-to-buy-celgenes-psoriasis-drug-otezla-for-13-4-billion-in-cash-idINKCN1VG19T
716.0,8/26/2019 3:51:06 PM,"Amgen will buy a blockbuster psoriasis drug for $13.4 billion — and it's part of a plan to get Celgene's mega-merger with Bristol-Myers Squibb approved (AMGN, CELG, BMY)",Business Insider,https://www.businessinsider.com/amgen-buys-celgene-psoriasis-drug-for-13-billion-antitrust-implications-2019-8
717.0,8/26/2019 4:45:33 PM,Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/BHWkucK3-gU/amgen-to-buy-celgene-psoriasis-drug-otezla-for-13-4-billion-idUSKCN1VG102
718.0,8/26/2019 4:46:13 PM,Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/KEvTed9r5pc/amgen-to-buy-celgene-psoriasis-drug-otezla-for-13-4-billion-idINKCN1VG19T
719.0,8/26/2019 5:53:32 PM,Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen,InvestorPlace,/news/stocks/celgene-news-has-celg-stock-up-1028475034
720.0,8/26/2019 7:32:00 PM,"5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY",InvestorPlace,/news/stocks/top-stock-trades-bmy-amgn-nflx-acb-fl-1028475024
721.0,8/26/2019 8:34:50 PM,"Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks",InvestorPlace,/news/stocks/stock-market-today-biotech-in-focus-trade-talks-steady-stocks-1028475022
722.0,8/26/2019 10:30:00 PM,Amgen Inc. -- Moody's: Amgen's Otezla acquisition brings high-growth asset but at a rich price,Moodys,/news/bonds/amgen-inc-moody-s-amgen-s-otezla-acquisition-brings-high-growth-asset-but-at-a-rich-price-1028474493
723.0,8/27/2019 2:55:00 PM,Amgen to Buy Celgene’s Otezla for $13.4B: Is the Deal Good for Amgen Stock?,InvestorPlace,/news/stocks/amgen-to-buy-celgenes-otezla-for-13-4b-is-the-deal-good-for-amgen-stock-1028482720
724.0,8/27/2019 3:01:27 PM,4 Biotech Stocks to Buy That Are on the Move,InvestorPlace,/news/stocks/4-biotech-stocks-to-buy-that-are-on-the-move-1028478921
725.0,8/28/2019 9:31:28 PM,U.S. judge rules for Sanofi in Amgen patent fight,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/gjAmXDhLLxQ/u-s-judge-rules-for-sanofi-in-amgen-patent-fight-idUSL2N25O1C0
726.0,8/28/2019 9:41:38 PM,UPDATE 1-U.S. judge rules for Sanofi in Amgen patent fight,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/sO1uDwEsNTk/update-1-u-s-judge-rules-for-sanofi-in-amgen-patent-fight-idUSL2N25O1DP
727.0,8/28/2019 10:13:51 PM,UPDATE 2-U.S. judge rules for Sanofi in Amgen patent fight,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/prRWADhWnfk/update-2-u-s-judge-rules-for-sanofi-in-amgen-patent-fight-idUSL2N25O1DP
728.0,8/28/2019 10:18:05 PM,U.S. judge rules for Sanofi in Amgen patent fight,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/yIRo-xjXlTI/u-s-judge-rules-for-sanofi-in-amgen-patent-fight-idINKCN1VI2GM
729.0,8/28/2019 10:49:47 PM,"UPDATE 3-U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/iPhAaw9LgQU/update-3-u-s-judge-rules-for-regeneron-sanofi-in-amgen-cholesterol-drug-patent-fight-idUSL2N25O1DP
730.0,8/28/2019 10:51:52 PM,"U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/4GYKdJmBzOM/u-s-judge-rules-for-regeneron-sanofi-in-amgen-cholesterol-drug-patent-fight-idUSKCN1VI2E9
731.0,8/28/2019 10:55:21 PM,"U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/-GPYyiS2c_Y/u-s-judge-rules-for-regeneron-sanofi-in-amgen-cholesterol-drug-patent-fight-idINKCN1VI2GM
732.0,9/8/2019 9:45:00 AM,Amgen drug shrinks lung cancer tumors in half of patients -study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/qXcFKVTBmGE/amgen-drug-shrinks-lung-cancer-tumors-in-half-of-patients-study-idUSL2N25V1E4
733.0,9/8/2019 3:52:11 PM,Amgen Drug Shrinks 54% Of Lung Cancer Tumors In Study ,RTTNews,/news/stocks/amgen-drug-shrinks-54-of-lung-cancer-tumors-in-study-1028507060
734.0,9/9/2019 7:44:46 AM,Novartis: Aimovig Shows Long-term Efficacy In Treatment Of Episodic Migraine ,RTTNews,/news/stocks/novartis-aimovig-shows-long-term-efficacy-in-treatment-of-episodic-migraine-1028507547
735.0,9/10/2019 2:55:17 PM,10 Healthcare Stocks to Buy Despite the Headlines,InvestorPlace,/news/stocks/10-healthcare-stocks-to-buy-despite-the-headlines-1028514931
736.0,9/13/2019 3:10:57 PM,Amgen's Phase 3 CANDOR Study Meets Primary Endpoint Of PFS - Quick Facts ,RTTNews,/news/stocks/amgen-s-phase-3-candor-study-meets-primary-endpoint-of-pfs-quick-facts-1028523295
737.0,9/27/2019 7:34:40 PM,7 Big Biotech Stocks to Watch,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-watch-1028560645
738.0,9/28/2019 7:30:00 AM,Low response rate reported for Amgen targeted drug in colon cancer trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/eGfi-RBQVEc/low-response-rate-reported-for-amgen-targeted-drug-in-colon-cancer-trial-idUSL2N26F1N8
739.0,9/28/2019 4:59:17 PM,UPDATE 1-Targeted Amgen drug has low response rate in colon cancer in study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/CjgTi6c3y-0/update-1-targeted-amgen-drug-has-low-response-rate-in-colon-cancer-in-study-idUSL2N26J04J
740.0,10/18/2019 7:18:18 AM,Amgen : EVENITY Gets Positive CHMP Opinion For Treatment Of Severe Osteoporosis ,RTTNews,/news/stocks/amgen-evenity-gets-positive-chmp-opinion-for-treatment-of-severe-osteoporosis-1028609784
741.0,10/18/2019 3:16:37 PM,Amgen: FDA Approves Earlier Use Of Nplate To Treat Immune Thrombocytopenia ,RTTNews,/news/stocks/amgen-fda-approves-earlier-use-of-nplate-to-treat-immune-thrombocytopenia-1028611063
742.0,10/18/2019 3:30:03 PM,3 Earnings Reports to Watch Next Week,InvestorPlace,/news/stocks/earnings-reports-to-watch-next-week-earnings-calendar-1028224242
743.0,10/23/2019 6:21:43 AM,"Amgen Appoints Peter Griffith As CFO, Succeeding David Meline, Effective Jan. 1 ",RTTNews,/news/stocks/amgen-appoints-peter-griffith-as-cfo-succeeding-david-meline-effective-jan-1-1028621331
744.0,10/24/2019 3:19:17 PM,Amgen Decides To Discontinue Original List Price Option For Repatha ,RTTNews,/news/stocks/amgen-decides-to-discontinue-original-list-price-option-for-repatha-1028627867
745.0,10/24/2019 3:20:18 PM,Amgen slashes price tag on cholesterol medicine Repatha by 60% for 2020,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SXK_gnSQUyU/amgen-slashes-price-tag-on-cholesterol-medicine-repatha-by-60-for-2020-idUSL3N2793WA
746.0,10/24/2019 4:30:06 PM,UPDATE 1-Amgen sets one lower list price for its cholesterol drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Gt792fl3Uyc/update-1-amgen-sets-one-lower-list-price-for-its-cholesterol-drug-idUSL3N2793YE
747.0,10/29/2019 9:04:44 PM,Amgen Inc. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q3-adjusted-earnings-beat-estimates-1028641208
748.0,10/29/2019 9:07:52 PM,"Amgen third-quarter revenue falls 3%, biosimilar sales rise",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/CGlmnc4GMKw/amgen-third-quarter-revenue-falls-3-biosimilar-sales-rise-idUSL2N27E18Y
749.0,10/29/2019 9:12:30 PM,"Amgen third-quarter revenue falls 3%, biosimilar sales rise",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/yeVAiEV3TFE/amgen-third-quarter-revenue-falls-3-biosimilar-sales-rise-idUSKBN1X82GQ
750.0,10/29/2019 9:30:29 PM,Amgen Updates Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-updates-guidance-quick-facts-1028641341
751.0,10/29/2019 10:12:09 PM,"UPDATE 1-Amgen third-quarter revenue falls 3%, biosimilar sales rise",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/flJzrzfhOK0/update-1-amgen-third-quarter-revenue-falls-3-biosimilar-sales-rise-idUSL2N27E1FJ
752.0,10/29/2019 10:16:21 PM,"Amgen third-quarter revenue falls 3%, biosimilar sales rise",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/67TuCaC8biY/amgen-third-quarter-revenue-falls-3-biosimilar-sales-rise-idINKBN1X82GS
753.0,10/29/2019 11:49:59 PM,"UPDATE 2-Amgen posts higher biosimilar sales, ends neuroscience program",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/h8uNAggupds/update-2-amgen-posts-higher-biosimilar-sales-ends-neuroscience-program-idUSL2N27E1FJ
754.0,10/29/2019 11:51:42 PM,"Amgen posts higher biosimilar sales, ends neuroscience program",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/crVqI1k1Hro/amgen-posts-higher-biosimilar-sales-ends-neuroscience-program-idINKBN1X82GS
755.0,10/29/2019 11:52:02 PM,"Amgen posts higher biosimilar sales, ends neuroscience program",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/CHLVANJVxBA/amgen-posts-higher-biosimilar-sales-ends-neuroscience-program-idUSKBN1X82GQ
756.0,10/31/2019 9:00:00 PM,Amgen to take 20.5% stake in BeiGene to expand in China,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JxPgH8skMvY/amgen-to-take-20-5-stake-in-beigene-to-expand-in-china-idUSL2N27G1K3
757.0,10/31/2019 9:14:41 PM,Amgen To Acquire 20.5% Stake In BeiGene For Approx. $2.7 Bln - Quick Facts ,RTTNews,/news/stocks/amgen-to-acquire-20-5-stake-in-beigene-for-approx-2-7-bln-quick-facts-1028649790
758.0,10/31/2019 11:32:04 PM,UPDATE 1-Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/h5955h9YS2U/update-1-amgen-takes-20-5-stake-in-beigene-to-sell-cancer-drugs-in-china-idUSL2N27G2KJ
759.0,11/1/2019 8:04:50 AM,"BGNE Soars, DRNA Hits New High On Roche Deal, FDA Heeds REPH's Request ",RTTNews,/news/stocks/bgne-soars-drna-hits-new-high-on-roche-deal-fda-heeds-reph-s-request-1028650492
760.0,11/1/2019 7:39:00 PM,Amgen Inc. -- Moody's: Amgen's BeiGene collaboration will expand geographic reach but reduce cash,Moodys,/news/bonds/amgen-inc-moody-s-amgen-s-beigene-collaboration-will-expand-geographic-reach-but-reduce-cash-1028652528
761.0,11/4/2019 12:10:45 PM,"The Gilead Stock Price Might Be Down, but That Doesn’t Mean It’s Cheap",InvestorPlace,/news/stocks/gilead-stock-price-down-mean-cheap-1028656095
762.0,11/5/2019 10:59:40 AM,Novartis gets U.S. nod for long-delayed Amgen copycat,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/k6qiMDX3VIc/novartis-gets-u-s-nod-for-long-delayed-amgen-copycat-idUSL8N27L28S
763.0,11/5/2019 12:10:29 PM,"3 Big Stock Charts for Tuesday: Verizon, McDonald’s, and Alexion Pharmaceuticals",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-verizon-mcdonalds-and-alexion-pharmaceuticals-1028659657
764.0,11/5/2019 5:58:51 PM,2020 Election Could Hurt Amgen Stock’s Healthy Dividend,InvestorPlace,/news/stocks/2020-election-could-hurt-amgen-stocks-healthy-dividend-1028661615
765.0,11/8/2019 9:31:09 PM,This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma,InvestorPlace,/news/stocks/biotech-stocks-big-pharma-deal-1028674828
766.0,11/17/2019 3:08:15 AM,Amgen Says New Analysis Shows Benefit Of Repatha In High-Risk Patients ,RTTNews,/news/stocks/amgen-says-new-analysis-shows-benefit-of-repatha-in-high-risk-patients-1028694388
767.0,11/18/2019 11:33:53 AM,"The Question is Not Why Amarin Stock May Go Up, But Should It?",InvestorPlace,/news/stocks/the-question-is-not-why-amarin-stock-may-go-up-but-should-it-1028696356
768.0,11/18/2019 10:42:20 PM,Chinese Biotech Stocks: The 100X Play as Big Pharma Money Moves In,InvestorPlace,/news/stocks/chinese-biotech-stocks-100x-play-1028698204
769.0,11/19/2019 5:39:58 PM,7 Catalysts Pointing to Massive Potential in Chinese Biotech Stocks,InvestorPlace,/news/stocks/chinese-biotech-stocks-start-massive-potential-1028701689
770.0,11/21/2019 12:40:38 PM,Amgen Boosts FY19 Outlook After Otezla Acquisition - Quick Facts ,RTTNews,/news/stocks/amgen-boosts-fy19-outlook-after-otezla-acquisition-quick-facts-1028707347
771.0,11/21/2019 12:41:02 PM,"Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/X3FS8NTK0NQ/amgen-raises-2019-profit-sales-view-after-buying-celgene-psoriasis-drug-idUSL3N28132R
772.0,11/25/2019 9:26:39 AM,"UPDATE 3-Novartis takes on Sanofi, Amgen with $9.7 bln takeover of heart drug maker",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FSc_xJPiNG0/update-3-novartis-takes-on-sanofi-amgen-with-9-7-bln-takeover-of-heart-drug-maker-idUSL8N2840NS
773.0,11/25/2019 9:27:30 AM,"Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/FtOi9lUMuM0/novartis-takes-on-sanofi-amgen-with-9-7-billion-takeover-of-heart-drug-maker-idINKBN1XZ07F
774.0,11/25/2019 9:32:15 AM,"Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/uZGWn0DBgXA/novartis-takes-on-sanofi-amgen-with-9-7-billion-takeover-of-heart-drug-maker-idUSKBN1XY0NL
775.0,11/25/2019 9:36:42 AM,"Healthcare Stocks That Hit New Highs (MTEM, AMGN, AMED...) ",RTTNews,/news/stocks/healthcare-stocks-that-hit-new-highs-mtem-amgn-amed-1028713855
776.0,11/25/2019 10:02:48 PM,The Most Overlooked Investment Theme Heading Into 2020,InvestorPlace,/news/stocks/the-most-overlooked-investment-theme-heading-into-2020-1028716437
777.0,11/26/2019 1:18:00 PM,Novartis Securities Investment Ltd -- Moody's affirms Novartis' A1 rating; stable outlook,Moodys,/news/bonds/novartis-securities-investment-ltd-moody-s-affirms-novartis-a1-rating-stable-outlook-1028717865
778.0,12/2/2019 5:26:57 AM,Biotech Stocks Facing FDA Decision In December 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2019-1028728368
779.0,12/9/2019 4:12:45 PM,3 Healthcare Stocks to Buy Before the End of 2019,InvestorPlace,/news/stocks/3-healthcare-stocks-to-buy-before-the-end-of-2019-1028748353
780.0,12/10/2019 2:00:51 PM,"Amgen: CANDOR Study Supports Combination Of KYPROLIS, DARZALEX - Quick Facts ",RTTNews,/news/stocks/amgen-candor-study-supports-combination-of-kyprolis-darzalex-quick-facts-1028750740
781.0,12/12/2019 3:50:21 PM,Best ETFs for 2020: Former Champion Invesco QQQ Trust Returns,InvestorPlace,/news/stocks/best-etfs-for-2020-former-champion-powershares-qqq-trust-returns-1028759881
782.0,12/16/2019 6:38:31 PM,Amarin’s Vascepa Approval Seems Fishy for Patients and AMRN Investors,InvestorPlace,/news/stocks/amarin-vascepa-fda-approval-seems-fishy-1028766686
783.0,12/20/2019 2:54:48 AM,"FDA Nod For BHC, Third Rituxan Biosim In The Offing, CBIO Soars, NERV Depressed ",RTTNews,/news/stocks/fda-nod-for-bhc-third-rituxan-biosim-in-the-offing-cbio-soars-nerv-depressed-1028777699
784.0,12/27/2019 6:36:42 PM,"U.S. Cannabis Stocks Will Make Cheap, Smart Buys in 2020",InvestorPlace,/news/stocks/u-s-cannabis-stocks-will-make-cheap-smart-buys-in-2020-1028786597
785.0,12/30/2019 12:40:34 PM,The Success of Vascepa Actually Might Be a Problem for Amarin,InvestorPlace,/news/stocks/can-amarin-go-it-alone-1028788266
786.0,12/31/2019 1:22:53 PM,Here’s Why Amarin Stock Slumped Despite the FDA Approval,InvestorPlace,/news/stocks/why-amarin-stock-slumped-fda-approval-1028789662
787.0,12/31/2019 5:01:53 PM,"Vascepa’s Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock",InvestorPlace,/news/stocks/vascepa-future-amarin-stock-amrn-fishy-1028789803
788.0,1/2/2020 3:37:42 PM,Amgen Completes Purchase Of About $2.8 Bln Of BeiGene Shares ,RTTNews,/news/stocks/amgen-completes-purchase-of-about-2-8-bln-of-beigene-shares-1028791606
789.0,1/2/2020 4:22:38 PM,3 of the Best Healthcare Stocks to Buy in 2020,InvestorPlace,/news/stocks/3-healthcare-stocks-to-buy-2020-1028791911
790.0,1/14/2020 12:00:00 PM,Amgen CEO expects 25% of growth to come from Asia in next decade,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FSBYIYLnszg/amgen-ceo-expects-25-of-growth-to-come-from-asia-in-next-decade-idUSL1N29J01J
791.0,1/14/2020 7:00:00 PM,Amgen Inc. -- Moody's announces completion of a periodic review of ratings of Amgen Inc.,Moodys,/news/bonds/amgen-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-amgen-inc-1028817170
792.0,1/23/2020 3:15:16 PM,Acasti’s Losing Drug and ACST Stock Are Not for Weak Hearts,InvestorPlace,/news/stocks/acasti-losing-drug-and-acst-stock-are-not-for-weak-hearts-1028840870
793.0,1/27/2020 3:11:27 PM,3 Healthcare Stocks Under Pressure from Bernie,InvestorPlace,/news/stocks/3-healthcare-stocks-under-pressure-from-bernie-1028847131
794.0,1/29/2020 11:00:56 AM,Why Teva Stock Could Be the Next General Electric Stock,InvestorPlace,/news/stocks/teva-stock-next-general-electric-1028854259
795.0,1/29/2020 3:02:11 PM,Here's what Wall Street expects from Amgen's earnings,Markets Insider Automation,/news/stocks/amgen-q4-earnings-preview-1028855271
796.0,1/30/2020 10:06:48 PM,Amgen Inc. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q4-adjusted-earnings-beat-estimates-1028861457
797.0,1/30/2020 10:17:45 PM,"Amgen quarterly profit beats estimates, 2020 outlook falls short",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/zhI-HuiE_4o/amgen-quarterly-profit-beats-estimates-2020-outlook-falls-short-idUSL1N29Z1AJ
798.0,1/30/2020 10:25:42 PM,Amgen Issues FY20 Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-issues-fy20-guidance-quick-facts-1028861538
799.0,1/30/2020 10:28:42 PM,"Amgen quarterly profit beats estimates, 2020 outlook falls short",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/YbCvcRflKPE/amgen-quarterly-profit-beats-estimates-2020-outlook-falls-short-idINKBN1ZT2Z9
800.0,1/30/2020 11:17:08 PM,"Amgen 2020 outlook falls short of Street estimates, shares down 3%",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/BKyirS9U6Ms/amgen-2020-outlook-falls-short-of-street-estimates-shares-down-3-idINKBN1ZT2Z9
801.0,1/30/2020 11:29:08 PM,"Amgen 2020 outlook falls short of Street estimates, shares down 3%",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/1UAtR0Cuj4g/amgen-2020-outlook-falls-short-of-street-estimates-shares-down-3-idUSKBN1ZT34R
802.0,1/31/2020 1:02:11 AM,Amgen 2020 outlook falls short of Street estimates; shares slump,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/90IPOwQhlIM/amgen-2020-outlook-falls-short-of-street-estimates-shares-slump-idINKBN1ZT2Z9
803.0,1/31/2020 1:10:05 AM,Amgen 2020 outlook falls short of Street estimates; shares slump,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/2UIN4NGtvpo/amgen-2020-outlook-falls-short-of-street-estimates-shares-slump-idUSKBN1ZT34R
804.0,2/3/2020 2:15:36 PM,There Are Better Pharmaceutical Names Than Teva Stock,InvestorPlace,/news/stocks/teva-stock-has-rebounded-off-its-lows-but-its-not-a-buy-right-now-1028868411
805.0,2/4/2020 4:40:51 PM,Teva Pharmaceutical Just Got a Little Migraine Relief ,InvestorPlace,/news/stocks/teva-stock-just-got-a-little-migraine-relief-1028873202
806.0,2/12/2020 12:36:07 PM,Transfer of Otezla OK'd in Canada,Seeking Alpha,https://seekingalpha.com/news/3540975-transfer-of-otezla-okd-in-canada?utm_source=markets.businessinsider.com&utm_medium=referral
807.0,2/18/2020 4:48:00 PM,Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook,Moodys,/news/bonds/amgen-inc-moody-s-assigns-baa1-rating-to-amgen-s-new-sr-unsecured-notes-stable-outlook-1028914866
808.0,2/21/2020 2:32:53 PM,Dems attack Trump over stalled efforts to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3544481-dems-attack-trump-over-stalled-efforts-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral
809.0,2/24/2020 3:10:04 PM,Sanders' big Nevada primary win shakes health-related stocks,Seeking Alpha,https://seekingalpha.com/news/3544817-sanders-big-nevada-primary-win-shakes-health-related-stocks?utm_source=markets.businessinsider.com&utm_medium=referral
810.0,3/5/2020 12:42:37 PM,BofA raises view on Amgen in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3548952-bofa-raises-view-on-amgen-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
811.0,3/5/2020 6:13:20 PM,No coronavirus-related supply problems - Amgen,Seeking Alpha,https://seekingalpha.com/news/3549112-no-coronavirus-related-supply-problems-amgen?utm_source=markets.businessinsider.com&utm_medium=referral
812.0,3/13/2020 12:36:02 PM,Healthcare stocks set for rally today,Seeking Alpha,https://seekingalpha.com/news/3551531-healthcare-stocks-set-for-rally-today?utm_source=markets.businessinsider.com&utm_medium=referral
813.0,3/16/2020 2:31:48 PM,7 Biotech Stocks to Buy and Hold in 2020,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-and-hold-in-2020-1028769847
814.0,3/16/2020 5:16:29 PM,Teva launches Herceptin biosimilar in U.S.,Seeking Alpha,https://seekingalpha.com/news/3552122-teva-launches-herceptin-biosimilar-in-u-s?utm_source=markets.businessinsider.com&utm_medium=referral
815.0,3/26/2020 2:53:50 PM,7 Buyout Targets to Watch for in 2020,InvestorPlace,/news/stocks/7-buyout-targets-to-watch-for-2020-1028793898
816.0,3/27/2020 1:55:24 PM,European advisory group backs Mylan's Enbrel biosimilar,Seeking Alpha,https://seekingalpha.com/news/3555884-european-advisory-group-backs-mylans-enbrel-biosimilar?utm_source=markets.businessinsider.com&utm_medium=referral
817.0,3/30/2020 12:06:23 PM,Raymond James likes Amgen in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3556223-raymond-james-likes-amgen-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
818.0,4/1/2020 3:05:57 AM,Amgen Purchases 49% Of Shares Of Amgen Astellas BioPharma ,RTTNews,/news/stocks/amgen-purchases-49-of-shares-of-amgen-astellas-biopharma-1029052574
819.0,4/2/2020 3:18:23 PM,"Amgen, Adaptive Partner To Find Neutralizing Antibodies For COVID-19 ",RTTNews,/news/stocks/amgen-adaptive-partner-to-find-neutralizing-antibodies-for-covid-19-1029058927
820.0,4/2/2020 7:06:50 PM,Don’t Pull the Trigger on AIM ImmunoTech Stock,InvestorPlace,/news/stocks/dont-pull-the-trigger-on-aim-immunotech-stock-1029060632
821.0,4/15/2020 11:11:23 AM,Guggenheim on fence with Amgen in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3560770-guggenheim-on-fence-amgen-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
822.0,4/16/2020 7:39:22 AM,Novartis: Real-world Data Supports Aimovig Clinical Trial Results - Quick Facts ,RTTNews,/news/stocks/novartis-real-world-data-supports-aimovig-clinical-trial-results-quick-facts-1029096841
823.0,4/17/2020 4:40:22 PM,4 Healthcare Stocks to Buy For Coronavirus Innovation,InvestorPlace,/news/stocks/4-healthcare-stocks-to-buy-for-coronavirus-innovation-1029103309
824.0,4/23/2020 9:00:34 PM,This Stock Points to the Massive China Biotech Trend,InvestorPlace,/news/stocks/zlab-stock-points-to-massive-china-biotech-stock-trend-1029124959
825.0,4/29/2020 3:02:39 PM,Here's what Wall Street expects from Amgen's earnings report,Markets Insider Automation,/news/stocks/amgen-stock-price-q1-earnings-preview-1029144604
826.0,4/30/2020 10:04:46 PM,"Amgen studying Otezla for coronavirus, 1st-qtr results beat Street estimates",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FvEZd_M3Mt0/amgen-studying-otezla-for-coronavirus-1st-qtr-results-beat-street-estimates-idUSL1N2CI1KH
827.0,4/30/2020 10:04:54 PM,Amgen Inc. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q1-adjusted-earnings-beat-estimates-1029152324
828.0,4/30/2020 10:06:48 PM,"Amgen studying Otezla for coronavirus, first-quarter results beat Street estimates",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ipDspqDRm-g/amgen-studying-otezla-for-coronavirus-first-quarter-results-beat-street-estimates-idUSKBN22C3NC
829.0,4/30/2020 11:39:03 PM,"UPDATE 1-Amgen studying Otezla for coronavirus, Q1 results beat Street estimates",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/l42cBpGdKWs/update-1-amgen-studying-otezla-for-coronavirus-q1-results-beat-street-estimates-idUSL1N2CI2X1
830.0,5/1/2020 12:51:54 AM,"UPDATE 2-Amgen studying Otezla for coronavirus, looking into other treatments",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/z68PhXNko9c/update-2-amgen-studying-otezla-for-coronavirus-looking-into-other-treatments-idUSL1N2CI2X1
831.0,5/1/2020 12:52:49 AM,"Amgen studying Otezla for coronavirus, looking into other treatments",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/aDMqjy5uLvs/amgen-studying-otezla-for-coronavirus-looking-into-other-treatments-idUSKBN22C3NC
832.0,5/4/2020 4:14:00 PM,Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook,Moodys,/news/bonds/amgen-inc-moody-s-assigns-baa1-rating-to-amgen-s-new-sr-unsecured-notes-stable-outlook-1029161041
833.0,5/5/2020 3:30:43 PM,Amgen: Court Ruling Prevents Cipla From Making Generic Version Of KYPROLIS ,RTTNews,/news/stocks/amgen-court-ruling-prevents-cipla-from-making-generic-version-of-kyprolis-1029166334
834.0,5/6/2020 1:54:05 PM,Amgen's Otezla shows positive action in mild psoriasis,Seeking Alpha,https://seekingalpha.com/news/3570077-amgens-otezla-shows-positive-action-in-mild-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral
835.0,5/6/2020 3:28:37 PM,Amgen Reports Positive Results For Otezla In Phase 3 Trial ,RTTNews,/news/stocks/amgen-reports-positive-results-for-otezla-in-phase-3-trial-1029170999
836.0,5/8/2020 3:21:02 PM,Amgen:FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure ,RTTNews,/news/stocks/amgen-fda-grants-fast-track-designation-for-omecamtiv-mecarbil-in-heart-failure-1029182237
837.0,5/8/2020 7:34:55 PM,"Time to buy these biopharma names is now, BofA says",Seeking Alpha,https://seekingalpha.com/news/3572315-time-to-buy-biopharma-names-is-now-bofa-says?utm_source=markets.businessinsider.com&utm_medium=referral
838.0,5/11/2020 8:59:10 AM,AstraZeneca Completes Recovery Of Global Rights To Brazikumab From Allergan ,RTTNews,/news/stocks/astrazeneca-completes-recovery-of-global-rights-to-brazikumab-from-allergan-1029186069
839.0,5/29/2020 6:00:00 AM,All eyes on ASCO,Seeking Alpha,https://seekingalpha.com/news/3578520-all-eyes-on-asco?utm_source=markets.businessinsider.com&utm_medium=referral
840.0,6/4/2020 2:14:47 PM,Moderna names Amgen executive David Meline as CFO,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/kBYmyYxJp9c/moderna-names-amgen-executive-david-meline-as-cfo-idUSL4N2DH2WS
841.0,6/4/2020 2:39:02 PM,UPDATE 1-Moderna names Amgen executive David Meline as CFO,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZrAm0KjeDMY/update-1-moderna-names-amgen-executive-david-meline-as-cfo-idUSL4N2DH2XY
842.0,6/9/2020 9:16:41 AM,3 Companies to Invest in on Republic’s Equity Funding Platform,InvestorPlace,/news/stocks/3-companies-to-invest-in-on-republics-crowd-investing-platform-1029291797
843.0,6/11/2020 2:55:31 PM,7 Great Biotech Stocks to Buy and Hold Now,InvestorPlace,/news/stocks/biotech-stocks-to-buy-for-long-term-1029301567
844.0,6/15/2020 12:14:28 PM,BeyondSpring's lead drug successful in late-stage neutropenia study,Seeking Alpha,https://seekingalpha.com/news/3582941-beyondsprings-lead-drug-successful-in-late-stage-neutropenia-study?utm_source=markets.businessinsider.com&utm_medium=referral
845.0,7/6/2020 6:43:12 PM,Moderna Stock Has a Bright Future After the Coronavirus,InvestorPlace,/news/stocks/moderna-mrna-stock-coronavirus-vaccine-drug-discovery-1029370223
846.0,7/6/2020 8:07:38 PM,4 California Stocks to Keep On Hold Until Post-Coronavirus,InvestorPlace,/news/stocks/4-california-stocks-to-keep-on-hold-until-post-coronavirus-1029370213
847.0,7/13/2020 4:43:58 AM,Amgen To Additionally Invest $421 Mln In China's BeiGene ,RTTNews,/news/stocks/amgen-to-additionally-invest-421-mln-in-china-s-beigene-1029385922
848.0,7/20/2020 6:21:31 PM,3 Top Stock Trades for the Week Ahead That Are From China,InvestorPlace,/news/stocks/top-stock-trades-for-this-week-1028813907
849.0,7/27/2020 3:01:45 PM,Amgen earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/amgen-stock-price-q2-earnings-preview-1029433849
850.0,7/28/2020 10:05:49 PM,Amgen Inc. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q2-adjusted-earnings-beat-estimates-1029440726
851.0,7/30/2020 2:41:26 PM,5 Undervalued Stocks Cooking Up Must-Have Technologies,InvestorPlace,/news/stocks/5-undervalued-stocks-cooking-up-must-have-tech-1029452323
852.0,7/30/2020 4:23:00 PM,Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook,Moodys,/news/bonds/amgen-inc-moody-s-assigns-baa1-rating-to-amgen-s-new-sr-unsecured-notes-stable-outlook-1029451919
853.0,8/3/2020 2:04:59 PM,"AbbVie, Amgen, Takeda Pharma Enroll First Patients In I-SPY COVID Trial ",RTTNews,/news/stocks/abbvie-amgen-takeda-pharma-enroll-first-patients-in-i-spy-covid-trial-1029461249
854.0,8/4/2020 9:31:42 AM,"ALRN To Report Data In Q4, IMUC Hits New High, VYGR Pulls Out Of ABBV Deal, VNDA To Face FDA In Dec. ",RTTNews,/news/stocks/alrn-to-report-data-in-q4-imuc-hits-new-high-vygr-pulls-out-of-abbv-deal-vnda-to-face-fda-in-dec-1029465250
855.0,8/7/2020 1:36:32 PM,This Company is the Landlord of Life Sciences,InvestorPlace,/news/stocks/this-company-is-the-landlord-of-life-sciences-1029482490
856.0,8/21/2020 5:34:04 AM,Amgen : FDA Approves New KYPROLIS For Multiple Myeloma ,RTTNews,/news/stocks/amgen-fda-approves-new-kyprolis-for-multiple-myeloma-1029522678
857.0,8/21/2020 5:42:52 PM,7 Index Funds To Buy For A Firm Portfolio Foundation,InvestorPlace,/news/stocks/7-index-funds-to-buy-for-a-firm-portfolio-foundation-1029524805
858.0,8/25/2020 1:46:20 PM,The 5 Best Tech ETFs to Buy for Safer Growth,InvestorPlace,/news/stocks/the-5-best-tech-etfs-to-buy-for-safer-growth-1029532192
859.0,8/25/2020 2:36:56 PM,Welcome Salesforce Stock to the Dow Jones,InvestorPlace,/news/stocks/salesforce-crm-stock-welcome-earnings-dow-jones-average-1029532756
860.0,8/25/2020 5:49:23 PM,"Exxon Mobil, Pfizer Exit Dow Jones Industrial Average ",RTTNews,/news/stocks/exxon-mobil-pfizer-exit-dow-jones-industrial-average-1029532639
861.0,8/27/2020 9:16:00 AM,Inovio Shares Have Been Hot in 2020 but Watch for a Volatile September,InvestorPlace,/news/stocks/ino-stock-has-been-hot-in-2020-but-watch-for-a-volatile-september-1029539174
862.0,8/28/2020 9:01:53 AM,Vaccine Race Also-ran iBio Stock Won’t See Earlier Highs Anytime Soon,InvestorPlace,/news/stocks/ibio-stock-wont-see-earlier-highs-1029543409
863.0,8/28/2020 5:51:26 PM,Novavax Is Conducting Clinical Trials: The Ride In NVAX Stock Will Continue To Be Wild,InvestorPlace,/news/stocks/novavax-is-conducting-clinical-trials-the-ride-in-nvax-stock-will-continue-to-be-wild-1029545047
864.0,9/1/2020 11:01:13 AM,CureVac Stock Has Been Hot Following Its Recent IPO,InvestorPlace,/news/stocks/curevac-stock-has-been-hot-following-its-recent-ipo-1029551661
865.0,9/2/2020 5:14:15 PM,Antibodies Against COVID Do Not Decline Within 4 Months Of Diagnosis: Study ,RTTNews,/news/stocks/antibodies-against-covid-do-not-decline-within-4-months-of-diagnosis-study-1029557028
866.0,9/17/2020 12:56:42 PM,"Eli Lilly, Amgen Ink Antibody Manufacturing Deal To Boost Supply For COVID-19 Therapies ",RTTNews,/news/stocks/eli-lilly-amgen-ink-antibody-manufacturing-deal-to-boost-supply-for-covid-19-therapies-1029597997
867.0,9/18/2020 3:34:34 PM,4 Biotech Stocks to Buy for Big Gains in 2020,InvestorPlace,/news/stocks/4-biotech-stocks-to-buy-for-big-gains-in-2020-1029603327
868.0,9/22/2020 10:40:44 AM,This Dow Reshuffling Is a Great Opportunity to Buy Exxon Mobil Stock,InvestorPlace,/news/stocks/buy-exxon-mobil-stock-dow-shuffle-1029611671
869.0,9/28/2020 5:50:40 PM,3 Reasons To Be Bullish On Biotech Giant Amgen,InvestorPlace,/news/stocks/3-reasons-to-be-bullish-on-biotech-giant-amgen-stock-1029628456
870.0,10/6/2020 4:26:08 AM,Amgen's sotorasib shows positive effect in mid-stage lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3619992-amgens-sotorasib-shows-positive-effect-in-mid-stage-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral
871.0,10/7/2020 4:27:48 PM,7 Biotech Stocks To Buy For Profit From The Vaccine Crunch,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-for-profit-from-the-vaccine-crunch-1029658673
872.0,10/8/2020 12:49:32 PM,Cytokinetics/Amgen omecamtiv mecarbil shows mixed results in heart failure study; CYTK down 37%,Seeking Alpha,https://seekingalpha.com/news/3620774-cytokinetics-amgen-omecamtiv-mecarbil-shows-mixed-results-in-heart-failure-study-cytk-down-37?utm_source=markets.businessinsider.com&utm_medium=referral
873.0,10/8/2020 2:48:49 PM,Amgen: GALACTIC-HF Trial Meets Primary Composite Endpoint; Fails To Meet Secondary Endpoint ,RTTNews,/news/stocks/amgen-galactic-hf-trial-meets-primary-composite-endpoint-fails-to-meet-secondary-endpoint-1029661616
874.0,10/9/2020 10:45:57 AM,7 Index Funds to Hold Through Thick and Thin,InvestorPlace,/news/stocks/7-index-funds-to-hold-through-thick-and-thin-1029665545
875.0,10/16/2020 4:12:31 PM,3 Biotech Stocks to Buy Right Now,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-right-now-1029689519
876.0,10/23/2020 5:29:04 PM,3 Newly Recruited Dow Jones Stocks to Trade,InvestorPlace,/news/stocks/3-newly-recruited-dow-jones-stocks-to-trade-1029715860
877.0,10/27/2020 3:02:09 PM,Amgen earnings: here's what to expect,Markets Insider Automation,/news/stocks/amgen-q3-earnings-preview-1029727434
878.0,10/27/2020 9:35:12 PM,Notable earnings after Wednesday's close,Seeking Alpha,https://seekingalpha.com/news/3626524-notable-earnings-after-wednesdays-close?utm_source=markets.businessinsider.com&utm_medium=referral
879.0,10/27/2020 9:35:16 PM,Amgen Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3626672-amgen-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
880.0,10/28/2020 12:59:39 PM,7 Cutting-Edge Biotech Stocks for Tomorrow ,InvestorPlace,/news/stocks/7-cutting-edge-biotech-stocks-for-tomorrow-1029734117
881.0,10/28/2020 8:38:04 PM,"Amgen Q3 product sales up 12%, non-GAAP earnings up 17%",Seeking Alpha,https://seekingalpha.com/news/3627680-amgen-q3-product-sales-up-12-non-gaap-earnings-up-17?utm_source=markets.businessinsider.com&utm_medium=referral
882.0,10/28/2020 9:08:19 PM,Amgen Inc. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q3-adjusted-earnings-beat-estimates-1029736779
883.0,10/29/2020 2:18:17 PM,Sanofi/Regeneron prevail in European patent dispute with Amgen over cholesterol drugs,Seeking Alpha,https://seekingalpha.com/news/3628348-sanofi-regeneron-prevail-in-european-patent-dispute-amgen-over-cholesterol-drugs?utm_source=markets.businessinsider.com&utm_medium=referral
884.0,10/29/2020 3:21:32 PM,"European Patent Office Rules In Favor Of Sanofi, Regeneron On Praluent ",RTTNews,/news/stocks/european-patent-office-rules-in-favor-of-sanofi-regeneron-on-praluent-1029742079
885.0,11/3/2020 12:23:20 PM,Bristol Myers' deucravacitinib tops Amgen's Otezla in late-stage psoriasis study,Seeking Alpha,https://seekingalpha.com/news/3630264-bristol-myers-deucravacitinib-tops-amgens-otezla-in-late-stage-psoriasis-study?utm_source=markets.businessinsider.com&utm_medium=referral
886.0,11/5/2020 8:06:56 PM,Cytonics: Invest In A Startup That’s Targeting Osteoarthritis,InvestorPlace,/news/stocks/cytonics-invest-in-a-startup-thats-targeting-osteoarthritis-1029772608
887.0,11/6/2020 8:30:45 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3633287-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
888.0,11/8/2020 3:52:03 PM,"Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing ",RTTNews,/news/stocks/week-ahead-in-pharma-fda-decisions-sitc-presentations-13d-sec-filing-1029778637
889.0,11/10/2020 9:16:20 AM,"AstraZeneca, Amgen Report Positive Results From Tezepelumab Trial In  Severe Asthma ",RTTNews,/news/stocks/astrazeneca-amgen-report-positive-results-from-tezepelumab-trial-in-severe-asthma-1029785137
890.0,11/10/2020 10:38:03 AM,Amgen and AstraZeneca's tezepelumab meets primary endpoint in late-stage asthma study; shares +4%,Seeking Alpha,https://seekingalpha.com/news/3634177-amgen-and-astrazenecas-tezepelumab-meets-primary-endpoint-in-late-stage-asthma-study?utm_source=markets.businessinsider.com&utm_medium=referral
891.0,11/13/2020 1:42:54 PM,European advisory group backs new uses of six medicines,Seeking Alpha,https://seekingalpha.com/news/3636126-european-advisory-group-backs-new-uses-of-six-medicines?utm_source=markets.businessinsider.com&utm_medium=referral
892.0,11/20/2020 7:13:02 AM,BeiGene's Xgeva OK'd in China for bone metastases due to cancer,Seeking Alpha,https://seekingalpha.com/news/3638223-beigenes-xgeva-okd-in-china-for-bone-metastases-due-to-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
893.0,11/23/2020 1:30:38 PM,"Amgen terminates partnership with Cytokinetics, will transition omecamtiv mecarbil and AMG 594 rights",Seeking Alpha,https://seekingalpha.com/news/3638644-amgen-terminates-partnership-cytokinetics-will-transition-omecamtiv-mecarbil-and-amg-594?utm_source=markets.businessinsider.com&utm_medium=referral
894.0,11/23/2020 2:37:01 PM,Amgen Terminates Collaboration With Cytokinetics On Omecamtiv Mecarbil And AMG 594 ,RTTNews,/news/stocks/amgen-terminates-collaboration-with-cytokinetics-on-omecamtiv-mecarbil-and-amg-594-1029829748
895.0,11/30/2020 2:12:00 AM,Biotech Stocks Facing FDA Decision In December 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2020-1029847132
896.0,12/1/2020 5:14:40 AM,"MRNA Faces AdCom On Dec.17, NVAX To Begin Phase 3 COVID Vaccine Trials In US, Mexico, AMGN On Watch ",RTTNews,/news/stocks/mrna-faces-adcom-on-dec-17-nvax-to-begin-phase-3-covid-vaccine-trials-in-us-mexico-amgn-on-watch-1029851327
897.0,12/3/2020 4:13:37 PM,3 Under-Loved Biotech Stocks to Buy for Profits Into 2021,InvestorPlace,/news/stocks/3-under-loved-biotech-stocks-to-buy-for-profits-into-2021-1029862758
898.0,12/3/2020 9:11:12 PM,Amgen to host investor event on BiTE platform December 8,Seeking Alpha,https://seekingalpha.com/news/3641518-amgen-to-host-investor-event-on-bite-platform-december-8?utm_source=markets.businessinsider.com&utm_medium=referral
899.0,12/4/2020 8:30:00 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3641078-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
900.0,12/8/2020 10:37:54 AM,BeiGene's Blincyto Ok'd in China for blood and bone marrow cancer,Seeking Alpha,https://seekingalpha.com/news/3642375-beigenes-blincyto-okd-in-china-for-blood-and-bone-marrow-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
901.0,12/8/2020 2:53:23 PM,Amgen's sotorasib nabs accelerated review for lung cancer,Seeking Alpha,https://seekingalpha.com/news/3642513-amgens-sotorasib-nabs-accelerated-review-for-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
902.0,12/13/2020 1:11:37 AM,"Week Ahead In Pharma: FDA Decision, Review Of COVID-19 Vaccine, Data Readouts (MRNA, BCRX, ARVN...) ",RTTNews,/news/stocks/week-ahead-in-pharma-fda-decision-review-of-covid-19-vaccine-data-readouts-mrna-bcrx-arvn-1029887411
903.0,12/14/2020 10:31:06 AM,The 7 Best Dow Jones Stocks to Buy Now As You Ready for the Coming Year,InvestorPlace,/news/stocks/7-best-dow-jones-stocks-to-buy-now-ibm-hd-mmm-aapl-msft-wmt-amgn-1029889146
904.0,12/14/2020 2:29:02 PM,3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover,Benzinga,/news/etf/3-etfs-for-astrazeneca-s-39b-alexion-pharmaceuticals-takeover-1029909523
905.0,12/15/2020 3:44:00 PM,Amgen Inc. -- Moody's announces completion of a periodic review of ratings of Amgen Inc.,Moodys,/news/bonds/amgen-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-amgen-inc-1029894426
906.0,12/16/2020 10:47:45 AM,Micro-cap oncology biotech Scopus Biopharma prices downsized $2.75M IPO,Seeking Alpha,https://seekingalpha.com/news/3644762-micro-cap-oncology-biotech-scopus-biopharma-prices-downsized-2_75m-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
907.0,12/16/2020 9:32:33 PM,Amgen increases dividend by 10% to $1.76,Seeking Alpha,https://seekingalpha.com/news/3645117-amgen-increases-dividend-10-to-1_76?utm_source=markets.businessinsider.com&utm_medium=referral
908.0,12/16/2020 10:17:47 PM,Amgen submits NDA for Sotorasib in non-small cell lung cancer,Seeking Alpha,https://seekingalpha.com/news/3645142-amgen-submits-nda-for-sotorasib-in-non-small-cell-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
909.0,12/17/2020 9:31:52 PM,Amgen’s RIABNI wins FDA approval for multiple disorders,Seeking Alpha,https://seekingalpha.com/news/3645524-amgen-s-riabni-wins-fda-approval-for-multiple-disorders?utm_source=markets.businessinsider.com&utm_medium=referral
910.0,12/20/2020 4:02:46 PM,"The Week Ahead In Biotech: Light Calendar In Abbreviated Week Features 1 IPO, 1 FDA Decision",Benzinga,/news/stocks/the-week-ahead-in-biotech-light-calendar-in-abbreviated-week-features-1-ipo-1-fda-decision-1029909484
911.0,12/22/2020 8:32:05 AM,Amgen: SOURCE Phase 3 Trial For Tezepelumab Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/amgen-source-phase-3-trial-for-tezepelumab-fails-to-meet-primary-endpoint-1029912788
912.0,12/22/2020 9:31:41 AM,AstraZeneca/Amgen's tezepelumab flunks late-stage asthma study,Seeking Alpha,https://seekingalpha.com/news/3646497-astrazeneca-amgens-tezepelumab-flunks-late-stage-asthma-study?utm_source=markets.businessinsider.com&utm_medium=referral
913.0,12/22/2020 1:45:09 PM,"The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes",Benzinga,/news/stocks/the-daily-biotech-pulse-ziopharm-to-start-blood-cancer-study-chemocentryx-soligenix-slump-on-adverse-clinical-trial-outcomes-1029913559
914.0,12/22/2020 2:44:53 PM,Amgen seeks marketing authorization for lung cancer therapy in Europe,Seeking Alpha,https://seekingalpha.com/news/3646668-amgen-seeks-marketing-authorization-for-lung-cancer-therapy-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral
915.0,12/22/2020 4:27:39 PM,Amgen Submits Sotorasib Marketing Authorization Application To EMA ,RTTNews,/news/stocks/amgen-submits-sotorasib-marketing-authorization-application-to-ema-1029914473
916.0,12/22/2020 9:09:56 PM,Amgen out-licenses tuberculosis/leprosy candidate to Medicines Development for Global Health,Seeking Alpha,https://seekingalpha.com/news/3646815-amgen-out-licenses-tuberculosis-leprosy-candidate-to-medicines-development-for-global-health?utm_source=markets.businessinsider.com&utm_medium=referral
917.0,12/24/2020 5:12:44 PM,"Analysts predict M&A poised to rebound in next year, fueled by $1.47T in deal making capital",Seeking Alpha,https://seekingalpha.com/news/3647399-analysts-predict-m-poised-to-rebound-in-next-year-fueled-1_47t-in-deal-making-capital?utm_source=markets.businessinsider.com&utm_medium=referral
918.0,12/29/2020 7:53:14 AM,Biotech Stocks Facing FDA Decision In January 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2021-1029922365
919.0,12/31/2020 12:49:45 PM,Viatris biosimilar faces regulatory delay,Seeking Alpha,https://seekingalpha.com/news/3648043-viatris-biosimilar-faces-regulatory-delay?utm_source=markets.businessinsider.com&utm_medium=referral
920.0,1/2/2021 4:45:58 PM,Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-january-pdufa-dates-1029928632
921.0,1/5/2021 11:37:37 PM,"BofA's biopharma picks into 2021 set to build with new launches, 'beatable' expectations",Seeking Alpha,https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?utm_source=markets.businessinsider.com&utm_medium=referral
922.0,1/11/2021 3:12:44 PM,"Amgen, AstraZeneca, Bristol Myers Squibb To Evaluate GRAIL's Cancer Early Detection Test ",RTTNews,/news/stocks/amgen-astrazeneca-bristol-myers-squibb-to-evaluate-grail-s-cancer-early-detection-test-1029955729
923.0,1/11/2021 3:23:01 PM,The 7 Best Cheap Stocks to Kick Off 2021,InvestorPlace,/news/stocks/the-7-best-cheap-stocks-to-kick-off-2021-1029956503
924.0,1/13/2021 12:37:27 PM,Amgen and EVOQ Therapeutics ink development deal for autoimmune disorders,Seeking Alpha,https://seekingalpha.com/news/3650999-amgen-and-evoq-therapeutics-ink-development-deal-for-autoimmune-disorders?utm_source=markets.businessinsider.com&utm_medium=referral
925.0,1/13/2021 1:25:38 PM,"The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations",Benzinga,/news/stocks/the-daily-biotech-pulse-bausch-health-issues-positive-pre-announcement-acorda-streamlines-operations-1029963908
926.0,1/20/2021 3:24:21 PM,The 7 Best Healthcare Stocks to Buy for 2021,InvestorPlace,/news/stocks/the-7-best-healthcare-stocks-to-buy-for-2021-1029987247
927.0,1/23/2021 3:14:04 PM,"The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-24-30-j-j-lilly-to-kickstart-big-pharma-earnings-amgen-fda-decision-and-more-1029996049
928.0,1/28/2021 2:03:49 PM,"The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-decision-day-for-amgen-zymeworks-sinks-on-data-ortho-clinical-diagnostics-ipo-1030014922
929.0,1/28/2021 5:03:51 PM,How to Ride the Covid-19 Bull with Moderna,InvestorPlace,/news/stocks/how-to-ride-covid-19-bull-moderna-stock-1030016518
930.0,1/28/2021 7:29:12 PM,BioThera BLA for Roche Avastin biosimilar accepted by FDA,Seeking Alpha,https://seekingalpha.com/news/3655629-biothera-bla-for-roche-avastin-biosimilar-accepted-by-fda?utm_source=markets.businessinsider.com&utm_medium=referral
931.0,1/28/2021 8:25:06 PM,Amgen lung cancer drug sotorasib shows strong results in Phase 2 trial,Seeking Alpha,https://seekingalpha.com/news/3655747-amgen-lung-cancer-drug-sotorasib-shows-strong-results-in-phase-2-trial?utm_source=markets.businessinsider.com&utm_medium=referral
932.0,1/29/2021 1:45:44 PM,"The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-vaccine-readout-clinical-hold-on-bellicum-study-lifted-lilly-earnings-nls-pharma-ipo-1030019600
933.0,1/30/2021 7:19:15 PM,"The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-merck-pfizer-in-earnings-mix-plus-adamas-mallinckrodt-fda-decisions-ipos-and-more-1030022250
934.0,1/31/2021 10:26:09 AM,Week Ahead In Pharma: Data Readouts Of COVID-19 Trials & FDA Decisions ,RTTNews,/news/stocks/week-ahead-in-pharma-data-readouts-of-covid-19-trials-fda-decisions-1030022652
935.0,1/31/2021 3:01:27 PM,What Wall Street expects from Amgen's earnings,Markets Insider Automation,/news/stocks/amgen-stock-price-q4-earnings-preview-1030023016
936.0,2/1/2021 6:52:34 PM,Amgen Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3656816-amgen-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
937.0,2/1/2021 10:35:28 PM,Notable earnings after Tuesday's close,Seeking Alpha,https://seekingalpha.com/news/3656740-notable-earnings-after-tuesdays-close?utm_source=markets.businessinsider.com&utm_medium=referral
938.0,2/2/2021 2:05:48 PM,"The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment",Benzinga,/news/stocks/the-daily-biotech-pulse-vertex-pfizer-earnings-tiziana-covid-19-vaccine-data-decision-day-for-mallinckrodt-s-burn-treatment-1030032611
939.0,2/2/2021 4:22:56 PM,7 Stocks to Buy for the Long Run,InvestorPlace,/news/stocks/7-stocks-to-buy-for-the-long-run-1030034388
940.0,2/2/2021 9:04:02 PM,"Amgen EPS beats by $0.47, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3657435-amgen-eps-beats-0_47-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
941.0,2/2/2021 10:05:01 PM,Amgen Inc. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/amgen-inc-q4-adjusted-earnings-beat-estimates-1030035054
942.0,2/3/2021 1:31:17 PM,"The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision",Benzinga,/news/stocks/the-daily-biotech-pulse-amgen-earnings-gsk-curevac-vaccine-collaboration-mallinckrodt-fda-decision-1030037844
943.0,2/3/2021 7:27:22 PM,Amgen is under pressure as Baird calls FY21 guidance ‘a bit disappointing’,Seeking Alpha,https://seekingalpha.com/news/3657970-amgen-is-under-pressure-as-baird-calls-fy21-guidance-a-bit-disappointing?utm_source=markets.businessinsider.com&utm_medium=referral
944.0,2/4/2021 4:16:13 PM,Citius Pharmaceuticals Is Addressing Several Unmet Needs In The Medical Field,Benzinga,/news/stocks/citius-pharmaceuticals-is-addressing-several-unmet-needs-in-the-medical-field-1030044503
945.0,2/5/2021 11:13:17 AM,Bolt Biotherapeutics raises $230M in IPO,Seeking Alpha,https://seekingalpha.com/news/3658964-bolt-biotherapeutics-raises-230m-in-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
946.0,2/5/2021 6:03:53 PM,3 Dividend Stocks for Market-Beating Yields and High Growth,InvestorPlace,/news/stocks/3-dividend-stocks-for-market-beating-yields-and-high-growth-1030049564
947.0,2/10/2021 2:20:40 AM,Lilly's COVID-19 Antibody Combination Receives Emergency Use Authorization In U.S. ,RTTNews,/news/stocks/lilly-s-covid-19-antibody-combination-receives-emergency-use-authorization-in-u-s-1030063212
948.0,2/17/2021 11:49:27 AM,Amgen receives FDA priority review status for lung cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3662708-amgen-receives-fda-priority-review-status-for-lung-cancer-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
949.0,2/17/2021 1:26:55 PM,"The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-funding-for-gene-therapy-research-priority-review-for-amgen-cancer-drug-pfizer-biontech-vaccine-supply-deal-1030091631
950.0,2/18/2021 5:52:08 PM,3 Biotech Stocks to Buy As Things Heat Up for the Sector,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-as-things-heat-up-for-the-sector-1030098722
951.0,2/18/2021 7:55:17 PM,Barclays initiates Cytokinetics with an outperform rating,Seeking Alpha,https://seekingalpha.com/news/3663584-barclays-initiates-cytokinetics-with-outperform-rating?utm_source=markets.businessinsider.com&utm_medium=referral
952.0,2/22/2021 3:22:59 PM,Amgen Submits SNDA For Otezla For Adults With Mild-To-Moderate Plaque Psoriasis ,RTTNews,/news/stocks/amgen-submits-snda-for-otezla-for-adults-with-mild-to-moderate-plaque-psoriasis-1030108147
953.0,2/22/2021 3:53:51 PM,Amgen submits Otezla plaque psoriasis marketing application to the FDA,Seeking Alpha,https://seekingalpha.com/news/3664353-amgen-submits-otezla-plaque-psoriasis-marketing-application-to-the-fda?utm_source=markets.businessinsider.com&utm_medium=referral
954.0,2/26/2021 2:16:52 PM,"The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-test-awaits-j-j-s-covid-19-vaccine-lilly-to-supply-additional-antibody-therapy-doses-to-us-regulatory-setback-for-tricida-1030129439
955.0,2/26/2021 3:27:45 PM,AstraZeneca and Amgen's tezepelumab successful in phase 3 for severe asthma,Seeking Alpha,https://seekingalpha.com/news/3667206-astrazeneca-and-amgens-tezepelumab-successful-in-phase-3-for-severe-asthma?utm_source=markets.businessinsider.com&utm_medium=referral
956.0,2/26/2021 3:52:09 PM,"AZN And Amgen's Tezepelumab Reduces Exacerbations In Patients With Severe, Uncontrolled Asthma ",RTTNews,/news/stocks/azn-and-amgen-s-tezepelumab-reduces-exacerbations-in-patients-with-severe-uncontrolled-asthma-1030129878
957.0,3/2/2021 9:29:47 PM,Amgen reports positive effect of Blincyto in children with lymphoblastic leukemia,Seeking Alpha,https://seekingalpha.com/news/3668510-amgen-reports-positive-effect-of-blincyto-in-children-with-lymphoblastic-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral
958.0,3/3/2021 1:46:17 PM,"The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study",Benzinga,/news/stocks/the-daily-biotech-pulse-kempharm-adhd-drug-gets-the-nod-medicinova-shelves-vaccine-study-1030144928
959.0,3/4/2021 2:00:02 PM,Amgen to acquire Five Prime Therapeutics for $1.9B,Seeking Alpha,https://seekingalpha.com/news/3669372-amgen-to-acquire-five-prime-therapeutics-for-19b?utm_source=markets.businessinsider.com&utm_medium=referral
960.0,3/4/2021 2:41:59 PM,Amgen To Acquire Five Prime Therapeutics - Quick Facts ,RTTNews,/news/stocks/amgen-to-acquire-five-prime-therapeutics-quick-facts-1030150473
961.0,3/4/2021 4:44:28 PM,FPRX Stock: The Huge Takeover News That Has Five Prime Therapeutics Shares Blasting Higher,InvestorPlace,/news/stocks/fprx-stock-the-huge-takeover-news-that-has-five-prime-therapeutics-shares-blasting-higher-1030151717
962.0,3/4/2021 5:35:40 PM,Amgen Pays $1.9B For Five Prime Therapeutics Acquisition,Benzinga,/news/stocks/amgen-pays-1-9b-for-five-prime-therapeutics-acquisition-1030151610
963.0,3/5/2021 1:38:40 PM,10 Biggest Price Target Changes For Friday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-friday-1030154662
964.0,3/5/2021 2:15:10 PM,"The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study",Benzinga,/news/stocks/the-daily-biotech-pulse-fulgent-s-big-quarter-gilead-awaits-fda-decision-apellis-winds-up-covid-19-study-1030154866
965.0,3/12/2021 4:29:00 PM,7 Pharmaceutical Stocks Working on Their Next Blockbuster   ,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-working-on-their-next-blockbuster-1030180657
966.0,3/14/2021 5:40:20 AM,"Big Pharma is pushing back the pandemic, but its stocks are cheap - Barron's",Seeking Alpha,https://seekingalpha.com/news/3672437-big-pharma-is-pushing-back-the-pandemic-but-its-stocks-are-cheap-barrons?utm_source=markets.businessinsider.com&utm_medium=referral
967.0,3/17/2021 2:15:17 PM,3 Biotech Stocks That Could Double In 12 Months,Benzinga,/news/stocks/3-biotech-stocks-that-could-double-in-12-months-1030219865
968.0,3/18/2021 8:42:08 AM,Laryngeal Cancer Therapeutics Market To See $635M Growth By 2025 And These 2 Companies Will Be Key Drivers: Research,Benzinga,/news/stocks/laryngeal-cancer-therapeutics-market-to-see-635m-growth-by-2025-and-these-2-companies-will-be-key-drivers-research-1030222527
969.0,3/19/2021 7:29:29 PM,"Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 Suitors",Benzinga,/news/stocks/though-potential-bidders-moved-away-amgen-s-bid-for-five-prime-outlasted-15-suitors-1030228976
970.0,3/23/2021 4:46:16 PM,Drug pricing legislation introduced by Sanders weighs on pharmas,Seeking Alpha,https://seekingalpha.com/news/3675361-drug-pricing-legislation-introduced-by-sanders-weighs-on-pharmas?utm_source=markets.businessinsider.com&utm_medium=referral
971.0,3/30/2021 8:18:56 PM,Amgen to bolster inflammation portfolio with the acquisition of Rodeo Therapeutics,Seeking Alpha,https://seekingalpha.com/news/3677780-amgen-to-acquire-rodeo-therapeutics?utm_source=markets.businessinsider.com&utm_medium=referral
972.0,3/31/2021 1:41:12 PM,"The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-vaccine-100-effective-in-adolescents-equillium-readout-amgen-goes-shopping-achilles-ipo-1030263061
973.0,4/6/2021 2:03:27 PM,8 Retirement Stocks to Buy for Any Market Conditions,InvestorPlace,/news/stocks/8-retirement-stocks-to-buy-for-any-market-conditions-1030277583
974.0,4/6/2021 2:55:42 PM,Is Silicon Valley Replacing Big Pharma In Neuroscience?,Benzinga,/news/stocks/is-silicon-valley-replacing-big-pharma-in-neuroscience-1030277135
975.0,4/16/2021 10:52:08 AM,Lilly requests withdrawal of emergency use nod of bamlanivimab alone in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682491-lilly-requests-withdrawal-of-emergency-use-nod-of-bamlanivimab-alone-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
976.0,4/16/2021 12:42:04 PM,Amgen completes $1.9B acquisition of Five Prime Therapeutics,Seeking Alpha,https://seekingalpha.com/news/3682565-amgen-completes-19b-acquisition-of-five-prime-therapeutics?utm_source=markets.businessinsider.com&utm_medium=referral
977.0,4/16/2021 12:50:40 PM,Eli Lilly Requests FDA Revoke EUA For Bamlanivimab 700 Mg Alone - Quick Facts ,RTTNews,/news/stocks/eli-lilly-requests-fda-revoke-eua-for-bamlanivimab-700-mg-alone-quick-facts-1030312052
978.0,4/16/2021 2:00:59 PM,"The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-precision-biosciences-regains-rights-to-car-t-candidates-cfo-changes-2-ipos-1030312278
979.0,4/18/2021 1:18:56 AM,AACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapy,Seeking Alpha,https://seekingalpha.com/news/3682763-eli-lillys-kras-battle-affimeds-new-cell-therapy-graced-aacr-2021?utm_source=markets.businessinsider.com&utm_medium=referral
980.0,4/19/2021 8:25:39 PM,FDA grants Amgen's bemarituzumab Breakthrough Therapy designation,Seeking Alpha,https://seekingalpha.com/news/3683144-fda-grants-amgens-bemarituzumab-breakthrough-therapy-designation?utm_source=markets.businessinsider.com&utm_medium=referral
981.0,4/19/2021 10:50:39 PM,Amgen's Investigational Bemarituzumab Receives Breakthrough Therapy Designation ,RTTNews,/news/stocks/amgen-s-investigational-bemarituzumab-receives-breakthrough-therapy-designation-1030319657
982.0,4/20/2021 2:06:58 PM,"The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex",Benzinga,/news/stocks/the-daily-biotech-pulse-q1-beat-from-johnson-johnson-kalvista-study-placed-on-hold-european-label-expansion-for-gw-pharma-s-epidiolex-1030322640
983.0,4/22/2021 7:47:21 PM,House Democrats reintroduce bill to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3684755-house-democrats-reintroduce-bill-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral
984.0,4/23/2021 8:29:48 PM,Amgen announces detailed results from positive Phase 3 trial for Otezla in plaque psoriasis,Seeking Alpha,https://seekingalpha.com/news/3685264-amgen-announces-detailed-results-from-positive-phase-3-trial-for-otezla-in-plaque-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral
985.0,4/24/2021 3:24:00 PM,"The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx-1030340692
986.0,4/25/2021 3:01:40 PM,Amgen earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/amgen-stock-price-quarter-earnings-preview-q1-1030341687
987.0,4/26/2021 9:35:15 PM,Amgen Q1 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3685582-amgen-q1-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
988.0,4/26/2021 9:35:48 PM,Notable earnings after Tuesday's close,Seeking Alpha,https://seekingalpha.com/news/3685587-notable-earnings-after-tuesdays-close?utm_source=markets.businessinsider.com&utm_medium=referral
989.0,4/27/2021 8:04:38 PM,"Amgen EPS misses by $0.34, misses on revenue",Seeking Alpha,https://seekingalpha.com/news/3686417-amgen-eps-misses-0_34-misses-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
990.0,4/27/2021 10:05:19 PM,Amgen Inc. Q1 adjusted earnings of $3.70 per share,RTTNews,/news/stocks/amgen-inc-q1-adjusted-earnings-of-3-70-per-share-1030353887
991.0,4/27/2021 11:52:50 PM,15 Stocks Moving In Tuesday's After-Hours Session,Benzinga,/news/stocks/15-stocks-moving-in-tuesday-s-after-hours-session-1030354295
992.0,4/28/2021 1:01:08 PM,25 Stocks Moving in Wednesday's Pre-Market Session,Benzinga,/news/stocks/25-stocks-moving-in-wednesday-s-pre-market-session-1030357233
993.0,4/28/2021 2:40:48 PM,Amgen updates on LUMAKRAS dose comparison study,Seeking Alpha,https://seekingalpha.com/news/3686934-amgen-updates-on-lumakras-dose-comparison-study?utm_source=markets.businessinsider.com&utm_medium=referral
994.0,4/28/2021 6:06:35 PM,41 Stocks Moving In Wednesday's Mid-Day Session,Benzinga,/news/stocks/41-stocks-moving-in-wednesday-s-mid-day-session-1030359435
995.0,4/29/2021 10:00:37 AM,7 Pharmaceutical Stocks To Buy For Valuation Plus Solid Dividends,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-to-buy-for-valuation-plus-solid-dividends-1030363716
996.0,4/29/2021 11:21:32 AM,60 Biggest Movers From Yesterday,Benzinga,/news/stocks/60-biggest-movers-from-yesterday-1030363445
997.0,4/29/2021 2:15:50 PM,"The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx",Benzinga,/news/stocks/the-daily-biotech-pulse-clinical-setback-for-adverum-galera-posts-data-readout-moderna-to-invest-in-vaccine-manufacturing-decision-day-for-ardelyx-1030364740
998.0,4/29/2021 6:10:51 PM,7 Health-Focused ETFs To Buy Now For the Post-Covid Future,InvestorPlace,/news/stocks/7-health-focused-etfs-to-buy-now-for-the-post-covid-future-1030366420
999.0,4/30/2021 11:35:10 AM,Revolution Medicines expects no data from Amgen-sponsored clinical trial for RMC-4630,Seeking Alpha,https://seekingalpha.com/news/3688568-revolution-medicines-expects-no-data-from-amgen-sponsored-clinical-trial-for-rmc-4630?utm_source=markets.businessinsider.com&utm_medium=referral
1000.0,4/30/2021 1:25:49 PM,"Bristol-Myers cut to neutral, Community Health upgraded in today's healthcare analyst action",Seeking Alpha,https://seekingalpha.com/news/3688674-bristol-myers-cut-to-neutral-at-morgan-stanly-community-health-upgraded-after-q1-results?utm_source=markets.businessinsider.com&utm_medium=referral
1001.0,5/1/2021 7:19:25 PM,"Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge",Benzinga,/news/stocks/week-ahead-in-biotech-may-2-8-chemocentryx-adcom-ophthalmology-conference-presentations-earnings-deluge-1030373608
1002.0,5/3/2021 8:48:47 PM,Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics,Benzinga,/news/stocks/astellas-walks-away-from-450m-research-discovery-partnership-with-cytokinetics-1030380319
1003.0,5/4/2021 1:06:04 PM,Amgen launches Humira biosimilar in Canada,Seeking Alpha,https://seekingalpha.com/news/3690138-amgen-launches-humira-biosimilar-in-canada?utm_source=markets.businessinsider.com&utm_medium=referral
1004.0,5/4/2021 3:40:26 PM,Shares of major drug makers in focus as House committees hold hearings on drug pricing bill,Seeking Alpha,https://seekingalpha.com/news/3690229-shares-of-major-drug-makers-in-focus-as-house-committees-hold-hearings-on-drug-pricing-bill?utm_source=markets.businessinsider.com&utm_medium=referral
1005.0,5/5/2021 1:24:06 PM,FDA accepts Amgen's Otezla application in plaque psoriasis,Seeking Alpha,https://seekingalpha.com/news/3691096-fda-accepts-amgens-otezla-application-in-plaque-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral
1006.0,5/5/2021 3:16:48 PM,Amgen: FDA To Review SNDA For Otezla - Quick Facts ,RTTNews,/news/stocks/amgen-fda-to-review-snda-for-otezla-quick-facts-1030391150
1007.0,5/9/2021 4:20:33 PM,"The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-9-15-heron-apellis-fda-decisions-presentations-and-earnings-1030405849
1008.0,5/11/2021 3:29:21 PM,Amgen To Present Four Cardiovascular Research Abstracts ,RTTNews,/news/stocks/amgen-to-present-four-cardiovascular-research-abstracts-1030415310
1009.0,5/13/2021 9:34:56 AM,"Amgen Says, 'Tezepelumab Reduced Exacerbations Requiring Hospitalization By 85%' ",RTTNews,/news/stocks/amgen-says-tezepelumab-reduced-exacerbations-requiring-hospitalization-by-85-1030424842
1010.0,5/14/2021 1:59:10 PM,"The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-cormedix-slumps-on-delay-in-resubmission-of-defencath-nda-apellis-awaits-fda-decision-vera-therapeutics-debuts-1030430449
1011.0,5/17/2021 5:17:56 PM,Sandoz Says US Supreme Court Denies Its Petition To Review Biosimilar Erelzi Case ,RTTNews,/news/stocks/sandoz-says-us-supreme-court-denies-its-petition-to-review-biosimilar-erelzi-case-1030437422
1012.0,5/17/2021 7:27:31 PM,Novartis suffers setback in plans to launch a generic version of Amgen’s Enbrel,Seeking Alpha,https://seekingalpha.com/news/3697319-novartis-suffers-setback-in-plans-to-launch-a-generic-version-of-amgens-enbrel?utm_source=markets.businessinsider.com&utm_medium=referral
1013.0,5/20/2021 2:12:01 PM,"Merck downgraded to hold at Argus, Allogene upped at Truist, and more in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3698655-merck-downgraded-to-hold-at-argus-allogene-upped-at-truist-and-more-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
1014.0,5/20/2021 3:48:51 PM,Sorrento Reports Encouraging Data From Sofusa-Administered Enbrel In Rheumatoid Arthritis,Benzinga,/news/stocks/sorrento-reports-encouraging-data-from-sofusa-administered-enbrel-in-rheumatoid-arthritis-1030451387
1015.0,5/28/2021 4:54:55 PM,Amgen and Mirati spike on FDA approval for KRAS inhibitor Lumakras in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3701306-amgen-and-mirati-spike-on-fda-approval-for-kras-inhibitor-lumakras-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1016.0,5/28/2021 7:00:20 PM,Amgen's Lumakras can target 13% of the NSCLC market,Seeking Alpha,https://seekingalpha.com/news/3701338-amgen-mirati-lumakras-can-target-13-of-the-nsclc-market?utm_source=markets.businessinsider.com&utm_medium=referral
1017.0,5/28/2021 7:30:56 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3701334-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
1018.0,5/31/2021 5:06:35 PM,"The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes",Benzinga,/news/stocks/the-week-ahead-in-biotech-asco-presentations-front-and-center-fda-decisions-due-for-scynexis-liminal-and-alkermes-1030479173
1019.0,6/1/2021 11:01:31 AM,"Amgen, Kyowa Kirin To Jointly Develop, Commercialize KHK4083 - Quick Facts ",RTTNews,/news/stocks/amgen-kyowa-kirin-to-jointly-develop-commercialize-khk4083-quick-facts-1030480549
1020.0,6/4/2021 4:21:24 PM,Amgen Says Follow-up Phase 2 FIGHT Trial Data Shows Improved OS - Quick Facts ,RTTNews,/news/stocks/amgen-says-follow-up-phase-2-fight-trial-data-shows-improved-os-quick-facts-1030495603
1021.0,6/4/2021 9:01:55 PM,"Data supports overall response, durable survival for Amgen's Lumakras in lung cancer",Seeking Alpha,https://seekingalpha.com/news/3703480-data-supports-overall-response-durable-survival-for-amgen-miratis-lumakras-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1022.0,6/7/2021 12:49:44 PM,"Merus upgraded on ASCO update, Cantor favors Harpoon after selloff; and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3703658-merus-upgraded-on-asco-update-citi-favors-harpoon-after-selloff-and-more-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
1023.0,6/7/2021 5:50:35 PM,Expert Ratings for Amgen,Benzinga,/news/stocks/expert-ratings-for-amgen-1030500413
1024.0,6/7/2021 9:25:20 PM,5 Top ETFs With Exposure To Biogen,Benzinga,/news/etf/5-top-etfs-with-exposure-to-biogen-1030500950
1025.0,6/15/2021 2:00:00 PM,Acclaimed Makeup Artist Allan Avendaño Opens Up About Personal Skin Condition: Provides INSIDE LOOK At Life With Plaque Psoriasis,PR Newswire,/news/stocks/acclaimed-makeup-artist-allan-avendaño-opens-up-about-personal-skin-condition-provides-inside-look-at-life-with-plaque-psoriasis-1030523437
1026.0,6/22/2021 3:12:00 PM,Sen. Wyden releases 'principles for drug pricing reform',Seeking Alpha,https://seekingalpha.com/news/3708721-sen-wyden-releases-principles-for-drug-price-reform?utm_source=markets.businessinsider.com&utm_medium=referral
1027.0,6/23/2021 8:54:51 AM,Amgen's Aimovig OK'd in Japan for migraine attacks in adults,Seeking Alpha,https://seekingalpha.com/news/3708996-amgens-aimovig-okd-in-japan-for-migraine-attacks-in-adults?utm_source=markets.businessinsider.com&utm_medium=referral
1028.0,6/23/2021 10:00:00 AM,Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults,PR Newswire,/news/stocks/amgen-announces-approval-of-aimovig-erenumab-in-japan-for-the-suppression-of-onset-of-migraine-attacks-in-adults-1030545733
1029.0,6/23/2021 12:04:56 PM,Amgen: Aimovig Approved In Japan To Suppress Onset Of Migraine Attacks In Adults ,RTTNews,/news/stocks/amgen-aimovig-approved-in-japan-to-suppress-onset-of-migraine-attacks-in-adults-1030545996
1030.0,6/23/2021 1:35:16 PM,"The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway",Benzinga,/news/stocks/the-daily-biotech-pulse-gemini-sinks-on-data-amgen-s-migraine-drug-approved-in-japan-liver-congress-gets-underway-1030546471
1031.0,6/23/2021 6:44:55 PM,14 Biotech Stocks To Watch Over The Next 6 Months,Benzinga,/news/stocks/14-biotech-stocks-to-watch-over-the-next-6-months-1030548271
1032.0,7/1/2021 9:29:25 PM,Labcorp launches companion diagnostic for Amgen's Lumakras,Seeking Alpha,https://seekingalpha.com/news/3712252-labcorp-launches-companion-diagnostic-for-amgens-lumakras?utm_source=markets.businessinsider.com&utm_medium=referral
1033.0,7/2/2021 1:38:37 PM,"The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures",Benzinga,/news/stocks/the-daily-biotech-pulse-iterum-s-regulatory-setback-decision-day-for-provention-bio-cidara-outset-medical-announce-cfo-departures-1030575170
1034.0,7/2/2021 1:44:10 PM,Famed oncology drugs researcher Jean-Charles Soria headed to Amgen - Endpoints,Seeking Alpha,https://seekingalpha.com/news/3712387-famed-oncology-drugs-researcher-jean-charles-soria-headed-to-amgen-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral
1035.0,7/8/2021 8:00:00 AM,Tezepelumab Granted Priority Review By U.S. FDA,PR Newswire,/news/stocks/tezepelumab-granted-priority-review-by-u-s-fda-1030588261
1036.0,7/8/2021 8:26:22 AM,Amgen : FDA Grants Priority Review For Tezepelumab In Treatment Of Asthma ,RTTNews,/news/stocks/amgen-fda-grants-priority-review-for-tezepelumab-in-treatment-of-asthma-1030588325
1037.0,7/8/2021 10:08:14 AM,FDA grants Priority Review to Amgen's tezepelumab application in asthma,Seeking Alpha,https://seekingalpha.com/news/3713522-fda-grants-priority-review-to-amgens-tezepelumab-application-in-asthma?utm_source=markets.businessinsider.com&utm_medium=referral
1038.0,7/8/2021 11:42:48 AM,AstraZeneca’s marketing application for asthma therapy accepted by FDA,Seeking Alpha,https://seekingalpha.com/news/3713553-astrazenecas-marketing-application-for-asthma-therapy-accepted-by-fda?utm_source=markets.businessinsider.com&utm_medium=referral
1039.0,7/8/2021 1:45:17 PM,"The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test",Benzinga,/news/stocks/the-daily-biotech-pulse-priority-review-for-amgen-s-asthma-treatment-evaxion-reports-positive-skin-cancer-readout-quidel-recalls-lyra-covid-19-test-1030589266
1040.0,7/8/2021 7:38:27 PM,"House Oversight report says pharmas spend more on buybacks, dividends than R&D",Seeking Alpha,https://seekingalpha.com/news/3713778-house-oversight-report-says-pharmas-spend-more-on-buybacks-dividends-than-research-development?utm_source=markets.businessinsider.com&utm_medium=referral
1041.0,7/9/2021 4:10:14 AM,BeiGene's Kyprolis OK'd in China for multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3713872-beigenes-kyprolis-okd-in-china-for-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral
1042.0,7/9/2021 1:36:16 PM,"The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-morphic-s-positive-data-at-ecco-humanigen-s-covid-treatment-gets-expedited-review-in-uk-transcode-ipo-1030592766
1043.0,7/11/2021 1:00:00 PM,"Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says",Seeking Alpha,https://seekingalpha.com/news/3714139-biotech-ma-may-heat-up-with-potential-targets-horizon-therapeutics-arrowhead-pharma?utm_source=markets.businessinsider.com&utm_medium=referral
1044.0,7/14/2021 2:00:00 PM,Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge,PR Newswire,/news/stocks/amgen-and-the-international-federation-of-psoriasis-associations-launch-uplift-innovation-challenge-1030606116
1045.0,7/19/2021 8:32:34 PM,Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data,Benzinga,/news/stocks/analysts-see-higher-success-chances-for-cytokinetics-heart-disease-candidate-after-positive-phase-2-data-1030621590
1046.0,7/27/2021 10:19:00 PM,Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments,PR Newswire,/news/stocks/amgen-to-acquire-privately-held-teneobio-for-900-million-in-cash-with-future-contingent-milestone-payments-1030652437
1047.0,7/28/2021 12:37:21 AM,Amgen To Acquire Teneobio For $900 Mln ,RTTNews,/news/stocks/amgen-to-acquire-teneobio-for-900-mln-1030652911
1048.0,7/29/2021 10:00:00 PM,Amgen Announces Webcast Of 2021 Second Quarter Financial Results,PR Newswire,/news/stocks/amgen-announces-webcast-of-2021-second-quarter-financial-results-1030664255
1049.0,7/30/2021 1:10:00 AM,Amgen Appoints S. Omar Ishrak To Board Of Directors,PR Newswire,/news/stocks/amgen-appoints-s-omar-ishrak-to-board-of-directors-1030664957
1050.0,7/30/2021 8:03:05 PM,Amgen declares $1.76 dividend,Seeking Alpha,https://seekingalpha.com/news/3722637-amgen-inc-declares-1_76-dividend?utm_source=markets.businessinsider.com&utm_medium=referral
1051.0,7/30/2021 10:00:00 PM,Amgen Announces 2021 Third Quarter Dividend,PR Newswire,/news/stocks/amgen-announces-2021-third-quarter-dividend-1030669371
1052.0,8/1/2021 3:01:51 PM,Here's what Wall Street expects from Amgen's earnings report,Markets Insider Automation,/news/stocks/amgen-q2-quarterly-earnings-preview-stock-1030671353
1053.0,8/2/2021 9:35:38 PM,Notable earnings after Tuesday's close,Seeking Alpha,https://seekingalpha.com/news/3722986-notable-earnings-after-tuesdays-close?utm_source=markets.businessinsider.com&utm_medium=referral
1054.0,8/3/2021 2:43:35 PM,What Will the Stock Market Do Today? 3 Big Stories to Watch.,InvestorPlace,/news/stocks/what-will-the-stock-market-do-today-3-big-stories-tcehy-stock-chinese-stocks-1030684399
1055.0,8/3/2021 8:02:51 PM,"Amgen EPS beats by $0.37, beats on revenue, boost buyback",Seeking Alpha,https://seekingalpha.com/news/3724309-amgen-eps-beats-by-037-beats-on-revenue-boost-buyback?utm_source=markets.businessinsider.com&utm_medium=referral
1056.0,8/3/2021 8:40:49 PM,Amgen lowers 2021 earnings guidance despite revenue beat,Seeking Alpha,https://seekingalpha.com/news/3724442-amgen-lowers-2021-earnings-guidance-despite-revenue-beat?utm_source=markets.businessinsider.com&utm_medium=referral
1057.0,8/3/2021 10:01:00 PM,Amgen Reports Second Quarter 2021 Financial Results,PR Newswire,/news/stocks/amgen-reports-second-quarter-2021-financial-results-1030685419
1058.0,8/3/2021 10:08:18 PM,Amgen Inc. Q2 adjusted earnings of $4.38 per share,RTTNews,/news/stocks/amgen-inc-q2-adjusted-earnings-of-4-38-per-share-1030685371
1059.0,8/5/2021 3:53:00 PM,Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook,Moodys,/news/bonds/amgen-inc-moody-s-assigns-baa1-rating-to-amgen-s-new-sr-unsecured-notes-stable-outlook-1030696706
1060.0,8/5/2021 4:00:00 PM,Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook,Moodys,/news/bonds/amgen-inc-moody-s-assigns-baa1-rating-to-amgen-s-new-sr-unsecured-notes-stable-outlook-1030696705
1061.0,8/6/2021 8:00:09 PM,Bioethicist Ezekiel Emanuel under consideration for FDA commissioner - Politico,Seeking Alpha,https://seekingalpha.com/news/3727179-bioethicist-ezekiel-emanuel-under-consideration-for-fda-commissioner-politico?utm_source=markets.businessinsider.com&utm_medium=referral
1062.0,8/7/2021 6:34:16 PM,UBS highlights 20 top dividend stocks in tough times for yield: Alpha Tactics,Seeking Alpha,https://seekingalpha.com/news/3727237-ubs-highlights-top-divident-stocks-in-tough-times-for-yield?utm_source=markets.businessinsider.com&utm_medium=referral
1063.0,8/10/2021 1:12:18 PM,"Moderna, on the cusp of a $200B market cap, surpasses Merck in value",Seeking Alpha,https://seekingalpha.com/news/3728197-moderna-on-the-cusp-of-a-200b-market-cap-surpasses-merck-in-value?utm_source=markets.businessinsider.com&utm_medium=referral
1064.0,8/10/2021 4:55:01 PM,Moderna's Stock Valuation Goes From 'Unreasonable To Ridiculous': Analyst,Benzinga,/news/stocks/moderna-s-stock-valuation-goes-from-unreasonable-to-ridiculous-analyst-1030714344
1065.0,8/12/2021 10:00:53 AM,3 Best Biotech Stocks To Buy for Upcoming Catalysts,InvestorPlace,/news/stocks/3-best-biotech-stocks-to-buy-for-upcoming-catalysts-1030723346
1066.0,8/20/2021 2:14:06 AM,Acting FDA head Woodcock ruled out as permanent nominee - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3732564-acting-fda-head-woodcock-ruled-out-as-permanent-nominee-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral
1067.0,8/24/2021 12:51:04 PM,Cara extends gains with positive views from analysts on approval for pruritus drug,Seeking Alpha,https://seekingalpha.com/news/3733478-cara-extends-gains-with-positive-views-from-analysts-on-approval-for-pruritus-drug?utm_source=markets.businessinsider.com&utm_medium=referral
1068.0,8/27/2021 10:30:00 AM,New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS),PR Newswire,/news/stocks/new-data-at-esc-congress-2021-shows-repatha-evolocumab-improves-features-of-plaque-stability-in-patients-with-acute-coronary-syndrome-acs-1030763089
1069.0,8/27/2021 1:06:42 PM,"CBO: Drug pricing bill could stymie pharma, biotech R&D",Seeking Alpha,https://seekingalpha.com/news/3734838-cbo-drug-pricing-bill-could-stymie-pharma-biotech-research-development?utm_source=markets.businessinsider.com&utm_medium=referral
1070.0,8/31/2021 10:00:13 AM,Atossa Therapeutics Has a Steep Climb Ahead of It,InvestorPlace,/news/stocks/atossa-therapeutics-atos-stock-has-a-steep-climb-ahead-of-it-1030769096
1071.0,9/1/2021 3:50:24 PM,Healthcare groups ask Democrats to back drug pricing reforms in reconciliation package,Seeking Alpha,https://seekingalpha.com/news/3736163-healthcare-groups-ask-democrats-to-back-drug-pricing-reforms-in-reconciliation-package?utm_source=markets.businessinsider.com&utm_medium=referral
1072.0,9/3/2021 10:00:00 PM,Amgen to Present at the 16th Annual Citi BioPharma Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-16th-annual-citi-biopharma-conference-1030780394
1073.0,9/5/2021 1:15:00 PM,New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps,PR Newswire,/news/stocks/new-tezepelumab-data-show-86-reduction-in-exacerbations-in-patients-with-severe-asthma-and-comorbid-nasal-polyps-1030780925
1074.0,9/5/2021 4:56:35 PM,Amgen's Tezepelumab Reduces Exacerbations In Patients With Severe Asthma & Comorbid Nasal Polyps ,RTTNews,/news/stocks/amgen-s-tezepelumab-reduces-exacerbations-in-patients-with-severe-asthma-comorbid-nasal-polyps-1030781005
1075.0,9/7/2021 4:02:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-7-2021-1030784466
1076.0,9/8/2021 10:00:00 PM,Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21,PR Newswire,/news/stocks/amgen-presents-new-data-from-thoracic-oncology-portfolio-at-wclc21-1030788325
1077.0,9/9/2021 11:00:00 PM,Amgen to Present at the 19th Annual Morgan Stanley Global Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-19th-annual-morgan-stanley-global-healthcare-conference-1030791358
1078.0,9/13/2021 3:00:00 PM,Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021,PR Newswire,/news/stocks/amgen-to-showcase-new-data-from-inflammation-portfolio-at-eadv-virtual-congress-2021-1030795891
1079.0,9/13/2021 10:00:00 PM,Amgen To Webcast Investor Call At ESMO 2021,PR Newswire,/news/stocks/amgen-to-webcast-investor-call-at-esmo-2021-1030796680
1080.0,9/13/2021 10:15:00 PM,Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-2021-bank-of-america-merrill-lynch-global-healthcare-conference-1030796706
1081.0,9/14/2021 1:47:32 PM,Zai Lab Reports Breakthrough Therapy Designation For Bemarituzumab In China ,RTTNews,/news/stocks/zai-lab-reports-breakthrough-therapy-designation-for-bemarituzumab-in-china-1030798121
1082.0,9/14/2021 1:50:13 PM,"The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-nrx-rises-on-covid-19-drug-collaboration-amgen-s-lung-cancer-drug-conditionally-approved-in-canada-coherus-data-readout-1030798122
1083.0,9/15/2021 8:23:34 PM,Narrower drug pricing bill introduced in House by centrist Democrats,Seeking Alpha,https://seekingalpha.com/news/3740127-narrower-drug-pricing-bill-introduced-in-house-by-centrist-democrats?utm_source=markets.businessinsider.com&utm_medium=referral
1084.0,9/15/2021 9:20:09 PM,House committee approves portion of spending package that includes drug price negotiation,Seeking Alpha,https://seekingalpha.com/news/3740192-house-committee-approves-portion-of-spending-package-that-includes-drug-price-negotiation?utm_source=markets.businessinsider.com&utm_medium=referral
1085.0,9/16/2021 10:30:00 AM,LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer,PR Newswire,/news/stocks/lumakras-sotorasib-combined-with-vectibix-panitumumab-showed-encouraging-efficacy-and-safety-in-patients-with-kras-g12c-mutated-colorectal-cancer-1030803777
1086.0,9/16/2021 12:04:17 PM,"Amgen: LUMAKRAS With Vectibix Showed Encouraging Efficacy, Safety In KRAS G12C-Mutated CRC ",RTTNews,/news/stocks/amgen-lumakras-with-vectibix-showed-encouraging-efficacy-safety-in-kras-g12c-mutated-crc-1030803991
1087.0,9/20/2021 3:18:54 PM,Penny Biotech Stocks: 8 Things for Verastem Investors to Know as VSTM Stock Shoots Higher,InvestorPlace,/news/stocks/penny-biotech-stocks-8-things-for-verastem-investors-to-know-as-vstm-stock-shoots-higher-1030810490
1088.0,9/21/2021 1:02:00 AM,Amgen Wins Patent Case on Otezla® (apremilast),PR Newswire,/news/stocks/amgen-wins-patent-case-on-otezla-apremilast-1030811332
1089.0,9/21/2021 2:20:50 PM,"The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data",Benzinga,/news/stocks/the-daily-biotech-pulse-aprea-jumps-on-esmo-presentation-verrica-sinks-on-regulatory-setback-aerie-ceo-quits-j-j-touts-positive-covid-19-booster-shot-data-1030812654
1090.0,9/22/2021 3:00:00 PM,Amgen Releases 8th Edition of Biosimilar Trends Report,PR Newswire,/news/stocks/amgen-releases-8th-edition-of-biosimilar-trends-report-1030816017
1091.0,9/22/2021 10:00:00 PM,Amgen To Present At The 2021 Cantor Global Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-2021-cantor-global-healthcare-conference-1030817234
1092.0,9/23/2021 4:06:30 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-23-2021-1030819280
1093.0,9/25/2021 2:09:00 AM,FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia,PR Newswire,/news/stocks/fda-approves-repatha-evolocumab-in-pediatric-patients-age-10-and-older-with-heterozygous-familial-hypercholesterolemia-1030822885
1094.0,9/29/2021 11:00:00 PM,Amgen To Webcast Investor Call At EADV 2021,PR Newswire,/news/stocks/amgen-to-webcast-investor-call-at-eadv-2021-1030832319
1095.0,9/30/2021 6:01:30 PM,House Judiciary Committee approves bill to expedite biosimilar drugs to market,Seeking Alpha,https://seekingalpha.com/news/3746703-house-judiciary-committee-approves-bill-to-expedite-biosimilar-drugs-to-market?utm_source=markets.businessinsider.com&utm_medium=referral
1096.0,10/1/2021 7:00:00 PM,"Catalyst watch for next week: GM, Box and IBM events, Altria drama and auto prices watch",Seeking Alpha,https://seekingalpha.com/news/3747111-catalyst-watch-for-next-week-gm-box-and-ibm-events-altria-drama-and-auto-prices-watch?utm_source=markets.businessinsider.com&utm_medium=referral
1097.0,10/2/2021 12:00:00 PM,Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress,PR Newswire,/news/stocks/amgen-and-kyowa-kirin-present-positive-late-breaking-data-from-phase-2-study-of-amg-451-khk4083-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-at-eadv-congress-1030838644
1098.0,10/4/2021 10:00:00 PM,Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment,PR Newswire,/news/stocks/amgen-announces-new-data-highlighting-global-trends-in-hip-fracture-incidence-and-treatment-1030841927
1099.0,10/7/2021 12:30:00 PM,Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases,PR Newswire,/news/stocks/amgen-and-neumora-therapeutics-announce-strategic-r-d-collaboration-to-accelerate-novel-precision-therapies-for-brain-diseases-1030849695
1100.0,10/7/2021 12:53:44 PM,"Amgen, Neumora Collaborate To Advance Neuroscience Discovery - Quick Facts ",RTTNews,/news/stocks/amgen-neumora-collaborate-to-advance-neuroscience-discovery-quick-facts-1030849730
1101.0,10/7/2021 2:23:53 PM,"The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-invests-in-africa-amgen-announces-neuroscience-r-d-collaboration-decision-day-for-chemocentryx-biophytis-to-restate-results-1030850125
1102.0,10/7/2021 3:00:00 PM,Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021,PR Newswire,/news/stocks/amgen-announces-new-lumakras-sotorasib-combination-data-from-phase-1b-codebreak-101-study-in-patients-with-kras-g12c-mutated-cancers-at-aacr-nci-eortc-2021-1030850367
1103.0,10/7/2021 4:59:53 PM,Amgen To Present Lumakras Combination Data From Phase 1b Study On KRAS G12C-mutated Cancers ,RTTNews,/news/stocks/amgen-to-present-lumakras-combination-data-from-phase-1b-study-on-kras-g12c-mutated-cancers-1030850874
1104.0,10/8/2021 1:25:08 PM,AstraZeneca: FDA Grants Orphan Drug Designation To Tezepelumab For Eosinophilic Esophagitis ,RTTNews,/news/stocks/astrazeneca-fda-grants-orphan-drug-designation-to-tezepelumab-for-eosinophilic-esophagitis-1030852664
1105.0,10/8/2021 1:31:18 PM,"The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-allogene-sinks-on-fda-clinical-hold-takeda-gets-adcom-backing-quidel-reports-q3-covid-revenues-ipos-1030852687
1106.0,10/12/2021 2:13:34 PM,"The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology",Benzinga,/news/stocks/the-daily-biotech-pulse-nrx-stitches-covid-19-drug-partnership-protara-gets-nod-for-starting-bladder-cancer-study-igm-moves-beyond-oncology-1030858924
1107.0,10/12/2021 6:31:38 PM,Expert Ratings For Amgen,Benzinga,/news/stocks/expert-ratings-for-amgen-1030860014
1108.0,10/19/2021 3:17:00 PM,"Amgen Successfully Completes Acquisition Of Teneobio, Inc.",PR Newswire,/news/stocks/amgen-successfully-completes-acquisition-of-teneobio-inc-1030877780
1109.0,10/19/2021 9:10:23 PM,3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat,Benzinga,/news/stocks/3-biopharma-stocks-to-watch-following-johnson-johnson-s-earnings-beat-1030878749
1110.0,10/21/2021 10:00:00 PM,Amgen Announces 2021 Fourth Quarter Dividend,PR Newswire,/news/stocks/amgen-announces-2021-fourth-quarter-dividend-1030887104
1111.0,10/26/2021 10:00:00 PM,Fortune and Great Place to Work® Name Amgen One of the World's Best Workplaces™ in 2021,PR Newswire,/news/stocks/fortune-and-great-place-to-work-name-amgen-one-of-the-world-s-best-workplaces-in-2021-1030901482
1112.0,10/28/2021 10:00:00 PM,Amgen Announces Webcast Of 2021 Third Quarter Financial Results,PR Newswire,/news/stocks/amgen-announces-webcast-of-2021-third-quarter-financial-results-1030911943
1113.0,10/29/2021 2:14:43 PM,Aurinia Pharma may be worth $45-$53/share in a potential sale - analyst,Seeking Alpha,https://seekingalpha.com/news/3760897-aurinia-pharma-may-be-worth-45-53share-in-a-potential-sale-analyst?utm_source=markets.businessinsider.com&utm_medium=referral
1114.0,10/31/2021 7:23:54 PM,"The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-31-nov-6-earnings-pick-up-pace-eton-awaits-seizure-drug-approval-kidney-conference-more-ipos-in-the-pipeline-1030917750
1115.0,11/1/2021 2:01:23 PM,Aurinia Pharma drops after GlaxoSmithKline denies report on potential bid,Seeking Alpha,https://seekingalpha.com/news/3761428-aurinia-pharma-drops-after-glaxosmithkline-denies-report-on-potential-bid?utm_source=markets.businessinsider.com&utm_medium=referral
1116.0,11/1/2021 3:01:13 PM,Amgen earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/amgen-q3-earnings-preview-stock-1030921779
1117.0,11/1/2021 9:35:39 PM,Amgen Q3 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3761522-amgen-q3-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
1118.0,11/1/2021 9:35:55 PM,Notable earnings after Tuesday's close,Seeking Alpha,https://seekingalpha.com/news/3761467-notable-earnings-after-tuesdays-close?utm_source=markets.businessinsider.com&utm_medium=referral
1119.0,11/2/2021 12:52:53 PM,"The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-reports-solid-q3-earnings-regulatory-setback-for-legend-lilly-to-supply-additional-covid-19-antibody-cocktails-to-us-1030925781
1120.0,11/2/2021 8:04:27 PM,"Amgen EPS beats by $0.45, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3763263-amgen-eps-beats-0_45-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
1121.0,11/2/2021 8:36:05 PM,Amgen Q3 non-GAAP net income rises 8% YoY driven by 4% increase in revenues,Seeking Alpha,https://seekingalpha.com/news/3763382-amgen-q3-non-gaap-net-income-rises-8-yoy-driven-by-4-increase-in-revenues?utm_source=markets.businessinsider.com&utm_medium=referral
1122.0,11/2/2021 9:01:00 PM,Amgen Reports Third Quarter 2021 Financial Results,PR Newswire,/news/stocks/amgen-reports-third-quarter-2021-financial-results-1030928055
1123.0,11/2/2021 9:07:47 PM,Amgen Inc. Q3 adjusted earnings Miss Estimates,RTTNews,/news/stocks/amgen-inc-q3-adjusted-earnings-miss-estimates-1030928073
1124.0,11/2/2021 9:29:48 PM,Amgen Posts Promising FY Outlook After Narrower Profit In Q3 ,RTTNews,/news/stocks/amgen-posts-promising-fy-outlook-after-narrower-profit-in-q3-1030928173
1125.0,11/3/2021 5:30:09 PM,Where Amgen Stands With Analysts,Benzinga,/news/stocks/where-amgen-stands-with-analysts-1030933435
1126.0,11/4/2021 1:35:00 PM,A drugmaker's solid quarter has 'no surprises' (and 15% downside) for Baird,Seeking Alpha,https://seekingalpha.com/news/3764762-a-drugmakers-solid-quarter-has-no-surprises-and-15-downside-for-baird?utm_source=markets.businessinsider.com&utm_medium=referral
1127.0,11/5/2021 7:00:37 PM,"Catalyst watch for next week: Rivian IPO, Hertz redux, Disney+ Day and AMD event",Seeking Alpha,https://seekingalpha.com/news/3766361-catalyst-watch-for-next-week-rivian-ipo-hertz-redux-disney-day-and-amd-event?utm_source=markets.businessinsider.com&utm_medium=referral
1128.0,11/5/2021 8:59:45 PM,Amgen to invest $365 million for new manufacturing site in Ohio,Seeking Alpha,https://seekingalpha.com/news/3766461-amgen-to-invest-365-million-for-new-manufacturing-site-in-ohio?utm_source=markets.businessinsider.com&utm_medium=referral
1129.0,11/5/2021 9:00:00 PM,Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio,PR Newswire,/news/stocks/amgen-begins-construction-on-new-biomanufacturing-plant-in-central-ohio-1030943665
1130.0,11/8/2021 10:09:00 PM,"First And Only Randomized, Double-blind, Head-to-head Study Comparing Aimovig® (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia",PR Newswire,/news/stocks/first-and-only-randomized-double-blind-head-to-head-study-comparing-aimovig-erenumab-aooe-an-anti-cgrp-pathway-therapy-to-topiramate-published-in-cephalalgia-1030950807
1131.0,11/9/2021 2:13:10 PM,"The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data",Benzinga,/news/stocks/the-daily-biotech-pulse-double-dose-of-positive-tidings-for-merck-alkermes-slips-on-partial-termination-of-j-j-licensing-deal-amgen-migraine-drug-data-1030953661
1132.0,11/10/2021 5:25:18 PM,3 Nasdaq Stocks to Buy and Hold for Years,InvestorPlace,/news/stocks/3-nasdaq-stocks-to-buy-and-hold-for-years-1030960698
1133.0,11/10/2021 10:00:00 PM,Amgen To Present At The 2021 Annual Cowen IO Summit,PR Newswire,/news/stocks/amgen-to-present-at-the-2021-annual-cowen-io-summit-1030961201
1134.0,11/12/2021 12:40:11 PM,Amgen's Lumykras gets EMA's positive recommendation for approval in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3769987-amgens-lumykras-gets-emas-positive-recommendation-for-approval-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1135.0,11/12/2021 1:30:00 PM,LUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer,PR Newswire,/news/stocks/lumykras-sotorasib-receives-positive-opinion-from-ema-chmp-for-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer-1030969807
1136.0,11/12/2021 1:57:14 PM,Amgen : Lumakras Gets Positive CHMP Opinion For Advanced Non-Small Cell Lung Cancer ,RTTNews,/news/stocks/amgen-lumakras-gets-positive-chmp-opinion-for-advanced-non-small-cell-lung-cancer-1030969867
1137.0,11/17/2021 3:00:00 PM,"Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge",PR Newswire,/news/stocks/amgen-awards-the-bath-institute-of-rheumatic-diseases-25-000-through-uplift-innovation-challenge-1030984553
1138.0,11/19/2021 4:08:55 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-19-2021-1030991825
1139.0,11/19/2021 6:00:56 PM,Analyst Ratings For Amgen,Benzinga,/news/stocks/analyst-ratings-for-amgen-1030992180
1140.0,11/22/2021 12:09:21 PM,Novartis plans new sales approach for cholesterol lowering drug - WSJ,Seeking Alpha,https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj?utm_source=markets.businessinsider.com&utm_medium=referral
1141.0,11/22/2021 1:30:10 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1030994500
1142.0,11/24/2021 10:00:00 PM,Amgen To Present At The 2021 Piper Sandler Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-2021-piper-sandler-healthcare-conference-1031002231
1143.0,11/24/2021 10:05:00 PM,Amgen To Present At The 2021 Evercore ISI Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-2021-evercore-isi-healthcare-conference-1031002233
1144.0,11/29/2021 8:53:36 AM,Biotech Stocks Facing FDA Decision In December 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2021-1031007771
1145.0,11/29/2021 10:00:00 PM,Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year,PR Newswire,/news/stocks/amgen-named-to-dow-jones-sustainability-world-index-for-eighth-consecutive-year-1031010028
1146.0,11/30/2021 7:29:27 PM,7 Drug Stocks to Buy Now While They’re Still on Sale,InvestorPlace,/news/stocks/7-drug-stocks-to-buy-now-while-theyre-still-on-sale-1031013701
1147.0,12/1/2021 7:28:00 PM,FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent ...,PR Newswire,/news/stocks/fda-approves-new-kyprolis-carfilzomib-combination-regimen-with-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-and-dexamethasone-for-patients-with-multiple-myeloma-at-first-or-subsequent-1031017251
1148.0,12/1/2021 9:39:35 PM,Amgen shares topline data for Otezla in late-stage study for psoriasis,Seeking Alpha,https://seekingalpha.com/news/3776199-amgen-shares-topline-data-for-otezla-in-late-stage-study-for-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral
1149.0,12/1/2021 10:00:00 PM,Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis,PR Newswire,/news/stocks/amgen-announces-positive-top-line-results-from-otezla-apremilast-phase-3-discreet-study-in-moderate-to-severe-genital-psoriasis-1031017553
1150.0,12/2/2021 4:36:02 AM,Amgen : FDA Approves Kyprolis Combination Regimen For Multiple Myeloma Treatment ,RTTNews,/news/stocks/amgen-fda-approves-kyprolis-combination-regimen-for-multiple-myeloma-treatment-1031017923
1151.0,12/2/2021 1:51:33 PM,"The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-pfizer-biontech-ink-new-vaccine-deals-with-uk-gsk-vir-antibody-show-activity-against-omicron-chemomab-gets-clearance-1031019589
1152.0,12/2/2021 4:06:41 PM,Aurinia Pharmaceuticals gains amid takeover speculation,Seeking Alpha,https://seekingalpha.com/news/3776494-aurinia-pharmaceuticals-gains-on-takeover-speculation?utm_source=markets.businessinsider.com&utm_medium=referral
1153.0,12/2/2021 6:02:11 PM,Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-december-pdufa-dates-1031020805
1154.0,12/3/2021 7:02:42 PM,House Oversight Committee schedules Dec. 9 hearing on prescription drug prices,Seeking Alpha,https://seekingalpha.com/news/3777032-house-oversight-committee-schedules-dec-9-hearing-on-prescription-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral
1155.0,12/3/2021 9:03:44 PM,Amgen raises dividend by 10.2%,Seeking Alpha,https://seekingalpha.com/news/3777076-amgen-raises-dividend-by-102?utm_source=markets.businessinsider.com&utm_medium=referral
1156.0,12/3/2021 9:13:38 PM,Amgen raises dividend by 10% for first quarter of 2022,Seeking Alpha,https://seekingalpha.com/news/3777082-amgen-raises-dividend-by-10-for-first-quarter-of-2022?utm_source=markets.businessinsider.com&utm_medium=referral
1157.0,12/3/2021 10:00:00 PM,Amgen Announces 10% Increase In 2022 First Quarter Dividend,PR Newswire,/news/stocks/amgen-announces-10-increase-in-2022-first-quarter-dividend-1031023993
1158.0,12/6/2021 4:05:46 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-6-2021-1031026544
1159.0,12/6/2021 5:10:41 PM,What 8 Analyst Ratings Have To Say About Amgen,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-amgen-1031026733
1160.0,12/6/2021 5:31:26 PM,Amgen initiated with a buy at Goldman Sachs; sees 27% upside,Seeking Alpha,https://seekingalpha.com/news/3777455-amgen-initiated-with-a-buy-at-goldman-sachs-sees-27-upside?utm_source=markets.businessinsider.com&utm_medium=referral
1161.0,12/6/2021 8:50:20 PM,Biden calls on Senate to pass legislation to tackle 'outrageously expensive' drug prices,Seeking Alpha,https://seekingalpha.com/news/3777526-biden-call-on-senate-to-pass-legislation-to-tackle-outrageously-expensive-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral
1162.0,12/6/2021 10:00:00 PM,Amgen Announces New Data Being Presented At ASH 2021,PR Newswire,/news/stocks/amgen-announces-new-data-being-presented-at-ash-2021-1031027300
1163.0,12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161
1164.0,12/10/2021 8:00:40 PM,"Catalyst watch for next week: FOMC drama, events for Lowe's and Delta Air Lines, Rivian earnings",Seeking Alpha,https://seekingalpha.com/news/3779254-catalyst-watch-for-next-week-fomc-drama-events-for-lowes-and-delta-air-lines-rivian-earnings?utm_source=markets.businessinsider.com&utm_medium=referral
1165.0,12/13/2021 7:32:25 PM,Why does Pfizer's $6.7B acquisition of Arena Pharmaceuticals make sense? Etrasimod,Seeking Alpha,https://seekingalpha.com/news/3779629-why-does-pfizer-67b-acquisition-of-arena-pharmaceuticals-make-sense-etrasimod?utm_source=markets.businessinsider.com&utm_medium=referral
1166.0,12/14/2021 5:14:22 PM,"Moderna, Amgen withdraw from J.P. Morgan Conference citing COVID-19 concerns - Stat",Seeking Alpha,https://seekingalpha.com/news/3780025-moderna-amgen-withdraw-from-jp-morgan-conference-citing-covid-19-concerns-stat?utm_source=markets.businessinsider.com&utm_medium=referral
1167.0,12/16/2021 9:36:15 AM,Syngene International extends collaboration with Amgen,Seeking Alpha,https://seekingalpha.com/news/3780652-syngene-international-extends-collaboration-with-amgen?utm_source=markets.businessinsider.com&utm_medium=referral
1168.0,12/17/2021 9:46:45 PM,Amgen announces FDA approval of asthma therapy,Seeking Alpha,https://seekingalpha.com/news/3781460-amgen-announces-fda-approval-of-asthma-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
1169.0,12/17/2021 10:30:00 PM,FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA,PR Newswire,/news/stocks/fda-approves-tezspire-tezepelumab-ekko-in-the-u-s-for-severe-asthma-1031054275
1170.0,12/20/2021 8:33:27 AM,AstraZeneca And Amgen's Tezspire Approved In US For Severe Asthma ,RTTNews,/news/stocks/astrazeneca-and-amgen-s-tezspire-approved-in-us-for-severe-asthma-1031055337
1171.0,12/20/2021 10:25:00 PM,"FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL",PR Newswire,/news/stocks/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-regardless-of-severity-level-1031057653
1172.0,12/20/2021 11:08:37 PM,Amgen's Otezla approved for plaque psoriasis regardless of severity,Seeking Alpha,https://seekingalpha.com/news/3782168-amgen-otezla-approved-for-plaque-psoriasis-regardless-of-severity?utm_source=markets.businessinsider.com&utm_medium=referral
1173.0,12/22/2021 6:50:31 PM,BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today,InvestorPlace,/news/stocks/bad-etf-the-top-sin-stock-holdings-in-the-new-anti-esg-fund-that-debuts-today-1031062665
1174.0,12/23/2021 10:00:00 PM,AMGEN TO PRESENT AT THE GOLDMAN SACHS 14TH ANNUAL HEALTHCARE CEOS UNSCRIPTED CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-goldman-sachs-14th-annual-healthcare-ceos-unscripted-conference-1031065065
1175.0,1/4/2022 2:11:21 PM,"The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives",Benzinga,/news/stocks/the-daily-biotech-pulse-liquidia-jumps-on-new-ceo-appointment-spectrum-aravive-secure-new-funding-allena-to-explore-strategic-alternatives-1031076048
1176.0,1/5/2022 3:54:26 PM,Amgen downgraded to Neutral at Bank of America,Seeking Alpha,https://seekingalpha.com/news/3785469-amgen-downgraded-to-neutral-at-bank-of-america?utm_source=markets.businessinsider.com&utm_medium=referral
1177.0,1/5/2022 4:08:49 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-5-2022-1031079571
1178.0,1/5/2022 5:02:31 PM,Expert Ratings For Amgen,Benzinga,/news/stocks/expert-ratings-for-amgen-1031079707
1179.0,1/6/2022 12:56:30 PM,7 Pharmaceutical Stocks That Could Make You Rich,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-that-could-make-you-rich-1031081342
1180.0,1/6/2022 2:14:13 PM,"Amgen inks multi-target, multi-modality research collaboration with Generate Biomedicines",Seeking Alpha,https://seekingalpha.com/news/3785832-amgen-inks-multi-target-multi-modality-research-collaboration-with-generate-biomedicines?utm_source=markets.businessinsider.com&utm_medium=referral
1181.0,1/6/2022 3:00:00 PM,"AMGEN AND GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH COLLABORATION AGREEMENT",PR Newswire,/news/stocks/amgen-and-generate-biomedicines-announce-multi-target-multi-modality-research-collaboration-agreement-1031081623
1182.0,1/6/2022 5:14:08 PM,"IBB, the Nasdaq Biotechnology ETF, drops to a 52-week intraday trading low",Seeking Alpha,https://seekingalpha.com/news/3785918-ibb-the-nasdaq-biotechnology-etf-drops-to-a-52-week-intraday-trading-low?utm_source=markets.businessinsider.com&utm_medium=referral
1183.0,1/6/2022 10:00:00 PM,AMGEN TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-1031082503
1184.0,1/9/2022 11:24:23 PM,2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?,Benzinga,/news/stocks/2-chamath-palihapitiya-spac-deals-rumored-will-he-land-the-year-s-first-deal-once-again-1031089191
1185.0,1/10/2022 6:00:00 AM,EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER,PR Newswire,/news/stocks/european-commission-approves-lumykras-sotorasib-for-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer-1031089306
1186.0,1/10/2022 7:19:46 AM,EC approves Amgen's Lumykras for patients with KRAS G12C-mutated lung cancer,Seeking Alpha,https://seekingalpha.com/news/3786456-ec-approves-amgens-lumykras-for-patients-with-kras-g12c-mutated-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1187.0,1/11/2022 2:24:09 PM,Amgen collaborates with Arrakis targeting multiple therapeutic areas,Seeking Alpha,https://seekingalpha.com/news/3787100-amgen-collaborates-with-arrakis-targeting-multiple-therapeutic-areas?utm_source=markets.businessinsider.com&utm_medium=referral
1188.0,1/11/2022 3:00:00 PM,AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS,PR Newswire,/news/stocks/amgen-and-arrakis-therapeutics-announce-multi-target-collaboration-to-identify-novel-rna-degrader-small-molecule-therapeutics-1031094121
1189.0,1/11/2022 3:37:02 PM,"Amgen, Arrakis Collaborate To Discover RNA Degrader Small Molecule Therapeutics ",RTTNews,/news/stocks/amgen-arrakis-collaborate-to-discover-rna-degrader-small-molecule-therapeutics-1031094301
1190.0,1/13/2022 12:46:34 PM,BridgeBio partners with Amgen for a combination study involving cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3787797-bridgebio-partners-with-amgen-for-a-combination-study-involving-cancer-candidate?utm_source=markets.businessinsider.com&utm_medium=referral
1191.0,1/13/2022 1:00:00 PM,TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA,PR Newswire,/news/stocks/tezspire-tezepelumab-ekko-now-available-in-the-united-states-for-the-treatment-of-severe-asthma-1031099748
1192.0,1/13/2022 1:19:57 PM,"Amgen, AstraZeneca's Tezspire now available in U.S. for severe asthma",Seeking Alpha,https://seekingalpha.com/news/3787829-amgen-astrazenecas-tezspire-now-available-in-us-for-severe-asthma?utm_source=markets.businessinsider.com&utm_medium=referral
1193.0,1/13/2022 1:24:18 PM,"AstraZeneca, Amgen Announce Market Availability Of Tezspire - Quick Facts ",RTTNews,/news/stocks/astrazeneca-amgen-announce-market-availability-of-tezspire-quick-facts-1031099821
1194.0,1/19/2022 6:15:39 PM,CytomX rises 7% on FDA nod for phase 1 trial of CX-904 to treat solid tumors,Seeking Alpha,https://seekingalpha.com/news/3789303-cytomx-rises-7-on-fda-nod-for-phase-1-trial-of-cx-904-to-treat-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral
1195.0,1/20/2022 10:30:00 AM,LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER,PR Newswire,/news/stocks/lumakras-sotorasib-receives-approval-in-japan-for-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer-1031115195
1196.0,1/20/2022 10:57:20 AM,Amgen's LUMAKRAS approved in Japan for the treatment of non-small cell lung cancer patients with KRAS G12C mutations,Seeking Alpha,https://seekingalpha.com/news/3789506-amgens-lumakras-approved-in-japan-for-the-treatment-of-non-small-cell-lung-cancer-patients-with-kras-g12c-mutations?utm_source=markets.businessinsider.com&utm_medium=referral
1197.0,1/20/2022 2:28:42 PM,"The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-covid-shot-authorized-in-australia-zymeworks-restructures-orphan-drug-designation-for-marker-s-pancreatic-cancer-drug-1031116000
1198.0,1/24/2022 5:58:07 PM,All eyes on J&J Q4 results with new CEO and plans of company split,Seeking Alpha,https://seekingalpha.com/news/3790850-all-eyes-on-jj-q4-results-with-new-ceo-and-plans-of-company-split?utm_source=markets.businessinsider.com&utm_medium=referral
1199.0,1/25/2022 6:17:15 PM,"CBO report finds skyrocketing price increases for brand Rx drugs for Medicare, Medicaid",Seeking Alpha,https://seekingalpha.com/news/3791432-cbo-report-finds-skyrocketing-price-increases-for-brand-rx-drugs-for-medicare-medicaid?utm_source=markets.businessinsider.com&utm_medium=referral
1200.0,1/25/2022 6:50:12 PM,Biopharmas need to personalize engagement in competitive oncology landscape - Accenture,Seeking Alpha,https://seekingalpha.com/news/3791441-biopharmas-need-to-personalize-engagement-in-competitive-oncology-landscape-accenture?utm_source=markets.businessinsider.com&utm_medium=referral
1201.0,1/27/2022 6:57:41 PM,Say Hello to 2022’s Dogs of the Dow: 10 Dividend Stocks to Watch,InvestorPlace,/news/stocks/say-hello-to-2022s-dogs-of-the-dow-10-dividend-stocks-to-watch-1031136826
1202.0,2/3/2022 3:00:00 PM,"AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES",PR Newswire,/news/stocks/amgen-and-plexium-announce-multi-year-drug-discovery-collaboration-to-identify-novel-targeted-protein-degradation-therapies-1031159083
1203.0,2/3/2022 3:20:58 PM,"Amgen, Plexium Collaborate To Identify Novel Targeted Protein Degradation Therapies ",RTTNews,/news/stocks/amgen-plexium-collaborate-to-identify-novel-targeted-protein-degradation-therapies-1031159227
1204.0,2/3/2022 10:00:00 PM,AMGEN TO HOST VIRTUAL BUSINESS REVIEW MEETING,PR Newswire,/news/stocks/amgen-to-host-virtual-business-review-meeting-1031160228
1205.0,2/4/2022 6:51:26 PM,What's in Amgen's Q4 Earnings prescription?,Seeking Alpha,https://seekingalpha.com/news/3796168-whats-in-amgens-q4-earnings-prescription?utm_source=markets.businessinsider.com&utm_medium=referral
1206.0,2/6/2022 3:01:13 PM,Amgen earnings: here's what to expect,Markets Insider Automation,/news/stocks/amgen-stock-price-q4-earnings-preview-1031164233
1207.0,2/7/2022 10:18:25 AM,"5 Stocks To Watch For February 7, 2022",Benzinga,/news/stocks/5-stocks-to-watch-for-february-7-2022-1031166255
1208.0,2/7/2022 11:22:21 AM,A Peek Into The Markets: US Stock Futures Down; Crude Oil Falls Over 1%,Benzinga,/news/stocks/a-peek-into-the-markets-us-stock-futures-down-crude-oil-falls-over-1-1031166389
1209.0,2/7/2022 9:02:53 PM,"Amgen Non-GAAP EPS of $4.36 beats by $0.35, revenue of $6.85B misses by $20M",Seeking Alpha,https://seekingalpha.com/news/3796882-amgen-non-gaap-eps-of-4_36-beats-0_35-revenue-of-6_85b-misses-20m?utm_source=markets.businessinsider.com&utm_medium=referral
1210.0,2/7/2022 9:39:37 PM,Amgen net income rises ~18% YoY even as product revenue remained flat,Seeking Alpha,https://seekingalpha.com/news/3796934-amgen-net-income-rises-18-yoy-even-as-product-revenue-remained-flat?utm_source=markets.businessinsider.com&utm_medium=referral
1211.0,2/7/2022 10:01:00 PM,AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-reports-fourth-quarter-and-full-year-2021-financial-results-1031168519
1212.0,2/7/2022 10:08:13 PM,"Amgen Inc. Q4 Profit Increases, beats estimates",RTTNews,/news/stocks/amgen-inc-q4-profit-increases-beats-estimates-1031168571
1213.0,2/8/2022 2:21:45 PM,Amgen sets lower than expected guidance for 2022; plans up to $6B buybacks in Q1,Seeking Alpha,https://seekingalpha.com/news/3797213-amgen-sets-lower-than-expected-guidance-for-2022-plans-for-6b-buybacks-in-q1?utm_source=markets.businessinsider.com&utm_medium=referral
1214.0,2/8/2022 2:29:54 PM,"The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-amgen-shares-slip-on-earnings-editas-terminates-chief-medical-officer-biogen-licenses-preclinical-rheumatoid-arthritis-biosimilar-1031171617
1215.0,2/8/2022 2:36:00 PM,AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING,PR Newswire,/news/stocks/amgen-provides-long-term-guidance-through-2030-during-business-review-meeting-1031171668
1216.0,2/8/2022 3:02:39 PM,Amgen Issues FY22 & Long-term Guidance - Quick Facts ,RTTNews,/news/stocks/amgen-issues-fy22-long-term-guidance-quick-facts-1031172062
1217.0,2/8/2022 4:20:00 PM,AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW,PR Newswire,/news/stocks/amgen-outlines-growth-strategy-through-2030-at-virtual-business-review-1031172440
1218.0,2/8/2022 5:16:27 PM,Mirati shares fall 13% due to disappointing sales of Amgen rival lung cancer drug,Seeking Alpha,https://seekingalpha.com/news/3797376-mirati-shares-fall-13-due-to-disappointing-sales-of-amgen-rival-lung-cancer-drug?utm_source=markets.businessinsider.com&utm_medium=referral
1219.0,2/9/2022 1:29:26 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1031176588
1220.0,2/9/2022 5:41:44 PM,Will AstraZeneca's Q4 earnings bring positive surprise?,Seeking Alpha,https://seekingalpha.com/news/3797953-will-astrazenecas-q4-earnings-bring-positive-surprise?utm_source=markets.businessinsider.com&utm_medium=referral
1221.0,2/9/2022 7:01:58 PM,What 10 Analyst Ratings Have To Say About Amgen,Benzinga,/news/stocks/what-10-analyst-ratings-have-to-say-about-amgen-1031178277
1222.0,2/10/2022 7:20:31 PM,Amgen gets price target increases from Street firms after quarterly earnings,Seeking Alpha,https://seekingalpha.com/news/3798762-amgen-gets-price-target-increases-from-street-firms-after-quarterly-earnings?utm_source=markets.businessinsider.com&utm_medium=referral
1223.0,2/14/2022 11:00:23 AM,7 Defensive Growth Stocks to Buy for February,InvestorPlace,/news/stocks/7-defensive-growth-stocks-to-buy-for-february-1031191037
1224.0,2/14/2022 11:00:00 PM,LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL,PR Newswire,/news/stocks/lumakras-sotorasib-shows-encouraging-and-clinically-meaningful-anticancer-activity-in-patients-with-kras-g12c-mutated-advanced-pancreatic-cancer-in-codebreak-100-trial-1031192868
1225.0,2/15/2022 5:41:23 PM,GlaxoSmithKline the latest drugmaker to restrict discounts under 340B program,Seeking Alpha,https://seekingalpha.com/news/3800248-glaxosmithkline-latest-drugmaker-restrict-discounts-340b-safety-net-program?utm_source=markets.businessinsider.com&utm_medium=referral
1226.0,2/16/2022 12:18:48 PM,Mirati KRAS inhibitor goes under FDA review for lung cancer,Seeking Alpha,https://seekingalpha.com/news/3800618-mrtx-stock-falls-as-kras-inhibitor-goes-under-fda-review-for-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1227.0,2/16/2022 1:46:01 PM,"The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa",Benzinga,/news/stocks/the-daily-biotech-pulse-avenue-tumbles-on-negative-adcom-verdict-moderna-s-expanded-deal-with-rovi-gilead-takes-equity-stake-in-hookipa-1031200248
1228.0,2/16/2022 6:15:19 PM,Mirati price targets cut at Street firms following longer adagrasib review timeline,Seeking Alpha,https://seekingalpha.com/news/3800845-mirati-price-targets-cut-at-street-firms-following-longer-adagrasib-review-timeline?utm_source=markets.businessinsider.com&utm_medium=referral
1229.0,2/16/2022 10:00:00 PM,AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE,PR Newswire,/news/stocks/amgen-recognized-for-outstanding-esg-performance-1031202153
1230.0,2/22/2022 9:05:57 PM,Amgen issues inaugural $750M green bond,Seeking Alpha,https://seekingalpha.com/news/3802869-amgen-issues-inaugural-750m-green-bond?utm_source=markets.businessinsider.com&utm_medium=referral
1231.0,2/22/2022 10:00:00 PM,AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS,PR Newswire,/news/stocks/amgen-issues-inaugural-green-bond-to-advance-esg-goals-1031217676
1232.0,2/26/2022 5:45:00 PM,NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS,PR Newswire,/news/stocks/new-data-further-reinforce-efficacy-of-tezspire-tezepelumab-ekko-in-a-broad-population-of-severe-asthma-patients-1031234148
1233.0,3/2/2022 1:35:33 PM,"Biden pushes for insulin price cap, Medicare drug negotiations in SOTU",Seeking Alpha,https://seekingalpha.com/news/3808400-biden-pushes-for-insulin-price-cap-medicare-drug-negotiations-in-sotu?utm_source=markets.businessinsider.com&utm_medium=referral
1234.0,3/2/2022 8:48:55 PM,36 Stocks To Watch After Biden's First State of The Union Address,Benzinga,/news/stocks/36-stocks-to-watch-after-biden-s-first-state-of-the-union-address-1031248946
1235.0,3/2/2022 9:06:02 PM,Amgen declares $1.94 dividend,Seeking Alpha,https://seekingalpha.com/news/3808641-amgen-declares-194-dividend?utm_source=markets.businessinsider.com&utm_medium=referral
1236.0,3/2/2022 10:00:00 PM,AMGEN ANNOUNCES 2022 SECOND QUARTER DIVIDEND,PR Newswire,/news/stocks/amgen-announces-2022-second-quarter-dividend-1031249059
1237.0,3/2/2022 10:15:00 PM,AMGEN TO PRESENT AT THE 42ND ANNUAL COWEN HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-42nd-annual-cowen-healthcare-conference-1031249127
1238.0,3/4/2022 10:07:55 AM,Amgen inks deal with UK's NHS for lung cancer drug Lumykras,Seeking Alpha,https://seekingalpha.com/news/3809482-amgen-inks-deal-with-uks-nhs-for-lung-cancer-drug-lumykras?utm_source=markets.businessinsider.com&utm_medium=referral
1239.0,3/4/2022 7:54:08 PM,Akebia slips as JPMorgan flags regulatory risk for kidney disease drug,Seeking Alpha,https://seekingalpha.com/news/3809799-akba-stock-slips-as-jpmorgan-flags-regulatory-risk?utm_source=markets.businessinsider.com&utm_medium=referral
1240.0,3/7/2022 10:00:00 PM,GLOBAL BIOTECHNOLOGY LEADER AMGEN BREAKS GROUND ON NEW MANUFACTURING FACILITY IN NORTH CAROLINA,PR Newswire,/news/stocks/global-biotechnology-leader-amgen-breaks-ground-on-new-manufacturing-facility-in-north-carolina-1031260561
1241.0,3/8/2022 12:30:50 PM,Can-Fite delays topline data from late-stage psoriasis trial for lead asset,Seeking Alpha,https://seekingalpha.com/news/3810545-can-fite-delays-topline-data-from-late-stage-psoriasis-trial-for-lead-asset?utm_source=markets.businessinsider.com&utm_medium=referral
1242.0,3/8/2022 10:30:00 PM,AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022,PR Newswire,/news/stocks/amgen-to-present-long-term-outcomes-for-lumakras-sotorasib-in-kras-g12c-mutated-nsclc-at-aacr-2022-1031264189
1243.0,3/9/2022 2:25:52 PM,"AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar",Benzinga,/news/stocks/abbvie-alvotech-resolve-us-patent-dispute-related-to-humira-biosimilar-1031266276
1244.0,3/9/2022 3:28:13 PM,7 Dividend Stocks to Finance Your Golden Years,InvestorPlace,/news/stocks/7-dividend-stocks-to-finance-your-golden-years-1031266985
1245.0,3/9/2022 6:56:41 PM,Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why,Benzinga,/news/stocks/truist-sees-350-upside-on-this-cancer-focused-biopharma-stock---read-why-1031267423
1246.0,3/10/2022 10:00:00 PM,Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference,PR Newswire,/news/stocks/amgen-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference-1031271643
1247.0,3/25/2022 2:00:00 PM,AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022,PR Newswire,/news/stocks/amgen-announces-new-otezla-apremilast-data-at-aad-congress-2022-1031308072
1248.0,3/28/2022 10:25:11 AM,Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs,InvestorPlace,/news/stocks/which-chinese-stocks-will-be-delisted-8-in-u-s-crosshairs-1031311449
1249.0,3/31/2022 10:13:21 AM,Fresenius Kabi's Neulasta biosimilar Stimufend gets approval in EU,Seeking Alpha,https://seekingalpha.com/news/3819195-fresenius-kabis-neulasta-biosimilar-stimufend-gets-approval-in-eu?utm_source=markets.businessinsider.com&utm_medium=referral
1250.0,4/5/2022 10:59:46 AM,7 Biotech Stocks to Buy With Key Catalysts for April,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-with-key-catalysts-for-april-1031332726
1251.0,4/7/2022 7:43:39 PM,"House, Senate Democrats introduce bills targeting 'abusive' pharma business practices",Seeking Alpha,https://seekingalpha.com/news/3821821-house-senate-democrats-introduce-bills-targeting-abusive-pharma-business-practices?utm_source=markets.businessinsider.com&utm_medium=referral
1252.0,4/10/2022 6:00:00 PM,LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER,PR Newswire,/news/stocks/lumakras-sotorasib-codebreak-100-study-shows-two-year-overall-survival-of-32-5-in-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer-1031344673
1253.0,4/12/2022 6:07:15 PM,Where Amgen Stands With Analysts,Benzinga,/news/stocks/where-amgen-stands-with-analysts-1031350524
1254.0,4/13/2022 12:07:31 PM,"Deciphera's DCC-3116/KRAS Inhibitor Combo Shows Deeper, Longer Tumor Regressions In Preclinical Studies",Benzinga,/news/stocks/deciphera-s-dcc-3116-kras-inhibitor-combo-shows-deeper-longer-tumor-regressions-in-preclinical-studies-1031352829
1255.0,4/13/2022 4:04:38 PM,AbbVie down 6% following departure of president though presents buying opportunity,Seeking Alpha,https://seekingalpha.com/news/3823128-abbvie-down-6-following-departure-of-president-though-presents-buying-opportunity?utm_source=markets.businessinsider.com&utm_medium=referral
1256.0,4/18/2022 5:55:54 PM,Amgen and Vertex price targets raised at Jefferies ahead of 1Q earnings,Seeking Alpha,https://seekingalpha.com/news/3823957-amgn-vrtx-stocks-lower-even-after-bullish-views-at-jefferies?utm_source=markets.businessinsider.com&utm_medium=referral
1257.0,4/18/2022 8:27:58 PM,Amgen's biosimilar candidate to Stelara shows no clinically meaningful differences in study,Seeking Alpha,https://seekingalpha.com/news/3824066-amgens-biosimilar-candidate-to-stelara-shows-no-clinically-meaningful-differences-in-study?utm_source=markets.businessinsider.com&utm_medium=referral
1258.0,4/18/2022 10:00:00 PM,"AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)",PR Newswire,/news/stocks/amgen-announces-positive-top-line-results-from-phase-3-study-of-abp-654-biosimilar-candidate-to-stelara-ustekinumab-1031361739
1259.0,4/19/2022 10:30:16 AM,Want to Invest Your Tax Refund? 3 Long-Term Stocks to Consider,InvestorPlace,/news/stocks/3-long-term-stocks-to-consider-1031363461
1260.0,4/19/2022 3:05:03 PM,"The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu",Benzinga,/news/stocks/the-daily-biotech-pulse-regeneron-acquires-checkmate-pharma-moderna-s-bivalent-booster-covid-19-vaccine-update-priority-review-for-astrazeneca-s-enhertu-1031364260
1261.0,4/21/2022 12:10:33 PM,7 Potential Biotech Stocks Buyout Targets in 2022,InvestorPlace,/news/stocks/7-potential-biotech-stocks-targets-in-2022-1031371733
1262.0,4/22/2022 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-first-quarter-financial-results-1031376090
1263.0,4/23/2022 8:00:00 PM,COVID therapies and vaccines propel rise in spending on medicines in 2021,Seeking Alpha,https://seekingalpha.com/news/3825965-covid-therapies-and-vaccines-propel-rise-in-spending-on-medicines-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral
1264.0,4/26/2022 10:30:18 AM,What Stocks to Buy That Should Do Well in a Recession — Our 7 Top Picks,InvestorPlace,/news/stocks/recession-stocks-to-buy-that-will-do-well-in-a-recession-our-7-top-picks-mcd-tgt-wmt-pg-abbv-mgn-nrg-1031384084
1265.0,4/26/2022 3:01:13 PM,Amgen earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/amgen-stock-quarter-earnings-preview-q1-1031385092
1266.0,4/26/2022 4:55:37 PM,Amgen Q1 2022 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3826949-amgen-q1-2022-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
1267.0,4/26/2022 9:35:28 PM,Notable earnings after Wednesday's close,Seeking Alpha,https://seekingalpha.com/news/3826818-notable-earnings-after-wednesdays-close?utm_source=markets.businessinsider.com&utm_medium=referral
1268.0,4/27/2022 12:01:35 PM,Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen,Benzinga,/news/stocks/molecular-partners-regains-rights-to-early-stage-cancer-asset-from-amgen-1031390145
1269.0,4/27/2022 1:48:52 PM,Amgen's Repatha sustains reduction in bad cholesterol as per long term data from 2 studies,Seeking Alpha,https://seekingalpha.com/news/3827627-amgens-repatha-sustains-reduction-in-bad-cholesterol-in-long-term-data-from-2-studies?utm_source=markets.businessinsider.com&utm_medium=referral
1270.0,4/27/2022 2:45:57 PM,"The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis",Benzinga,/news/stocks/the-daily-biotech-pulse-molecular-partners-plunges-on-double-bad-news-pfizer-biontech-seek-nod-for-covid-19-shot-in-kids-pfizer-invests-in-zentalis-1031391072
1271.0,4/27/2022 3:00:00 PM,AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB),PR Newswire,/news/stocks/amgen-announces-results-from-two-open-label-extension-studies-of-repatha-evolocumab-1031391300
1272.0,4/27/2022 8:03:23 PM,"Amgen Non-GAAP EPS of $4.25 beats by $0.12, revenue of $6.2B beats by $90M",Seeking Alpha,https://seekingalpha.com/news/3827933-amgen-non-gaap-eps-of-4_25-beats-0_12-revenue-of-6_2b-beats-90m?utm_source=markets.businessinsider.com&utm_medium=referral
1273.0,4/27/2022 8:29:40 PM,Amgen posts Q1 beat driven by volumes even as Enbrel and Otezla sales decline,Seeking Alpha,https://seekingalpha.com/news/3828042-amgn-stock-slips-after-q1-2022-beat?utm_source=markets.businessinsider.com&utm_medium=referral
1274.0,4/27/2022 10:01:00 PM,AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-reports-first-quarter-2022-financial-results-1031392859
1275.0,4/27/2022 10:04:29 PM,"Amgen Inc. Q1 Profit Decreases, but beats estimates",RTTNews,/news/stocks/amgen-inc-q1-profit-decreases-but-beats-estimates-1031392903
1276.0,4/28/2022 2:52:43 PM,"The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-seeks-fda-approval-for-covid-19-shot-for-children-2-6-tax-disclosure-for-amgen-fast-track-tags-for-sqz-biotech-timber-pharma-candidates-1031397312
1277.0,4/28/2022 3:14:55 PM,Where Amgen Stands With Analysts,Benzinga,/news/stocks/where-amgen-stands-with-analysts-1031397751
1278.0,4/28/2022 6:04:17 PM,Piper Sandler Maintains Overweight Rating for Amgen: Here's What You Need To Know,Benzinga,/news/stocks/piper-sandler-maintains-overweight-rating-for-amgen-here-s-what-you-need-to-know-1031398394
1279.0,5/2/2022 2:26:53 PM,"The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-1-7-phathom-fda-decision-pfizer-vertex-pharma-lead-earnings-news-ophthalmology-conference-presentations-and-more-1031408449
1280.0,5/2/2022 3:00:00 PM,"AMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT",PR Newswire,/news/stocks/amgen-releases-annual-environmental-social-governance-report-1031408861
1281.0,5/3/2022 10:34:01 AM,Goldman highlights top sector picks for high dividend growth and yield,Seeking Alpha,https://seekingalpha.com/news/3830044-goldman-highlights-sector-picks-for-high-dividend-growth-and-yield?utm_source=markets.businessinsider.com&utm_medium=referral
1282.0,5/4/2022 10:39:59 AM,"Starbucks, Meta, Exxon among many stocks dropping off BofA's Alpha Surprise screen",Seeking Alpha,https://seekingalpha.com/news/3831217-starbucks-meta-exxon-among-many-stocks-dropping-off-bofas-alpa-surprise-screen?utm_source=markets.businessinsider.com&utm_medium=referral
1283.0,5/6/2022 11:33:52 AM,7 Defensive Dividend Healthcare Stocks to Buy Now,InvestorPlace,/news/stocks/7-defensive-healthcare-stocks-to-buy-now-1031430769
1284.0,5/6/2022 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-bank-of-america-healthcare-conference-1031431921
1285.0,5/10/2022 2:44:44 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1031441878
1286.0,5/10/2022 2:46:06 PM,Neurogenerative disease drug developer Vigil Neuroscience sees stock rally 19%,Seeking Alpha,https://seekingalpha.com/news/3835988-neurogenerative-disease-drug-developer-vigil-neuroscience-sees-stock-rally?utm_source=markets.businessinsider.com&utm_medium=referral
1287.0,5/12/2022 11:57:47 AM,Bristol Myers' deucravacitinib maintains efficacy at 2 years against plaque psoriasis in study,Seeking Alpha,https://seekingalpha.com/news/3837653-bristol-myers-deucravacitinib-maintains-efficacy-at-2-years-against-plaque-psoriasis-in-study?utm_source=markets.businessinsider.com&utm_medium=referral
1288.0,5/12/2022 2:00:00 PM,AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS,PR Newswire,/news/stocks/amgen-and-lance-bass-partner-to-encourage-people-to-do-a-double-take-to-recognize-the-early-signs-of-psoriatic-arthritis-1031453246
1289.0,5/17/2022 10:15:22 AM,5 Beaten-Down Blue-Chip Stocks to Buy Now,InvestorPlace,/news/stocks/5-beaten-down-blue-chip-stocks-to-buy-now-1031467700
1290.0,5/17/2022 2:41:55 PM,"Glenview Capital added Valvoline, exited Amgen, expanded position in US Foods, narrowed stake in Bausch Health",Seeking Alpha,https://seekingalpha.com/news/3840022-glenview-capital-added-valvoline-exited-amgen-expanded-position-in-us-foods-narrowed-stake-in-bausch-health?utm_source=markets.businessinsider.com&utm_medium=referral
1291.0,5/19/2022 11:43:19 AM,7 Dividend Stocks to Boost Your Retirement Savings,InvestorPlace,/news/stocks/7-dividend-stocks-to-boost-your-retirement-savings-1031475396
1292.0,5/19/2022 10:00:38 PM,7 Cheap Biotech Stocks to Buy Now,InvestorPlace,/news/stocks/7-cheap-biotech-stocks-to-buy-now-2-1031477266
1293.0,5/23/2022 4:33:42 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-23-2022-1031482320
1294.0,5/23/2022 5:26:51 PM,Analyst Ratings for Amgen,Benzinga,/news/stocks/analyst-ratings-for-amgen-1031482447
1295.0,5/25/2022 1:11:44 PM,7 Retirement Stocks to Buy to Turbocharge Your Savings,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-to-turbocharge-your-savings-2-1031488560
1296.0,5/26/2022 9:31:16 PM,Quant Ratings Updated on 75 Stocks,InvestorPlace,/news/stocks/quant-ratings-updated-on-75-stocks-1031494096
1297.0,5/26/2022 11:00:00 PM,NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022,PR Newswire,/news/stocks/new-data-showcases-how-amgen-is-advancing-all-angles-of-cancer-care-through-innovative-oncology-portfolio-and-pipeline-at-asco-2022-1031491996
1298.0,5/27/2022 11:08:09 AM,"Amneal, Kashiv's biosimilar therapy to Amgen's Neulasta gets FDA approval",Seeking Alpha,https://seekingalpha.com/news/3843389-amneal-kashivs-biosimilar-therapy-to-amgens-neulasta-gets-fda-approval?utm_source=markets.businessinsider.com&utm_medium=referral
1299.0,5/27/2022 12:30:55 PM,Mirati extends losses after KRAS inhibitor data; Stifel says selloff is overdone,Seeking Alpha,https://seekingalpha.com/news/3843434-mrtx-stock-extends-losses-as-stifel-says-selloff-is-overdone?utm_source=markets.businessinsider.com&utm_medium=referral
1300.0,5/27/2022 5:00:26 PM,"Catalyst watch: GameStop earnings, box office buzz, eyes on Amazon split",Seeking Alpha,https://seekingalpha.com/news/3843507-catalyst-watch-gamestop-earnings-box-office-buzz-eyes-on-amazon-split?utm_source=markets.businessinsider.com&utm_medium=referral
1301.0,5/31/2022 3:00:00 PM,AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a),PR Newswire,/news/stocks/amgen-announces-positive-topline-phase-2-data-for-investigational-olpasiran-in-adults-with-elevated-lipoprotein-a-1031498401
1302.0,5/31/2022 3:28:08 PM,Amgen Positive Topline Data In Phase 2 Trial For Olpasiran In Adults With Elevated Lipoprotein ,RTTNews,/news/stocks/amgen-positive-topline-data-in-phase-2-trial-for-olpasiran-in-adults-with-elevated-lipoprotein-1031498541
1303.0,5/31/2022 4:42:31 PM,Amgen's olpasiran helps reduce cholesterol level in patients with heart condition in trial,Seeking Alpha,https://seekingalpha.com/news/3844052-amgens-olpasiran-helps-reduce-cholesterol-level-in-patients-with-heart-condition-in-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1304.0,6/1/2022 8:44:10 PM,Sana Biotechnology to develop Washington manufacturing facility saving $100M,Seeking Alpha,https://seekingalpha.com/news/3844761-sana-biotechnology-to-develop-washington-manufacturing-facility-saving-100m?utm_source=markets.businessinsider.com&utm_medium=referral
1305.0,6/3/2022 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-jefferies-healthcare-conference-1031509280
1306.0,6/5/2022 2:00:00 PM,NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTA...,PR Newswire,/news/stocks/new-head-to-head-data-show-vectibix-panitumumab-demonstrated-superior-overall-survival-compared-to-bevacizumab-in-combination-with-chemotherapy-in-japanese-patients-with-wild-type-ras-colorecta-1031509680
1307.0,6/6/2022 9:11:28 AM,Amgen/Takeda's Vectibix beats Roche's Avastin in improving survival in colorectal cancer subtype in Japan trial,Seeking Alpha,https://seekingalpha.com/news/3845798-amgentakedas-vectibix-beats-roches-avastin-in-improving-survival-in-colorectal-cancer-subtype-in-japan-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1308.0,6/6/2022 1:37:10 PM,Amgen's biosimilar to Roche/Biogen's Rituxan gets FDA approval for rheumatoid arthritis,Seeking Alpha,https://seekingalpha.com/news/3845930-amgens-biosimilar-to-rochebiogens-rituxan-gets-fda-approval-for-rheumatoid-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral
1309.0,6/6/2022 3:00:00 PM,"FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS",PR Newswire,/news/stocks/fda-approves-riabni-rituximab-arrx-a-biosimilar-to-rituxan-rituximab-for-adults-with-moderate-to-severe-rheumatoid-arthritis-1031510971
1310.0,6/6/2022 3:23:25 PM,Amgen: FDA Approves RIABNI For Adults With Moderate To Severely Active Rheumatoid Arthritis ,RTTNews,/news/stocks/amgen-fda-approves-riabni-for-adults-with-moderate-to-severely-active-rheumatoid-arthritis-1031511091
1311.0,6/7/2022 8:00:16 PM,"New drugs cost an average of $180K per year, new study finds",Seeking Alpha,https://seekingalpha.com/news/3846439-new-drugs-cost-an-average-of-180k-per-year-new-study-finds?utm_source=markets.businessinsider.com&utm_medium=referral
1312.0,6/9/2022 10:15:05 AM,7 of the Hottest ETFs to Buy Right Now,InvestorPlace,/news/stocks/7-of-the-hottest-etfs-to-buy-right-now-1031518693
1313.0,6/9/2022 6:26:10 PM,Wells Fargo highlights potential targets as biotech M&A accelerates,Seeking Alpha,https://seekingalpha.com/news/3847403-wells-fargo-highlights-potential-targets-as-biotech-ma-accelerates?utm_source=businessinsider&utm_medium=referral
1314.0,6/10/2022 10:15:00 PM,AMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-announces-webcast-of-goldman-sachs-43rd-annual-healthcare-conference-1031522966
1315.0,6/11/2022 10:43:20 AM,7 Dividend Stocks to Buy for Your Grandkids,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-for-your-grandkids-1031523169
1316.0,6/14/2022 1:57:38 PM,Wells Fargo unveils its recession stock portfolio,Seeking Alpha,https://seekingalpha.com/news/3848418-wells-fargo-unveils-its-recession-stock-portfolio?utm_source=businessinsider&utm_medium=referral
1317.0,6/20/2022 3:00:00 PM,"AMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM",PR Newswire,/news/stocks/amgen-foundation-more-than-doubles-commitment-to-labxchange-free-virtual-science-education-platform-1031538067
1318.0,6/29/2022 11:43:37 AM,Amgen to sell Turkish unit Gensenta for $135M,Seeking Alpha,https://seekingalpha.com/news/3852767-amgen-to-sell-turkish-unit-gensenta-for-135m?utm_source=businessinsider&utm_medium=referral
1319.0,6/29/2022 12:40:51 PM,Can-Fite stock rises 23% as psoriasis drug beats placebo but lags behind Otezla in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3852810-can-fite-stock-rises-23-as-psoriasis-drug-beats-placebo-but-lags-behind-otezla-in-phase-3-trial?utm_source=businessinsider&utm_medium=referral
1320.0,6/29/2022 5:52:05 PM,"ReCode Therapeutics raises $120M in round co-led by Bayer, with participation from Amgen",Seeking Alpha,https://seekingalpha.com/news/3852958-recode-therapeutics-raises-120m-in-round-co-led-by-bayer-with-participation-from-amgen?utm_source=businessinsider&utm_medium=referral
1321.0,7/1/2022 10:45:50 PM,"Only 8 Of The 30 Dow Jones Stocks Were Positive In The First Half Of 2022: Chevron Leads, But Who Else Was Up?",Benzinga,/news/etf/only-8-of-the-30-dow-jones-stocks-were-positive-in-the-first-half-of-2022-chevron-leads-but-who-else-was-up-1031564229
1322.0,7/6/2022 5:22:36 PM,U.S. Senate Democrats advance deal to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3854684-us-senate-democrats-in-agreement-to-lower-drug-prices?utm_source=businessinsider&utm_medium=referral
1323.0,7/12/2022 11:14:56 PM,Amgen Lumakras combination data in lung cancer held until August - Reuters,Seeking Alpha,https://seekingalpha.com/news/3856239-amgen-lumakras-combination-data-in-lung-cancer-held-until-august-reuters?utm_source=businessinsider&utm_medium=referral
1324.0,7/13/2022 7:41:51 PM,Amgen Touts Early Lumakras Combo Data In KRAS Cancer Settings,Benzinga,/news/stocks/amgen-touts-early-lumakras-combo-data-in-kras-cancer-settings-1031585475
1325.0,7/15/2022 11:50:01 AM,3 Biotech Stocks Outperforming a Bear Market,InvestorPlace,/news/stocks/biotech-stocks-1031590050
1326.0,7/18/2022 6:58:43 PM,Top pharma lobby says R&D spending reached a peak in 2021,Seeking Alpha,https://seekingalpha.com/news/3857699-top-pharma-lobby-says-rd-spending-reached-a-peak-in-2021?utm_source=businessinsider&utm_medium=referral
1327.0,7/18/2022 7:57:40 PM,DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs,Seeking Alpha,https://seekingalpha.com/news/3857738-dice-therapeutics-initiated-at-buy-at-wainwright-on-platform-for-small-molecule-drugs?utm_source=businessinsider&utm_medium=referral
1328.0,7/18/2022 9:31:13 PM,HC Wainwright Is Bullish On DICE Therapeutics - Read Why,Benzinga,/news/stocks/hc-wainwright-is-bullish-on-dice-therapeutics---read-why-1031594876
1329.0,7/19/2022 12:53:18 PM,Celsion adds Moderna chief commercial officer as CEO,Seeking Alpha,https://seekingalpha.com/news/3858022-clsn-stock-on-watch-as-company-adds-moderna-chief-commercial-officer-as-ceo?utm_source=businessinsider&utm_medium=referral
1330.0,7/20/2022 10:00:43 PM,7 Best Pharmaceutical Stocks to Buy Now,InvestorPlace,/news/stocks/best-pharmaceutical-stocks-1031602627
1331.0,7/22/2022 1:41:19 PM,EMA panel backs approval of Amgen/AstraZeneca's asthma drug Tezspire; Ultomiris for expanded use,Seeking Alpha,https://seekingalpha.com/news/3859634-ema-panel-backs-approval-of-amgenastrazenecas-asthma-drug-tezspire-ultomiris-for-expanded-use?utm_source=businessinsider&utm_medium=referral
1332.0,7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral
1333.0,7/25/2022 8:59:36 AM,AstraZeneca: CHMP Recommends Tezspire For Severe Asthma In EU ,RTTNews,/news/stocks/astrazeneca-chmp-recommends-tezspire-for-severe-asthma-in-eu-1031610642
1334.0,7/27/2022 4:35:02 PM,IDEAYA's Cancer Candidate Shows Early Tumor Modulation,Benzinga,/news/stocks/ideaya-s-cancer-candidate-shows-early-tumor-modulation-1031621299
1335.0,7/27/2022 5:07:01 PM,"IDEAYA, Amgen in clinical trial deal for small molecule cancer agent",Seeking Alpha,https://seekingalpha.com/news/3861525-idya-stock-on-watch-as-ideaya-forms-trial-deal-with-amgen-for-cancer-agent?utm_source=businessinsider&utm_medium=referral
1336.0,7/29/2022 4:41:48 PM,"Earnings Week Ahead: Starbucks, Caterpillar, AMD, Uber, Moderna, JetBlue, and more",Seeking Alpha,https://seekingalpha.com/news/3863301-earnings-week-ahead-starbucks-caterpillar-amd-uber-moderna-jetblue-and-more?utm_source=businessinsider&utm_medium=referral
1337.0,7/31/2022 3:21:24 PM,Biotech Investors: August's Key PDUFA Catalysts You Must Know,Benzinga,/news/stocks/biotech-investors-august-s-key-pdufa-catalysts-you-must-know-1031631857
1338.0,8/1/2022 4:26:05 PM,Amgen disputes IRS over $10.7B tax bill - WSJ,Seeking Alpha,https://seekingalpha.com/news/3863813-amgen-disputes-irs-over-107b-tax-bill-wsj?utm_source=businessinsider&utm_medium=referral
1339.0,8/1/2022 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-second-quarter-financial-results-1031636669
1340.0,8/2/2022 5:15:51 PM,10 Highest Yielding Dow Jones Stocks: Which Stocks Pay Out 3.2% To 5.5% To Investors?,Benzinga,/news/etf/10-highest-yielding-dow-jones-stocks-which-stocks-pay-out-3-2-to-5-5-to-investors-1031640635
1341.0,8/2/2022 10:00:00 PM,AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022,PR Newswire,/news/stocks/amgen-to-webcast-investor-meeting-at-wclc-2022-1031641202
1342.0,8/3/2022 3:01:13 PM,Amgen earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/amgen-stock-q2-earnings-preview-1031645306
1343.0,8/3/2022 3:48:10 PM,Sales of Enbrel and Otezla in focus for Amgen's Q2 result,Seeking Alpha,https://seekingalpha.com/news/3865848-sales-of-enbrel-and-otezla-in-focus-for-amgens-q2-result?utm_source=businessinsider&utm_medium=referral
1344.0,8/3/2022 8:01:23 PM,Amgen declares $1.94 dividend,Seeking Alpha,https://seekingalpha.com/news/3866307-amgen-declares-194-dividend?utm_source=businessinsider&utm_medium=referral
1345.0,8/3/2022 10:00:00 PM,AMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND,PR Newswire,/news/stocks/amgen-announces-2022-third-quarter-dividend-1031647017
1346.0,8/3/2022 10:05:00 PM,AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS,PR Newswire,/news/stocks/amgen-appoints-michael-v-drake-to-board-of-directors-1031647108
1347.0,8/4/2022 12:44:48 PM,ChemoCentryx soars 109% as Amgen agrees to buy for $3.7B in cash,Seeking Alpha,https://seekingalpha.com/news/3867132-amgen-agreed-to-buy-chemocentryx-for-37b?utm_source=businessinsider&utm_medium=referral
1348.0,8/4/2022 2:00:00 PM,AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH,PR Newswire,/news/stocks/amgen-to-acquire-chemocentryx-for-4-billion-in-cash-1031650634
1349.0,8/4/2022 2:47:58 PM,Amgen To Buy TAVNEOS Developer ChemoCentryx In $3.7 Bln Cash Deal ,RTTNews,/news/stocks/amgen-to-buy-tavneos-developer-chemocentryx-in-3-7-bln-cash-deal-1031650999
1350.0,8/4/2022 3:05:28 PM,ChemoCentryx Stock More Than Doubles On $4B Buyout,Benzinga,/news/stocks/chemocentryx-stock-more-than-doubles-on-4b-buyout-1031651310
1351.0,8/4/2022 3:06:29 PM,"Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",Benzinga,/news/stocks/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazeneca-s-lynparza-in-early-stage-breast-cancer-decision-day-for-alzheimer-s-associated-hallucinations-candidate-1031651306
1352.0,8/4/2022 3:30:35 PM,ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition,InvestorPlace,/news/stocks/chemocentryx-ccxi-stock-soars-100-on-amgen-acquisition-1031651809
1353.0,8/4/2022 6:18:09 PM,ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why,Benzinga,/news/stocks/chemocentryx-shares-are-jumping-110-thursday-here-s-why-1031651943
1354.0,8/4/2022 8:02:54 PM,Amgen tops Q2 expectations; tightens FY22 revenue guidance,Seeking Alpha,https://seekingalpha.com/news/3867472-amgen-non-gaap-eps-of-465-beats-by-032-revenue-of-66b-beats-by-70m-lowers-fy22-revenue-guidance?utm_source=businessinsider&utm_medium=referral
1355.0,8/4/2022 8:30:41 PM,"Amgen posts 2Q beat, trims earnings guidance; new drugs outperform",Seeking Alpha,https://seekingalpha.com/news/3867617-amgen-posts-2q-beat-trims-earnings-guidance-new-drugs-outperform?utm_source=businessinsider&utm_medium=referral
1356.0,8/4/2022 10:01:00 PM,AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-reports-second-quarter-2022-financial-results-1031652316
1357.0,8/4/2022 10:05:37 PM,Amgen Inc. Announces Increase In Q2 Profit,RTTNews,/news/stocks/amgen-inc-announces-increase-in-q2-profit-1031652450
1358.0,8/5/2022 1:34:21 AM,Athenex soars 70% as Dr Reddy's and Intas race to form buyout deal,Seeking Alpha,https://seekingalpha.com/news/3867942-atnx-stock-surges-as-dr-reddys-and-intas-race-to-buyout-deal?utm_source=businessinsider&utm_medium=referral
1359.0,8/5/2022 11:25:28 PM,Analyst Ratings for Amgen,Benzinga,/news/stocks/analyst-ratings-for-amgen-1031656657
1360.0,8/6/2022 8:00:00 PM,"Biotech poised for H2 recovery as stocks rise amid quarterly results, M&A activity",Seeking Alpha,https://seekingalpha.com/news/3868377-biotech-poised-for-h2-recovery-as-stocks-rise-amid-quarterly-results-ma-activity?utm_source=businessinsider&utm_medium=referral
1361.0,8/7/2022 10:10:00 AM,AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS,PR Newswire,/news/stocks/amgen-data-at-wclc-2022-highlights-potential-to-deliver-transformative-medicines-for-historically-difficult-to-treat-lung-cancers-1031657383
1362.0,8/7/2022 1:24:26 PM,Amgen data for new cancer agent shows liver toxicity with immunotherapies,Seeking Alpha,https://seekingalpha.com/news/3868535-amgen-data-for-new-cancer-agent-shows-liver-toxicity-with-immunotherapies?utm_source=businessinsider&utm_medium=referral
1363.0,8/8/2022 1:21:44 PM,Mirati gains as Amgen posts new combination data for rival cancer drug,Seeking Alpha,https://seekingalpha.com/news/3868793-mrtx-stock-gains-as-amgen-posts-new-combination-data-for-rival-cancer-drug?utm_source=businessinsider&utm_medium=referral
1364.0,8/8/2022 8:17:00 PM,AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022,PR Newswire,/news/stocks/amgen-presents-new-tarlatamab-clinical-data-at-wclc-2022-1031662338
1365.0,8/9/2022 1:30:27 PM,Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock,Benzinga,/news/stocks/karuna-therapeutics-to-276-plus-svb-leerink-almost-doubles-price-target-on-this-stock-1031665142
1366.0,8/9/2022 8:42:39 PM,"ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M",Seeking Alpha,https://seekingalpha.com/news/3870218-chemocentryx-gaap-eps-of-0_44-misses-0_03-revenue-of-11_76m-misses-9_89m?utm_source=businessinsider&utm_medium=referral
1367.0,8/11/2022 4:15:52 PM,4 Index Funds to Buy and Hold Forever,InvestorPlace,/news/stocks/index-funds-to-buy-and-hold-1031676777
1368.0,8/11/2022 8:44:15 PM,3 Best Funds for Aggressive Investors,InvestorPlace,/news/stocks/best-funds-for-aggressive-investors-1031677463
1369.0,8/11/2022 9:22:02 PM,"J&J, Merck, Regeneron most exposed to Medicare drug price negotiation - Bloomberg",Seeking Alpha,https://seekingalpha.com/news/3871983-johnson-johnson-merck-regeneron-most-exposed-to-medicare-drug-price-negotiation-bloomberg?utm_source=businessinsider&utm_medium=referral
1370.0,8/11/2022 9:42:59 PM,Amgen under fire from Sen. Wyden over tax practices - Reuters,Seeking Alpha,https://seekingalpha.com/news/3872054-amgen-under-fire-from-sen-wyden-over-tax-practices-reuters?utm_source=businessinsider&utm_medium=referral
1371.0,8/14/2022 5:48:06 PM,Analysts rule out major industry impact from drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3872629-analysts-rule-out-major-industry-impact-from-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral
1372.0,8/15/2022 3:49:49 PM,IDEAYA downgraded to hold at Stifel after GSK waives development of cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3873018-ideaya-downgraded-to-hold-at-stifel-after-gsk-waives-development-of-cancer-candidate?utm_source=businessinsider&utm_medium=referral
1373.0,8/17/2022 7:37:02 PM,"Apple, IBM Get CNBC 'Fast Money' Mentions, While This Stock Popped Nearly 1% In Seconds",Benzinga,/news/stocks/apple-ibm-are-cnbc-fast-money-calls-of-the-day-1031690906
1374.0,8/18/2022 2:10:43 PM,"CNBC's Final Trades: Easterly Government Properties, ExxonMobil, Illinois Tool Works And This Health Care Company",Benzinga,/news/stocks/cnbc-s-final-trades-easterly-government-properties-exxonmobil-illinois-tool-works-and-this-health-care-company-1031692735
1375.0,8/19/2022 2:05:21 PM,DaVita upgraded to buy at UBS on growth prospects,Seeking Alpha,https://seekingalpha.com/news/3875053-davita-upgraded-to-buy-at-ubs-on-growth-prospects?utm_source=businessinsider&utm_medium=referral
1376.0,8/22/2022 3:00:00 PM,AMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS,PR Newswire,/news/stocks/amgen-to-present-new-data-at-esc-congress-2022-highlighting-up-to-8-5-years-of-repatha-evolocumab-safety-and-tolerability-data-in-high-risk-ascvd-patient-populations-1031698048
1377.0,8/23/2022 1:34:34 PM,Amgen shares positive late-stage data for AstraZeneca's Soliris biosimilar,Seeking Alpha,https://seekingalpha.com/news/3875803-amgen-announces-positive-late-stage-data-for-astrazeneca-biosimilar-in-pnh?utm_source=businessinsider&utm_medium=referral
1378.0,8/23/2022 3:00:00 PM,"AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)",PR Newswire,/news/stocks/amgen-announces-positive-top-line-results-from-phase-3-study-of-abp-959-biosimilar-candidate-to-soliris-eculizumab-1031700609
1379.0,8/23/2022 3:14:02 PM,Amgen shares positive late-stage data for AstraZeneca's Soliris biosimilar,Seeking Alpha,https://seekingalpha.com/news/3875803-amgen-shares-positive-late-stage-data-for-astrazenecas-soliris-biosimilar?utm_source=businessinsider&utm_medium=referral
1380.0,8/23/2022 3:31:03 PM,Amgen Announces Positive Top-line Results From Phase 3 DAHLIA Study Of ABP 959 ,RTTNews,/news/stocks/amgen-announces-positive-top-line-results-from-phase-3-dahlia-study-of-abp-959-1031700780
1381.0,8/24/2022 12:53:43 AM,Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031701797
1382.0,8/25/2022 11:02:29 AM,Alvotech begins confirmatory trial of Amgen Prolia/Xgeva biosimilar,Seeking Alpha,https://seekingalpha.com/news/3876539-alvotech-begins-confirmatory-trial-of-amgen-proliaxgeva-biosimilar?utm_source=businessinsider&utm_medium=referral
1383.0,8/29/2022 9:10:00 AM,NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS,PR Newswire,/news/stocks/new-amgen-data-at-esc-2022-show-long-term-ldl-c-lowering-with-repatha-evolocumab-was-well-tolerated-for-more-than-8-years-1031710043
1384.0,8/30/2022 3:00:00 PM,"AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022",PR Newswire,/news/stocks/amgen-to-present-new-positive-clinical-and-real-world-data-across-inflammation-portfolio-at-eadv-2022-1031713454
1385.0,8/30/2022 8:18:48 PM,Amgen meets key goal for Lumakras in late-stage lung cancer trial,Seeking Alpha,https://seekingalpha.com/news/3878026-amgen-meets-key-goals-for-lumakras-in-late-stage-lung-cancer-trial?utm_source=businessinsider&utm_medium=referral
1386.0,8/30/2022 10:03:00 PM,AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER,PR Newswire,/news/stocks/amgen-announces-topline-data-from-lumakras-sotorasib-phase-3-trial-in-non-small-cell-lung-cancer-1031714503
1387.0,8/31/2022 12:07:15 AM,Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031714707
1388.0,8/31/2022 10:49:01 AM,Mirati jumps 11% as Amgen meets key goal for rival cancer drug,Seeking Alpha,https://seekingalpha.com/news/3878826-mrtx-stock-jumps-as-amgen-meets-key-goal-for-rival-cancer-drug?utm_source=businessinsider&utm_medium=referral
1389.0,8/31/2022 8:52:36 PM,"Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know",Benzinga,/news/stocks/bluebird-bio-seeks-back-to-back-nods-go-or-no-go-for-revance-s-botox-rival-amylyx-twin-hurdles-and-more-september-s-key-pdufa-catalysts-biotech-investors-must-know-1031717312
1390.0,9/2/2022 6:54:23 PM,"FDA approves Fresenius Kabi's cancer drug Stimufend, a biosimilar to Amgen's Neulasta",Seeking Alpha,https://seekingalpha.com/news/3880073-fda-approves-fresenius-kabis-cancer-drug-stimufend-a-biosimilar-to-amgens-neulasta?utm_source=businessinsider&utm_medium=referral
1391.0,9/2/2022 10:00:00 PM,"Micron, Intel among new ideas in BofA's Alpha Surprise screen",Seeking Alpha,https://seekingalpha.com/news/3879926-micron-intel-among-new-ideas-in-bofas-alpha-surprise-screen?utm_source=businessinsider&utm_medium=referral
1392.0,9/2/2022 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-citi-global-healthcare-conference-1031722728
1393.0,9/2/2022 10:05:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-wells-fargo-healthcare-conference-1031722749
1394.0,9/6/2022 6:55:35 PM,7 Dow Stocks With Superior Fundamentals,InvestorPlace,/news/stocks/7-dow-stocks-with-superior-fundamentals-1031727239
1395.0,9/7/2022 10:00:00 PM,AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022,PR Newswire,/news/stocks/amgen-to-webcast-investor-call-at-esmo-2022-1031730348
1396.0,9/8/2022 2:15:00 PM,AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST),PR Newswire,/news/stocks/amgen-announces-positive-new-data-at-eadv-2022-for-otezla-apremilast-1031731846
1397.0,9/8/2022 3:06:20 PM,Amgen: Phase 3 Studies Of Oral Otezla Shows Efficacy In Moderate To Severe Psoriasis ,RTTNews,/news/stocks/amgen-phase-3-studies-of-oral-otezla-shows-efficacy-in-moderate-to-severe-psoriasis-1031732151
1398.0,9/8/2022 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-morgan-stanley-global-healthcare-conference-1031733278
1399.0,9/9/2022 7:00:17 PM,"Catalyst watch: Amgen data, Starbucks & Roblox events and Twitter vote on Elon Musk deal",Seeking Alpha,https://seekingalpha.com/news/3881705-catalyst-watch-amgen-data-starbucks-roblox-events-and-twitter-vote-on-elon-musk-deal?utm_source=businessinsider&utm_medium=referral
1400.0,9/12/2022 12:05:00 AM,LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER,PR Newswire,/news/stocks/lumakras-lumykras-sotorasib-demonstrates-superior-progression-free-survival-over-docetaxel-in-first-positive-phase-3-trial-of-a-kras-g12c-inhibitor-in-non-small-cell-lung-cancer-1031736053
1401.0,9/12/2022 9:53:10 AM,Amgen Lumakras/Vectibix combo shows promise in phase 1 trial in colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3881887-amgen-lumakrasvectibix-combo-shows-promise-in-phase-1-trial-in-colorectal-cancer?utm_source=businessinsider&utm_medium=referral
1402.0,9/12/2022 10:22:20 AM,Bristol Myers stock rises on FDA approval of psoriasis therapy Sotyktu; presents long-term efficacy data,Seeking Alpha,https://seekingalpha.com/news/3881893-bristol-myers-stock-rises-on-fda-approval-of-psoriasis-therapy-sotyktu-presents-long-term-efficacy-data?utm_source=businessinsider&utm_medium=referral
1403.0,9/12/2022 10:25:00 AM,LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER,PR Newswire,/news/stocks/lumakras-sotorasib-combined-with-vectibix-panitumumab-shows-confirmed-30-objective-response-rate-in-patients-with-kras-g12c-mutated-metastatic-colorectal-cancer-1031736575
1404.0,9/12/2022 11:28:03 AM,"Amgen Announces Positive Result For Phase 1b Study Of Combination Of Vectibix, Lumakras ",RTTNews,/news/stocks/amgen-announces-positive-result-for-phase-1b-study-of-combination-of-vectibix-lumakras-1031736659
1405.0,9/12/2022 1:37:05 PM,Bristol-Myers Squibb (BMY) Stock Jumps 8% as FDA Approves Psoriasis Treatment,InvestorPlace,/news/stocks/bristol-myers-squibb-bmy-stock-jumps-8-as-fda-approves-psoriasis-treatment-1031737488
1406.0,9/12/2022 2:48:55 PM,Ventyx stock soars 69% as analysts see Sotyktu approval sans warning a 'win' for TYK2 class,Seeking Alpha,https://seekingalpha.com/news/3882039-ventyx-stock-soars-as-analysts-see-sotyktu-approval-sans-warning-a-win-for-tyk2-class?utm_source=businessinsider&utm_medium=referral
1407.0,9/12/2022 5:08:15 PM,"Livent, Amgen And Some Other Big Stocks Moving Lower On Monday",Benzinga,/news/stocks/livent-amgen-and-some-other-big-stocks-moving-lower-on-monday-1031737753
1408.0,9/12/2022 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-bank-of-america-merrill-lynch-global-healthcare-conference-1031738238
1409.0,9/13/2022 5:22:53 PM,The 7 Best Retirement Stocks for Gen-Z Investors,InvestorPlace,/news/stocks/best-retirement-stocks-for-gen-z-investors-1031573560
1410.0,9/13/2022 8:38:58 PM,Amgen drops to six-month low amid latest challenges to pipeline,Seeking Alpha,https://seekingalpha.com/news/3882497-amgn-stock-drops-to-six-month-low-amid-latest-challenges?utm_source=businessinsider&utm_medium=referral
1411.0,9/14/2022 1:18:29 PM,"Bristol-Myers cut to hold at Bereneberg citing U.S. pricing reforms, patent cliff",Seeking Alpha,https://seekingalpha.com/news/3882692-bmy-stock-cut-to-hold-at-bereneberg-on-us-pricing-reforms-patent-cliff?utm_source=businessinsider&utm_medium=referral
1412.0,9/15/2022 2:24:15 PM,Mirati wins bullish view at Piper on prospects for new cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3883115-mrtx-stock-wins-bullish-view-at-piper-on-prospects-for-new-cancer-therapy?utm_source=businessinsider&utm_medium=referral
1413.0,9/15/2022 4:04:05 PM,Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial,Seeking Alpha,https://seekingalpha.com/news/3883149-sorrento-sofusa-drug-delivery-system-shows-benefit-vs-subcutaneous-injection-in-trial?utm_source=businessinsider&utm_medium=referral
1414.0,9/17/2022 8:00:18 PM,"BioNTech, Moderna, Pfizer led biopharma revenue growth from 2020-2021",Seeking Alpha,https://seekingalpha.com/news/3883566-biontech-moderna-pfizer-led-biopharma-revenue-growth-from-2020-2021?utm_source=businessinsider&utm_medium=referral
1415.0,9/19/2022 2:28:30 AM,The 7 Best Market Sectors for Q4,InvestorPlace,/news/stocks/best-market-sectors-1031594318
1416.0,9/20/2022 9:15:21 AM,"Novartis biosimilar matches Amgen's bone disorder drug Prolia, meeting trial's goal",Seeking Alpha,https://seekingalpha.com/news/3884209-novartis-biosimilar-matches-amgens-bone-disorder-drug-prolia-meeting-trials-goal?utm_source=businessinsider&utm_medium=referral
1417.0,9/20/2022 5:45:25 PM,The 7 Best Biotech Stocks to Buy,InvestorPlace,/news/stocks/best-biotech-stocks-1031575358
1418.0,9/21/2022 8:27:03 AM,"Amgen, AstraZeneca's Tezspire for severe asthma gets approval in EU",Seeking Alpha,https://seekingalpha.com/news/3884687-amgen-astrazenecas-tezspire-for-severe-asthma-gets-approval-in-eu?utm_source=businessinsider&utm_medium=referral
1419.0,9/22/2022 7:25:05 PM,Healthcare outperforms S&P 500 as large cap pharma rebounds,Seeking Alpha,https://seekingalpha.com/news/3885399-healthcare-outperforms-sp-500-as-large-cap-pharma-rebounds?utm_source=businessinsider&utm_medium=referral
1420.0,9/25/2022 6:00:00 PM,The prostate cancer therapy market will soar. Here are the companies that could benefit.,Seeking Alpha,https://seekingalpha.com/news/3885824-the-prostate-cancer-therapy-market-will-soar-here-are-the-companies-that-could-benefit?utm_source=businessinsider&utm_medium=referral
1421.0,9/27/2022 8:47:41 AM,"Amgen, AstraZeneca's Tezspire for severe asthma gets approval in Japan",Seeking Alpha,https://seekingalpha.com/news/3886235-amgen-astrazenecas-tezspire-for-severe-asthma-gets-approval-in-japan?utm_source=businessinsider&utm_medium=referral
1422.0,9/27/2022 11:15:11 AM,The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market,InvestorPlace,/news/stocks/the-7-best-stocks-to-buy-to-tap-into-a-hidden-bull-market-1031766644
1423.0,9/27/2022 4:22:11 PM,Warning! A Housing Market Crash Will Tank These 3 Stocks.,InvestorPlace,/news/stocks/warning-a-housing-market-crash-will-tank-these-3-stocks-1031767832
1424.0,10/3/2022 11:56:59 PM,The Short List Of Dow Jones Stocks That Are Actually Up This Year: Hint — It's Very Short,Benzinga,/news/etf/the-short-list-of-dow-jones-stocks-that-are-actually-up-this-year-hint-—-it-s-very-short-1031780150
1425.0,10/4/2022 6:09:33 PM,HHS change to Medicare payments for biosimilars aims to spur uptake,Seeking Alpha,https://seekingalpha.com/news/3888611-hhs-change-to-medicare-payments-for-biosimilars-aims-to-spur-uptake?utm_source=businessinsider&utm_medium=referral
1426.0,10/4/2022 10:24:19 PM,HHS buying $290M worth of Amgen drug Nplate for radiation sickness in nuclear emergency,Seeking Alpha,https://seekingalpha.com/news/3888692-hhs-buying-290m-worth-of-amgen-drug-nplate-for-radiation-sickness-in-nuclear-emergency?utm_source=businessinsider&utm_medium=referral
1427.0,10/6/2022 3:00:00 PM,AMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA,PR Newswire,/news/stocks/amgen-opens-new-state-of-the-art-research-and-development-laboratory-site-in-san-francisco-bay-area-1031787383
1428.0,10/7/2022 9:43:33 AM,HHS says anti-radiation drug contract not in 'response to situation in Ukraine',Seeking Alpha,https://seekingalpha.com/news/3889559-hhs-says-anti-radiation-drug-contract-not-in-response-to-situation-in-ukraine?utm_source=businessinsider&utm_medium=referral
1429.0,10/9/2022 12:18:04 PM,7 Value Stocks That Are Too Cheap to Ignore,InvestorPlace,/news/stocks/7-value-stocks-too-cheap-to-ignore-1031791337
1430.0,10/10/2022 6:09:22 PM,GOP senators introduce bill to undo Medicare prescription drug negotiation,Seeking Alpha,https://seekingalpha.com/news/3890099-gop-senators-introduce-bill-to-undo-medicare-prescription-drug-negotiation?utm_source=businessinsider&utm_medium=referral
1431.0,10/11/2022 2:15:00 PM,Apple To $155? Plus Morgan Stanley Cuts Price Target On Zoom Video,Benzinga,/news/stocks/apple-to-155-plus-morgan-stanley-cuts-price-target-on-zoom-video-1031795815
1432.0,10/11/2022 2:41:11 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1031796552
1433.0,10/11/2022 4:06:25 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-11-2022-1031796429
1434.0,10/11/2022 4:08:51 PM,"Amgen up 6%, leading S&P 500, following bullish call from Morgan Stanley",Seeking Alpha,https://seekingalpha.com/news/3890404-amgen-up-6-leading-sp-500-following-bullish-call-from-morgan-stanley?utm_source=businessinsider&utm_medium=referral
1435.0,10/11/2022 4:39:04 PM,"DICE Therapeutics, Amgen And Some Other Big Stocks Moving Higher On Tuesday",Benzinga,/news/stocks/dice-therapeutics-amgen-and-some-other-big-stocks-moving-higher-on-tuesday-1031796515
1436.0,10/11/2022 5:47:55 PM,A Congressman Just Sold JPMorgan Stock Ahead Of Earnings: See Two Dividend Stocks He Is Also Trading,Benzinga,/news/stocks/a-congressman-just-sold-jpmorgan-stock-ahead-of-earnings-see-two-dividend-stocks-he-is-also-trading-1031796708
1437.0,10/11/2022 5:49:38 PM,"BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status",Seeking Alpha,https://seekingalpha.com/news/3890439-bridgebio-stock-rises-as-bbp-398-lumakras-combo-gets-fda-fast-track-status?utm_source=businessinsider&utm_medium=referral
1438.0,10/11/2022 10:07:46 PM,Analyst Ratings for Amgen,Benzinga,/news/stocks/analyst-ratings-for-amgen-1031797253
1439.0,10/11/2022 11:56:56 PM,Expert Ratings for Amgen,Benzinga,/news/stocks/expert-ratings-for-amgen-1031797426
1440.0,10/12/2022 3:00:00 PM,AMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS,PR Newswire,/news/stocks/amgen-s-annual-trends-report-finds-competition-created-by-biosimilars-contributed-21-billion-in-u-s-healthcare-system-savings-1031799617
1441.0,10/12/2022 8:19:24 PM,What 6 Analyst Ratings Have To Say About Amgen,Benzinga,/news/stocks/what-6-analyst-ratings-have-to-say-about-amgen-1031800677
1442.0,10/14/2022 12:24:33 PM,Biden to sign Executive Order tasking HHS to find additional ways to lower drug costs,Seeking Alpha,https://seekingalpha.com/news/3891387-biden-to-sign-executive-order-tasking-hhs-to-find-additional-ways-to-lower-drug-costs-medicare?utm_source=businessinsider&utm_medium=referral
1443.0,10/14/2022 7:52:20 PM,Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts,Benzinga,/news/stocks/replimune-gets-33-price-target-bump-ahead-of-upcoming-readouts-analyst-lists-the-catalysts-1031806894
1444.0,10/17/2022 11:58:18 AM,"Amgen joins TIAP, Evotec at innovation hub for forming life science companies",Seeking Alpha,https://seekingalpha.com/news/3891761-amgen-joins-tiap-evotec-at-innovation-hub-for-forming-life-science-companies?utm_source=businessinsider&utm_medium=referral
1445.0,10/17/2022 2:34:50 PM,Morgan Stanley says large cap healthcare remains attractive amid macro concerns,Seeking Alpha,https://seekingalpha.com/news/3891861-morgan-stanely-says-large-cap-healthcare-remains-attractive-amid-macro-concerns?utm_source=businessinsider&utm_medium=referral
1446.0,10/18/2022 9:45:49 PM,ChemoCentryx shareholders approve $4.7B merger with Amgen,Seeking Alpha,https://seekingalpha.com/news/3892468-chemocentryx-shareholders-approve-47b-merger-with-amgen?utm_source=businessinsider&utm_medium=referral
1447.0,10/20/2022 1:36:54 PM,AbbVie to acquire DJS Antibodies for $255M to bolster immunology pipeline,Seeking Alpha,https://seekingalpha.com/news/3893196-abbvie-to-acquire-djs-antibodies-for-255m-to-bolster-immunology-pipeline?utm_source=businessinsider&utm_medium=referral
1448.0,10/20/2022 3:05:00 PM,AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX,PR Newswire,/news/stocks/amgen-successfully-completes-acquisition-of-chemocentryx-1031821346
1449.0,10/20/2022 5:19:54 PM,Prescription drugs make up a rising share of Medicare spending – study,Seeking Alpha,https://seekingalpha.com/news/3893317-prescription-drugs-account-for-a-rising-chunk-of-medicare-spending-study?utm_source=businessinsider&utm_medium=referral
1450.0,10/21/2022 5:56:11 PM,"Talks begin with pharma, health insurers over negotiating drug prices for Medicare",Seeking Alpha,https://seekingalpha.com/news/3893788-talks-begin-with-pharma-health-insurers-over-negotiating-drug-prices-for-medicare?utm_source=businessinsider&utm_medium=referral
1451.0,10/26/2022 12:31:10 PM,"Amgen, AstraZeneca's severe asthma therapy Tezspire launches in Canada",Seeking Alpha,https://seekingalpha.com/news/3895446-amgen-astrazenecas-severe-asthma-therapy-tezspire-launches-in-canada?utm_source=businessinsider&utm_medium=referral
1452.0,10/26/2022 12:31:40 PM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and HCA Healthcare (HCA),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-hca-healthcare-hca-1031837979
1453.0,10/28/2022 6:30:28 PM,"Catalyst watch: FOMC jitters, Starbucks and Pfizer earnings, Boeing and AMD events",Seeking Alpha,https://seekingalpha.com/news/3897337-catalyst-watch-fomc-jitters-starbucks-and-pfizer-earnings-boeing-and-amd-events?utm_source=businessinsider&utm_medium=referral
1454.0,10/28/2022 8:01:46 PM,Amgen declares $1.94 dividend,Seeking Alpha,https://seekingalpha.com/news/3897465-amgen-inc-declares-1_94-dividend?utm_source=businessinsider&utm_medium=referral
1455.0,10/28/2022 10:00:00 PM,AMGEN ANNOUNCES 2022 FOURTH QUARTER DIVIDEND,PR Newswire,/news/stocks/amgen-announces-2022-fourth-quarter-dividend-1031849401
1456.0,10/31/2022 4:11:24 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), BioMarin Pharmaceutical (BMRN) and Teladoc (TDOC)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-amgen-amgn-biomarin-pharmaceutical-bmrn-and-teladoc-tdoc-1031850870
1457.0,10/31/2022 1:21:04 PM,Amgen downgraded at Barclays citing rally fueled by weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/3897732-amgn-stock-downgraded-at-barclays-citing-rally-fueled-by-weight-loss-therapy?utm_source=businessinsider&utm_medium=referral
1458.0,10/31/2022 2:37:16 PM,What 6 Analyst Ratings Have To Say About Amgen,Benzinga,/news/stocks/what-6-analyst-ratings-have-to-say-about-amgen-1031853722
1459.0,10/31/2022 3:01:39 PM,6 Analysts Have This to Say About Amgen,Benzinga,/news/stocks/6-analysts-have-this-to-say-about-amgen-1031854007
1460.0,10/31/2022 3:13:15 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-31-2022-1031854074
1461.0,10/31/2022 7:52:38 PM,Analyst Ratings for Amgen,Benzinga,/news/stocks/analyst-ratings-for-amgen-1031854929
1462.0,10/31/2022 9:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 THIRD QUARTER FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-third-quarter-financial-results-1031855018
1463.0,11/2/2022 3:01:13 PM,Here's what Wall Street expects from Amgen's earnings report,Markets Insider Automation,/news/stocks/amgen-stock-price-quarter-earnings-preview-q3-1031864782
1464.0,11/2/2022 9:00:00 PM,AMGEN TO WEBCAST INVESTOR CALL AT AHA 2022,PR Newswire,/news/stocks/amgen-to-webcast-investor-call-at-aha-2022-1031866043
1465.0,11/3/2022 12:12:16 PM,"US Stocks In For Another Tough Day After Fed Rate Hike As Nasdaq, S&P 500 Futures Fall — Roku, Qualcomm Plunge On Earnings Disappointment",Benzinga,/news/stocks/us-stocks-in-for-another-tough-day-after-fed-rate-hike-as-nasdaq-s-p-500-futures-fall-—-roku-qualcomm-plunge-on-earnings-disappointment-1031869714
1466.0,11/3/2022 4:30:26 PM,"Cancer drugs launch prices soaring, straining Medicare, report finds",Seeking Alpha,https://seekingalpha.com/news/3901117-cancer-drugs-launch-prices-soaring-straining-medicare-report-finds?utm_source=businessinsider&utm_medium=referral
1467.0,11/3/2022 8:03:13 PM,"Amgen Non-GAAP EPS of $4.70 beats by $0.25, revenue of $6.65B beats by $90M",Seeking Alpha,https://seekingalpha.com/news/3901274-amgen-non-gaap-eps-of-4_70-beats-0_25-revenue-of-6_65b-beats-90m?utm_source=businessinsider&utm_medium=referral
1468.0,11/3/2022 8:55:08 PM,Mizuho Securities Sticks to Its Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-sticks-to-its-hold-rating-for-amgen-amgn-1031872801
1469.0,11/3/2022 9:01:00 PM,AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-reports-third-quarter-2022-financial-results-1031872200
1470.0,11/3/2022 9:04:47 PM,Amgen Inc. Profit Advances In Q3,RTTNews,/news/stocks/amgen-inc-profit-advances-in-q3-1031872221
1471.0,11/3/2022 9:12:47 PM,Amgen revises 2022 guidance as Q3 results beat on top and bottom lines,Seeking Alpha,https://seekingalpha.com/news/3901421-amgen-revises-2022-guidance-as-q3-results-beat-on-top-and-bottom-lines?utm_source=businessinsider&utm_medium=referral
1472.0,11/4/2022 2:01:56 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Fate Therapeutics (FATE) and Intellia Therapeutics (NTLA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-fate-therapeutics-fate-and-intellia-therapeutics-ntla-1031876185
1473.0,11/4/2022 5:30:43 PM,"Catalyst watch: CPI downtick, election ripples, Disney and Rivian earnings, Roblox conference call",Seeking Alpha,https://seekingalpha.com/news/3902134-catalyst-watch-cpi-downtick-election-ripples-disney-and-rivian-earnings-roblox-conference-call?utm_source=businessinsider&utm_medium=referral
1474.0,11/4/2022 9:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 CREDIT SUISSE GLOBAL HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-credit-suisse-global-healthcare-conference-1031877083
1475.0,11/4/2022 9:04:17 PM,"Supreme Court to hear Amgen appeal on Repatha spat with Sanofi, Regeneron",Seeking Alpha,https://seekingalpha.com/news/3902317-supreme-court-to-hear-amgen-appeal-on-repatha-spat-with-sanofi-regeneron?utm_source=businessinsider&utm_medium=referral
1476.0,11/6/2022 5:00:24 PM,"Off-patent drugs make up 91% of prescriptions, but only 18% of spending - report",Seeking Alpha,https://seekingalpha.com/news/3902378-off-patent-drugs-make-up-91-of-prescriptions-18-of-spending?utm_source=businessinsider&utm_medium=referral
1477.0,11/7/2022 12:13:00 AM,AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS,PR Newswire,/news/stocks/amgen-presents-new-phase-2-data-that-show-olpasiran-delivers-significant-reduction-in-lipoprotein-a-levels-1031878557
1478.0,11/7/2022 2:30:34 AM,Amgen : Phase 2 Data Show Olpasiran Delivers Significant Reduction In Lipoprotein(A) Levels ,RTTNews,/news/stocks/amgen-phase-2-data-show-olpasiran-delivers-significant-reduction-in-lipoprotein-a-levels-1031878600
1479.0,11/7/2022 3:26:36 AM,Amgen (AMGN) Gets a Hold from SVB Securities,TipRanks,/news/stocks/amgen-amgn-gets-a-hold-from-svb-securities-1031878625
1480.0,11/7/2022 10:15:49 AM,Amgen's olpasiran cuts cholesterol levels by 95% in heart disease patients in trial,Seeking Alpha,https://seekingalpha.com/news/3902423-amgens-olpasiran-cuts-cholesterol-levels-by-95-in-heart-disease-patients-in-trial?utm_source=businessinsider&utm_medium=referral
1481.0,11/7/2022 3:00:00 PM,AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022,PR Newswire,/news/stocks/amgen-to-present-new-research-across-serious-inflammatory-and-bone-diseases-at-acr-2022-1031881744
1482.0,11/7/2022 10:16:00 PM,AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022,PR Newswire,/news/stocks/amgen-presents-new-repatha-evolocumab-data-at-aha-2022-1031883091
1483.0,11/8/2022 2:25:15 AM,Mizuho Securities Reaffirms Their Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-hold-rating-on-amgen-amgn-1031883688
1484.0,11/8/2022 1:55:30 PM,Jefferies Keeps Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/jefferies-keeps-their-buy-rating-on-amgen-amgn-1031887178
1485.0,11/8/2022 2:05:11 PM,Jefferies Sticks to Their Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/jefferies-sticks-to-their-buy-rating-for-amgen-amgn-1031887247
1486.0,11/8/2022 2:50:22 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Xencor (XNCR) and Beam Therapeutics (BEAM)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-xencor-xncr-and-beam-therapeutics-beam-1031887439
1487.0,11/8/2022 3:50:50 PM,Amgen reaches all-time high; stock up 30% YTD,Seeking Alpha,https://seekingalpha.com/news/3903612-amgen-reaches-all-time-high-stock-up-30-ytd?utm_source=businessinsider&utm_medium=referral
1488.0,11/9/2022 1:46:37 PM,Arrowhead sells royalty interest in olpasiran to Royalty Pharma for $250M,Seeking Alpha,https://seekingalpha.com/news/3904532-arrowhead-sells-royalty-interest-in-olpasiran-to-royalty-pharma-for-250m?utm_source=businessinsider&utm_medium=referral
1489.0,11/9/2022 2:59:51 PM,Royalty Pharma To Acquire Royalty Interest In Amgen's Olpasiran From Arrowhead Pharma ,RTTNews,/news/stocks/royalty-pharma-to-acquire-royalty-interest-in-amgen-s-olpasiran-from-arrowhead-pharma-1031892212
1490.0,11/10/2022 4:26:49 AM,SVB Securities Issues a Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/svb-securities-issues-a-hold-rating-on-amgen-amgn-1031894677
1491.0,11/11/2022 8:16:39 PM,"Healthcare stocks come off lows, worst performing sector among defensive losers (update)",Seeking Alpha,https://seekingalpha.com/news/3906637-healthcare-stocks-fall-across-the-board-as-traders-move-out-of-defensive-sectors?utm_source=businessinsider&utm_medium=referral
1492.0,11/12/2022 3:32:19 PM,This US Representative Just Bought Shares Of Airbnb And These 2 Dividend-Paying Stocks,Benzinga,/news/stocks/this-us-representative-just-bought-shares-of-airbnb-and-these-2-dividend-paying-stocks-1031906004
1493.0,11/16/2022 7:38:58 PM,Spectrum downgraded to neutral at B Riley on doubts over approval of poziotinib,Seeking Alpha,https://seekingalpha.com/news/3908816-spectrum-downgraded-to-neutral-at-b-riley-on-doubts-over-approval-of-poziotinib?utm_source=businessinsider&utm_medium=referral
1494.0,11/17/2022 1:50:22 AM,"Analysts Are Neutral on These Healthcare Stocks: Amgen (AMGN), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-neutral-on-these-healthcare-stocks-amgen-amgn-regeneron-regn-1031920436
1495.0,11/18/2022 11:30:33 AM,7 Top-Tier Dividend Stocks to Buy for 2023,InvestorPlace,/news/stocks/7-top-tier-dividend-stocks-to-buy-for-2023-1031924843
1496.0,11/18/2022 1:01:28 PM,Where Amgen Stands With Analysts,Benzinga,/news/stocks/where-amgen-stands-with-analysts-1031924936
1497.0,11/18/2022 5:01:11 PM,Analyst Ratings for Amgen,Benzinga,/news/stocks/analyst-ratings-for-amgen-1031925741
1498.0,11/18/2022 5:58:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-18-2022-1031925925
1499.0,11/18/2022 6:02:03 PM,What 7 Analyst Ratings Have To Say About Amgen,Benzinga,/news/stocks/what-7-analyst-ratings-have-to-say-about-amgen-1031925918
1500.0,11/18/2022 8:50:18 PM,Credit Suisse Sets Bearish Tone For Amgen; Says Current Setup Not Ideal For Growth,Benzinga,/news/stocks/credit-suisse-sets-bearish-tone-for-amgen-says-current-setup-not-ideal-for-growth-1031926222
1501.0,11/18/2022 9:02:29 PM,Where Amgen Stands With Analysts,Benzinga,/news/stocks/where-amgen-stands-with-analysts-1031926249
1502.0,11/23/2022 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-evercore-isi-healthcare-conference-1031935035
1503.0,11/28/2022 10:00:00 PM,AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022,PR Newswire,/news/stocks/amgen-to-webcast-investor-call-at-wcirdc-2022-1031940657
1504.0,11/30/2022 3:54:10 PM,Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today?,InvestorPlace,/news/stocks/why-is-horizon-therapeutics-hznp-stock-up-30-today-1031945358
1505.0,11/30/2022 7:52:36 PM,Analyst Forecasts $101-117/Share Offer Price For Horizon Therapeutics' Buyout,Benzinga,/news/stocks/analyst-forecasts-101-117-share-offer-price-for-horizon-therapeutics-buyout-1031946005
1506.0,12/1/2022 3:30:00 PM,AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022,PR Newswire,/news/stocks/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022-1031948052
1507.0,12/1/2022 3:58:43 PM,"Form 8.3 - The Vanguard Group, Inc.: Amgen Inc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-amgen-inc-1031965966
1508.0,12/2/2022 2:15:08 AM,Mizuho Securities Sticks to Their Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-hold-rating-for-amgen-amgn-1031949307
1509.0,12/2/2022 12:01:03 PM,"Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors",Benzinga,/news/stocks/mirati-plays-catch-up-with-amgen-gilead-s-2nd-try-with-aids-drug-cytokinetics-adcom-test-and-more-key-nov-fda-decisions-for-biotech-investors-1031949927
1510.0,12/4/2022 11:15:15 PM,Mizuho Securities Remains a Hold on Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-remains-a-hold-on-amgen-amgn-1031951836
1511.0,12/5/2022 11:30:25 AM,7 Christmas Stocks to Buy for Happy Holidays,InvestorPlace,/news/stocks/7-christmas-stocks-to-buy-now-for-happy-holidays-1031952613
1512.0,12/5/2022 1:40:22 PM,"Analysts Offer Insights on Healthcare Companies: Vaxxinity Inc (VAXX), Amgen (AMGN) and LivaNova (LIVN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-vaxxinity-inc-vaxx-amgen-amgn-and-livanova-livn-1031953239
1513.0,12/5/2022 2:40:16 PM,Wall Street Analysts Are Neutral on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-neutral-on-top-healthcare-picks-1031953414
1514.0,12/7/2022 4:25:15 AM,Amgen (AMGN) Receives a Hold from SVB Securities,TipRanks,/news/stocks/amgen-amgn-receives-a-hold-from-svb-securities-1031956952
1515.0,12/7/2022 2:02:21 PM,Cytokinetics starts dosing of heart failure drug in phase 1 trial,Seeking Alpha,https://seekingalpha.com/news/3914869-cytokinetics-starts-dosing-of-heart-failure-drug-in-phase-1-trial?utm_source=businessinsider&utm_medium=referral
1516.0,12/8/2022 4:42:14 PM,Sen. Wyden again presses Amgen for information on taxes and offshore subsidiaries,Seeking Alpha,https://seekingalpha.com/news/3915389-sen-wyden-again-presses-amgen-for-information-on-taxes-and-offshore-subsidiaries?utm_source=businessinsider&utm_medium=referral
1517.0,12/8/2022 5:27:09 PM,Revolution Medicines to regain rights to cancer candidate from Sanofi,Seeking Alpha,https://seekingalpha.com/news/3915416-revolution-medicines-to-regain-rights-to-cancer-candidate-from-sanofi?utm_source=businessinsider&utm_medium=referral
1518.0,12/11/2022 5:00:50 PM,"Lilly, Novo dominance in weight loss market intact despite Amgen entry – BofA",Seeking Alpha,https://seekingalpha.com/news/3915950-lly-stock-novo-nordisk-to-dominate-obesity-despite-amgen-entry?utm_source=businessinsider&utm_medium=referral
1519.0,12/11/2022 7:24:02 PM,Amgen said in advanced talks to buy Horizon Therapeutics for well over $20B - WSJ,Seeking Alpha,https://seekingalpha.com/news/3915954-amgen-said-in-advanced-talks-to-buy-horizon-therapeutics-wsj?utm_source=businessinsider&utm_medium=referral
1520.0,12/12/2022 2:19:47 AM,Sanofi Says Doesn't Intend To Make Offer For Horizon; But Amgen Reportedly In Advanced Talks ,RTTNews,/news/stocks/sanofi-says-doesn-t-intend-to-make-offer-for-horizon-but-amgen-reportedly-in-advanced-talks-1031964257
1521.0,12/12/2022 3:15:14 AM,Mizuho Securities Sticks to Their Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-hold-rating-for-amgen-amgn-1031964275
1522.0,12/12/2022 11:47:32 AM,Amgen to acquire Horizon Therapeutics for $27.8B in cash,Seeking Alpha,https://seekingalpha.com/news/3916023-amgen-to-acquire-horizon-therapeutics-for-278b-in-cash?utm_source=businessinsider&utm_medium=referral
1523.0,12/12/2022 12:00:00 PM,Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc,PR Newswire,/news/stocks/rule-2-7-announcement-amgen-inc-to-acquire-horizon-therapeutics-plc-1031964909
1524.0,12/12/2022 12:05:00 PM,AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS,PR Newswire,/news/stocks/amgen-to-host-webcast-investor-call-following-announced-acquisition-of-horizon-therapeutics-1031964914
1525.0,12/12/2022 2:01:23 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Cytokinetics (CYTK) and Legend Biotech (LEGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-cytokinetics-cytk-and-legend-biotech-legn-1031965429
1526.0,12/12/2022 2:47:43 PM,Horizon Therapeutics (HZNP) Stock Pops on HUGE Amgen Deal,InvestorPlace,/news/stocks/horizon-therapeutics-hznp-stock-pops-on-huge-amgen-deal-1031967131
1527.0,12/12/2022 3:27:26 PM,"S&P, Nasdaq, Dow edge higher to kick off Fed week",Seeking Alpha,https://seekingalpha.com/news/3916014-sp500-nasdaq-dow-jones-stock-market?utm_source=businessinsider&utm_medium=referral
1528.0,12/12/2022 9:06:19 PM,"Dow, S&P 500, Nasdaq start week with gains ahead of Fed, CPI",Seeking Alpha,https://seekingalpha.com/news/3916288-dow-sp-500-nasdaq-start-week-with-gains-ahead-of-fed-cpi?utm_source=businessinsider&utm_medium=referral
1529.0,12/12/2022 10:28:44 PM,Mirati non-small cell lung cancer treatment adagrasib gains FDA approval - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3916337-mirati-non-small-cell-lung-cancer-treatment-adagrasib-gains-fda-approval-bloomberg?utm_source=businessinsider&utm_medium=referral
1530.0,12/13/2022 1:50:00 AM,AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND,PR Newswire,/news/stocks/amgen-announces-10-increase-in-2023-first-quarter-dividend-1031967876
1531.0,12/13/2022 5:13:16 AM,Amgen raises dividend by 10% to $2.13,Seeking Alpha,https://seekingalpha.com/news/3916356-amgen-inc-declares-2_13-dividend?utm_source=businessinsider&utm_medium=referral
1532.0,12/13/2022 12:30:23 PM,"Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Edwards Lifesciences (EW) and Horizon Therapeutics (HZNP)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-edwards-lifesciences-ew-and-horizon-therapeutics-hznp-1031968908
1533.0,12/13/2022 12:57:25 PM,Eli Lilly dips after issuing underwhelming 2023 guidance,Seeking Alpha,https://seekingalpha.com/news/3916459-lly-stock-dips-after-issuing-underwhelming-2023-guidance-?utm_source=businessinsider&utm_medium=referral
1534.0,12/13/2022 1:43:35 PM,Cramers Says These 3 Big Deals Aided Monday's Market Rally: 'When Companies Start Buying Each Other At A Big Premium...',Benzinga,/news/stocks/cramers-says-these-3-big-deals-aided-monday-s-market-rally-when-companies-start-buying-each-other-at-a-big-premium-1031968925
1535.0,12/13/2022 3:01:42 PM,Pinterest To Rally Around 23%? Here Are 10 Other Price Target Changes For Tuesday,Benzinga,/news/stocks/pinterest-to-rally-around-23-here-are-10-other-price-target-changes-for-tuesday-1031969253
1536.0,12/13/2022 8:44:02 PM,Amgen shares extend losses after all-cash deal for Horizon,Seeking Alpha,https://seekingalpha.com/news/3916666-amgn-stock-extends-losses-after-cash-deal-for-horizon?utm_source=businessinsider&utm_medium=referral
1537.0,12/13/2022 10:00:00 PM,BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL),PR Newswire,/news/stocks/blincyto-blinatumomab-added-to-consolidation-chemotherapy-significantly-improves-survival-in-adult-patients-with-measurable-residual-disease-negative-b-lineage-acute-lymphoblastic-leukemia-b-all-1031970267
1538.0,12/14/2022 3:55:22 AM,Amgen (AMGN) Receives a Hold from SVB Securities,TipRanks,/news/stocks/amgen-amgn-receives-a-hold-from-svb-securities-1031970551
1539.0,12/14/2022 2:25:33 PM,BMO Capital Reaffirms Their Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/bmo-capital-reaffirms-their-hold-rating-on-amgen-amgn-1031971958
1540.0,12/14/2022 4:51:43 PM,Fresenius Kabi becomes latest drugmaker to win approval of biosimilar of AbbVie's Humira,Seeking Alpha,https://seekingalpha.com/news/3916989-fresenius-kabi-becomes-latest-drugmaker-to-win-approval-of-biosimilar-of-abbvie-humira?utm_source=businessinsider&utm_medium=referral
1541.0,12/14/2022 7:02:53 PM,Colorado becomes fourth state to ask feds to import drugs from Canada,Seeking Alpha,https://seekingalpha.com/news/3917055-colorado-becomes-fourth-state-to-ask-feds-to-import-drugs-from-canada?utm_source=businessinsider&utm_medium=referral
1542.0,12/14/2022 8:36:01 PM,Mirati draws Hold rating at Needham despite recent selloff,Seeking Alpha,https://seekingalpha.com/news/3917179-mrtx-stock-draws-hold-rating-eedham-despite-recent-selloff?utm_source=businessinsider&utm_medium=referral
1543.0,12/15/2022 7:03:54 PM,"GILD vs. AMGN: Two Splendid Dividend Stocks, but One Looks Better",TipRanks,/news/stocks/gild-vs-amgn-two-splendid-dividend-stocks-but-one-looks-better-1031975702
1544.0,12/18/2022 9:34:20 PM,The 7 Best Retirement Stocks to Buy Now,InvestorPlace,/news/stocks/best-retirement-stocks-1031562793
1545.0,12/19/2022 7:59:03 PM,Viridian Therapeutics initiated at buy at Needham on lead asset for thyroid eye disease,Seeking Alpha,https://seekingalpha.com/news/3918698-viridian-therapeutics-initiated-at-buy-at-needham-on-lead-asset-for-thyroid-eye-disease?utm_source=businessinsider&utm_medium=referral
1546.0,12/20/2022 5:23:36 PM,Arrowhead receives $25M milestone payment from Amgen for heart disease treatment,Seeking Alpha,https://seekingalpha.com/news/3919011-arrowhead-receives-25m-milestone-payment-from-amgen-for-heart-disease-treatment?utm_source=businessinsider&utm_medium=referral
1547.0,12/22/2022 2:33:19 PM,Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday,Benzinga,/news/stocks/alphabet-to-115-here-are-10-other-price-target-changes-for-thursday-1031986994
1548.0,12/23/2022 3:10:46 PM,Amgen in $4B term loan credit agreement to finance Horizon Therapeutics acquisition,Seeking Alpha,https://seekingalpha.com/news/3920327-amgen-in-4b-term-loan-credit-agreement-to-finance-horizon-therapeutics-acquisition?utm_source=businessinsider&utm_medium=referral
1549.0,12/25/2022 5:00:44 PM,Goldman Sachs highlights key healthcare themes for 2023,Seeking Alpha,https://seekingalpha.com/news/3920634-goldman-sachs-micro-over-macro-healthcare-themes-2023?utm_source=businessinsider&utm_medium=referral
1550.0,12/27/2022 11:49:48 AM,Amgen in licensing deal with LegoChem for antibody drug conjugates,Seeking Alpha,https://seekingalpha.com/news/3920683-amgen-in-licensing-deal-with-legochem-for-antibody-drug-conjugates?utm_source=businessinsider&utm_medium=referral
1551.0,1/3/2023 3:01:59 PM,Amgen's Repatha under fire over cardiovascular outcomes data in key trial,Seeking Alpha,https://seekingalpha.com/news/3921575-amgen-repatha-under-fire-over-cardiovascular-outcomes-data-in-key-trial?utm_source=businessinsider&utm_medium=referral
1552.0,1/3/2023 7:53:16 PM,10 Best Stock Traders In Congress In 2022 (Spoiler: Nancy Pelosi Isn't No. 1),Benzinga,/news/stocks/10-best-stock-traders-in-congress-in-2022-spoiler-nancy-pelosi-isn-t-no-1-1031998484
1553.0,1/4/2023 5:30:15 PM,The 10 Best Dividend Stocks of All Time ,InvestorPlace,/news/stocks/best-dividend-stocks-of-all-time-1031596593
1554.0,1/4/2023 10:00:00 PM,AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-1032000862
1555.0,1/6/2023 11:26:24 PM,5 Top Pharma Stocks of 2022 to Buy for the Long Haul,InvestorPlace,/news/stocks/5-top-pharma-stocks-of-2022-to-buy-for-the-long-haul-1032005182
1556.0,1/9/2023 4:29:40 PM,"Illumina, Amgen to genome sequence 35K DNA samples",Seeking Alpha,https://seekingalpha.com/news/3923041-illumina-amgen-to-genome-sequence-35k-dna-samples?utm_source=businessinsider&utm_medium=referral
1557.0,1/10/2023 9:02:09 PM,Illumina Shares Tank After Annual Guidance Fall Short Of Expectations,Benzinga,/news/stocks/illumina-shares-tank-after-annual-guidance-fall-short-of-expectations-1032010615
1558.0,1/11/2023 2:35:11 PM,BMO Capital Sticks to Its Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/bmo-capital-sticks-to-its-hold-rating-for-amgen-amgn-1032012565
1559.0,1/11/2023 8:35:28 PM,Medicare to publish drugs targeted for pricing negotiations in September,Seeking Alpha,https://seekingalpha.com/news/3923880-medicare-publish-drugs-targeted-pricing-negotiations-in-september?utm_source=businessinsider&utm_medium=referral
1560.0,1/13/2023 9:33:29 AM,"Amgen, AstraZeneca's asthma therapy Tezspire's self-administration option gets approval in EU",Seeking Alpha,https://seekingalpha.com/news/3924412-amgen-astrazenecas-asthma-therapy-tezspires-self-administration-option-gets-approval-in-eu?utm_source=businessinsider&utm_medium=referral
1561.0,1/18/2023 2:04:58 PM,Horizon says auto-immune disease candidate met another main goal in phase 2 trial,Seeking Alpha,https://seekingalpha.com/news/3925403-horizon-says-auto-immune-disease-drug-met-another-main-goal-in-phase-2-trial?utm_source=businessinsider&utm_medium=referral
1562.0,1/18/2023 3:51:23 PM,BeiGene therapies get expanded coverage on China's national reimbursement drug list,Seeking Alpha,https://seekingalpha.com/news/3925466-beigene-therapies-get-expanded-coverage-on-chinas-national-reimbursement-drug-list?utm_source=businessinsider&utm_medium=referral
1563.0,1/19/2023 12:40:50 PM,"Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), Evolus (EOLS)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-amgen-amgn-evolus-eols-1032028191
1564.0,1/19/2023 1:00:21 PM,Analyst Expectations for Amgen's Future,Benzinga,/news/stocks/analyst-expectations-for-amgen-s-future-1032028077
1565.0,1/19/2023 6:19:18 PM,Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide,Benzinga,/news/stocks/analyst-views-novo-nordisk-s-upcoming-obesity-drug-data-to-lay-grounds-for-eli-lilly-s-tirzepatide-1032029171
1566.0,1/21/2023 9:40:00 PM,"AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs",Seeking Alpha,https://seekingalpha.com/news/3926479-astrazeneca-biogen-bristol-and-eli-lilly-among-companies-with-blockbuster-potential-drugs?utm_source=businessinsider&utm_medium=referral
1567.0,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral
1568.0,1/24/2023 8:53:48 PM,Dogs of the Dow 2023: 5 Dividend Stocks for Income Investors,InvestorPlace,/news/stocks/dogs-of-the-dow-2023-5-dividend-stocks-for-income-investors-1032038002
1569.0,1/26/2023 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-announces-webcast-of-2022-fourth-quarter-and-full-year-financial-results-1032044947
1570.0,1/27/2023 11:53:00 AM,"Horizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)",Seeking Alpha,https://seekingalpha.com/news/3928615-horizon-pharma-opiant-fall-on-report-elizabeth-warren-concerned-about-pharma-deals?utm_source=businessinsider&utm_medium=referral
1571.0,1/27/2023 5:23:16 PM,Aerojet ticks lower amid Sen. Elizabeth Warren call for FTC to block L3Harris deal (update),Seeking Alpha,https://seekingalpha.com/news/3929001-aerojet-ticks-lower-amid-sen-elizabeth-warren-call-for-ftc-to-block-l3harris-deal?utm_source=businessinsider&utm_medium=referral
1572.0,1/27/2023 5:55:12 PM,"Earnings week ahead: Amazon, Apple, Meta, Alphabet, ExxonMobil, GM, AMD and more",Seeking Alpha,https://seekingalpha.com/news/3929027-earnings-week-ahead-amazon-apple-meta-alphabet-exxonmobil-gm-amd-and-more?utm_source=businessinsider&utm_medium=referral
1573.0,1/27/2023 7:15:05 PM,"Catalyst watch: Eyes on tech earnings, Chinese EV stocks, Peloton and Church & Dwight",Seeking Alpha,https://seekingalpha.com/news/3929095-catalyst-watch-eyes-on-tech-earnings-chinese-ev-stocks-peloton-and-church-dwight?utm_source=businessinsider&utm_medium=referral
1574.0,1/29/2023 5:00:25 PM,AbbVie’s global bestseller to face knockoffs starting this week,Seeking Alpha,https://seekingalpha.com/news/3929211-abbvies-global-bestseller-to-face-knockoffs-starting-this-week?utm_source=businessinsider&utm_medium=referral
1575.0,1/29/2023 11:25:33 PM,"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",Benzinga,/news/stocks/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among-key-quarterly-reports-to-watch-1032048678
1576.0,1/30/2023 8:50:17 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Resmed (RMD) and Sarepta Therapeutics (SRPT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-resmed-rmd-and-sarepta-therapeutics-srpt-1032050147
1577.0,1/30/2023 3:01:13 PM,Here's what Wall Street expects from Amgen's earnings report,Markets Insider Automation,/news/stocks/amgen-q4-earnings-preview-stock-1032051016
1578.0,1/30/2023 4:11:01 PM,"Amgen lays off 300 employees, mostly on commercial team - Endpoints News",Seeking Alpha,https://seekingalpha.com/news/3929424-amgen-lays-off-300-employees-mostly-on-commercial-team-endpoints-news?utm_source=businessinsider&utm_medium=referral
1579.0,1/30/2023 5:33:58 PM,What to expect from Amgen's Q4 earnings?,Seeking Alpha,https://seekingalpha.com/news/3929481-what-to-expect-from-amgens-q4-earnings?utm_source=businessinsider&utm_medium=referral
1580.0,1/30/2023 7:34:32 PM,Amgen Layoffs 2023: What to Know About the Latest AMGN Job Cuts,InvestorPlace,/news/stocks/amgen-layoffs-2023-what-to-know-about-the-latest-amgn-job-cuts-1032051817
1581.0,1/30/2023 10:35:25 PM,Notable earnings after Tuesday's close,Seeking Alpha,https://seekingalpha.com/news/3929403-notable-earnings-after-tuesdays-close?utm_source=businessinsider&utm_medium=referral
1582.0,1/31/2023 11:40:30 AM,Amgen's biosimilar of AbbVie's Humira enters US market,Seeking Alpha,https://seekingalpha.com/news/3929723-amgens-biosimilar-to-humira-enters-us-market?utm_source=businessinsider&utm_medium=referral
1583.0,1/31/2023 12:00:00 PM,"AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES",PR Newswire,/news/stocks/amjevita-adalimumab-atto-first-biosimilar-to-humira-now-available-in-the-united-states-1032053544
1584.0,1/31/2023 12:37:37 PM,"Nasdaq, S&P Futures Lower As Powell & Team Kick Off 2-Day Fed Meeting: Analyst Says Positive January Harbinger Of Good Times",Benzinga,/news/stocks/nasdaq-s-p-futures-lower-as-powell-team-kick-off-2-day-fed-meeting-analyst-says-positive-january-harbinger-of-good-times-1032053686
1585.0,1/31/2023 3:25:05 PM,Horizon Therapeutics briefly ticked lower on report of FTC 2nd request in Amgen deal,Seeking Alpha,https://seekingalpha.com/news/3929901-horizon-therapeutics-ticks-lower-on-report-of-ftc-2nd-request-in-amgen-deal?utm_source=businessinsider&utm_medium=referral
1586.0,1/31/2023 8:17:22 PM,"Nasdaq, S&P, Dow set to end Jan. with strong gains ahead of 2023's first Fed meet",Seeking Alpha,https://seekingalpha.com/news/3929929-nasdaq-sp500-dow-jones-stock-market-economic-data-earnings?utm_source=businessinsider&utm_medium=referral
1587.0,1/31/2023 9:02:54 PM,"Amgen Non-GAAP EPS of $4.09 in-line, revenue of $6.8B beats by $30M",Seeking Alpha,https://seekingalpha.com/news/3930090-amgen-non-gaap-eps-of-4_09-in-line-revenue-of-6_8b-beats-30m?utm_source=businessinsider&utm_medium=referral
1588.0,1/31/2023 9:24:07 PM,Horizon Therapeutics confirms FTC Second Request in Amgen deal,Seeking Alpha,https://seekingalpha.com/news/3930133-horizon-therapeutics-confirms-ftc-second-request-in-amgen-deal?utm_source=businessinsider&utm_medium=referral
1589.0,1/31/2023 10:01:00 PM,AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-reports-fourth-quarter-and-full-year-2022-financial-results-1032055680
1590.0,1/31/2023 10:05:35 PM,Amgen Inc. Bottom Line Declines In Q4,RTTNews,/news/stocks/amgen-inc-bottom-line-declines-in-q4-1032055700
1591.0,1/31/2023 10:07:23 PM,Amgen (AMGN) Gets a Hold from Mizuho Securities,TipRanks,/news/stocks/amgen-amgn-gets-a-hold-from-mizuho-securities-1032055887
1592.0,1/31/2023 10:19:23 PM,"Amgen 2023 EPS, revenue estimates within expectations; Lumakras, Evenity see big YoY gains",Seeking Alpha,https://seekingalpha.com/news/3930196-amgen-2023-eps-revenue-estimates-within-expectations-lumakras-evenity-see-big-yoy-gains?utm_source=businessinsider&utm_medium=referral
1593.0,2/1/2023 5:34:00 AM,AMGEN POSTS FULL TRANSCRIPT AND AUDIO REPLAY OF FOURTH QUARTER AND FULL YEAR 2022 EARNINGS WEBCAST,PR Newswire,/news/stocks/amgen-posts-full-transcript-and-audio-replay-of-fourth-quarter-and-full-year-2022-earnings-webcast-1032056119
1594.0,2/1/2023 1:56:58 PM,Barclays Issues a Sell Rating on Amgen (AMGN),TipRanks,/news/stocks/barclays-issues-a-sell-rating-on-amgen-amgn-1032058720
1595.0,2/1/2023 2:06:55 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), GlaxoSmithKline (GSK) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-glaxosmithkline-gsk-and-abbvie-abbv-1032059161
1596.0,2/1/2023 8:45:13 PM,"Nasdaq, S&P, Dow rip higher after Fed chief Powell says progress made against inflation",Seeking Alpha,https://seekingalpha.com/news/3930502-nasdaq-sp500-dow-jones-stock-market-fed-meet-economic-data-earnings?utm_source=businessinsider&utm_medium=referral
1597.0,2/1/2023 9:13:15 PM,"Nasdaq, S&P 500, Dow stage late rally on Fed 'disinflation' hopes",Seeking Alpha,https://seekingalpha.com/news/3930814-nasdaq-sp-500-dow-stage-late-rally-on-fed-disinflation-hopes?utm_source=businessinsider&utm_medium=referral
1598.0,2/2/2023 10:54:14 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Bio-Rad Laboratories (BIO) and Edwards Lifesciences (EW)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-amgen-amgn-bio-rad-laboratories-bio-and-edwards-lifesciences-ew-1032062083
1599.0,2/2/2023 10:58:17 AM,SVB Securities Sticks to Its Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/svb-securities-sticks-to-its-hold-rating-for-amgen-amgn-1032062225
1600.0,2/2/2023 11:00:26 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Hologic (HOLX) and Koninklijke Philips (PHG)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-hologic-holx-and-koninklijke-philips-phg-1032062182
1601.0,2/2/2023 2:42:40 PM,"Amgen, AstraZeneca's asthma therapy Tezspire's self-administration option gets FDA approval",Seeking Alpha,https://seekingalpha.com/news/3931285-amgen-astrazenecas-asthma-therapy-tezspires-self-administration-option-gets-fda-approval?utm_source=businessinsider&utm_medium=referral
1602.0,2/2/2023 3:00:00 PM,TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN,PR Newswire,/news/stocks/tezspire-approved-for-self-administration-in-the-u-s-with-a-new-pre-filled-pen-1032063023
1603.0,2/2/2023 3:18:05 PM,"AstraZeneca, Amgen's Tezspire Pre-filled Pen Receives FDA Approval In US For Asthma ",RTTNews,/news/stocks/astrazeneca-amgen-s-tezspire-pre-filled-pen-receives-fda-approval-in-us-for-asthma-1032063108
1604.0,2/2/2023 7:11:33 PM,U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates,Seeking Alpha,https://seekingalpha.com/news/3931486-uk-pharma-lobby-urges-govt-to-halt-plans-to-raise-revenue-recovery-rates?utm_source=businessinsider&utm_medium=referral
1605.0,2/2/2023 7:35:34 PM,The 7 Most Undervalued Dow Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-dow-stocks-to-buy-in-february-2023-1032064008
1606.0,2/2/2023 8:20:04 PM,"Nasdaq, S&P off session highs but on track to extend post-Fed rally; Dow in the red",Seeking Alpha,https://seekingalpha.com/news/3931346-sp500-nasdaq-dow-jones-stock-market-meta-earnings-post-fed-rally?utm_source=businessinsider&utm_medium=referral
1607.0,2/3/2023 3:10:09 AM,"Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Humana (HUM) and Sarepta Therapeutics (SRPT)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-humana-hum-and-sarepta-therapeutics-srpt-1032064479
1608.0,2/5/2023 5:00:57 PM,Drug price inflation continues upward momentum at 3.8% – report,Seeking Alpha,https://seekingalpha.com/news/3932101-drug-price-inflation-continues-upward-momentum-at-38-report?utm_source=businessinsider&utm_medium=referral
1609.0,2/6/2023 12:03:10 PM,AbbVie pins hopes on newer drugs and deals to face Humira knockoffs – WSJ,Seeking Alpha,https://seekingalpha.com/news/3932220-abbvie-pins-hopes-on-newer-drugs-and-deals-to-face-humira-knockoffs?utm_source=businessinsider&utm_medium=referral
1610.0,2/6/2023 5:56:09 PM,Teva follows AbbVie to leave top pharma industry group,Seeking Alpha,https://seekingalpha.com/news/3932426-teva-follows-abbvie-to-leave-top-pharma-industry-group?utm_source=businessinsider&utm_medium=referral
1611.0,2/6/2023 11:02:13 PM,Arrowhead Pharmaceuticals' fiscal 2023 Q1 revenue surge helped by milestone payments,Seeking Alpha,https://seekingalpha.com/news/3932645-arrowhead-pharmaceuticals-fiscal-2023-q1-revenue-surge-helped-by-milestone-payments?utm_source=businessinsider&utm_medium=referral
1612.0,2/7/2023 9:43:21 AM,"Novartis' biosimilar of Amgen's bone disorder drugs Prolia, Xgeva gets FDA review",Seeking Alpha,https://seekingalpha.com/news/3932690-novartis-biosimilar-of-amgens-bone-disorder-drugs-prolia-xgeva-gets-fda-review?utm_source=businessinsider&utm_medium=referral
1613.0,2/9/2023 5:38:02 PM,AbbVie gains after revising estimates for Humira sales erosion,Seeking Alpha,https://seekingalpha.com/news/3934365-abbvie-gains-after-revising-estimates-for-humira-sales-erosion?utm_source=businessinsider&utm_medium=referral
1614.0,2/9/2023 10:00:00 PM,AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-2023-svb-securities-global-biopharma-conference-1032084266
1615.0,2/9/2023 11:06:48 PM,Amgen files mixed securities shelf offering,Seeking Alpha,https://seekingalpha.com/news/3934649-amgen-files-mixed-securities-shelf-offering?utm_source=businessinsider&utm_medium=referral
1616.0,2/10/2023 12:18:08 PM,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,Seeking Alpha,https://seekingalpha.com/news/3934728-medicare-mulls-rebates-in-2025-for-drug-prices-rising-faster-than-inflation?utm_source=businessinsider&utm_medium=referral
1617.0,2/13/2023 12:25:05 PM,Truist Financial Sticks to Their Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/truist-financial-sticks-to-their-hold-rating-for-amgen-amgn-1032090975
1618.0,2/13/2023 2:28:08 PM,Top 5 Health Care Stocks That Could Blast Off This Month,Benzinga,/news/stocks/top-5-health-care-stocks-that-could-blast-off-this-month-1032091185
1619.0,2/13/2023 7:18:57 PM,"OmniAb initiated with a buy at H.C. Wainwright on antibody collaborations, partnerships",Seeking Alpha,https://seekingalpha.com/news/3935341-omniab-initiated-with-a-buy-at-hc-wainwright-on-antibody-collaborations-partnerships?utm_source=businessinsider&utm_medium=referral
1620.0,2/13/2023 7:49:54 PM,ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood,InvestorPlace,/news/stocks/ark-invest-the-7-words-that-explain-why-wall-street-cant-stand-cathie-wood-1032092169
1621.0,2/15/2023 4:37:53 PM,Why Billionaires Paul Tudor Jones and George Soros Bought Up Horizon (HZNP) Stock,InvestorPlace,/news/stocks/why-billionaires-paul-tudor-jones-and-george-soros-bought-up-horizon-hznp-stock-1032099734
1622.0,2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral
1623.0,2/15/2023 7:06:06 PM,Amgen bond offering to help fund Horizon Therapeutics acquisition,Seeking Alpha,https://seekingalpha.com/news/3936574-amgen-bond-offering-to-help-fund-horizon-therapeutics-acquisition?utm_source=businessinsider&utm_medium=referral
1624.0,2/17/2023 8:00:02 PM,"Catalyst watch: Spotlight on retail earnings, Lucid Group, Silvergate Capital and Radware",Seeking Alpha,https://seekingalpha.com/news/3937806-catalyst-watch-spotlight-on-retail-earnings-lucid-group-silvergate-capital-and-radware?utm_source=businessinsider&utm_medium=referral
1625.0,2/17/2023 9:05:38 PM,"S&P 500, Dow, Nasdaq finish mixed as Fed debate continues",Seeking Alpha,https://seekingalpha.com/news/3937828-sp-500-dow-nasdaq-finish-mixed-as-fed-debate-continues?utm_source=businessinsider&utm_medium=referral
1626.0,2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral
1627.0,2/21/2023 6:45:09 PM,Mizuho Securities Remains a Hold on Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-remains-a-hold-on-amgen-amgn-1032112793
1628.0,2/22/2023 3:00:00 PM,AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS,PR Newswire,/news/stocks/amgen-announces-cardiovascular-study-to-evaluate-association-between-lipoprotein-a-and-cardiovascular-risk-in-african-americans-1032115947
1629.0,2/23/2023 11:41:46 AM,Top dividend stocks picked using a UBS machine-learning model,Seeking Alpha,https://seekingalpha.com/news/3939207-top-dividend-stocks-machine-learning-ai-screen-picks?utm_source=businessinsider&utm_medium=referral
1630.0,2/24/2023 7:00:00 PM,"Catalyst watch: Tesla event, Microsoft talks OpenAI, Rivian earnings and Chevron",Seeking Alpha,https://seekingalpha.com/news/3940433-catalyst-watch-tesla-event-microsoft-talks-chatgpt-rivian-earnings-and-chevron?utm_source=businessinsider&utm_medium=referral
1631.0,2/24/2023 10:31:17 PM,Horizon Therapeutics shareholders overwhelmingly approve acquisition by Amgen,Seeking Alpha,https://seekingalpha.com/news/3940898-horizon-therapeutics-shareholders-overwhelmingly-approve-acquisition-by-amgen?utm_source=businessinsider&utm_medium=referral
1632.0,2/25/2023 9:00:00 PM,"Pharmas, medtechs dominate list of innovation leaders thanks to patents",Seeking Alpha,https://seekingalpha.com/news/3940793-pharmas-medtechs-dominate-list-of-innovation-leaders-thanks-to-patents?utm_source=businessinsider&utm_medium=referral
1633.0,2/26/2023 4:15:00 PM,M&A activity in the Americas cooled in 2022 amid ongoing macro uncertainty,Seeking Alpha,https://seekingalpha.com/news/3940889-ma-activity-in-the-americas-cooled-in-2022-amid-ongoing-macro-uncertainty?utm_source=businessinsider&utm_medium=referral
1634.0,2/28/2023 11:30:12 AM,Stocks most and least liked by hedge funds and mutual funds -  Goldman,Seeking Alpha,https://seekingalpha.com/news/3941168-stocks-most-and-least-liked-by-hedge-funds-and-mutual-funds-goldman?utm_source=businessinsider&utm_medium=referral
1635.0,3/1/2023 3:00:00 PM,AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC,PR Newswire,/news/stocks/amgen-to-present-new-repatha-evolocumab-and-olpasiran-data-at-acc-1032136480
1636.0,3/2/2023 8:15:35 AM,Barclays Sticks to Its Sell Rating for Amgen (AMGN),TipRanks,/news/stocks/barclays-sticks-to-its-sell-rating-for-amgen-amgn-1032139237
1637.0,3/3/2023 11:30:17 AM,7 Over-$100 Stocks That Are Worth Every Penny,InvestorPlace,/news/stocks/7-over-100-stocks-over-100-stocks-to-buy-worth-every-penny-1032143389
1638.0,3/3/2023 1:50:05 PM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Dexcom (DXCM),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-amgen-amgn-and-dexcom-dxcm-1032143817
1639.0,3/3/2023 10:00:00 PM,AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-43rd-annual-td-cowen-healthcare-conference-1032144872
1640.0,3/6/2023 6:45:59 PM,Merck to start phase 3 of oral PCSK9 inhibitor for cholesterol following mid-stage results,Seeking Alpha,https://seekingalpha.com/news/3944574-merck-to-start-phase-3-of-oral-pcsk9-inhibitor-for-cholesterol-following-mid-stage-results?utm_source=businessinsider&utm_medium=referral
1641.0,3/7/2023 12:33:25 PM,Biden to announce plan to keep Medicare solvent beyond 2050,Seeking Alpha,https://seekingalpha.com/news/3944823-biden-to-announce-plan-to-keep-medicare-solvent-beyond-2050?utm_source=businessinsider&utm_medium=referral
1642.0,3/7/2023 10:00:00 PM,AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND,PR Newswire,/news/stocks/amgen-announces-2023-second-quarter-dividend-1032151567
1643.0,3/8/2023 2:52:13 AM,Amgen declares $2.13 dividend,Seeking Alpha,https://seekingalpha.com/news/3945049-amgen-inc-declares-2_13-dividend?utm_source=businessinsider&utm_medium=referral
1644.0,3/9/2023 11:20:00 PM,AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-33rd-annual-oppenheimer-healthcare-conference-1032158208
1645.0,3/10/2023 2:36:14 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-delivering-high-dividend-yields-1032159995
1646.0,3/10/2023 7:10:43 PM,"Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs",Benzinga,/news/stocks/hefty-listing-price-of-new-drugs-for-cancer-rare-diseases-put-pressure-on-annual-hike-for-older-drugs-1032160689
1647.0,3/10/2023 9:35:07 PM,Mizuho Securities Sticks to Its Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-sticks-to-its-hold-rating-for-amgen-amgn-1032160925
1648.0,3/12/2023 2:00:00 PM,Biosimilars expected to save $180B over next five years as more gain approval,Seeking Alpha,https://seekingalpha.com/news/3946583-biosimilars-expected-to-save-180b-over-next-five-years-as-more-gain-approval?utm_source=businessinsider&utm_medium=referral
1649.0,3/12/2023 5:00:16 PM,New weight loss therapies can burden Medicare - experts,Seeking Alpha,https://seekingalpha.com/news/3946678-new-weight-loss-therapies-can-burden-medicare?utm_source=businessinsider&utm_medium=referral
1650.0,3/13/2023 11:55:12 AM,Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows,Benzinga,/news/stocks/nasdaq-futures-climb-solidly-after-past-week-s-rout-analyst-flags-key-s-p-500-support-to-stay-above-october-lows-1032162772
1651.0,3/13/2023 3:49:27 PM,Amgen upgraded at Wells Fargo citing a post-Horizon deal opportunity,Seeking Alpha,https://seekingalpha.com/news/3946901-amgen-upgraded-at-wells-fargo-citing-a-post-horizon-deal-opportunity?utm_source=businessinsider&utm_medium=referral
1652.0,3/13/2023 4:00:45 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-13-2023-1032163649
1653.0,3/13/2023 6:00:40 PM,What 14 Analyst Ratings Have To Say About Amgen,Benzinga,/news/stocks/what-14-analyst-ratings-have-to-say-about-amgen-1032163965
1654.0,3/14/2023 3:49:15 AM,Amgen facing class action suit over owing more than $10B in back taxes and penalties,Seeking Alpha,https://seekingalpha.com/news/3947090-amgen-facing-class-action-suit-over-owing-more-than-10b-in-back-taxes-and-penalties?utm_source=businessinsider&utm_medium=referral
1655.0,3/16/2023 8:30:00 PM,"AMGN ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amgen Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AMGN",PR Newswire,/news/stocks/amgn-alert-rosen-trusted-investor-counsel-encourages-amgen-inc-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-deadline-in-securities-class-action-amgn-1032173981
1656.0,3/17/2023 8:47:56 AM,More U.S. companies layoff as Amgen deepens job cuts amid pressure on drug prices and inflation woes,Seeking Alpha,https://seekingalpha.com/news/3948432-more-us-companies-layoffs-as-amgen-deepens-job-cuts-amid-pressure-on-drug-prices-and-inflations-woes?utm_source=businessinsider&utm_medium=referral
1657.0,3/17/2023 2:40:10 PM,Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Acurx Pharmaceuticals (ACXP),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-and-acurx-pharmaceuticals-acxp-1032176028
1658.0,3/21/2023 6:58:24 PM,Altimmune leads obesity drug developers lower after data for lead asset,Seeking Alpha,https://seekingalpha.com/news/3949662-altimmune-leads-obesity-drug-developers-lower-after-data-for-lead-asset?utm_source=businessinsider&utm_medium=referral
1659.0,3/24/2023 12:05:26 PM,Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-keeps-their-hold-rating-on-amgen-amgn-1032190678
1660.0,3/24/2023 5:01:00 PM,FDA draft guidance impacts companies using accelerated approval for oncology drugs,Seeking Alpha,https://seekingalpha.com/news/3951000-fda-draft-guidance-impacts-companies-accelerated-approval-oncology-drugs?utm_source=businessinsider&utm_medium=referral
1661.0,3/24/2023 7:10:00 PM,"ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN",PR Newswire,/news/stocks/rosen-a-leading-law-firm-encourages-amgen-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-amgn-1032191625
1662.0,3/27/2023 3:27:26 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields-1032194249
1663.0,3/27/2023 5:45:10 PM,Supreme Court hears arguments in Amgen Repatha patent case against Sanofi,Seeking Alpha,https://seekingalpha.com/news/3951571-supreme-court-arguments-repatha-patent-case-sanofi-regeneron?utm_source=businessinsider&utm_medium=referral
1664.0,3/28/2023 10:25:43 AM,Amgen (AMGN) Receives a Hold from SVB Securities,TipRanks,/news/stocks/amgen-amgn-receives-a-hold-from-svb-securities-1032196494
1665.0,3/28/2023 9:00:00 PM,"Viking Therapeutics' Initial VK2735 'Data Resoundingly Beat Expectations,' Analyst Says",Benzinga,/news/stocks/viking-therapeutics-initial-vk2735-data-resoundingly-beat-expectations-analyst-says-1032198283
1666.0,3/29/2023 9:26:13 AM,"Amgen, AstraZeneca's asthma therapy Tezspire gets UK's NICE backing",Seeking Alpha,https://seekingalpha.com/news/3952134-amgen-astrazenecas-asthma-therapy-tezspire-gets-uks-nice-backing?utm_source=businessinsider&utm_medium=referral
1667.0,3/29/2023 2:50:46 PM,WHO to weigh adding obesity therapies to 'essential' medicines list – Reuters,Seeking Alpha,https://seekingalpha.com/news/3952303-who-to-weigh-adding-obesity-therapies-to-essential-medicines-list-reuters?utm_source=businessinsider&utm_medium=referral
1668.0,3/31/2023 12:00:00 AM,"ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN",PR Newswire,/news/stocks/rosen-top-ranked-investor-counsel-encourages-amgen-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-amgn-1032205042
1669.0,3/31/2023 12:40:06 PM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Eledon Pharmaceuticals (ELDN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-eledon-pharmaceuticals-eldn-1032207042
1670.0,4/2/2023 2:00:37 PM,"Seagen/Pfizer deal spread becoming increasingly attractive, analyst says",Seeking Alpha,https://seekingalpha.com/news/3953374-seagenpfizer-deal-spread-becoming-increasingly-attractive-analyst-says?utm_source=businessinsider&utm_medium=referral
1671.0,4/4/2023 12:30:39 PM,"Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), OncoCyte (OCX)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-amgen-amgn-oncocyte-ocx-1032213645
1672.0,4/5/2023 1:06:03 PM,3 Must-Buy Dow Stocks for Your April Buy List,InvestorPlace,/news/stocks/3-must-buy-dow-stocks-for-your-april-buy-list-1032216784
1673.0,4/5/2023 3:56:43 PM,AbbVie downgraded to hold at Argus on Humira competition in US,Seeking Alpha,https://seekingalpha.com/news/3954728-abbvie-downgraded-hold-argus-humira-competition-us?utm_source=businessinsider&utm_medium=referral
1674.0,4/6/2023 3:09:09 PM,"Morgan Stanley cuts Comcast, adds Becton Dickinson to its model portfolio",Seeking Alpha,https://seekingalpha.com/news/3954991-morgan-stanley-cuts-comcast-adds-becton-dickinson-to-its-model-portfolio?utm_source=businessinsider&utm_medium=referral
1675.0,4/6/2023 4:35:54 PM,FDA forces pre-term birth drug off the market after 12 years,Seeking Alpha,https://seekingalpha.com/news/3955084-fda-pulls-pre-term-birth-drug-makena-off-market?utm_source=businessinsider&utm_medium=referral
1676.0,4/6/2023 9:39:54 PM,7 Very Undervalued Penny Stocks to Buy in April 2023,InvestorPlace,/news/stocks/7-very-undervalued-penny-stocks-to-buy-in-april-2023-1032220195
1677.0,4/7/2023 1:45:17 PM,Mizuho Securities Keeps Their Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-keeps-their-hold-rating-on-amgen-amgn-1032220711
1678.0,4/7/2023 6:15:29 PM,"Catalyst Watch: Eyes on inflation data, big bank earnings",Seeking Alpha,https://seekingalpha.com/news/3955188-catalyst-watch-eyes-on-inflation-data-big-bank-earnings?utm_source=businessinsider&utm_medium=referral
1679.0,4/7/2023 9:35:00 PM,"ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN",PR Newswire,/news/stocks/rosen-top-ranked-global-counsel-encourages-amgen-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-amgn-1032220889
1680.0,4/8/2023 1:50:26 AM,"Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Amgen (AMGN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-alnylam-pharma-alny-amgen-amgn-and-regeneron-regn-1032220940
1681.0,4/9/2023 4:00:00 PM,"Premier cancer research event, AACR is starting this week; Here is what to expect",Seeking Alpha,https://seekingalpha.com/news/3955202-aacr-2023-is-starting-this-week-here-is-what-to-expect?utm_source=businessinsider&utm_medium=referral
1682.0,4/10/2023 2:10:52 PM,Horizon posts positive Phase 4 data for thyroid eye disease therapy Tepezza,Seeking Alpha,https://seekingalpha.com/news/3955312-horizon-stock-posts-positive-phase-4-data-for-tepezza?utm_source=businessinsider&utm_medium=referral
1683.0,4/11/2023 8:25:05 AM,Barclays Keeps Their Sell Rating on Amgen (AMGN),TipRanks,/news/stocks/barclays-keeps-their-sell-rating-on-amgen-amgn-1032223643
1684.0,4/12/2023 3:24:09 PM,These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/these-3-health-care-stocks-delivering-high-dividend-yields-are-recommended-by-wall-street-s-most-accurate-analysts-1032227483
1685.0,4/12/2023 10:22:15 PM,Amgen acquisition of Horizon Therapeutics on track to close in 1H - report,Seeking Alpha,https://seekingalpha.com/news/3956121-amgen-acquisition-of-horizon-therapeutics-on-track-to-close-in-1h-report?utm_source=businessinsider&utm_medium=referral
1686.0,4/14/2023 8:25:13 AM,Amgen (AMGN) Receives a Sell from Barclays,TipRanks,/news/stocks/amgen-amgn-receives-a-sell-from-barclays-1032232152
1687.0,4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral
1688.0,4/14/2023 12:45:05 PM,Amgen (AMGN) Receives a Hold from Mizuho Securities,TipRanks,/news/stocks/amgen-amgn-receives-a-hold-from-mizuho-securities-1032232832
1689.0,4/14/2023 3:01:22 PM,Where Amgen Stands With Analysts,Benzinga,/news/stocks/where-amgen-stands-with-analysts-1032232878
1690.0,4/14/2023 3:26:47 PM,Horizon Therapeutics gains as May date set for Irish court hearing on sale to Amgen,Seeking Alpha,https://seekingalpha.com/news/3956641-horizon-pharmaceuticals-gains-as-may-date-set-for-irish-court-hearing?utm_source=businessinsider&utm_medium=referral
1691.0,4/15/2023 9:24:00 PM,"ROSEN, A TOP RANKED FIRM, Encourages Amgen Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN",PR Newswire,/news/stocks/rosen-a-top-ranked-firm-encourages-amgen-inc-investors-with-losses-to-secure-counsel-before-important-deadline-in-securities-class-action-amgn-1032234158
1692.0,4/16/2023 6:52:57 PM,7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-that-are-backed-by-strong-cash-flows-1032234643
1693.0,4/18/2023 10:01:39 AM,"Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Resmed (RMD) and Travere Therapeutics (TVTX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-resmed-rmd-and-travere-therapeutics-tvtx-1032239087
1694.0,4/19/2023 8:16:05 PM,Amgen wins appeals court ruling in patent dispute over psoriasis drug Otezla,Seeking Alpha,https://seekingalpha.com/news/3957938-amgen-stock-wins-appeals-court-ruling-otezla-patent-dispute?utm_source=businessinsider&utm_medium=referral
1695.0,4/19/2023 10:45:00 PM,AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST),PR Newswire,/news/stocks/amgen-wins-patent-appeal-on-otezla-apremilast-1032244716
1696.0,4/20/2023 7:15:29 AM,Amgen (AMGN) Receives a Sell from Barclays,TipRanks,/news/stocks/amgen-amgn-receives-a-sell-from-barclays-1032245852
1697.0,4/21/2023 12:06:03 PM,Amgen (AMGN) Receives a Hold from Mizuho Securities,TipRanks,/news/stocks/amgen-amgn-receives-a-hold-from-mizuho-securities-1032249729
1698.0,4/21/2023 7:43:19 PM,VMware/Broadcom deal spread widens amid notice of FTC closed door meetings,Seeking Alpha,https://seekingalpha.com/news/3958788-vmwarebroadcom-deal-spread-widens-amid-notice-of-ftc-closed-door-meetings?utm_source=businessinsider&utm_medium=referral
1699.0,4/21/2023 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-announces-webcast-of-2023-first-quarter-financial-results-1032250719
1700.0,4/23/2023 1:30:00 AM,"ROSEN, A RESPECTED AND LEADING FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN",PR Newswire,/news/stocks/rosen-a-respected-and-leading-firm-encourages-amgen-inc-investors-with-losses-to-secure-counsel-before-important-deadline-in-securities-class-action-amgn-1032251149
1701.0,4/25/2023 5:30:35 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Bluebird Bio (BLUE) and InMode (INMD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-bluebird-bio-blue-and-inmode-inmd-1032259616
1702.0,4/26/2023 3:01:13 PM,Amgen is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/amgen-quarter-earnings-preview-q1-1032263723
1703.0,4/26/2023 5:21:35 PM,Democratic senators introduce bill to enhance CMS drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3960629-democratic-senators-introduce-bill-enhance-cms-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1704.0,4/26/2023 7:53:48 PM,Will Amgen's streak of EPS beats continue in Q1?,Seeking Alpha,https://seekingalpha.com/news/3960783-will-amgen-streak-of-eps-beats-continue-in-q1?utm_source=businessinsider&utm_medium=referral
1705.0,4/26/2023 9:35:19 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/3960471-notable-earnings-after-thursdays-close?utm_source=businessinsider&utm_medium=referral
1706.0,4/27/2023 10:55:09 AM,Lilly obesity therapy shows ~16% weight loss in Phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3961177-lilly-stock-obesity-therapy-shows-weight-loss?utm_source=businessinsider&utm_medium=referral
1707.0,4/27/2023 1:04:48 PM,"Stocks Rise On Strong Earnings, Expectation Of Fed Rate Hikes Ending: Analyst Says 'No Earnings Recession In Cards Yet'",Benzinga,/news/stocks/us-stocks-eye-higher-open-as-meta-q1-uplifts-tech-sector-analyst-says-no-earnings-recession-in-cards-yet-1032268050
1708.0,4/27/2023 8:04:21 PM,"Amgen Non-GAAP EPS of $3.98 in-line, revenue of $6.1B misses by $140M",Seeking Alpha,https://seekingalpha.com/news/3961600-amgen-non-gaap-eps-of-3_98-in-line-revenue-of-6_1b-misses-140m?utm_source=businessinsider&utm_medium=referral
1709.0,4/27/2023 8:52:22 PM,"Amgen 2023 revenue, earnings outlook include consensus estimates",Seeking Alpha,https://seekingalpha.com/news/3961737-amgen-2023-revenue-earnings-outlook-consensus-estimates?utm_source=businessinsider&utm_medium=referral
1710.0,4/27/2023 9:05:11 PM,Mizuho Securities Sticks to Their Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-hold-rating-for-amgen-amgn-1032270501
1711.0,4/27/2023 10:01:00 PM,AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-reports-first-quarter-financial-results-1032270218
1712.0,4/27/2023 10:06:02 PM,"Amgen Inc. Q1 Profit Increases, beats estimates",RTTNews,/news/stocks/amgen-inc-q1-profit-increases-beats-estimates-1032270239
1713.0,4/28/2023 8:25:30 AM,Goldman Sachs Reaffirms Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/goldman-sachs-reaffirms-their-buy-rating-on-amgen-amgn-1032272686
1714.0,4/28/2023 11:20:21 AM,"Analysts’ Top Healthcare Picks: Amgen (AMGN), Dexcom (DXCM)",TipRanks,/news/stocks/analysts-top-healthcare-picks-amgen-amgn-dexcom-dxcm-1032273344
1715.0,4/28/2023 12:30:19 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Dexcom (DXCM) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-dexcom-dxcm-and-merck-company-mrk-1032273730
1716.0,4/29/2023 9:28:00 PM,"ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN",PR Newswire,/news/stocks/rosen-a-highly-recognized-law-firm-encourages-amgen-inc-investors-with-losses-to-secure-counsel-before-important-may-12-deadline-in-securities-class-action-amgn-1032275361
1717.0,5/1/2023 9:15:16 AM,Amgen (AMGN) Gets a Sell from Barclays,TipRanks,/news/stocks/amgen-amgn-gets-a-sell-from-barclays-1032277530
1718.0,5/1/2023 2:13:40 PM,Coherus spikes as Truist starts at Buy on biosimilar business,Seeking Alpha,https://seekingalpha.com/news/3962639-coherus-stock-spikes-truist-starts-buy-biosimilars?utm_source=businessinsider&utm_medium=referral
1719.0,5/1/2023 2:45:10 PM,Robert W. Baird Remains a Sell on Amgen (AMGN),TipRanks,/news/stocks/robert-w-baird-remains-a-sell-on-amgen-amgn-1032278612
1720.0,5/1/2023 2:55:43 PM,SVB Securities Remains a Hold on Amgen (AMGN),TipRanks,/news/stocks/svb-securities-remains-a-hold-on-amgen-amgn-1032278584
1721.0,5/1/2023 8:36:49 PM,"Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business'",Benzinga,/news/stocks/analyst-sees-a-multibagger-initiates-coverage-on-this-top-notch-biosimilar-business-1032279133
1722.0,5/2/2023 1:46:38 AM,RBC Capital Keeps Their Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/rbc-capital-keeps-their-hold-rating-on-amgen-amgn-1032279706
1723.0,5/3/2023 4:11:48 PM,"Horizon Therapeutics Q1 miss irrelevant, deal still likely to close - analyst",Seeking Alpha,https://seekingalpha.com/news/3964571-horizon-therapeutics-q1-miss-irrelevant-deal-still-likely-to-close-analyst?utm_source=businessinsider&utm_medium=referral
1724.0,5/4/2023 10:01:33 PM,7 Blue-Chip Stocks to Buy in May 2023,InvestorPlace,/news/stocks/7-blue-chip-stocks-to-buy-in-may-2023-1032294556
1725.0,5/5/2023 5:25:07 PM,Horizon Pharma gains on report about Amgen potential deal close on May 23,Seeking Alpha,https://seekingalpha.com/news/3966633-horizon-pharma-gains-on-report-about-amgen-potential-deal-close-on-may-23?utm_source=businessinsider&utm_medium=referral
1726.0,5/7/2023 4:00:27 PM,Spending on weight loss drugs to rise 378% in 2023 – 2027: report,Seeking Alpha,https://seekingalpha.com/news/3966814-spending-weight-loss-drugs-wegovy-mounjaro-2023-2027?utm_source=businessinsider&utm_medium=referral
1727.0,5/8/2023 2:00:16 PM,Amgen highlights benefit of Prolia over Fosamax in fracture risk,Seeking Alpha,https://seekingalpha.com/news/3967066-amgen-highlights-benefit-prolia-over-fosamax-fracture-risk?utm_source=businessinsider&utm_medium=referral
1728.0,5/8/2023 2:08:22 PM,Amgen osteoporosis drug Prolia outperforms commonly used therapy,Seeking Alpha,https://seekingalpha.com/news/3967081-amgen-stock-osteoporosis-drug-prolia-beat-commonly-used-therapy?utm_source=businessinsider&utm_medium=referral
1729.0,5/8/2023 3:00:00 PM,NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE,PR Newswire,/news/stocks/new-data-from-amgen-s-prolia-denosumab-demonstrates-significant-reduction-in-osteoporotic-fracture-risk-compared-to-alendronate-1032302376
1730.0,5/8/2023 3:22:35 PM,Amgen: Prolia Shows Greater Fracture Risk Reduction Than With Alendronate In Real-world Study ,RTTNews,/news/stocks/amgen-prolia-shows-greater-fracture-risk-reduction-than-with-alendronate-in-real-world-study-1032302541
1731.0,5/8/2023 6:25:22 PM,"Amgen, Entera end research collaboration",Seeking Alpha,https://seekingalpha.com/news/3967335-amgen-entera-end-research-collaboration?utm_source=businessinsider&utm_medium=referral
1732.0,5/9/2023 1:05:00 AM,"AMGN FINAL DEADLINE MAY 12: ROSEN, A TOP RANKED LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - AMGN",PR Newswire,/news/stocks/amgn-final-deadline-may-12-rosen-a-top-ranked-law-firm-encourages-amgen-inc-investors-to-secure-counsel-before-important-friday-deadline-in-securities-class-action-amgn-1032303930
1733.0,5/9/2023 2:09:59 PM,TScan jumps 102% after deal with Amgen for Crohn’s disease,Seeking Alpha,https://seekingalpha.com/news/3968029-tscan-jumps-after-deal-amgen-crohns-disease?utm_source=businessinsider&utm_medium=referral
1734.0,5/9/2023 3:00:00 PM,AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE,PR Newswire,/news/stocks/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohn-s-disease-1032307051
1735.0,5/9/2023 3:16:56 PM,Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/check-out-3-health-care-stocks-with-over-3-dividend-yields-from-wall-street-s-most-accurate-analysts-1032307234
1736.0,5/9/2023 4:30:16 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Axsome Therapeutics (AXSM) and Shockwave Medical (SWAV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-axsome-therapeutics-axsm-and-shockwave-medical-swav-1032308113
1737.0,5/9/2023 9:01:14 PM,Analyst Ratings for Amgen,Benzinga,/news/stocks/analyst-ratings-for-amgen-1032308418
1738.0,5/12/2023 7:56:01 PM,Horizon Therapeutics ticks higher amid report FTC meeting unrelated to Amgen deal,Seeking Alpha,https://seekingalpha.com/news/3971010-horizon-therapeutics-ticks-higher-amid-report-ftc-meeting-unrelated-to-amgen-deal?utm_source=businessinsider&utm_medium=referral
1739.0,5/16/2023 4:36:27 AM,FTC To Sue To Block Amgen's Acquisition Of Horizon Therapeutics : Reports ,RTTNews,/news/stocks/ftc-to-sue-to-block-amgen-s-acquisition-of-horizon-therapeutics-reports-1032329105
1740.0,5/16/2023 11:27:00 AM,Horizon Therapeutics tumbles amid reports FTC preparing suit to block Amgen deal  (update),Seeking Alpha,https://seekingalpha.com/news/3971829-horizon-therapeutics-tumbles-on-report-ftc-preparing-suit-to-block-amgen-deal?utm_source=businessinsider&utm_medium=referral
1741.0,5/16/2023 12:41:41 PM,"Seagen, Prometheus Biosciences fall amid news of FTC planned block of Horizon/Amgen deal",Seeking Alpha,https://seekingalpha.com/news/3972034-seagen-prometheus-biosciences-fall-amid-news-of-ftc-planned-block-of-horizonamgen-deal?utm_source=businessinsider&utm_medium=referral
1742.0,5/16/2023 12:52:10 PM,AstraZeneca to exit leading U.S. drug industry group PhRMA,Seeking Alpha,https://seekingalpha.com/news/3972045-astrazeneca-stock-exits-leading-us-drug-lobby-phrma?utm_source=businessinsider&utm_medium=referral
1743.0,5/16/2023 1:36:28 PM,HZNP Stock Alert: Why Is Horizon Therapeutics Plunging Today,InvestorPlace,/news/stocks/hznp-stock-alert-why-is-horizon-therapeutics-plunging-today-1032331576
1744.0,5/16/2023 2:25:23 PM,Amgen will mount a `very aggressive' defense if FTC sues to block Horizon Therapeutics - report,Seeking Alpha,https://seekingalpha.com/news/3972136-amgen-will-mount-a-very-aggressive-defense-if-ftc-sues-to-block-horizon?utm_source=businessinsider&utm_medium=referral
1745.0,5/16/2023 2:49:10 PM,FTC files suit to block Amgen's $28B purchase of Horizon Therapeutics,Seeking Alpha,https://seekingalpha.com/news/3972162-ftc-files-suit-to-block-amgens-28b-purchase-of-horizon-therapeutics?utm_source=businessinsider&utm_medium=referral
1746.0,5/16/2023 4:56:20 PM,Hot Stocks: SE and IQ slip after earnings; HZNP down on FTC lawsuit; VOD fall on job cuts; AMD and VKTX gain,Seeking Alpha,https://seekingalpha.com/news/3972244-hot-stocks-se-and-iq-slip-after-earnings-hznp-down-on-ftc-lawsuit-vod-fall-on-job-cuts-amd-and-vktx-gain?utm_source=businessinsider&utm_medium=referral
1747.0,5/16/2023 5:31:00 PM,AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS,PR Newswire,/news/stocks/amgen-responds-to-ftc-action-re-proposed-acquisition-of-horizon-therapeutics-1032331934
1748.0,5/16/2023 6:04:07 PM,FTC suit against Horizon deal may have chilling effect on biotech M&A,Seeking Alpha,https://seekingalpha.com/news/3972260-ftc-suit-against-horizon-amgen-deal-chilling-effect-biotech?utm_source=businessinsider&utm_medium=referral
1749.0,5/16/2023 6:30:14 PM,Pfizer bond offering to fund Seagen deal said to be among largest on record,Seeking Alpha,https://seekingalpha.com/news/3972277-pfizer-bond-offering-fund-seagen-deal-among-largest?utm_source=businessinsider&utm_medium=referral
1750.0,5/16/2023 8:17:55 PM,Horizon Therapeutics plunges as FTC lawsuit increases risk to Amgen deal (update),Seeking Alpha,https://seekingalpha.com/news/3972015-horizon-therapeutics-plunges-as-potential-ftc-lawsuit-increases-risk-to-amgen-deal?utm_source=businessinsider&utm_medium=referral
1751.0,5/16/2023 10:26:14 PM,"Seagen, impacted by FTC Amgen/Horizon suit, closes down 6%",Seeking Alpha,https://seekingalpha.com/news/3972383-seagen-impacted-by-ftc-amgen-horizon-suit-closed-down-6?utm_source=businessinsider&utm_medium=referral
1752.0,5/17/2023 12:30:41 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Compugen (CGEN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-compugen-cgen-and-eli-lilly-co-lly-1032332838
1753.0,5/17/2023 3:31:29 AM,FTC Sues To Block Amgen's $27.8 Bln Acquisition Of Horizon Therapeutics ,RTTNews,/news/stocks/ftc-sues-to-block-amgen-s-27-8-bln-acquisition-of-horizon-therapeutics-1032332859
1754.0,5/17/2023 11:20:54 AM,Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and ReShape Lifesciences (RSLS),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-and-reshape-lifesciences-rsls-1032334533
1755.0,5/17/2023 2:41:26 PM,"Horizon Therapeutics gains as investors see actual FTC suit, potential for settlement down the road",Seeking Alpha,https://seekingalpha.com/news/3972610-horizon-therapeutics-gain-amid-speculation-on-ftc-settlement-in-amgen-case?utm_source=businessinsider&utm_medium=referral
1756.0,5/17/2023 2:42:12 PM,Regeneron CEO supports FTC suit against Amgen acquisition of Horizon - FT,Seeking Alpha,https://seekingalpha.com/news/3972603-regeneron-ceo-supports-ftc-suit-against-amgen-acquistion-horizon?utm_source=businessinsider&utm_medium=referral
1757.0,5/17/2023 3:20:38 PM,"Applied Materials, Lowe's added to Jefferies franchise picks list",Seeking Alpha,https://seekingalpha.com/news/3971999-applied-materials-lowes-added-to-jeffries-franchise-picks-list?utm_source=businessinsider&utm_medium=referral
1758.0,5/17/2023 3:33:02 PM,Amgen deal for Horizon likely to go through despite FTC objection: Guggenheim,Seeking Alpha,https://seekingalpha.com/news/3972621-amgen-deal-horizon-likely-go-through-despite-ftc-objection?utm_source=businessinsider&utm_medium=referral
1759.0,5/18/2023 1:25:44 PM,Amgen agrees not to close Horizon deal before Sept. 15 in court agreement with FTC,Seeking Alpha,https://seekingalpha.com/news/3973021-amgen-agrees-to-not-close-horizon-deal-before-sept-15-in-agreement-with-ftc?utm_source=businessinsider&utm_medium=referral
1760.0,5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral
1761.0,5/19/2023 4:37:11 AM,U.S. Supreme Court Rules Against Amgen In Cholesterol Drug Patent Dispute With Sanofi ,RTTNews,/news/stocks/u-s-supreme-court-rules-against-amgen-in-cholesterol-drug-patent-dispute-with-sanofi-1032338671
1762.0,5/21/2023 4:00:17 PM,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,Seeking Alpha,https://seekingalpha.com/news/3973623-billions-fda-shortcut-allows-half-proven-drugs?utm_source=businessinsider&utm_medium=referral
1763.0,5/22/2023 10:49:30 AM,Ideaya announces FDA nod to run Amgen-sponsored tumor study,Seeking Alpha,https://seekingalpha.com/news/3973706-ideaya-stock-says-fda-cleared-amgen-sponsored-tumor-trial?utm_source=businessinsider&utm_medium=referral
1764.0,5/22/2023 12:27:38 PM,IDEAYA: FDA Approves To Proceed With Evaluation Of IDE397 In Combination With AMG 193 ,RTTNews,/news/stocks/ideaya-fda-approves-to-proceed-with-evaluation-of-ide397-in-combination-with-amg-193-1032342181
1765.0,5/23/2023 4:38:56 PM,FTC's suit to block Amgen's purchase of Horizon Therapeutics set for Sept. 11 trial,Seeking Alpha,https://seekingalpha.com/news/3974266-ftcs-suit-to-block-amgens-purchase-of-horizon-therapeutics-set-for-sept-11-trial?utm_source=businessinsider&utm_medium=referral
1766.0,5/23/2023 5:17:29 PM,"Bayer, Amgen looked at Iveric before agreeing to Astellas sale - report",Seeking Alpha,https://seekingalpha.com/news/3974293-bayer-amgen-looked-at-iveric-before-agreeing-to-astellas-sale-report?utm_source=businessinsider&utm_medium=referral
1767.0,5/23/2023 6:30:03 PM,"Amgen, J&J settle lawsuit over Stelara biosimilar",Seeking Alpha,https://seekingalpha.com/news/3974310-amgen-johnson-johnson-settle-lawsuit-stelara-biosimilar?utm_source=businessinsider&utm_medium=referral
1768.0,5/25/2023 8:59:52 AM,"Novartis' Sandoz gets EMA review for biosimilar to Amgen's Prolia, Xgeva",Seeking Alpha,https://seekingalpha.com/news/3974936-novartis-gets-ema-review-for-biosimilar-to-amgens-prolia-xgeva?utm_source=businessinsider&utm_medium=referral
1769.0,5/25/2023 4:19:09 PM,3 Dogs of the Dow for High-Yield Investors,InvestorPlace,/news/stocks/3-dogs-of-the-dow-for-high-yield-investors-1032352414
1770.0,5/26/2023 10:00:00 PM,AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT,PR Newswire,/news/stocks/amgen-to-present-at-the-td-cowen-4th-annual-oncology-innovation-summit-1032355115
1771.0,5/30/2023 2:55:26 PM,Viridian an outperform at RBC on thyroid eye disease candidate,Seeking Alpha,https://seekingalpha.com/news/3975837-viridian-outperform-rbc-thyroid-eye-disease-candidate?utm_source=businessinsider&utm_medium=referral
1772.0,5/30/2023 8:30:36 PM,Quant Ratings Updated on 107 Stocks,InvestorPlace,/news/stocks/20230530-quant-ratings-1032359328
1773.0,5/31/2023 12:00:00 AM,AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023,PR Newswire,/news/stocks/amgen-presents-new-research-on-otezla-apremilast-in-psoriatic-arthritis-at-eular-2023-1032359450
1774.0,6/1/2023 1:23:14 PM,Mark Cuban online pharmacy to offer AbbVie Humira biosimilar,Seeking Alpha,https://seekingalpha.com/news/3976594-mark-cuban-online-pharmacy-offer-abbvie-humira-biosimilar?utm_source=businessinsider&utm_medium=referral
1775.0,6/1/2023 3:00:00 PM,AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023,PR Newswire,/news/stocks/amgen-presents-new-scientific-and-clinical-research-across-its-diverse-oncology-portfolio-and-pipeline-at-asco-2023-1032364437
1776.0,6/1/2023 4:11:01 PM,House Committee starts probe into FTC Chair Lina Khan,Seeking Alpha,https://seekingalpha.com/news/3976720-house-committee-starts-probe-into-ftc-chair-lina-khan?utm_source=businessinsider&utm_medium=referral
1777.0,6/1/2023 6:17:38 PM,"AbbVie, Amgen hit 52-week lows as Coherus unveils cheapest Humira version",Seeking Alpha,https://seekingalpha.com/news/3976787-abbvie-stock-amgen-stock-slump-coherus-cheapest-humira?utm_source=businessinsider&utm_medium=referral
1778.0,6/2/2023 11:55:32 AM,3 Undervalued Biotech Stocks to Buy Before They Blast Off,InvestorPlace,/news/stocks/3-undervalued-biotech-stocks-to-buy-before-they-blast-off-1032367065
1779.0,6/3/2023 12:40:39 PM,Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Natera (NTRA),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-and-natera-ntra-1032368546
1780.0,6/4/2023 2:00:00 PM,AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023,PR Newswire,/news/stocks/amgen-presents-new-lumakras-sotorasib-codebreak-200-cns-data-at-asco-2023-1032368878
1781.0,6/4/2023 4:00:08 PM,Morgan Stanley sees broader MedTech impact from weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3977410-morgan-stanley-sees-medtech-impact-from-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral
1782.0,6/4/2023 6:53:53 PM,"Novo Nordisk, Lilly facing increased competition in obesity drug market",Seeking Alpha,https://seekingalpha.com/news/3977415-novo-nordisk-lilly-facing-increased-competition-in-obesity-drug-market?utm_source=businessinsider&utm_medium=referral
1783.0,6/5/2023 4:51:20 PM,Amgen sees potential for Horizon to close by mid-December under court schedule,Seeking Alpha,https://seekingalpha.com/news/3977640-amgen-sees-potential-for-horizon-to-close-by-mid-december-under-court-schedule?utm_source=businessinsider&utm_medium=referral
1784.0,6/5/2023 5:51:22 PM,Iveric Bio gains after holder vote on Astellas takeover set for July 6,Seeking Alpha,https://seekingalpha.com/news/3977667-iveric-bio-gains-after-holder-vote-on-astellas-takeover-set-for-july-6?utm_source=businessinsider&utm_medium=referral
1785.0,6/8/2023 10:30:23 AM,The 3 Best Long-Term Dividend Stocks to Buy in June,InvestorPlace,/news/stocks/the-3-best-long-term-dividend-stocks-to-buy-in-june-1032378017
1786.0,6/8/2023 3:07:36 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields-1032378537
1787.0,6/9/2023 1:26:24 PM,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",Seeking Alpha,https://seekingalpha.com/news/3978943-abbvie-among-firms-targeted-for-medicare-inflation-penalties?utm_source=businessinsider&utm_medium=referral
1788.0,6/9/2023 6:52:57 PM,Seagen gains as antitrust deadline for Pfizer purchase nears on Monday,Seeking Alpha,https://seekingalpha.com/news/3979010-seagen-gains-as-antitrust-deadline-for-pfizer-purchases-nears-on-monday?utm_source=businessinsider&utm_medium=referral
1789.0,6/9/2023 10:00:00 PM,AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-1032381570
1790.0,6/12/2023 11:58:31 AM,"Teva, Alvotech in pact with Johnson & Johnson over Stelara knockoff",Seeking Alpha,https://seekingalpha.com/news/3979152-teva-stock-alvotech-pact-jnj-stelara-knockoff?utm_source=businessinsider&utm_medium=referral
1791.0,6/12/2023 3:51:15 PM,5 Stocks to Buy With Explosive 500% Potential,InvestorPlace,/news/stocks/5-stocks-to-buy-with-explosive-500-potential-1032384018
1792.0,6/15/2023 12:01:30 AM,"BTIG starts Virdian at buy, cites market potential for thyroid eye drug",Seeking Alpha,https://seekingalpha.com/news/3980000-btig-starts-virdian-at-buy-cites-market-potential-for-thyroid-eye-drug?utm_source=businessinsider&utm_medium=referral
1793.0,6/15/2023 12:51:12 AM,Amgen reportedly hires Moderna chief medical officer as new CMO,Seeking Alpha,https://seekingalpha.com/news/3980001-amgen-reportedly-hires-moderna-chief-medical-officer-as-new-cmo?utm_source=businessinsider&utm_medium=referral
1794.0,6/18/2023 8:56:10 PM,How to Retire Rich: Biotech Stocks Edition,InvestorPlace,/news/stocks/how-to-retire-rich-biotech-stocks-edition-1032395848
1795.0,6/21/2023 1:26:50 PM,Amgen wins full approval for leukemia therapy Blincyto,Seeking Alpha,https://seekingalpha.com/news/3981405-amgen-wins-full-approval-leukemia-therapy-blincyto?utm_source=businessinsider&utm_medium=referral
1796.0,6/21/2023 3:00:00 PM,FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA,PR Newswire,/news/stocks/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukemia-1032401796
1797.0,6/21/2023 3:21:15 PM,Amgen: FDA Grants Full Approval For BLINCYTO - Quick Facts ,RTTNews,/news/stocks/amgen-fda-grants-full-approval-for-blincyto-quick-facts-1032401918
1798.0,6/21/2023 3:44:52 PM,Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3981469-top-pharma-lobby-sues-us-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral
1799.0,6/22/2023 9:15:06 PM,Six states join FTC lawsuit to block Amgen's planned purchase of Horizon,Seeking Alpha,https://seekingalpha.com/news/3982236-five-states-join-ftc-lawsuit-to-block-amgens-planned-purchase-of-horizon?utm_source=businessinsider&utm_medium=referral
1800.0,6/22/2023 9:31:56 PM,Six states join FTC lawsuit to block Amgen's planned purchase of Horizon,Seeking Alpha,https://seekingalpha.com/news/3982236-six-states-join-ftc-lawsuit-to-block-amgens-planned-purchase-of-horizon?utm_source=businessinsider&utm_medium=referral
1801.0,6/23/2023 1:46:02 PM,"Amgen had settlement talks with FTC over Horizon, though no agreement - report",Seeking Alpha,https://seekingalpha.com/news/3982396-amgen-had-settlement-talks-ftc-over-horizon-though-no-agreement-report?utm_source=businessinsider&utm_medium=referral
1802.0,6/24/2023 12:13:16 AM,FTC files suit with ALJ on Horizon/Amgen deal (update),Seeking Alpha,https://seekingalpha.com/news/3982473-ftc-said-to-have-filed-suit-with-alj-on-horizon-therapeuticsamgen-deal?utm_source=businessinsider&utm_medium=referral
1803.0,6/25/2023 4:00:43 PM,What is behind big pharma's underperformance?,Seeking Alpha,https://seekingalpha.com/news/3982575-pharma-underperforms-amid-regulatory-woes?utm_source=businessinsider&utm_medium=referral
1804.0,6/26/2023 11:00:27 PM,7 Analysts Have This to Say About Amgen,Benzinga,/news/stocks/7-analysts-have-this-to-say-about-amgen-1032410828
1805.0,6/27/2023 11:00:21 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY) and Amgen (AMGN),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-alnylam-pharma-alny-and-amgen-amgn-1032411882
1806.0,6/29/2023 9:08:31 AM,Morgan Stanley shakes up its global dividend portfolio,Seeking Alpha,https://seekingalpha.com/news/3983853-morgan-stanley-shakes-up-its-global-dividend-portfolio?utm_source=businessinsider&utm_medium=referral
1807.0,6/29/2023 7:03:01 PM,"Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck",Benzinga,/news/etf/amgen-out-rio-tinto-in-as-morgan-stanley-shuffles-dividend-deck-1032418601
1808.0,6/29/2023 7:43:11 PM,Pfizer sees second request as likely in FTC's review of Seagen deal - analyst,Seeking Alpha,https://seekingalpha.com/news/3984259-pfizer-sees-second-request-as-likely-in-ftcs-review-of-seagen-deal-analyst?utm_source=businessinsider&utm_medium=referral
1809.0,6/30/2023 4:41:16 PM,Medicare revises guidance on drug price negotiations amid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3984642-medicare-revises-guidance-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1810.0,6/30/2023 6:06:43 PM,"15 Stocks Up, 15 Stocks Down: A Look At The Dow Jones Industrial Average Halfway Through 2023",Benzinga,/news/etf/15-stocks-up-15-stocks-down-a-look-at-the-dow-jones-industrial-average-halfway-through-2023-1032421047
1811.0,7/1/2023 3:03:04 PM,Organon launches biosimilar of AbbVie's Humira,Seeking Alpha,https://seekingalpha.com/news/3984821-organon-launches-biosimilar-abbvie-humira?utm_source=businessinsider&utm_medium=referral
1812.0,7/5/2023 4:57:34 PM,Celltrion launches biosimilar of AbbVie's Humira in US,Seeking Alpha,https://seekingalpha.com/news/3985654-celltrion-launches-biosimilar-of-abbvie-humira-in-us?utm_source=businessinsider&utm_medium=referral
1813.0,7/6/2023 12:24:53 AM,3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025,InvestorPlace,/news/stocks/triple-digit-return-biotech-stocks-3-ai-picks-2025-1032428652
1814.0,7/7/2023 12:12:17 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032432188
1815.0,7/9/2023 1:00:00 PM,"New M&A rules likely to delay deals by months, add significant costs",Seeking Alpha,https://seekingalpha.com/news/3986337-new-merger-rules-likely-to-delays-deals-by-months-add-significant-costs?utm_source=businessinsider&utm_medium=referral
1816.0,7/9/2023 4:00:00 PM,Goldman Sachs sees rays of hope in underperforming health sector,Seeking Alpha,https://seekingalpha.com/news/3986286-goldman-sachs-sees-hope-underperforming-health-sector?utm_source=businessinsider&utm_medium=referral
1817.0,7/10/2023 5:40:24 PM,AbbVie slips as Cigna adds more Humira biosimilars for coverage,Seeking Alpha,https://seekingalpha.com/news/3986544-abbvie-stock-slips-cigna-adds-humira-biosimilars?utm_source=businessinsider&utm_medium=referral
1818.0,7/11/2023 1:46:27 AM,Amgen (AMGN) Gets a Hold from RBC Capital,TipRanks,/news/stocks/amgen-amgn-gets-a-hold-from-rbc-capital-1032436106
1819.0,7/11/2023 9:35:07 AM,Barclays Sticks to Its Sell Rating for Amgen (AMGN),TipRanks,/news/stocks/barclays-sticks-to-its-sell-rating-for-amgen-amgn-1032437141
1820.0,7/11/2023 3:37:40 PM,"iRobot, Seagen, Horizon gain amid Microsoft win in Activision case",Seeking Alpha,https://seekingalpha.com/news/3986814-irobot-seagen-horizon-gain-amid-microsoft-win-in-activision-case?utm_source=businessinsider&utm_medium=referral
1821.0,7/12/2023 8:01:03 PM,Analyst Expectations for Amgen's Future,Benzinga,/news/stocks/analyst-expectations-for-amgen-s-future-1032442224
1822.0,7/14/2023 6:24:52 PM,SCHD vs. VYM: Which is the Better Dividend ETF?,TipRanks,/news/stocks/schd-vs-vym-which-is-the-better-dividend-etf-1032448246
1823.0,7/14/2023 7:00:24 PM,"Catalyst Watch: Microsoft-Activision Blizzard drama, Splunk event and Nasdaq 100 rebalancing countdown",Seeking Alpha,https://seekingalpha.com/news/3987769-catalyst-watch-microsoft-activision-blizzard-drama-splunk-event-and-nasdaq-100-rebalancing-countdown?utm_source=businessinsider&utm_medium=referral
1824.0,7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral
1825.0,7/18/2023 10:22:03 AM,3 Biotech Stocks for Getting Rich in 2023,InvestorPlace,/news/stocks/3-biotech-stocks-for-getting-rich-in-2023-1032454309
1826.0,7/19/2023 6:19:52 PM,"Amgen, FTC said there are no ongoing talks, though open to settlement over Horizon",Seeking Alpha,https://seekingalpha.com/news/3988867-amgen-ftc-said-they-are-no-ongoing-talks-to-settle-over-horizon-therapeutics-deal?utm_source=businessinsider&utm_medium=referral
1827.0,7/20/2023 5:58:57 PM,Lawmakers reintroduce bill to offer Medicare coverage for weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3989310-bill-offer-medicare-coverage-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral
1828.0,7/20/2023 6:24:37 PM,Key Horizon drug Tepezza has hearing loss warning added to labeling,Seeking Alpha,https://seekingalpha.com/news/3989316-horizon-tepezza-hearing-loss-warning-added-labeling?utm_source=businessinsider&utm_medium=referral
1829.0,7/21/2023 11:08:26 AM,Mirati fails to win EU backing for lung cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3989558-mirati-fails-win-eu-backing-lung-cancer-therapy?utm_source=businessinsider&utm_medium=referral
1830.0,7/21/2023 3:02:07 PM,Tepezza warning label unlikely to have any impact on Horizon/Amgen deal - analyst,Seeking Alpha,https://seekingalpha.com/news/3989690-tepezza-warning-label-unlikely-to-have-impact-on-horizonamgen-deal-analyst?utm_source=businessinsider&utm_medium=referral
1831.0,7/21/2023 7:31:28 PM,The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-now-july-2023-1032466871
1832.0,7/26/2023 4:20:16 AM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-biogen-biib-1032476900
1833.0,7/26/2023 12:35:51 PM,AbbVie says Skyrizi beat Amgen’s Otezla in plaque psoriasis trial,Seeking Alpha,https://seekingalpha.com/news/3991142-abbvies-skyrizi-beats-amgens-otezla-plaque-psoriasis?utm_source=businessinsider&utm_medium=referral
1834.0,7/26/2023 3:58:07 PM,AbbVie under pressure ahead of Q2 results amid Humira cliff,Seeking Alpha,https://seekingalpha.com/news/3991264-abbvie-stock-sold-off-ahead-q2-print-humira-cliff?utm_source=businessinsider&utm_medium=referral
1835.0,7/27/2023 1:08:44 PM,Inside AbbVie: Signs of stabilization in Humira sales?,Seeking Alpha,https://seekingalpha.com/news/3992077-inside-abbvie-signs-stabilization-humira-sales?utm_source=businessinsider&utm_medium=referral
1836.0,7/28/2023 5:56:18 PM,Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated,Benzinga,/news/stocks/reata-s-acquisition-fits-biogen-s-strategy-despite-high-cost-analyst-says-high-level-regulatory-scrutiny-not-anticipated-1032490800
1837.0,7/28/2023 6:00:40 PM,"Catalyst Watch: Amazon earnings, jobs report, and will Apple talk AI?",Seeking Alpha,https://seekingalpha.com/news/3992944-catalyst-watch-amazon-earnings-jobs-report-and-will-apple-talk-ai?utm_source=businessinsider&utm_medium=referral
1838.0,7/31/2023 9:50:22 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Icon (ICLR) and Edwards Lifesciences (EW)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-icon-iclr-and-edwards-lifesciences-ew-1032494583
1839.0,7/31/2023 5:03:19 PM,"Rising Stars, Falling Trends: July's Industry ETF Winners And Losers",Benzinga,/news/etf/rising-stars-falling-trends-july-s-industry-etf-winners-and-losers-1032496121
1840.0,7/31/2023 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-announces-webcast-of-2023-second-quarter-financial-results-1032496900
1841.0,8/1/2023 8:43:47 PM,Amgen declares $2.13 dividend,Seeking Alpha,https://seekingalpha.com/news/3994601-amgen-inc-declares-2_13-dividend?utm_source=businessinsider&utm_medium=referral
1842.0,8/1/2023 10:00:00 PM,AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND,PR Newswire,/news/stocks/amgen-announces-2023-third-quarter-dividend-1032502395
1843.0,8/2/2023 3:01:13 PM,Here's what Wall Street expects from Amgen's earnings,Markets Insider Automation,/news/stocks/amgen-q2-quarterly-earnings-preview-1032506929
1844.0,8/2/2023 6:20:25 PM,"Amgen looks to Q2 top, bottom line beats after missing in Q1",Seeking Alpha,https://seekingalpha.com/news/3995374-amgen-looks-q2-top-bottom-line-beats-after-missing-q1?utm_source=businessinsider&utm_medium=referral
1845.0,8/3/2023 8:05:07 PM,"Amgen Non-GAAP EPS of $5.00 beats by $0.51, revenue of $6.98B beats by $300M",Seeking Alpha,https://seekingalpha.com/news/3996899-amgen-non-gaap-eps-of-5_00-beats-0_51-revenue-of-6_98b-beats-300m?utm_source=businessinsider&utm_medium=referral
1846.0,8/3/2023 8:54:31 PM,Amgen guides 2023 EPS above consensus while revenue in-line,Seeking Alpha,https://seekingalpha.com/news/3997078-amgen-guides-2023-eps-above-consensus-revenue-in-line?utm_source=businessinsider&utm_medium=referral
1847.0,8/3/2023 8:55:17 PM,Amgen (AMGN) Gets a Hold from Mizuho Securities,TipRanks,/news/stocks/amgen-amgn-gets-a-hold-from-mizuho-securities-1032514512
1848.0,8/3/2023 10:02:47 PM,Amgen says FTC has ignored commitments it made to address Horizon deal concerns (update),Seeking Alpha,https://seekingalpha.com/news/3997117-amgen-says-ftc-has-ignored-commitments-it-made-to-address-horizon-deal-concerns?utm_source=businessinsider&utm_medium=referral
1849.0,8/3/2023 10:06:49 PM,"Amgen Inc. Q2 Profit Increases, beats estimates",RTTNews,/news/stocks/amgen-inc-q2-profit-increases-beats-estimates-1032514253
1850.0,8/4/2023 8:05:43 AM,Amgen (AMGN) Gets a Sell from Barclays,TipRanks,/news/stocks/amgen-amgn-gets-a-sell-from-barclays-1032517001
1851.0,8/4/2023 11:16:32 AM,"Dividend Roundup: IBM, Walmart, BP, Kimberly-Clark, and more",Seeking Alpha,https://seekingalpha.com/news/3996876-dividend-roundup-ibm-walmart-bp-kimberly-clark-and-more?utm_source=businessinsider&utm_medium=referral
1852.0,8/4/2023 11:45:18 AM,Amgen (AMGN) Gets a Hold from BMO Capital,TipRanks,/news/stocks/amgen-amgn-gets-a-hold-from-bmo-capital-1032517736
1853.0,8/6/2023 4:00:54 PM,Nearly half of U.S. adults want weight-loss drugs – KFF poll,Seeking Alpha,https://seekingalpha.com/news/3997955-nearly-half-of-americans-want-weight-loss-drugs-kff-poll?utm_source=businessinsider&utm_medium=referral
1854.0,8/6/2023 7:35:00 PM,2023 shaping up to be biggest year for biopharma M&A since pandemic,Seeking Alpha,https://seekingalpha.com/news/3997958-2023-shaping-up-to-be-biggest-year-for-biopharma-ma-since-pandemic?utm_source=businessinsider&utm_medium=referral
1855.0,8/7/2023 2:30:35 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Cigna (CI) and Ultragenyx Pharmaceutical (RARE)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-cigna-ci-and-ultragenyx-pharmaceutical-rare-1032520686
1856.0,8/8/2023 9:15:10 AM,Amgen (AMGN) Receives a Sell from Robert W. Baird,TipRanks,/news/stocks/amgen-amgn-receives-a-sell-from-robert-w-baird-1032527907
1857.0,8/8/2023 2:47:02 PM,Watch weight loss stocks after cardiovascular data for Wegovy,Seeking Alpha,https://seekingalpha.com/news/3999115-watch-weight-loss-stocks-cardiovascular-data-for-wegovy?utm_source=businessinsider&utm_medium=referral
1858.0,8/9/2023 3:37:39 AM,3 Biotech Stocks You’ll Regret Not Buying Soon,InvestorPlace,/news/stocks/3-biotech-stocks-youll-regret-not-buying-soon-1032531443
1859.0,8/9/2023 7:25:33 AM,Barclays Sticks to Its Sell Rating for Amgen (AMGN),TipRanks,/news/stocks/barclays-sticks-to-its-sell-rating-for-amgen-amgn-1032533550
1860.0,8/9/2023 8:00:01 PM,The 3 Best Biotech Stocks to Buy in August,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-august-1032536499
1861.0,8/11/2023 8:52:36 AM,"Uber Crowded, Battleground and Sweet 16 stock portfolios from Jefferies",Seeking Alpha,https://seekingalpha.com/news/3999208-uber-crowded-battleground-and-sweet-16-stock-portfolios-from-jefferies?utm_source=businessinsider&utm_medium=referral
1862.0,8/11/2023 10:01:24 PM,"Nasdaq Suffers Second Straight Week of Losses, Breaks Key Support Level As Tech Bears Return: Is This Time Different?",Benzinga,/news/etf/nasdaq-suffers-second-straight-week-of-losses-breaks-key-support-level-as-tech-bears-return-is-this-time-different-1032547898
1863.0,8/13/2023 1:24:10 PM,"Horizon Therapeutics, Activision among best bets for M&A deals to close",Seeking Alpha,https://seekingalpha.com/news/4002057-horizon-therapeutics-activision-among-best-bets-for-ma-deals-to-close?utm_source=businessinsider&utm_medium=referral
1864.0,8/13/2023 6:00:00 PM,Pharma under threat from bill to expand drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4002034-pharma-under-threat-bill-expand-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1865.0,8/14/2023 2:08:05 PM,"QUALCOMM, AIG And 2 Other Stocks Insiders Are Selling",Benzinga,/news/stocks/qualcomm-aig-and-2-other-stocks-insiders-are-selling-1032551051
1866.0,8/14/2023 10:00:37 PM,The Latest Analyst Ratings for Amgen,Benzinga,/news/stocks/the-latest-analyst-ratings-for-amgen-1032552803
1867.0,8/15/2023 1:53:55 PM,"Tudor Investment boosts stakes in Big Tech, exits VMware, BAH, HRL",Seeking Alpha,https://seekingalpha.com/news/4002924-tudor-investment-boosts-stakes-in-big-tech-exits-vmware-bah-hrl?utm_source=businessinsider&utm_medium=referral
1868.0,8/17/2023 9:12:48 AM,The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-now-august-2023-1032562527
1869.0,8/17/2023 9:06:53 PM,"Jefferies starts BeiGene at buy, cites deep pipeline, Novartis partnership",Seeking Alpha,https://seekingalpha.com/news/4004181-jefferies-starts-beigene-at-buy-cites-deep-pipeline-novartis-partnership?utm_source=businessinsider&utm_medium=referral
1870.0,8/18/2023 5:10:25 PM,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",Seeking Alpha,https://seekingalpha.com/news/4004411-aarp-public-citizen-file-briefs-medicare-drug-price-negotiations-case?utm_source=businessinsider&utm_medium=referral
1871.0,8/21/2023 2:28:45 PM,Amgen's Lumakras facing FDA advisory panel for full approval,Seeking Alpha,https://seekingalpha.com/news/4004750-amgen-lumakras-facing-fda-advisory-panel-full-approval?utm_source=businessinsider&utm_medium=referral
1872.0,8/21/2023 8:00:10 PM,Horizon Therapeutics gains amid speculation on potential FTC settlement on Amgen,Seeking Alpha,https://seekingalpha.com/news/4004914-horizon-therapeutics-gains-amid-speculation-on-potential-ftc-settlement-on-amgen?utm_source=businessinsider&utm_medium=referral
1873.0,8/21/2023 8:20:38 PM,These Are the ONLY 3 Biotech Stocks to Consider in August 2023,InvestorPlace,/news/stocks/these-are-the-only-3-biotech-stocks-to-consider-in-august-2023-1032570998
1874.0,8/21/2023 10:00:00 PM,AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING,PR Newswire,/news/stocks/amgen-to-discuss-application-for-lumakras-sotorasib-for-the-treatment-of-kras-g12c-positive-nsclc-at-fda-advisory-committee-meeting-1032570951
1875.0,8/22/2023 1:55:07 PM,Amgen (AMGN) Gets a Buy from Jefferies,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-jefferies-1032573280
1876.0,8/23/2023 3:27:44 PM,Amgen says FTC case to block Horizon Therapeutics deal `defies logic',Seeking Alpha,https://seekingalpha.com/news/4005582-amgen-says-ftc-case-to-block-horizon-therapeutics-deal-defies-logic?utm_source=businessinsider&utm_medium=referral
1877.0,8/24/2023 1:44:18 PM,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,Seeking Alpha,https://seekingalpha.com/news/4005992-drug-list-picked-medicare-price-negotiations-due-tuesday?utm_source=businessinsider&utm_medium=referral
1878.0,8/24/2023 4:13:54 PM,"FTC likely to lose its challenge to the Horizon/Amgen deal, legal experts say - analyst",Seeking Alpha,https://seekingalpha.com/news/4006073-ftc-likely-to-lose-its-challenge-to-the-horizonamgen-deal-legal-experts-say-analyst?utm_source=businessinsider&utm_medium=referral
1879.0,8/25/2023 2:43:48 PM,Merck starts phase 3 program for oral PCSK9 inhibitor to lower cholesterol,Seeking Alpha,https://seekingalpha.com/news/4006430-merck-starts-phase-3-oral-pcsk9-inhibitor-lower-cholesterol?utm_source=businessinsider&utm_medium=referral
1880.0,8/25/2023 8:29:02 PM,Horizon Therapeutics gains as FTC withdraws in-house trial on Amgen deal,Seeking Alpha,https://seekingalpha.com/news/4006551-horizon-therapeutics-gains-as-ftc-seeks-delay-of-in-house-trial-on-amgen-deal?utm_source=businessinsider&utm_medium=referral
1881.0,8/25/2023 9:08:21 PM,Horizon Therapeutics jumps as FTC withdraws in-house trial on $28B Amgen deal (update),Seeking Alpha,https://seekingalpha.com/news/4006558-horizon-therapeutics-jumps-as-ftc-withdraws-in-house-trial-on-28b-amgen-deal?utm_source=businessinsider&utm_medium=referral
1882.0,8/26/2023 4:45:00 PM,AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023,PR Newswire,/news/stocks/amgen-presents-late-breaking-phase-2-olpasiran-data-at-esc-2023-1032583945
1883.0,8/26/2023 5:06:58 PM,Amgen : Olpasiran Phase 2 Data Shows Continued Reduction Of Lp(a) Nearly A Year After Last Dose ,RTTNews,/news/stocks/amgen-olpasiran-phase-2-data-shows-continued-reduction-of-lp-a-nearly-a-year-after-last-dose-1032583950
1884.0,8/26/2023 6:00:00 PM,Crohn's disease drugmakers set to benefit from expected rise in cases,Seeking Alpha,https://seekingalpha.com/news/4006563-crohns-disease-drugmakers-benefit-expected-rise-cases?utm_source=businessinsider&utm_medium=referral
1885.0,8/27/2023 4:00:00 PM,Wall Street lists potential targets for Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4006581-wall-street-lists-targets-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1886.0,8/28/2023 12:15:27 PM,Horizon Therapeutics jumps after FTC pauses Amgen challenge for settlement talks,Seeking Alpha,https://seekingalpha.com/news/4006682-horizon-therapeutics-jumps-after-ftc-pauses-amgen-challenge-for-settlement-talks?utm_source=businessinsider&utm_medium=referral
1887.0,8/28/2023 1:29:55 PM,Amgen could reach settlement with FTC over Horizon in next few weeks - report,Seeking Alpha,https://seekingalpha.com/news/4006718-amgen-could-reach-settlement-with-ftc-over-horizon-in-next-few-weeks-report?utm_source=businessinsider&utm_medium=referral
1888.0,8/28/2023 1:45:07 PM,BMO Capital Issues a Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/bmo-capital-issues-a-hold-rating-on-amgen-amgn-1032586155
1889.0,8/28/2023 2:21:53 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields-1032585778
1890.0,8/28/2023 4:37:09 PM,"Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories",Benzinga,/news/stocks/hawaiian-electric-says-power-lines-not-responsible-for-deadly-lahaina-fire-china-targets-stock-market-revival-ftc-pauses-legal-battle-with-amgen-s-28b-horizon-deal-today-s-top-stories-1032586588
1891.0,8/29/2023 11:45:20 AM,Medicare lists first ten drugs selected for pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4006764-medicare-lists-first-ten-drugs-picked-pricing-talks?utm_source=businessinsider&utm_medium=referral
1892.0,8/29/2023 6:31:22 PM,Initial Medications Chosen By HHS For Medicare Drug Price Negotiations ,RTTNews,/news/stocks/initial-medications-chosen-by-hhs-for-medicare-drug-price-negotiations-1032590160
1893.0,8/30/2023 8:46:25 PM,NuVasive/Globus Medical spread widens amid notice of FTC meeting (update),Seeking Alpha,https://seekingalpha.com/news/4007564-nuvasiveglobus-medical-spread-widens-amid-notice-of-ftc-closed-door-meeting?utm_source=businessinsider&utm_medium=referral
1894.0,8/30/2023 10:10:35 PM,Court hearing on FTC's challenge to Horizon/Amgen rescheduled until next week,Seeking Alpha,https://seekingalpha.com/news/4007752-court-hearing-on-ftcs-challenge-to-horizonamgen-rescheduled-until-next-week?utm_source=businessinsider&utm_medium=referral
1895.0,9/1/2023 1:30:00 AM,AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-2023-wells-fargo-healthcare-conference-and-the-citi-global-healthcare-conference-1032597974
1896.0,9/1/2023 1:14:19 PM,Horizon Therapeutics gains afer FTC settles with Amgen over $28B deal  (update),Seeking Alpha,https://seekingalpha.com/news/4008313-horizon-therapeutics-gains-after-ftc-settles-with-amgen-over-28b-deal?utm_source=businessinsider&utm_medium=referral
1897.0,9/1/2023 1:22:00 PM,"4 stocks to watch on Friday: lululemon athletica, Papa John's and more",Seeking Alpha,https://seekingalpha.com/news/4008332-4-stocks-to-watch-on-friday-lululemon-athletica-papa-johns-and-more?utm_source=businessinsider&utm_medium=referral
1898.0,9/1/2023 3:20:00 PM,"AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION",PR Newswire,/news/stocks/amgen-and-horizon-therapeutics-plc-resolve-ftc-lawsuit-clearing-path-to-close-acquisition-1032599581
1899.0,9/1/2023 3:58:28 PM,"Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4 ",RTTNews,/news/stocks/amgen-horizon-therapeutics-reach-settlement-on-ftc-lawsuit-seeks-to-close-acquisition-in-q4-1032599692
1900.0,9/2/2023 6:00:00 PM,"Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag",Seeking Alpha,https://seekingalpha.com/news/4008548-lilly-novo-nordisk-top-pharma-performers-august-astrazeneca-roche-lag?utm_source=businessinsider&utm_medium=referral
1901.0,9/3/2023 4:00:00 PM,Why is big pharma unmoved despite Medicare pricing threat?,Seeking Alpha,https://seekingalpha.com/news/4008703-why-big-pharma-unmoved-despite-medicare-pricing-threat?utm_source=businessinsider&utm_medium=referral
1902.0,9/4/2023 12:47:34 AM,The 3 Most Promising Dow Stocks to Own Now,InvestorPlace,/news/stocks/the-3-most-promising-dow-stocks-to-own-now-1032601405
1903.0,9/5/2023 1:37:34 PM,Irish High Court hearing for Horizon's $28B sale to Amgen set for Oct. 5,Seeking Alpha,https://seekingalpha.com/news/4009052-irish-high-court-hearing-for-horizons-28b-sale-to-amgen-set-for-oct-5?utm_source=businessinsider&utm_medium=referral
1904.0,9/5/2023 7:00:23 PM,8 Analysts Have This to Say About Amgen,Benzinga,/news/stocks/8-analysts-have-this-to-say-about-amgen-1032606475
1905.0,9/6/2023 5:00:38 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-6-2023-1032609929
1906.0,9/7/2023 10:00:00 PM,AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference-1032614278
1907.0,9/10/2023 3:00:00 PM,AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC,PR Newswire,/news/stocks/amgen-presents-new-lumakras-sotorasib-plus-chemotherapy-data-in-first-line-kras-g12c-nsclc-at-wclc-1032617956
1908.0,9/10/2023 4:00:00 PM,"Eli Lilly, Novo to lead $100B weight loss drug market in 2030: JPMorgan",Seeking Alpha,https://seekingalpha.com/news/4010426-eli-lilly-novo-lead-weight-loss-drug-market-jpmorgan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1909.0,9/10/2023 5:16:35 PM,Amgen Reports Positive Data From Phase 1 Study Of Lumakras Combination In Non-small Cell Lung Cancer ,RTTNews,/news/stocks/amgen-reports-positive-data-from-phase-1-study-of-lumakras-combination-in-non-small-cell-lung-cancer-1032618038
1910.0,9/10/2023 6:25:20 PM,Oppenheimer Keeps Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/oppenheimer-keeps-their-buy-rating-on-amgen-amgn-1032618292
1911.0,9/10/2023 7:17:31 PM,"HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead",Seeking Alpha,https://seekingalpha.com/news/4010430-hsbc-bullish-on-iqvia-zoetis-bluebird-actinium-bearish-on-gilead?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1912.0,9/11/2023 10:00:00 PM,AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-1032621216
1913.0,9/12/2023 12:59:40 PM,Horizon Therapeutics ticks higher as Amgen end date extended until December (update),Seeking Alpha,https://seekingalpha.com/news/4010905-horizon-therapeutics-ticks-higher-as-amgen-end-date-extended-until-december?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1914.0,9/13/2023 1:22:52 AM,The 3 Most Undervalued Biotech Stocks to Buy in September 2023,InvestorPlace,/news/stocks/undervalued-biotech-stocks-to-buy-1032625098
1915.0,9/13/2023 1:35:22 PM,These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/these-3-health-care-stocks-with-over-3-dividend-yields-are-recommended-by-wall-street-s-most-accurate-analysts-1032626536
1916.0,9/20/2023 10:00:00 PM,AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS,PR Newswire,/news/stocks/amgen-launches-partners-of-choice-network-of-eight-leading-oncology-academic-centers-1032644797
1917.0,9/25/2023 11:00:34 AM,"Analysts’ Top Healthcare Picks: Cytokinetics (CYTK), Amgen (AMGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-cytokinetics-cytk-amgen-amgn-1032652566
1918.0,9/25/2023 9:35:08 PM,FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients,Benzinga,/news/stocks/fda-strikes-off-coherus-biosciences-new-injector-biosimilar-treatment-for-cancer-patients-1032654084
1919.0,9/27/2023 6:04:52 PM,"September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average",Benzinga,/news/etf/september-s-shakeout-s-p-500-nasdaq-100-see-just-13-of-stocks-above-50-day-average-1032660395
1920.0,9/28/2023 5:55:09 AM,DBS Remains a Buy on Amgen (AMGN),TipRanks,/news/stocks/dbs-remains-a-buy-on-amgen-amgn-1032661518
1921.0,9/28/2023 12:45:04 PM,3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals,InvestorPlace,/news/stocks/3-biotech-stocks-to-watch-ahead-of-potential-obesity-drug-approvals-1032662925
1922.0,10/3/2023 9:30:41 PM,Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns,Benzinga,/news/stocks/is-amgen-s-lung-cancer-drug-lumakras-up-to-the-mark-fda-briefing-raises-concerns-1032675777
1923.0,10/4/2023 11:11:03 AM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Intellia Therapeutics (NTLA),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-intellia-therapeutics-ntla-1032677455
1924.0,10/4/2023 5:00:00 PM,Large-scale proteomics in population-based studies from UK and Iceland,PR Newswire,/news/stocks/large-scale-proteomics-in-population-based-studies-from-uk-and-iceland-1032678670
1925.0,10/5/2023 7:40:16 AM,"Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veralto Corporation (VLTO) and Amgen (AMGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-intellia-therapeutics-ntla-veralto-corporation-vlto-and-amgen-amgn-1032680183
1926.0,10/6/2023 1:50:24 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Regeneron (REGN) and Alnylam Pharma (ALNY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-regeneron-regn-and-alnylam-pharma-alny-1032683118
1927.0,10/6/2023 11:21:36 AM,"Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Amgen (AMGN) and Neurocrine (NBIX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-immunic-imux-amgen-amgn-and-neurocrine-nbix-1032684283
1928.0,10/6/2023 1:10:18 PM,"Analysts Are Bullish on These Healthcare Stocks: United Therapeutics (UTHR), Amgen (AMGN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-united-therapeutics-uthr-amgen-amgn-1032684595
1929.0,10/6/2023 2:30:00 PM,AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC,PR Newswire,/news/stocks/amgen-completes-acquisition-of-horizon-therapeutics-plc-1032684441
1930.0,10/6/2023 2:54:33 PM,Amgen Concludes Horizon Therapeutics Acquisition ,RTTNews,/news/stocks/amgen-concludes-horizon-therapeutics-acquisition-1032684503
1931.0,10/6/2023 6:44:33 PM,Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts,Benzinga,/news/stocks/amgen-s-adcomm-meeting-paves-way-to-launch-boost-for-mirati-therapeutics-lung-cancer-drug-analysts-1032685361
1932.0,10/9/2023 11:14:48 PM,GCOW: An ETF for Dividend and Free Cash Flow Lovers,TipRanks,/news/stocks/gcow-an-etf-for-dividend-and-free-cash-flow-lovers-1032690138
1933.0,10/11/2023 10:45:39 AM,"Analysts Conflicted on These Healthcare Names: Baxter International (BAX), Amgen (AMGN) and Alnylam Pharma (ALNY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-baxter-international-bax-amgen-amgn-and-alnylam-pharma-alny-1032696006
1934.0,10/11/2023 6:00:38 PM,Expert Ratings for Amgen,Benzinga,/news/stocks/expert-ratings-for-amgen-1032697596
1935.0,10/14/2023 1:00:44 PM,Johnson & Johnson Stock: Is Now the Time to Sell?,InvestorPlace,/news/stocks/johnson-johnson-stock-is-now-the-time-to-sell-1032705305
1936.0,10/16/2023 3:00:00 PM,AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023,PR Newswire,/news/stocks/amgen-to-present-new-research-from-oncology-portfolio-and-pipeline-at-esmo-2023-1032708454
1937.0,10/16/2023 9:06:11 PM,"Amgen’s Future: Evaluating Growth, Pipeline Progress and Risks Post-Horizon Acquisition",TipRanks,/news/stocks/amgen-s-future-evaluating-growth-pipeline-progress-and-risks-post-horizon-acquisition-1032709992
1938.0,10/19/2023 12:56:11 PM,"Amgen’s Growth Potential: A Comprehensive Analysis of Stock Rally, EPS Expectations, and Emerging Catalysts",TipRanks,/news/stocks/amgen-s-growth-potential-a-comprehensive-analysis-of-stock-rally-eps-expectations-and-emerging-catalysts-1032720799
1939.0,10/19/2023 10:00:00 PM,AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023,PR Newswire,/news/stocks/amgen-to-webcast-investor-call-at-esmo-2023-1032722224
1940.0,10/20/2023 2:00:00 PM,AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER,PR Newswire,/news/stocks/amgen-presents-new-tarlatamab-data-in-small-cell-lung-cancer-1032724134
1941.0,10/22/2023 4:30:00 PM,AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER,PR Newswire,/news/stocks/amgen-presents-new-lumakras-sotorasib-plus-vectibix-panitumumab-data-in-patients-with-kras-g12c-mutated-metastatic-colorectal-cancer-1032726072
1942.0,10/24/2023 7:08:25 PM,Amgen Layoffs 2023: What to Know About the Latest AMGN Job Cuts,InvestorPlace,/news/stocks/amgen-layoffs-2023-what-to-know-about-the-latest-amgn-job-cuts-2-1032734930
1943.0,10/24/2023 10:00:00 PM,AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND,PR Newswire,/news/stocks/amgen-announces-2023-fourth-quarter-dividend-1032734979
1944.0,10/25/2023 8:47:43 AM,Amgen’s Promising Oncology Pipeline Progress and Favorable Clinical Trials Fuel Analyst’s Buy Rating,TipRanks,/news/stocks/amgen-s-promising-oncology-pipeline-progress-and-favorable-clinical-trials-fuel-analyst-s-buy-rating-1032740520
1945.0,10/25/2023 11:20:41 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Danaher (DHR) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-danaher-dhr-and-sanofi-othersnynf-1032740780
1946.0,10/25/2023 10:00:00 PM,AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS,PR Newswire,/news/stocks/amgen-announces-webcast-of-2023-third-quarter-financial-results-1032740295
1947.0,10/27/2023 6:55:45 AM,Amgen’s Promising Oncology Pipeline: A Buy Rating Driven by T-Cell Engagers’ Potential,TipRanks,/news/stocks/amgen-s-promising-oncology-pipeline-a-buy-rating-driven-by-t-cell-engagers-potential-1032749701
1948.0,10/27/2023 7:40:17 AM,"Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Immutep (IMMP) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-immutep-immp-and-bristol-myers-squibb-bmy-1032749776
1949.0,10/27/2023 10:33:58 PM,"Bears Roam Wall Street As Middle East Conflict, Earnings Outlook Raise Concerns Despite Strong Q3 US Economic Growth: This Week In Markets",Benzinga,/news/etf/bears-roam-wall-street-as-middle-east-conflict-earnings-outlook-raise-concerns-despite-strong-q3-us-economic-growth-this-week-in-markets-1032749881
1950.0,10/30/2023 3:01:13 PM,Here's what Wall Street expects from Amgen's earnings,Markets Insider Automation,/news/stocks/amgen-stock-price-quarter-earnings-preview-q3-1032754312
1951.0,10/31/2023 9:40:21 AM,"Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Qiagen (QGEN) and HCA Healthcare (HCA)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-qiagen-qgen-and-hca-healthcare-hca-1032761358
1952.0,10/31/2023 12:08:41 PM,"Amgen Inc. Q3 Profit Decreases, but beats estimates",RTTNews,/news/stocks/amgen-inc-q3-profit-decreases-but-beats-estimates-1032758661
1953.0,10/31/2023 12:48:26 PM,"Amgen Lifts FY23 Adj. Earnings, Revenue Outlook - Update ",RTTNews,/news/stocks/amgen-lifts-fy23-adj-earnings-revenue-outlook-update-1032758836
1954.0,10/31/2023 5:01:24 PM,"Treasury Announcement More Important Than Fed's, Japan Abandons Yield Control, Tesla Under $200",Benzinga,/news/stocks/treasury-announcement-more-important-than-fed-s-japan-abandons-yield-control-tesla-under-200-1032760413
1955.0,10/31/2023 6:14:37 PM,"Stocks Lack Direction As Traders Remain Cautious Ahead Of Fed Meeting, Nvidia Falls On Export Controls: What's Driving Markets Tuesday?",Benzinga,/news/etf/stocks-lack-direction-as-traders-remain-cautious-ahead-of-fed-meeting-nvidia-falls-on-export-controls-what-s-driving-markets-tuesday-1032760794
1956.0,11/1/2023 12:36:13 AM,"Amgen’s Stock Rated as Buy: Promising Earnings, HZNP Acquisition Impact, and Product Pipeline Strengths",TipRanks,/news/stocks/amgen-s-stock-rated-as-buy-promising-earnings-hznp-acquisition-impact-and-product-pipeline-strengths-1032764943
1957.0,11/1/2023 2:30:26 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), AbbVie (ABBV) and Crispr Therapeutics AG (CRSP)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-abbvie-abbv-and-crispr-therapeutics-ag-crsp-1032765965
1958.0,11/1/2023 4:49:47 AM,FDA Approves Amgen's Wezlana For Multiple Inflammatory Diseases ,RTTNews,/news/stocks/fda-approves-amgen-s-wezlana-for-multiple-inflammatory-diseases-1032761763
1959.0,11/1/2023 10:40:09 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-biogen-biib-and-vertex-pharmaceuticals-vrtx-1032767548
1960.0,11/1/2023 11:26:23 AM,Hold Rating on Amgen: Balancing Expectations with Underperformance and Future Prospects,TipRanks,/news/stocks/hold-rating-on-amgen-balancing-expectations-with-underperformance-and-future-prospects-1032767647
1961.0,11/1/2023 1:35:59 PM,Positive Prospects for Amgen: A Comprehensive Analysis of Q3 Performance and Future Catalysts,TipRanks,/news/stocks/positive-prospects-for-amgen-a-comprehensive-analysis-of-q3-performance-and-future-catalysts-1032767835
1962.0,11/1/2023 2:00:00 PM,AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO,PR Newswire,/news/stocks/amgen-to-present-data-at-acr-2023-across-expanded-rheumatology-pipeline-and-portfolio-1032765014
1963.0,11/1/2023 7:18:33 PM,These Analysts Revise Their Forecasts On Amgen After Q3 Results,Benzinga,/news/stocks/these-analysts-revise-their-forecasts-on-amgen-after-q3-results-1032766910
1964.0,11/2/2023 5:20:07 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Beam Therapeutics (BEAM) and Argenx Se (ARGX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-beam-therapeutics-beam-and-argenx-se-argx-1032771697
1965.0,11/2/2023 5:31:09 AM,Concerns Over Amgen’s Performance and Future Prospects: An In-Depth Sell Rating Analysis,TipRanks,/news/stocks/concerns-over-amgen-s-performance-and-future-prospects-an-in-depth-sell-rating-analysis-1032771766
1966.0,11/2/2023 5:31:20 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Eli Lilly & Co (LLY) and Repligen (RGEN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-eli-lilly-co-lly-and-repligen-rgen-1032771764
1967.0,11/2/2023 6:20:21 AM,Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Amgen (AMGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-rani-therapeutics-holdings-rani-and-amgen-amgn-1032771899
1968.0,11/2/2023 1:00:00 PM,AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE),PR Newswire,/news/stocks/amgen-presents-new-data-that-show-blood-pressure-decreases-for-adults-treated-with-krystexxa-pegloticase-1032769969
1969.0,11/2/2023 8:01:04 PM,"Amgen Wins Big With FDA, Analyst Sees Soaring Potential",Benzinga,/news/stocks/amgen-wins-big-with-fda-analyst-sees-soaring-potential-1032771966
1970.0,11/3/2023 2:30:51 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), IQVIA Holdings (IQV) and Argenx Se (ARGX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-iqvia-holdings-iqv-and-argenx-se-argx-1032776513
1971.0,11/3/2023 8:15:09 AM,Morgan Stanley Sticks to Its Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/morgan-stanley-sticks-to-its-hold-rating-for-amgen-amgn-1032777561
1972.0,11/6/2023 5:00:00 PM,"Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition",PR Newswire,/news/stocks/epidemiology-and-genetics-of-clonal-hematopoiesis-a-premalignant-hematopoietic-stem-cell-condition-1032782913
1973.0,11/7/2023 10:00:00 PM,AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023,PR Newswire,/news/stocks/amgen-presents-new-data-from-phase-2-trial-of-dazodalibep-in-sjoegren-s-syndrome-at-acr-2023-1032789589
1974.0,11/7/2023 10:05:00 PM,AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023,PR Newswire,/news/stocks/amgen-presents-new-research-in-early-psoriatic-arthritis-at-acr-2023-1032789700
1975.0,11/9/2023 6:00:23 PM,20 Analysts Have This to Say About Amgen,Benzinga,/news/stocks/20-analysts-have-this-to-say-about-amgen-1032802018
1976.0,11/10/2023 3:00:00 PM,AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023,PR Newswire,/news/stocks/amgen-presents-new-cardiovascular-research-at-aha-2023-1032806916
1977.0,11/22/2023 10:00:00 PM,AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE,PR Newswire,/news/stocks/amgen-to-present-at-the-evercore-isi-healthconx-conference-1032844068
1978.0,11/29/2023 7:00:20 PM,Analyst Ratings for Amgen,Benzinga,/news/stocks/analyst-ratings-for-amgen-1032859741
1979.0,11/30/2023 2:25:35 AM,Truist Financial Sticks to Their Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-amgen-amgn-1032862774
1980.0,11/30/2023 8:53:23 AM,Biotech Stocks Facing FDA Decision In December 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2023-1032861195
1981.0,12/1/2023 1:47:49 PM,‘From Hype to Clinical‘: Cowen Suggests 2 AI Healthcare Stocks to Consider,TipRanks,/news/stocks/from-hype-to-clinical-cowen-suggests-2-ai-healthcare-stocks-to-consider-1032867930
1982.0,12/3/2023 9:14:00 PM,"Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says Oppenheimer — Here Are 2 Stocks to Take Advantage",TipRanks,/news/stocks/obesity-drugs-have-multi-billion-dollar-market-potential-says-oppenheimer-—-here-are-2-stocks-to-take-advantage-1032869643
1983.0,12/8/2023 10:30:15 AM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Edwards Lifesciences (EW),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-edwards-lifesciences-ew-1032886934
1984.0,12/8/2023 3:00:00 PM,AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023,PR Newswire,/news/stocks/amgen-highlights-hematology-portfolio-at-ash-2023-1032885601
1985.0,12/12/2023 2:00:33 PM,PVH To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday,Benzinga,/news/stocks/pvh-to-rally-around-11-here-are-10-top-analyst-forecasts-for-tuesday-1032892947
1986.0,12/12/2023 10:00:00 PM,AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE,PR Newswire,/news/stocks/amgen-announces-2024-first-quarter-dividend-increase-to-2-25-per-share-1032894848
1987.0,12/13/2023 10:00:00 PM,FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer,PR Newswire,/news/stocks/fda-grants-priority-review-to-amgen-s-tarlatamab-application-for-advanced-small-cell-lung-cancer-1032898663
1988.0,12/13/2023 10:20:21 PM,FDA Grants Priority Review To Amgen's Application For Small Cell Lung Cancer Treatment ,RTTNews,/news/stocks/fda-grants-priority-review-to-amgen-s-application-for-small-cell-lung-cancer-treatment-1032898713
1989.0,12/14/2023 11:00:00 AM,AMGEN TO SPONSOR THE IRISH OPEN,PR Newswire,/news/stocks/amgen-to-sponsor-the-irish-open-1032900218
1990.0,12/14/2023 3:00:00 PM,AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION,PR Newswire,/news/stocks/amgen-announces-executive-appointments-to-accelerate-innovation-1032901104
1991.0,12/14/2023 4:08:57 PM,Amgen Appoints David Reese As Chief Technology Officer ,RTTNews,/news/stocks/amgen-appoints-david-reese-as-chief-technology-officer-1032901729
1992.0,12/19/2023 1:30:24 PM,Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday,Benzinga,/news/stocks/uber-to-rally-over-13-here-are-10-top-analyst-forecasts-for-tuesday-1032912123
1993.0,12/19/2023 7:01:10 PM,In-Depth Examination Of 18 Analyst Recommendations For Amgen,Benzinga,/news/stocks/in-depth-examination-of-18-analyst-recommendations-for-amgen-1032913724
1994.0,12/19/2023 8:42:29 PM,"Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst",Benzinga,/news/stocks/amgen-provides-exposure-to-obesity-drug-at-a-reasonable-price-says-bullish-analyst-1032913911
1995.0,12/20/2023 2:43:53 PM,CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief,InvestorPlace,/news/stocks/crsp-stock-alert-crispr-therapeutics-is-losing-its-medical-chief-1032916256
1996.0,12/21/2023 4:23:17 PM,3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-in-the-tradesmith-green-zone-1032920051
1997.0,12/26/2023 3:00:00 PM,AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB),PR Newswire,/news/stocks/amgen-provides-regulatory-update-on-status-of-lumakras-sotorasib-1032925637
1998.0,12/26/2023 3:14:34 PM,Amgen Says FDA Completes Review Of SNDA Seeking Full Approval For LUMAKRAS ,RTTNews,/news/stocks/amgen-says-fda-completes-review-of-snda-seeking-full-approval-for-lumakras-1032925657
1999.0,1/2/2024 7:22:32 PM,"Dogs Of The Dow: Top 10 Highest Yielding Dow Jones Stocks, How To Get Dividends Of 3% to 7.4% In 2024",Benzinga,/news/etf/dogs-of-the-dow-top-10-highest-yielding-dow-jones-stocks-how-to-get-dividends-of-3-to-7-4-in-2024-1032937754
2000.0,1/3/2024 9:00:19 PM,Revenge of the Boring Stocks! Dividends Are Sexy Again.,InvestorPlace,/news/stocks/revenge-of-the-boring-stocks-dividends-are-sexy-again-1032941212
2001.0,1/6/2024 1:50:27 AM,"Analysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-innate-pharma-sa-otheriphyf-amgen-amgn-and-regeneron-regn-1032947412
2002.0,1/9/2024 10:05:26 AM,Amgen Hold Rating Justified by Promising Pipeline and Measured Growth Expectations,TipRanks,/news/stocks/amgen-hold-rating-justified-by-promising-pipeline-and-measured-growth-expectations-1032955162
2003.0,1/9/2024 2:25:17 PM,BMO Capital Sticks to Their Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/bmo-capital-sticks-to-their-buy-rating-for-amgen-amgn-1032955446
2004.0,1/9/2024 11:35:21 PM,Buy Rating for Amgen Backed by Strong Pipeline and Strategic Acquisitions,TipRanks,/news/stocks/buy-rating-for-amgen-backed-by-strong-pipeline-and-strategic-acquisitions-1032956127
2005.0,1/10/2024 1:40:14 PM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Sarepta Therapeutics (SRPT),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-sarepta-therapeutics-srpt-1032958060
2006.0,1/10/2024 9:53:14 PM,Dogs of the Dow: January’s Top 3 Picks to Buy for Big Gains,InvestorPlace,/news/stocks/dogs-of-the-dow-januarys-top-3-picks-to-buy-for-big-gains-1032958666
2007.0,1/11/2024 5:40:37 PM,"Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance",Benzinga,/news/stocks/large-drugmakers-show-enthusiasm-to-embrace-100b-obesity-market-despite-novo-and-lilly-s-dominance-1032961467
2008.0,1/15/2024 5:05:38 AM,Optimistic Outlook for Amgen: Robust Financial Health and Strategic R&D Expansion Fuel Buy Rating,TipRanks,/news/stocks/optimistic-outlook-for-amgen-robust-financial-health-and-strategic-r-d-expansion-fuel-buy-rating-1032966565
2009.0,1/17/2024 4:39:40 AM,Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units,Benzinga,/news/etf/cathie-wood-s-ark-invest-liquidates-15-8m-worth-of-proshares-bitcoin-strategy-etf-units-1032972078
2010.0,1/19/2024 4:45:33 AM,Verastem : Avutometinib Combination Receives Fast Track Designation For KRAS G12C-Mutant NSCLC ,RTTNews,/news/stocks/verastem-avutometinib-combination-receives-fast-track-designation-for-kras-g12c-mutant-nsclc-1032978498
2011.0,1/19/2024 4:52:40 PM,FDA issues boxed warning for Amgen's osteoporosis drug,Seeking Alpha,https://seekingalpha.com/news/4056511-fda-issues-boxed-warning-for-amgens-osteoporosis-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2012.0,1/23/2024 8:25:33 AM,Amgen (AMGN) Gets a Sell from Barclays,TipRanks,/news/stocks/amgen-amgn-gets-a-sell-from-barclays-1032987158
2013.0,1/25/2024 11:00:00 AM,Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs,InvestorPlace,/news/stocks/?p=2636389-1032996128
2014.0,1/25/2024 10:31:03 PM,Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs,InvestorPlace,/news/stocks/stocks-to-watch-3-companies-working-on-next-gen-weight-loss-drugs-1032998751
2015.0,1/26/2024 11:10:24 AM,"Analysts’ Top Healthcare Picks: Amgen (AMGN), Argenx Se (ARGX)",TipRanks,/news/stocks/analysts-top-healthcare-picks-amgen-amgn-argenx-se-argx-1033001013
2016.0,1/26/2024 12:16:34 PM,PBMs ramp up lobbying efforts amid growing public scrutiny,Seeking Alpha,https://seekingalpha.com/news/4058952-pbms-ramp-up-lobbying-amid-growing-public-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2017.0,1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2018.0,1/29/2024 6:00:25 PM,Expert Outlook: Amgen Through The Eyes Of 11 Analysts,Benzinga,/news/stocks/expert-outlook-amgen-through-the-eyes-of-11-analysts-1033006668
2019.0,2/1/2024 1:00:58 PM,"Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Insmed (INSM) and Amgen (AMGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-boston-scientific-bsx-insmed-insm-and-amgen-amgn-1033021689
2020.0,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-ppening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2021.0,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-opening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2022.0,2/1/2024 5:10:01 PM,AbbVie Q4 in focus as Humira patent cliff reaches one-year mark,Seeking Alpha,https://seekingalpha.com/news/4061472-abbvie-q4-focus-humira-patent-cliff-reaches-one-year?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2023.0,2/2/2024 8:00:00 PM,"Catalyst watch: Alibaba earnings, World Defense Show, Fed speakers unleashed and Super Bowl buzz",Seeking Alpha,https://seekingalpha.com/news/4060879-catalyst-watch-alibaba-earnings-world-defense-show-fed-speakers-unleashed-and-super-bowl-buzz?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2024.0,2/4/2024 1:45:00 PM,"Earnings week ahead: Alibaba, PepsiCo, Disney, Palantir, McDonalds, Ford and more",Seeking Alpha,https://seekingalpha.com/news/4062246-earnings-week-ahead-alibaba-pepsico-disney-palantir-mcdonalds-philip-morris-ford-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2025.0,2/4/2024 10:16:46 PM,Investors growing more bullish on SMID cap biotech stocks,Seeking Alpha,https://seekingalpha.com/news/4062396-investors-growing-more-bullish-on-smid-cap-biotech-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2026.0,2/5/2024 11:35:53 AM,Amgen weight loss drug shows promising early data,Seeking Alpha,https://seekingalpha.com/news/4062458-amgen-weight-loss-drug-shows-promising-early-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2027.0,2/5/2024 3:01:13 PM,Amgen is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/amgen-q4-quarterly-earnings-preview-stock-1033030206
2028.0,2/5/2024 6:07:04 PM,Amgen’s obesity prospects in focus ahead of Q4 results,Seeking Alpha,https://seekingalpha.com/news/4062762-amgens-obesity-prospects-focus-ahead-q4-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2029.0,2/5/2024 7:18:07 PM,"NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?",InvestorPlace,/news/stocks/nvo-lly-or-azn-which-pharma-stock-is-the-best-weight-loss-investment-1033031555
2030.0,2/5/2024 10:35:34 PM,Notable earnings after Tuesday's close,Seeking Alpha,https://seekingalpha.com/news/4062589-notable-earnings-after-tuesdays-close?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2031.0,2/6/2024 4:05:50 AM,3 Fantastic Dow Stocks to Buy in February 2024,InvestorPlace,/news/stocks/3-fantastic-dow-stocks-to-buy-in-february-2024-1033032121
2032.0,2/6/2024 12:26:35 PM,Amgen’s Promising AMG 133 Trials and Strategic Acquisitions Merit a Buy Rating,TipRanks,/news/stocks/amgen-s-promising-amg-133-trials-and-strategic-acquisitions-merit-a-buy-rating-1033035956
2033.0,2/6/2024 2:15:00 PM,"6 stocks to watch on Tuesday: Spotify, Eli Lilly, Chipotle, DocuSign and more",Seeking Alpha,https://seekingalpha.com/news/4063134-6-stocks-to-watch-on-tuesday-spotify-eli-lilly-chipotle-docusign-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2034.0,2/6/2024 2:45:00 PM,Amgen hosts conference call for investors,Markets Insider Automation,/news/stocks/amgen_conference-1029945498
2035.0,2/6/2024 8:24:05 PM,"Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?",Benzinga,/news/etf/tech-slides-chinese-stocks-rebound-new-york-community-bancorp-tumbles-what-s-driving-markets-tuesday-1033036589
2036.0,2/6/2024 9:03:50 PM,"Amgen Non-GAAP EPS of $4.71 beats by $0.12, revenue of $8.2B beats by $90M",Seeking Alpha,https://seekingalpha.com/news/4063410-amgen-non-gaap-eps-of-4_71-beats-0_12-revenue-of-8_2b-beats-90m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2037.0,2/6/2024 9:18:21 PM,"Amgen in charts: Q4 sales for Prolia, XGEVA, and Otezla rises, while Enbrel dips Y/Y",Seeking Alpha,https://seekingalpha.com/news/4063400-amgen-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2038.0,2/6/2024 9:31:15 PM,The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition,InvestorPlace,/news/stocks/the-top-25-stocks-to-buy-immediately-according-to-ai-february-2024-edition-1033036939
2039.0,2/6/2024 10:07:24 PM,"Amgen Inc. Q4 Profit Decreases, but beats estimates",RTTNews,/news/stocks/amgen-inc-q4-profit-decreases-but-beats-estimates-1033036790
2040.0,2/7/2024 2:30:29 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Qiagen (QGEN) and Waters (WAT)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-amgen-amgn-qiagen-qgen-and-waters-wat-1033038372
2041.0,2/7/2024 10:16:45 AM,Amgen (AMGN) Receives a Sell from Barclays,TipRanks,/news/stocks/amgen-amgn-receives-a-sell-from-barclays-1033040688
2042.0,2/7/2024 12:25:36 PM,Hold Rating on Amgen Amid Uncertainty in Obesity Drug Efficacy and Competitive Concerns,TipRanks,/news/stocks/hold-rating-on-amgen-amid-uncertainty-in-obesity-drug-efficacy-and-competitive-concerns-1033041725
2043.0,2/7/2024 12:25:55 PM,Amgen’s Stock Buoyed by Obesity Drug Prospects and Pipeline Developments Despite EPS Guidance and AMG-133 Concerns,TipRanks,/news/stocks/amgen-s-stock-buoyed-by-obesity-drug-prospects-and-pipeline-developments-despite-eps-guidance-and-amg-133-concerns-1033041724
2044.0,2/7/2024 12:30:49 PM,Amgen (AMGN) Gets a Buy from RBC Capital,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-rbc-capital-1033041820
2045.0,2/7/2024 12:35:38 PM,Buy Rating Affirmed: Amgen’s Strong Q4 Performance and Promising 2024 Pipeline Outlook,TipRanks,/news/stocks/buy-rating-affirmed-amgen-s-strong-q4-performance-and-promising-2024-pipeline-outlook-1033041775
2046.0,2/7/2024 1:21:26 PM,"Analysts’ Top Healthcare Picks: Amgen (AMGN), Qiagen (QGEN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-amgen-amgn-qiagen-qgen-1033042016
2047.0,2/7/2024 2:34:00 PM,Amgen cut at Leerink on heavy obesity expectations,Seeking Alpha,https://seekingalpha.com/news/4063851-amgen-stock-cut-leerink-obesity-prospects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2048.0,2/7/2024 3:25:38 PM,Amgen Hold Rating Affirmed Amid Financial Outlook and Drug Pipeline Developments,TipRanks,/news/stocks/amgen-hold-rating-affirmed-amid-financial-outlook-and-drug-pipeline-developments-1033042509
2049.0,2/7/2024 7:40:43 PM,"S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?",Benzinga,/news/stocks/s-p-500-flirts-with-5-000-as-magnificent-7-tops-13-trillion-nycb-sinks-what-s-driving-markets-wednesday-1033042553
2050.0,2/7/2024 8:36:27 PM,Investors' Focus Around Amgen's Obesity Drug Data Shadows Better Than Expected Q4 Earnings,Benzinga,/news/stocks/investors-focus-around-amgen-s-obesity-drug-data-shadows-better-than-expected-q4-earnings-1033042620
2051.0,2/7/2024 9:39:31 PM,Amgen stock suffers worst day in over 2-1/2 years as analysts debate weight loss prospects,Seeking Alpha,https://seekingalpha.com/news/4064227-amgen-stock-suffers-worst-day-in-over-2-12-years-as-analysts-debate-weight-loss-prospects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2052.0,2/9/2024 4:20:07 AM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and UnitedHealth (UNH),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-unitedhealth-unh-1033049711
2053.0,2/11/2024 5:00:03 PM,Booming weight-loss drug market to lift “pick-and-shovel” plays: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4065355-weight-loss-drug-market-lifts-pick-and-shovel-plays?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2054.0,2/12/2024 6:03:02 PM,Amgen stock snaps six-day losing streak,Seeking Alpha,https://seekingalpha.com/news/4065693-amgen-set-to-snap-six-day-losing-streak?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2055.0,2/13/2024 2:01:27 AM,Federal judge dismisses PhRMA challenge to Medicare price negotiations,Seeking Alpha,https://seekingalpha.com/news/4065840-federal-judge-tosses-phrma-lawsuit-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2056.0,2/13/2024 6:07:35 PM,Eli Lilly partner BioAge wins $170M to study Zepbound combo,Seeking Alpha,https://seekingalpha.com/news/4066258-eli-lilly-partner-bioage-wins-170m-zepbound-combo-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2057.0,2/14/2024 7:43:49 PM,7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution,InvestorPlace,/news/stocks/7-must-buy-pharma-stocks-amid-the-weight-loss-drug-revolution-1033068096
2058.0,2/15/2024 9:13:52 PM,7 Contrarian Biotech Stocks to Consider Amid Sector Weakness,InvestorPlace,/news/stocks/7-contrarian-biotech-stocks-to-consider-amid-sector-weakness-1033073521
2059.0,2/16/2024 3:29:22 PM,Novartis aiming to develop next-generation weight-loss drugs,Seeking Alpha,https://seekingalpha.com/news/4068274-novartis-aiming-to-develop-next-generation-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2060.0,2/16/2024 8:00:59 PM,"Catalyst watch: Nvidia, Walmart and Home Depot are under the earnings spotlight",Seeking Alpha,https://seekingalpha.com/news/4068256-catalyst-watch-nvidia-walmart-and-home-depot-are-under-the-earnings-spotlight?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2061.0,2/21/2024 12:13:01 PM,"Regeneron, Vertex Pharma join $100B club in biotech",Seeking Alpha,https://seekingalpha.com/news/4069456-regeneron-vertex-pharma-join-100b-club-biotech?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2062.0,2/22/2024 7:41:34 PM,Obesity drugs to expand U.S. GDP by 1% in the coming years: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/4070545-obesity-drugs-expand-us-gdp-goldman-sachs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2063.0,2/22/2024 11:00:53 PM,"3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024",InvestorPlace,/news/stocks/3-biotech-stocks-to-turn-10000-into-1-million-february-2024-1033095198
2064.0,2/23/2024 8:15:18 AM,Barclays Sticks to Their Sell Rating for Amgen (AMGN),TipRanks,/news/stocks/barclays-sticks-to-their-sell-rating-for-amgen-amgn-1033096927
2065.0,2/23/2024 10:20:27 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Alnylam Pharma (ALNY) and Bausch Health Companies (BHC)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-amgen-amgn-alnylam-pharma-alny-and-bausch-health-companies-bhc-1033097303
2066.0,2/23/2024 10:56:59 AM,Amgen’s Strategic Growth and Market Expansion in Rare Diseases Bolster Buy Rating,TipRanks,/news/stocks/amgen-s-strategic-growth-and-market-expansion-in-rare-diseases-bolster-buy-rating-1033097450
2067.0,2/23/2024 12:26:41 PM,Buy Rating Affirmed: Growth and Expansion in Amgen’s Rare Disease Portfolio Post-Horizon Acquisition,TipRanks,/news/stocks/buy-rating-affirmed-growth-and-expansion-in-amgen-s-rare-disease-portfolio-post-horizon-acquisition-1033098080
2068.0,2/26/2024 4:30:52 AM,Balanced Outlook for Amgen: Growth Potential Amidst Challenges and Uncertainties,TipRanks,/news/stocks/balanced-outlook-for-amgen-growth-potential-amidst-challenges-and-uncertainties-1033101085
2069.0,2/26/2024 5:01:01 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), Teleflex (TFX) and Amgen (AMGN)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-exact-sciences-exas-teleflex-tfx-and-amgen-amgn-1033101166
2070.0,2/26/2024 3:26:56 PM,Amgen To Open Manufacturing Site In Central Ohio; To Offer 400 Full-time Jobs ,RTTNews,/news/stocks/amgen-to-open-manufacturing-site-in-central-ohio-to-offer-400-full-time-jobs-1033102808
2071.0,2/26/2024 7:25:33 PM,"Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs",Benzinga,/news/stocks/amgen-s-upcoming-catalysts-in-2024-set-to-unlock-multi-billion-dollar-markets-says-goldman-sachs-1033104128
2072.0,2/29/2024 10:50:36 AM,"Analysts’ Top Healthcare Picks: Amgen (AMGN), Sarepta Therapeutics (SRPT)",TipRanks,/news/stocks/analysts-top-healthcare-picks-amgen-amgn-sarepta-therapeutics-srpt-1033118226
2073.0,3/1/2024 6:12:04 AM,Amgen’s Sell Rating Justified by Emerging Competition and Safety Concerns in Obesity Drug Market,TipRanks,/news/stocks/amgen-s-sell-rating-justified-by-emerging-competition-and-safety-concerns-in-obesity-drug-market-1033122369
2074.0,3/1/2024 1:52:54 PM,Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields-1033123155
2075.0,3/1/2024 4:39:59 PM,Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List,Benzinga,/news/stocks/apple-sinks-after-wall-street-titan-pulls-magnificent-7-stock-from-conviction-list-1033124291
2076.0,3/1/2024 5:29:42 PM,"Merck, Vertex cut from Goldman Sachs conviction list; Amgen added",Seeking Alpha,https://seekingalpha.com/news/4074740-merck-vertex-cut-goldman-sachs-conviction-list-amgen-added?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2077.0,3/1/2024 6:10:27 PM,Medicare price negotiations survive another legal challenge,Seeking Alpha,https://seekingalpha.com/news/4074801-medicare-price-negotiations-survive-legal-challenge?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2078.0,3/4/2024 3:06:12 PM,It’s Time! 3 Dodgy Pharma Stocks to Sell in February,InvestorPlace,/news/stocks/its-time-3-dodgy-pharma-stocks-to-sell-in-february-1033129175
2079.0,3/4/2024 7:08:25 PM,Biden says drugmakers to continue to engage in Medicare drug price negoiations,Seeking Alpha,https://seekingalpha.com/news/4075531-biden-says-drugmakers-continue-engage-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2080.0,3/4/2024 7:56:37 PM,Biden to launch task force to target health care costs - report,Seeking Alpha,https://seekingalpha.com/news/4075586-biden-launch-task-force-target-health-care-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2081.0,3/5/2024 7:33:12 PM,"Sandoz biosimilars targeting Amgen’s Prolia, Xgeva cleared",Seeking Alpha,https://seekingalpha.com/news/4076208-sandoz-biosimilars-targeting-amgens-prolia-xgeva-cleared?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2082.0,3/6/2024 9:01:42 PM,Amgen declares $2.25 dividend,Seeking Alpha,https://seekingalpha.com/news/4076804-amgen-inc-declares-2_25-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2083.0,3/6/2024 10:40:54 PM,Biden to push for expanding Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/4076912-biden-to-push-for-expanding-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2084.0,3/7/2024 7:13:09 PM,Cigna eyes $0 out-of-pocket for Humira biosimilar this year,Seeking Alpha,https://seekingalpha.com/news/4077324-cigna-eyes-0-out-of-pocket-humira-biosimilar?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2085.0,3/8/2024 12:06:31 AM,Novo Nordisk expects Wegovy approval in China this year: report,Seeking Alpha,https://seekingalpha.com/news/4077511-novo-nordisk-expects-wegovy-approval-in-china-this-year-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2086.0,3/8/2024 12:30:38 PM,"Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-amgen-amgn-regeneron-regn-1033146997
2087.0,3/8/2024 12:50:18 PM,"Dividend Roundup: Qualcomm, Amgen, AIG, Gilead Sciences, and more",Seeking Alpha,https://seekingalpha.com/news/4077588-dividend-roundup-qualcomm-amgen-aig-gilead-sciences-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2088.0,3/8/2024 4:25:31 PM,Novo Nordisk sees launching new obesity drugs before Wegovy patent expires,Seeking Alpha,https://seekingalpha.com/news/4077692-novo-nordisk-sees-launching-new-obesity-drugs-before-wegovy-patent-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2089.0,3/10/2024 7:05:39 PM,Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks,InvestorPlace,/news/stocks/obesity-drugs-2024-the-skinny-on-the-top-3-weight-loss-stocks-1033148628
2090.0,3/11/2024 4:03:46 PM,The Dow’s Best Friends: 3 ‘Dogs’ Ready to Fetch Huge Returns,InvestorPlace,/news/stocks/the-dows-best-friends-3-dogs-ready-to-fetch-huge-returns-1033151926
2091.0,3/13/2024 1:24:40 PM,Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields-1033159199
2092.0,3/14/2024 11:20:30 AM,Biotech group backs anti-China bill; part ways with WuXi AppTec,Seeking Alpha,https://seekingalpha.com/news/4079392-biotech-group-backs-anti-china-bill-splits-wuxi-apptec?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2093.0,3/14/2024 3:44:36 PM,UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates,Seeking Alpha,https://seekingalpha.com/news/4079564-ubs-sees-lilly-glp-1sleep-apnea-study-falling-short-of-street-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2094.0,3/14/2024 11:23:16 PM,Terns to report Phase 1 data on GLP-1 drug in 2H 2024,Seeking Alpha,https://seekingalpha.com/news/4079774-terns-to-report-phase-1-data-on-glp-1-drug-in-2h-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2095.0,3/20/2024 7:46:08 PM,Hot Stocks: The 3 Best Opportunities for Investing in the Dow,InvestorPlace,/news/stocks/hot-stocks-the-3-best-opportunities-for-investing-in-the-dow-1033182125
2096.0,3/21/2024 9:29:47 PM,Hot Stocks: The 3 Best Opportunities for Investing in Biotech ,InvestorPlace,/news/stocks/hot-stocks-the-3-best-opportunities-for-investing-in-biotech-1033186701
2097.0,3/25/2024 12:01:08 PM,"Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Amgen (AMGN) and Petiq (PETQ)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-amgen-amgn-and-petiq-petq-1033193895
2098.0,3/25/2024 5:05:25 PM,Buffett’s Backdoor Buys: 3 Stocks His Secret Portfolio Is Quietly Accumulating,InvestorPlace,/news/stocks/buffetts-backdoor-buys-3-stocks-his-secret-portfolio-is-quietly-accumulating-1033194278
2099.0,3/25/2024 7:00:00 PM,Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich,InvestorPlace,/news/stocks/wall-streets-favorite-biotech-stocks-3-names-that-could-make-you-filthy-rich-1033194514
2100.0,3/26/2024 11:37:54 AM,Viking Therapeutics gains on early data for oral weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4083623-viking-therapeutics-stock-gains-data-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2101.0,3/26/2024 6:01:03 PM,Cytokinetics gains amid renewed takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4083918-cytokinetics-gains-amid-renewed-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2102.0,3/27/2024 10:00:00 AM,7 Dow Stocks to Buy on the Dip: March 2024,InvestorPlace,/news/stocks/7-dow-stocks-to-buy-on-the-dip-march-2024-1033200339
2103.0,3/27/2024 5:07:58 PM,3 Biotech Stocks to Buy on the Dip: March 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-on-the-dip-march-2024-1033202429
2104.0,3/28/2024 5:11:15 PM,Xeris gains as Oppenheimer highlights drug technology,Seeking Alpha,https://seekingalpha.com/news/4085090-xeris-stock-gains-oppenheimer-bullish-view?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2105.0,4/2/2024 8:30:04 PM,5 Healthcare Stocks to Buy for 2024,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-2024-1033216722
2106.0,4/3/2024 11:00:53 AM,"Analysts’ Top Healthcare Picks: Amgen (AMGN), Intra-Cellular Therapies (ITCI)",TipRanks,/news/stocks/analysts-top-healthcare-picks-amgen-amgn-intra-cellular-therapies-itci-1033219490
2107.0,4/3/2024 5:00:32 PM,7 Analysts Have This To Say About Amgen,Benzinga,/news/stocks/7-analysts-have-this-to-say-about-amgen-1033219671
2108.0,4/7/2024 6:00:00 PM,The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-sp-500-stocks-to-buy-in-april-2024-1033227751
2109.0,4/9/2024 11:00:00 AM,3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April,InvestorPlace,/news/stocks/3-high-growth-biotech-stocks-investors-shouldnt-sleep-on-in-april-1033232893
2110.0,4/9/2024 8:30:00 PM,Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?,InvestorPlace,/news/stocks/election-year-encore-can-2020s-top-7-stock-winners-repeat-their-performance-in-2024-1033234848
2111.0,4/10/2024 12:02:12 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Bausch Health Companies (BHC) and Ultragenyx Pharmaceutical (RARE)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-bausch-health-companies-bhc-and-ultragenyx-pharmaceutical-rare-1033238024
2112.0,4/13/2024 2:52:04 PM,AbbVie keeps Humira market share near 100% despite biosimilars: report,Seeking Alpha,https://seekingalpha.com/news/4089412-abbvie-retains-humira-market-despite-copycats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2113.0,4/15/2024 11:40:06 AM,"Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-pfizer-pfe-vertex-pharmaceuticals-vrtx-and-amgen-amgn-1033249994
2114.0,4/15/2024 12:01:29 PM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Notable Labs (NTBL),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-notable-labs-ntbl-1033250096
2115.0,4/15/2024 7:07:27 PM,3 Stocks to Buy Low Today With High Hopes for Tomorrow,InvestorPlace,/news/stocks/three-stocks-to-buy-low-today-with-high-hopes-for-tomorrow-1033250704
2116.0,4/16/2024 4:22:50 PM,"As more rare disease therapies launch, their prices are rising",Seeking Alpha,https://seekingalpha.com/news/4089415-more-rare-disease-therapies-launch-their-prices-rising?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2117.0,4/16/2024 8:30:00 PM,The 3 Best Biotech Stocks to Buy Now: Q2 Edition,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-now-q2-edition-1033255028
2118.0,4/17/2024 7:25:52 AM,Barclays Keeps Their Sell Rating on Amgen (AMGN),TipRanks,/news/stocks/barclays-keeps-their-sell-rating-on-amgen-amgn-1033257112
2119.0,4/17/2024 9:45:43 AM,Buy Rating on Amgen: Tezspire’s Market Potential in COPD Treatment Undervalued,TipRanks,/news/stocks/buy-rating-on-amgen-tezspire-s-market-potential-in-copd-treatment-undervalued-1033257800
2120.0,4/17/2024 12:00:00 PM,Coming FDA Approvals Could Send These 3 Drug Stocks Soaring,InvestorPlace,/news/stocks/coming-fda-approvals-could-send-these-3-drug-stocks-soaring-1033257666
2121.0,4/17/2024 12:00:00 PM,Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble,InvestorPlace,/news/stocks/sell-these-3-blue-chip-stocks-before-the-next-earnings-stumble-1033257665
2122.0,4/17/2024 1:26:31 PM,CVS favors Humira copycats hurting AbbVie’s market share: Evercore,Seeking Alpha,https://seekingalpha.com/news/4090466-cvs-favors-humira-copycats-hurting-abbvies-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2123.0,4/17/2024 2:21:45 PM,Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday,Benzinga,/news/stocks/visa-to-rally-around-18-here-are-10-top-analyst-forecasts-for-wednesday-1033257667
2124.0,4/17/2024 8:39:46 PM,Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick,Benzinga,/news/stocks/amgen-astrazeneca-s-asthma-drug-tezspire-vs-sanofi-regeneron-s-blockbuster-dupixent---analyst-gives-his-pick-1033259296
2125.0,4/18/2024 4:29:18 AM,Analyst Holds on Amgen’s Tezspire amid COPD Trial Uncertainties and Pending Competitor Comparisons,TipRanks,/news/stocks/analyst-holds-on-amgen-s-tezspire-amid-copd-trial-uncertainties-and-pending-competitor-comparisons-1033260723
2126.0,4/19/2024 11:14:00 AM,The Dividend Goldmine: 3 Shining Stocks With Growing Payouts,InvestorPlace,/news/stocks/the-dividend-goldmine-3-shining-stocks-with-growing-payouts-1033265718
2127.0,4/22/2024 12:04:07 AM,13 new obesity drugs could hit the market by 2029 amid surging demand,Seeking Alpha,https://seekingalpha.com/news/4091726-13-new-obesity-drugs-could-hit-the-market-by-2029-amid-surging-demand?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2128.0,4/22/2024 12:27:48 PM,Piper Sandler Sticks to Its Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/piper-sandler-sticks-to-its-buy-rating-for-amgen-amgn-1033271992
2129.0,4/24/2024 10:30:20 AM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Bausch + Lomb Corporation (BLCO),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-bausch-+-lomb-corporation-blco-1033282277
2130.0,4/24/2024 8:29:17 PM,Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?,Benzinga,/news/stocks/why-is-cullinan-therapeutics-stock-trading-higher-on-wednesday-1033283831
2131.0,4/25/2024 12:37:36 PM,AstraZeneca rises as oncology business drives Q1 beat,Seeking Alpha,https://seekingalpha.com/news/4094079-astrazeneca-stock-rises-q1-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2132.0,4/26/2024 3:33:00 PM,Amgen Announces Imminent Submission Of MAA To European Medicines Agency For Teprotumumab ,RTTNews,/news/stocks/amgen-announces-imminent-submission-of-maa-to-european-medicines-agency-for-teprotumumab-1033294162
2133.0,4/26/2024 4:56:53 PM,19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095057-19-out-20-sp-500-healthcare-companies-beat-profit-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2134.0,4/26/2024 7:00:06 PM,"Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day",Seeking Alpha,https://seekingalpha.com/news/4094989-catalyst-watch-apple-earnings-viking-ipo-chinese-ev-deliveries-and-russell-indices-rank-day?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2135.0,4/27/2024 7:39:17 PM,Amgen’s Blincyto data send Cullinan higher,Seeking Alpha,https://seekingalpha.com/news/4095218-cullinan-stock-rises-amgens-blincyto-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2136.0,4/28/2024 12:00:00 PM,"Earnings week ahead: Amazon, Apple, Pfizer, AMD, Coca-Cola, Starbucks and more",Seeking Alpha,https://seekingalpha.com/news/4094953-earnings-week-ahead-amazon-apple-pfizer-amd-qualcomm-coca-cola-starbucks-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2137.0,4/28/2024 5:00:22 PM,"J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade",Seeking Alpha,https://seekingalpha.com/news/4095228-johnson-johnson-roche-astrazeneca-poised-have-highest-orphan-drug-sales-by-end-decade?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2138.0,4/30/2024 7:32:48 AM,"Sandoz, Amgen reach agreement resolving patent litigation over biosimilars",Seeking Alpha,https://seekingalpha.com/news/4095970-sandoz-amgen-reach-agreement-resolving-patent-litigation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2139.0,4/30/2024 11:21:54 AM,Amgen (AMGN) Gets a Buy from Truist Financial,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-truist-financial-1033307285
2140.0,4/30/2024 12:01:27 PM,"Analysts’ Top Healthcare Picks: Laboratory (LH), Amgen (AMGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-laboratory-lh-amgen-amgn-1033307604
2141.0,4/30/2024 3:23:00 PM,Amgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelled (update),Seeking Alpha,https://seekingalpha.com/news/4095693-amgen-court-hearing-in-patent-lawsuit-vs-sandoz-over-generic-prolia-cancelled?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2142.0,5/1/2024 2:42:56 PM,CytomX surges on upcoming data for Amgen-partnered cancer drug,Seeking Alpha,https://seekingalpha.com/news/4097393-cytomx-stock-rises-upcoming-data-amgen-partnered-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2143.0,5/1/2024 3:01:13 PM,Amgen earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/amgen-stock-price-quarter-earnings-preview-q1-1033312957
2144.0,5/1/2024 3:46:43 PM,Amgen Q1 Earnings Preview: Obesity treatment updates to be the focus this season,Seeking Alpha,https://seekingalpha.com/news/4097477-amgen-q1-earnings-preview-obesity-treatment-updates-to-be-the-focus-this-season?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2145.0,5/1/2024 7:00:28 PM,Ticking Time Bombs: 3 Dow Stocks to Dump While You Still Can,InvestorPlace,/news/stocks/ticking-time-bombs-3-dow-stocks-to-dump-while-you-still-can-1033315185
2146.0,5/1/2024 9:35:20 PM,Notable earnings after Thursday's close,Seeking Alpha,https://seekingalpha.com/news/4097359-notable-earnings-after-thursdays-close?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2147.0,5/2/2024 7:42:06 PM,"Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?",Benzinga,/news/etf/wall-street-inches-up-after-powell-s-inflation-remarks-chipmakers-rebound-gold-crude-falter-what-s-driving-markets-thursday-1033321858
2148.0,5/2/2024 8:03:44 PM,"Amgen Non-GAAP EPS of $3.96 beats by $0.05, revenue of $7.45B in-line",Seeking Alpha,https://seekingalpha.com/news/4099057-amgen-non-gaap-eps-of-3_96-beats-0_05-revenue-of-7_45b-in-line?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2149.0,5/2/2024 8:16:09 PM,"Amgen in charts: Major drug sales grow at slower pace Y/Y, rev from Enbrel dips in Q1",Seeking Alpha,https://seekingalpha.com/news/4099096-amgen-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2150.0,5/2/2024 8:17:14 PM,Arrowhead Pharmaceuticals secures $50M milestone from Royalty Pharma,Seeking Alpha,https://seekingalpha.com/news/4099116-arrowhead-pharmaceuticals-secures-50m-milestone-from-royalty-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2151.0,5/2/2024 9:40:21 PM,"Amgen stock rallies 13% amid weight-loss drug updates, tweaked guidance",Seeking Alpha,https://seekingalpha.com/news/4099298-amgen-stock-rallies-on-weight-loss-drug-updates-tweaked-guidanace?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2152.0,5/2/2024 10:04:58 PM,Amgen Inc. Q1 Earnings Summary,RTTNews,/news/stocks/amgen-inc-q1-earnings-summary-1033322128
2153.0,5/3/2024 12:59:40 AM,"AMGN Stock Earnings: Amgen Beats EPS, Beats Revenue for Q1 2024",InvestorPlace,/news/stocks/amgn-stock-earnings-amgen-for-q1-of-2024-1033322807
2154.0,5/3/2024 10:43:49 AM,RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-buy-rating-on-amgen-amgn-1033326789
2155.0,5/3/2024 10:47:29 AM,"Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ultragenyx-pharmaceutical-rare-amgen-amgn-and-zimmer-biomet-holdings-zbh-1033326776
2156.0,5/3/2024 11:07:32 AM,"Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Amgen (AMGN) and Omnicell (OMCL)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-day-one-biopharmaceuticals-dawn-amgen-amgn-and-omnicell-omcl-1033327140
2157.0,5/3/2024 12:06:45 PM,Amgen (AMGN) Receives a Buy from Piper Sandler,TipRanks,/news/stocks/amgen-amgn-receives-a-buy-from-piper-sandler-1033327542
2158.0,5/3/2024 12:08:17 PM,Oppenheimer Remains a Buy on Amgen (AMGN),TipRanks,/news/stocks/oppenheimer-remains-a-buy-on-amgen-amgn-1033327532
2159.0,5/3/2024 2:00:40 PM,"Biggest stock movers today: WOW, AAPL, SQ, and more",Seeking Alpha,https://seekingalpha.com/news/4099378-biggest-stock-movers-today-aapl-sq-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2160.0,5/3/2024 2:28:54 PM,Amgen stock rallies 13% on GLP-1 weight-loss drug update,Seeking Alpha,https://seekingalpha.com/news/4099749-amgen-stock-rallies-on-glp-1-weight-loss-drug-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2161.0,5/3/2024 2:41:30 PM,AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?,InvestorPlace,/news/stocks/amgn-stock-alert-is-amgen-the-next-hot-weight-loss-drug-company-1033327435
2162.0,5/3/2024 3:17:53 PM,Why Is WideOpenWest (WOW) Stock Up 30% Today?,InvestorPlace,/news/stocks/why-is-wideopenwest-wow-stock-up-30-today-1033327559
2163.0,5/3/2024 3:34:15 PM,"Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Kura Oncology (KURA) and Amgen (AMGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cardinal-health-cah-kura-oncology-kura-and-amgen-amgn-1033328201
2164.0,5/3/2024 4:29:38 PM,"William Blair, Barclays upgrade Amgen following GLP-1 drug update",Seeking Alpha,https://seekingalpha.com/news/4099803-william-blair-barclays-upgrade-amgen-following-glp-1-drug-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2165.0,5/3/2024 5:24:02 PM,"Amgen Outlook Is Bright, Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value",Benzinga,/news/stocks/amgen-outlook-is-bright-analyst-predict-obesity-focused-drug-potential-will-drive-shareholder-value-1033327558
2166.0,5/3/2024 7:51:03 PM,"Stocks Rally As Jobs Report Rekindles Rate Cut Hopes, Apple Rockets, Bitcoin Soars Above $61,000: What's Driving Markets Friday?",Benzinga,/news/stocks/stocks-rally-as-jobs-report-rekindles-rate-cut-hopes-apple-rockets-bitcoin-soars-above-61-000-what-s-driving-markets-friday-1033328110
2167.0,5/4/2024 4:25:55 AM,BMO Capital Reaffirms Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/bmo-capital-reaffirms-their-buy-rating-on-amgen-amgn-1033328576
2168.0,5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2169.0,5/4/2024 8:47:00 PM,16 out of 24 health care companies beat topline numbers this week- Earnings scorecard,Seeking Alpha,https://seekingalpha.com/news/4099757-16-out-of-24-health-care-companies-beat-topline-numbers-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2170.0,5/5/2024 9:16:32 PM,Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update,Benzinga,/news/etf/cathie-wood-s-ark-invest-snaps-up-3-54m-worth-of-shares-in-this-biopharma-company-following-positive-obesity-pipeline-update-1033329716
2171.0,5/6/2024 5:05:47 AM,Amgen’s Strong Q1 Performance and Promising Pipeline Justify Buy Rating,TipRanks,/news/stocks/amgen-s-strong-q1-performance-and-promising-pipeline-justify-buy-rating-1033331814
2172.0,5/6/2024 4:41:30 PM,CytomX raised to buy at Jefferies in anticipation of phase 1 solid tumors asset data,Seeking Alpha,https://seekingalpha.com/news/4100520-cytomx-raised-buy-jefferies-anticipation-phase-1-solid-tumors-asset-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2173.0,5/7/2024 7:28:45 PM,3 Tried and True Dividend Stocks to Buy for Your Portfolio,InvestorPlace,/news/stocks/3-tried-and-true-dividend-stocks-to-buy-for-your-portfolio-1033341844
2174.0,5/8/2024 4:10:12 AM,"Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-procept-biorobotics-prct-amgen-amgn-and-elevation-oncology-elev-1033345372
2175.0,5/8/2024 4:30:18 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Crinetics Pharmaceuticals (CRNX) and Alignment Healthcare (ALHC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-crinetics-pharmaceuticals-crnx-and-alignment-healthcare-alhc-1033345476
2176.0,5/8/2024 8:20:11 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Teleflex (TFX) and Axsome Therapeutics (AXSM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-teleflex-tfx-and-axsome-therapeutics-axsm-1033346570
2177.0,5/9/2024 11:00:00 AM,Sector Superstars: 3 Stocks Generating the Most Buzz on Wall Street,InvestorPlace,/news/stocks/sector-superstars-3-stocks-generating-the-most-buzz-on-wall-street-1033355357
2178.0,5/9/2024 2:34:23 PM,7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025,InvestorPlace,/news/stocks/7-weight-loss-drug-stocks-poised-for-explosive-growth-by-2025-1033357058
2179.0,5/9/2024 3:33:48 PM,CytomX slides after early data for Amgen-partnered cancer drug,Seeking Alpha,https://seekingalpha.com/news/4103826-cytomx-stock-slips-data-amgen-partnered-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2180.0,5/13/2024 3:00:00 PM,The 3 Best Dow Stocks to Buy in May 2024,InvestorPlace,/news/stocks/the-3-best-dow-stocks-to-buy-in-may-2024-1033371658
2181.0,5/15/2024 9:43:25 PM,Should You Hold Viking Therapeutics in Your Portfolio?,Benzinga,/news/stocks/should-you-hold-viking-therapeutics-in-your-portfolio-1033386466
2182.0,5/15/2024 10:18:24 PM,"S&P 500, Nasdaq 100, Dow Jones Shatter Record Highs In Unstoppable Bull Market Rally",Benzinga,/news/etf/s-p-500-nasdaq-100-dow-jones-shatter-record-highs-in-unstoppable-bull-market-rally-1033386611
2183.0,5/16/2024 10:48:39 AM,Roche obesity therapy leads to ~19% weight loss in Phase 1 trial,Seeking Alpha,https://seekingalpha.com/news/4107185-roche-obesity-therapy-causes-19-weight-loss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2184.0,5/16/2024 7:40:44 PM,Amgen wins FDA nod for new lung cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4107689-amgen-wins-fda-nod-new-lung-cancer-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2185.0,5/16/2024 10:56:20 PM,Balancing Early Approval and Market Challenges: Amgen’s Imdelltra Receives a Hold Rating from Carter Gould,TipRanks,/news/stocks/balancing-early-approval-and-market-challenges-amgen-s-imdelltra-receives-a-hold-rating-from-carter-gould-1033395351
2186.0,5/17/2024 3:01:02 AM,Amgen: FDA Approves Imdelltra For Extensive-Stage Small Cell Lung Cancer Treatment ,RTTNews,/news/stocks/amgen-fda-approves-imdelltra-for-extensive-stage-small-cell-lung-cancer-treatment-1033395319
2187.0,5/17/2024 11:10:11 AM,"Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-amgen-amgn-eli-lilly-co-lly-1033399669
2188.0,5/17/2024 11:40:10 AM,"Analysts’ Top Healthcare Picks: Amgen (AMGN), Aytu BioScience (AYTU)",TipRanks,/news/stocks/analysts-top-healthcare-picks-amgen-amgn-aytu-bioscience-aytu-1033399797
2189.0,5/17/2024 12:11:11 PM,"Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Amgen (AMGN) and Orasure Technologies (OSUR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-caredx-cdna-amgen-amgn-and-orasure-technologies-osur-1033399960
2190.0,5/17/2024 6:40:17 PM,Here are the biggest single-session post-results gains from the recent earnings season,Seeking Alpha,https://seekingalpha.com/news/4108012-top-30-largest-1-day-gains-by-stocks-from-their-respected-earnings-announcements?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2191.0,5/17/2024 7:02:01 PM,Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?,InvestorPlace,/news/stocks/pharma-stocks-outlook-where-are-2024s-top-performers-headed-next-1033400641
2192.0,5/17/2024 9:24:26 PM,"4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly",Benzinga,/news/stocks/4-stocks-that-could-break-novo-nordisk-lilly-s-obesity-duopoly-1033400634
2193.0,5/18/2024 4:19:14 PM,"Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch",Benzinga,/news/stocks/cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks-to-watch-1033400987
2194.0,5/20/2024 3:38:29 AM,AstraZeneca: New Data Shows Tezspire's Role In Future COPD Treatment ,RTTNews,/news/stocks/astrazeneca-new-data-shows-tezspire-s-role-in-future-copd-treatment-1033401813
2195.0,5/20/2024 12:01:46 PM,Analysts Have Conflicting Sentiments on These Healthcare Companies: AbSci (ABSI) and Amgen (AMGN),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-absci-absi-and-amgen-amgn-1033404051
2196.0,5/20/2024 12:30:24 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033404110
2197.0,5/20/2024 4:49:46 PM,"AstraZeneca, Amgen release mid-stage data on Tezspire for COPD",Seeking Alpha,https://seekingalpha.com/news/4108441-astrazeneca-amgen-release-mid-stage-data-tezspire-copd?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2198.0,5/20/2024 5:34:36 PM,7 Biotech Stocks That Could Breathe New Life Into Your Portfolio,InvestorPlace,/news/stocks/7-biotech-stocks-that-could-breathe-new-life-into-your-portfolio-1033404432
2199.0,5/21/2024 7:46:20 AM,Barclays Sticks to Its Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/barclays-sticks-to-its-hold-rating-for-amgen-amgn-1033406644
2200.0,5/21/2024 11:37:09 AM,Amgen (AMGN) Gets a Buy from Truist Financial,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-truist-financial-1033408001
2201.0,5/21/2024 11:40:43 AM,"Analysts’ Top Healthcare Picks: GE Healthcare Technologies Inc (GEHC), Compugen (CGEN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-ge-healthcare-technologies-inc-gehc-compugen-cgen-1033407995
2202.0,5/21/2024 1:44:06 PM,7 Reliable Blue-Chip Stocks That Cannot Miss,InvestorPlace,/news/stocks/7-reliable-blue-chip-stocks-that-cannot-miss-1033407489
2203.0,5/21/2024 10:35:00 PM,EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic,Benzinga,/news/stocks/exclusive-roundhill-investments-launches-weight-loss-etf-for-exposure-to-blockbuster-drugs-like-ozempic-1033408932
2204.0,5/22/2024 4:36:11 AM,Tezspire’s Potential in COPD Treatment: Navigating Efficacy and Market Dynamics,TipRanks,/news/stocks/tezspire-s-potential-in-copd-treatment-navigating-efficacy-and-market-dynamics-1033410388
2205.0,5/22/2024 5:56:21 AM,Maintaining Hold on Amgen: Mixed Clinical Results and Cautious Adoption of New Therapy,TipRanks,/news/stocks/maintaining-hold-on-amgen-mixed-clinical-results-and-cautious-adoption-of-new-therapy-1033410748
2206.0,5/22/2024 7:32:02 AM,Roche: FDA Grants Breakthrough Device Designation For Bood Test Measuring Lp(a) ,RTTNews,/news/stocks/roche-fda-grants-breakthrough-device-designation-for-bood-test-measuring-lp-a-1033410177
2207.0,5/22/2024 9:20:44 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Omnicell (OMCL), Tandem Diabetes Care (TNDM) and Amgen (AMGN)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-omnicell-omcl-tandem-diabetes-care-tndm-and-amgen-amgn-1033411347
2208.0,5/24/2024 11:00:00 AM,Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now,InvestorPlace,/news/stocks/stocks-to-buy-7-undeniable-dow-darlings-to-pile-into-now-1033419440
2209.0,5/25/2024 2:24:03 PM,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/4110471-viking-crispr-cytokinetics-m-a-targets-wells-fargo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2210.0,5/26/2024 5:36:00 PM,SA Asks: Who will launch the next big weight-loss drug?,Seeking Alpha,https://seekingalpha.com/news/4110093-sa-asks-who-will-launch-the-next-big-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2211.0,5/28/2024 1:21:20 PM,CytomX upgraded at Piper Sandler on validation of cancer therapeutics platform,Seeking Alpha,https://seekingalpha.com/news/4110729-cytomx-upgraded-piper-sandler-validation-cancer-therapeutics-technology?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2212.0,5/28/2024 3:32:01 PM,OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF,InvestorPlace,/news/stocks/ozem-etf-7-things-to-know-about-the-new-roundhill-glp-1-weight-loss-etf-1033427842
2213.0,5/29/2024 3:50:26 PM,AstraZeneca touts PCSK9 inhibitor in lowering LDL cholesterol when added to statin,Seeking Alpha,https://seekingalpha.com/news/4111181-astrazeneca-touts-pcsk9-inhibitor-lowering-ldl-cholesterol-added-statin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2214.0,5/29/2024 5:01:37 PM,Amgen wins approval of first biosimilar of AstraZeneca's Soliris,Seeking Alpha,https://seekingalpha.com/news/4111216-amgen-wins-approval-first-biosimilar-astrazeneca-soliris?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2215.0,5/30/2024 11:21:35 AM,Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris ,RTTNews,/news/stocks/amgen-s-bkemv-approved-as-first-interchangeable-biosimilar-to-soliris-1033435304
2216.0,5/30/2024 11:55:49 AM,Biotech Stocks Facing FDA Decision In June 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2024-1033435348
2217.0,5/30/2024 3:22:06 PM,Goldman Sachs raises obesity drug market estimate to $130B,Seeking Alpha,https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2218.0,6/2/2024 2:00:00 PM,SA Asks: Which weight-loss stocks should investors be watching?,Seeking Alpha,https://seekingalpha.com/news/4112116-sa-asks-which-weight-loss-stocks-should-investors-be-watching?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2219.0,6/5/2024 1:41:38 PM,Amgen posts late-stage win for Uplizna in immune-mediated disorder,Seeking Alpha,https://seekingalpha.com/news/4113160-amgen-posts-uplizna-trial-win-igg4-rd?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2220.0,6/5/2024 3:50:46 PM,Amgen Reports Positive Results For Phase 3 Trial Of Uplizna For IgG4-RD ,RTTNews,/news/stocks/amgen-reports-positive-results-for-phase-3-trial-of-uplizna-for-igg4-rd-1033453737
2221.0,6/7/2024 12:10:56 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Qiagen (QGEN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-qiagen-qgen-and-eli-lilly-co-lly-1033461868
2222.0,6/7/2024 7:00:58 PM,"Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility",Seeking Alpha,https://seekingalpha.com/news/4114173-catalyst-watch-apples-wwdc-teslas-shareholder-meeting-fomc-meeting-and-gamestop-volatility?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2223.0,6/10/2024 10:20:32 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), InflaRx (IFRX) and Axsome Therapeutics (AXSM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-inflarx-ifrx-and-axsome-therapeutics-axsm-1033465660
2224.0,6/11/2024 1:14:04 PM,Viridian gains after R&D update; Wolfe starts at Outperform,Seeking Alpha,https://seekingalpha.com/news/4114835-viridian-stock-gains-on-wolfe-rating?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2225.0,6/12/2024 10:45:58 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Align Tech (ALGN) and Ultragenyx Pharmaceutical (RARE)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-align-tech-algn-and-ultragenyx-pharmaceutical-rare-1033472870
2226.0,6/12/2024 4:33:43 PM,GLP-1 obesity drug coverage dropped by Blue Cross Michigan: report,Seeking Alpha,https://seekingalpha.com/news/4115246-glp-1-drug-coverage-dropped-by-blue-cross-michigan-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2227.0,6/13/2024 10:15:00 AM,3 Stocks to Buy as Ozempic Surges in Popularity,InvestorPlace,/news/stocks/3-stocks-to-buy-as-ozempic-surges-in-popularity-1033475495
2228.0,6/14/2024 7:00:25 PM,Expert Ratings For Amgen,Benzinga,/news/stocks/expert-ratings-for-amgen-1033480750
2229.0,6/14/2024 9:13:58 PM,FDA grants expanded approval for Amgen's Blincyto in ALL,Seeking Alpha,https://seekingalpha.com/news/4116442-fda-grants-expanded-approval-for-amgens-blincyto-in-all?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2230.0,6/15/2024 4:41:49 AM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-gilead-sciences-gild-1033481201
2231.0,6/17/2024 7:27:56 PM,7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline,InvestorPlace,/news/stocks/7-breakthrough-biotech-stocks-for-a-shot-of-portfolio-adrenaline-1033485033
2232.0,6/23/2024 6:00:00 PM,"Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit",Seeking Alpha,https://seekingalpha.com/news/4118072-lilly-novo-nordisk-dominate-weight-loss-therapy-sa-investing-summit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2233.0,6/29/2024 7:44:55 PM,Rising drug costs force a third of Americans to leave prescriptions unfilled: report,Seeking Alpha,https://seekingalpha.com/news/4120808-many-prescriptions-remain-unfilled-amid-soaring-drug-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2234.0,7/1/2024 12:30:56 AM,"Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2",Seeking Alpha,https://seekingalpha.com/news/4120874-alnylam-lilly-astrzeneca-best-performing-pharmas-biotechs-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2235.0,7/2/2024 4:04:07 PM,Alvotech reports positive study results for Prolia/Xgeva biosimilar,Seeking Alpha,https://seekingalpha.com/news/4121768-alvotech-reports-positive-study-results-for-proliaxgeva-biosimilar?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2236.0,7/3/2024 7:04:02 PM,"S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?",Benzinga,/news/etf/s-p-500-nasdaq-100-climb-to-record-highs-as-data-fosters-rate-cut-optimism-ahead-of-fed-minutes-gold-bonds-rally-what-s-driving-markets-wednesday-1033527636
2237.0,7/4/2024 10:35:00 AM,The 3 Best Healthcare Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-3-best-healthcare-stocks-to-buy-in-july-2024-1033529151
2238.0,7/5/2024 7:04:46 PM,"Study links GLP-1 drugs, metformin to lower risk of certain cancers",Seeking Alpha,https://seekingalpha.com/news/4122404-study-links-glp-1-drugs-metformin-to-lower-risk-of-certain-cancers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2239.0,7/7/2024 3:39:52 PM,"EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO",Benzinga,/news/stocks/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo-1033533664
2240.0,7/8/2024 11:58:27 AM,Ideaya stock jumps after positive study data from cancer study,Seeking Alpha,https://seekingalpha.com/news/4122536-ideaya-stock-jumps-after-positive-study-data-from-cancer-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2241.0,7/8/2024 12:15:27 PM,Buy Rating on Amgen: Promising Rocatinlimab Pipeline and Market Opportunities,TipRanks,/news/stocks/buy-rating-on-amgen-promising-rocatinlimab-pipeline-and-market-opportunities-1033536574
2242.0,7/8/2024 2:04:40 PM,3 Dividend Stocks Crushing the S&P 500 With 30%+ Annual Total Returns,InvestorPlace,/news/stocks/3-dividend-stocks-crushing-the-sp-500-with-30-annual-total-returns-1033536348
2243.0,7/8/2024 2:38:54 PM,3 Small-Cap Stocks With Explosive 2X Growth Potential,InvestorPlace,/news/stocks/3-small-cap-stocks-with-explosive-2x-growth-potential-1033536419
2244.0,7/9/2024 10:00:00 AM,7 Cheap Biotech Stocks With Major Upside Potential,InvestorPlace,/news/stocks/7-cheap-biotech-stocks-with-major-upside-potential-1033538625
2245.0,7/10/2024 8:58:27 AM,Barclays Remains a Hold on Amgen (AMGN),TipRanks,/news/stocks/barclays-remains-a-hold-on-amgen-amgn-1033543036
2246.0,7/12/2024 8:12:28 AM,"This weight loss stock is the best alternative to Eli Lilly, Novo - SA Sentiment",Seeking Alpha,https://seekingalpha.com/news/4123754-weight-loss-amgen-stock-obesity-plays?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2247.0,7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2248.0,7/15/2024 12:20:17 PM,Analysts Offer Insights on Healthcare Companies: Eisai Co (OtherESALF) and Amgen (AMGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eisai-co-otheresalf-and-amgen-amgn-1033556104
2249.0,7/16/2024 1:04:00 AM,3 Biotech Stocks to Buy Now: Q3 Edition,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-now-q3-edition-1033556892
2250.0,7/16/2024 10:30:00 AM,3 Quantum AI Stocks That Could Redefine Computing,InvestorPlace,/news/stocks/3-quantum-ai-stocks-that-could-redefine-computing-1033558686
2251.0,7/17/2024 11:00:00 AM,7 Dividend Stocks That Just Raised Their Payouts: July 2024,InvestorPlace,/news/stocks/7-dividend-stocks-that-just-raised-their-payouts-july-2024-1033563485
2252.0,7/18/2024 10:19:19 AM,Amgen’s Mixed Financial Outlook: Balancing Revenue Prospects with Operational Concerns and Product Pipeline Uncertainty,TipRanks,/news/stocks/amgen-s-mixed-financial-outlook-balancing-revenue-prospects-with-operational-concerns-and-product-pipeline-uncertainty-1033568624
2253.0,7/18/2024 10:59:13 PM,"EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'",Benzinga,/news/stocks/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-won-t-be-dominated-by-just-2-players-1033570253
2254.0,7/19/2024 12:15:54 PM,Amgen (AMGN) Gets a Buy from Jefferies,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-jefferies-1033573068
2255.0,7/21/2024 11:00:00 AM,Here are Big Pharma’s leading blockbuster makers,Seeking Alpha,https://seekingalpha.com/news/4126044-eli-lilly-astrazeneca-top-blockbuster-makers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2256.0,7/23/2024 10:39:33 AM,Amgen (AMGN) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-piper-sandler-1033582774
2257.0,7/23/2024 11:35:43 AM,TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/td-cowen-reaffirms-their-buy-rating-on-amgen-amgn-1033583308
2258.0,7/23/2024 5:23:57 PM,3 Stocks That Are Melting Up. Is There Room to Run?,InvestorPlace,/news/stocks/3-stocks-that-are-melting-up-is-there-room-to-run-1033583979
2259.0,7/23/2024 6:57:01 PM,7 Biotech Stocks to Keep on Your Clinical Radar,InvestorPlace,/news/stocks/7-biotech-stocks-to-keep-on-your-clinical-radar-1033584230
2260.0,7/24/2024 7:40:28 PM,3 Fabulous Growth Stocks to Buy and Hold Forever,InvestorPlace,/news/stocks/3-fabulous-growth-stocks-to-buy-and-hold-forever-1033590657
2261.0,7/25/2024 11:01:43 AM,"Viking sends Lilly, Novo lower as obesity drug enters late-stage program",Seeking Alpha,https://seekingalpha.com/news/4128191-viking-stock-climbs-obesity-drug-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2262.0,7/29/2024 10:00:00 AM,3 Dividend-Paying ETFs to Secure Your Passive Income Stream,InvestorPlace,/news/stocks/3-dividend-paying-etfs-to-secure-your-passive-income-stream-1033605444
2263.0,7/31/2024 12:07:29 PM,Oppenheimer Sticks to Their Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/oppenheimer-sticks-to-their-buy-rating-for-amgen-amgn-1033619435
2264.0,7/31/2024 8:30:00 PM,The Top 3 Biotech Stocks to Buy Now Summer 2024,InvestorPlace,/news/stocks/the-top-3-biotech-stocks-to-buy-now-summer-2024-1033620880
2265.0,8/2/2024 12:18:42 PM,Amgen (AMGN) Receives a Buy from TD Cowen,TipRanks,/news/stocks/amgen-amgn-receives-a-buy-from-td-cowen-1033633141
2266.0,8/2/2024 5:54:56 PM,3 Biotech Stocks That Could Have Investors Grinning Soon,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-have-investors-grinning-soon-1033633904
2267.0,8/2/2024 7:00:00 PM,"Catalyst Watch: Disney earnings, Costco sales update, MicroStrategy split, and eyes on AI patents",Seeking Alpha,https://seekingalpha.com/news/4132451-catalyst-watch-disney-earnings-costco-sales-update-microstrategy-split-and-eyes-on-ai-patents?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2268.0,8/2/2024 8:42:33 PM,Amgen declares $2.25 dividend,Seeking Alpha,https://seekingalpha.com/news/4133578-amgen-inc-declares-2_25-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2269.0,8/4/2024 12:00:00 PM,"Earnings week ahead: Disney, Duke Energy, Palantir, Shopify, Uber and more",Seeking Alpha,https://seekingalpha.com/news/4133349-earnings-week-ahead-disney-duke-energy-palantir-shopify-uber-plug-power-nikola-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2270.0,8/4/2024 2:54:00 PM,19 out of 21 Healthcare companies topped profit estimates this week: Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4132480-healthcare-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2271.0,8/5/2024 2:55:31 PM,"Amgen Q2 Earnings Preview: Focus on weight-loss drug updates, Horizon integration",Seeking Alpha,https://seekingalpha.com/news/4133998-amgen-q2-earnings-preview-focus-on-weight-loss-drug-updates-horizon-integration?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2272.0,8/5/2024 3:01:13 PM,What Wall Street expects from Amgen's earnings,Markets Insider Automation,/news/stocks/amgen-stock-price-quarter-earnings-preview-q2-1033638818
2273.0,8/5/2024 4:20:49 PM,Best volatility ranking stocks with low moves and straddle premiums vs. history - BofA,Seeking Alpha,https://seekingalpha.com/news/4134163-best-volatility-ranking-stocks-with-low-moves-and-straddle-premiums-vs-history-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2274.0,8/6/2024 1:39:00 PM,"4 stocks to watch on Tuesday: CAT, ABNB and more",Seeking Alpha,https://seekingalpha.com/news/4134909-4-stocks-to-watch-on-tuesday-cat-abnb-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2275.0,8/6/2024 8:02:17 PM,"Amgen Non-GAAP EPS of $4.97 misses by $0.03, revenue of $8.39B beats by $40M",Seeking Alpha,https://seekingalpha.com/news/4135276-amgen-non-gaap-eps-of-4_97-misses-0_03-revenue-of-8_39b-beats-40m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2276.0,8/6/2024 8:11:41 PM,"Amgen in charts: Sales of Prolia, XGEVA continue to gain Y/Y, Enbrel and Otezla fall in Q2",Seeking Alpha,https://seekingalpha.com/news/4135259-amgen-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2277.0,8/6/2024 9:23:25 PM,"Amgen narrows guidance ranges for 2024 EPS, revenue",Seeking Alpha,https://seekingalpha.com/news/4135457-amgen-narrows-guidance-ranges-2024-eps-revenue?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2278.0,8/6/2024 10:04:46 PM,"Amgen Inc. Q2 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/amgen-inc-q2-profit-decreases-but-beats-estimates-1033647239
2279.0,8/7/2024 1:00:33 AM,"AMGN Stock Earnings: Amgen Misses EPS, Beats Revenue for Q2 2024",InvestorPlace,/news/stocks/amgn-stock-earnings-amgen-for-q2-of-2024-1033648016
2280.0,8/7/2024 3:55:50 AM,Amgen’s Strong Quarterly Performance and Promising Drug Prospects Merit a Buy Rating,TipRanks,/news/stocks/amgen-s-strong-quarterly-performance-and-promising-drug-prospects-merit-a-buy-rating-1033650764
2281.0,8/7/2024 7:56:51 AM,Barclays Sticks to Their Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/barclays-sticks-to-their-hold-rating-for-amgen-amgn-1033651810
2282.0,8/7/2024 10:18:43 AM,Balancing Potential and Uncertainty: Hold Rating on Amgen Amid Mixed Performance and Pipeline Prospects,TipRanks,/news/stocks/balancing-potential-and-uncertainty-hold-rating-on-amgen-amid-mixed-performance-and-pipeline-prospects-1033653154
2283.0,8/7/2024 10:44:36 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Sensei Biotherapeutics (SNSE) and Annovis Bio (ANVS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-sensei-biotherapeutics-snse-and-annovis-bio-anvs-1033653301
2284.0,8/7/2024 11:12:33 AM,RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-buy-rating-on-amgen-amgn-1033653846
2285.0,8/7/2024 11:23:30 AM,Piper Sandler Releases a Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/piper-sandler-releases-a-buy-rating-on-amgen-amgn-1033653781
2286.0,8/7/2024 11:39:48 AM,Amgen’s Growth Trajectory and Resilience: A Comprehensive Buy Rating Analysis,TipRanks,/news/stocks/amgen-s-growth-trajectory-and-resilience-a-comprehensive-buy-rating-analysis-1033653901
2287.0,8/7/2024 12:09:12 PM,Oppenheimer Remains a Buy on Amgen (AMGN),TipRanks,/news/stocks/oppenheimer-remains-a-buy-on-amgen-amgn-1033654154
2288.0,8/7/2024 12:11:57 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Caribou Biosciences (CRBU) and Surgery Partners (SGRY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-caribou-biosciences-crbu-and-surgery-partners-sgry-1033654129
2289.0,8/7/2024 12:18:15 PM,Amgen cut at Wells Fargo; says obesity success is already priced in,Seeking Alpha,https://seekingalpha.com/news/4135878-amgen-stock-cut-wells-fargo-maritide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2290.0,8/7/2024 12:50:45 PM,Wall Street Analysts Are Neutral on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-neutral-on-top-healthcare-picks-1033654533
2291.0,8/9/2024 9:52:16 AM,Amgen Hold Rating: Balancing Solid Q2 Performance with Cautious Pipeline Projections,TipRanks,/news/stocks/amgen-hold-rating-balancing-solid-q2-performance-with-cautious-pipeline-projections-1033668945
2292.0,8/9/2024 10:52:14 AM,Amgen Faces Financial Headwinds: Sell Rating Justified Amid Patent Losses and Underwhelming Product Performance,TipRanks,/news/stocks/amgen-faces-financial-headwinds-sell-rating-justified-amid-patent-losses-and-underwhelming-product-performance-1033669191
2293.0,8/9/2024 10:52:39 AM,"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Amgen (AMGN) and ACADIA Pharmaceuticals (ACAD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-amgen-amgn-and-acadia-pharmaceuticals-acad-1033669189
2294.0,8/9/2024 3:14:42 PM,"Amgen Hold Rating Justified by Mixed Financial Results, Pipeline Uncertainties, and Competitive Challenges",TipRanks,/news/stocks/amgen-hold-rating-justified-by-mixed-financial-results-pipeline-uncertainties-and-competitive-challenges-1033670884
2295.0,8/9/2024 4:38:50 PM,Amgen’s Stock Poised for Growth: Solid Financials and Promising Clinical Updates Underpin Buy Rating,TipRanks,/news/stocks/amgen-s-stock-poised-for-growth-solid-financials-and-promising-clinical-updates-underpin-buy-rating-1033670989
2296.0,8/10/2024 5:04:00 PM,"Notable analyst calls this week: Disney, Super Micro and Amgen among top picks",Seeking Alpha,https://seekingalpha.com/news/4138112-notable-analyst-calls-this-week-disney-super-micro-and-amgen-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2297.0,8/11/2024 11:57:04 AM,About 73% of the S&P 500 names beat on EPS during the week - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4138410-about-73-of-the-sp-500-names-beat-on-eps-during-the-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2298.0,8/14/2024 7:28:06 PM,"Tudor Investment buys/sells in Q2 feature Bristol Myers, PepsiCo, AMD, others",Seeking Alpha,https://seekingalpha.com/news/4139985-tudor-investment-buyssells-in-q2-feature-bristol-myers-pepsico-amd-others?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2299.0,8/15/2024 11:27:19 AM,U.S. government targets $6B in savings from first Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4140341-us-government-targets-6b-in-saving-from-first-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2300.0,8/15/2024 11:40:09 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Incyte (INCY) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-incyte-incy-and-gilead-sciences-gild-1033695853
2301.0,8/15/2024 11:44:07 AM,U.S. announces final drug prices after Medicare negotiations,Seeking Alpha,https://seekingalpha.com/news/4140356-us-posts-final-drug-prices-medicare-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2302.0,8/16/2024 12:06:05 PM,Amgen (AMGN) Gets a Buy from Jefferies,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-jefferies-1033701028
2303.0,8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2304.0,8/21/2024 1:31:52 PM,BioMarin appoints new business chief and R&D head,Seeking Alpha,https://seekingalpha.com/news/4142322-biomarin-stock-focus-amid-leadership-shakeup?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2305.0,8/23/2024 11:07:39 AM,Piper Sandler Sticks to Their Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/piper-sandler-sticks-to-their-buy-rating-for-amgen-amgn-1033718551
2306.0,8/25/2024 6:00:00 PM,"Eli Lilly, Novo Nordisk to maintain 'two horse race' in GLP-1 weight loss market",Seeking Alpha,https://seekingalpha.com/news/4143506-eli-lilly-novo-nordisk-maintain-two-horse-race-glp-1-weight-loss-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2307.0,8/29/2024 10:26:46 AM,"New Medicare drug price caps could help seniors save over $1,000 a year - AARP",Seeking Alpha,https://seekingalpha.com/news/4144962-new-medicare-drug-price-caps-could-help-seniors-save-over-1000-a-year-aarp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2308.0,8/29/2024 3:49:40 PM,J&J submits FDA application for myasthenia gravis drug nipocalimab,Seeking Alpha,https://seekingalpha.com/news/4145151-jj-submits-fda-application-for-myasthenia-gravis-drug-nipocalimab?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2309.0,9/9/2024 5:47:15 AM,Wells Fargo Issues a Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/wells-fargo-issues-a-hold-rating-on-amgen-amgn-1033756482
2310.0,9/9/2024 12:47:33 PM,Terns stock jumps as weight loss drug succeeds in early trial,Seeking Alpha,https://seekingalpha.com/news/4147984-terns-stock-jumps-as-weight-loss-drug-succeeds-in-early-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2311.0,9/10/2024 4:15:21 PM,Assessing Amgen’s Position Amid Rising Competition from Viridian’s Veligrotug,TipRanks,/news/stocks/assessing-amgen-s-position-amid-rising-competition-from-viridian-s-veligrotug-1033761788
2312.0,9/10/2024 5:19:09 PM,"UnitedHealth joins Cigna, CVS in removing AbbVie's Humira from formularies: report",Seeking Alpha,https://seekingalpha.com/news/4148432-abbvie-stock-slips-unitedhealth-removing-humira?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2313.0,9/10/2024 7:15:52 PM,Viridian hits five-month high after trial data for lead asset (update),Seeking Alpha,https://seekingalpha.com/news/4148281-viridian-stock-jumps-data-lead-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2314.0,9/10/2024 10:56:30 PM,16 new GLP-1 weight-loss drugs could be launched by 2029: report,Seeking Alpha,https://seekingalpha.com/news/4148522-16-new-glp-1-weight-loss-drugs-could-be-launched-by-2029-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2315.0,9/15/2024 2:07:52 PM,Do queasy side effects mean the end of weight-loss drug stock hype?,Seeking Alpha,https://seekingalpha.com/news/4149819-do-nauseating-side-effects-mean-the-end-of-weight-loss-drug-stock-hype?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2316.0,9/17/2024 11:36:04 AM,Oppenheimer Reaffirms Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/oppenheimer-reaffirms-their-buy-rating-on-amgen-amgn-1033777875
2317.0,9/17/2024 12:17:04 PM,Amgen (AMGN) Gets a Buy from Jefferies,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-jefferies-1033778003
2318.0,9/23/2024 7:13:36 PM,Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar,Seeking Alpha,https://seekingalpha.com/news/4152159-regeneron-falls-after-judge-denies-motion-for-injunction-in-a-patent-case-with-amgen?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2319.0,9/23/2024 7:17:40 PM,UCB gets expanded FDA approval for psoriasis drug Bimzelx,Seeking Alpha,https://seekingalpha.com/news/4152277-ucb-gets-expanded-fda-approval-for-psoriasis-drug-bimzelx?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2320.0,9/24/2024 10:37:18 AM,Amgen’s Uplizna and Rocatinlimab: A Cautious Hold Amidst Clinical Trial Anticipation,TipRanks,/news/stocks/amgen-s-uplizna-and-rocatinlimab-a-cautious-hold-amidst-clinical-trial-anticipation-1033793793
2321.0,9/24/2024 1:03:50 PM,Regeneron downgraded at Leerink after Amgen’s court win; Truist defends,Seeking Alpha,https://seekingalpha.com/news/4152576-regeneron-stock-cut-leerink-amgen-court-win?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2322.0,9/24/2024 8:12:01 PM,Amgen gets Japanese approval of Tepezza for thyroid eye disease,Seeking Alpha,https://seekingalpha.com/news/4152873-amgen-gets-japanese-approval-of-tepezza-for-thyroid-eye-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2323.0,9/24/2024 10:15:08 PM,"Amgen stock slips 3% following Phase 3 data for rocatinlimab, Uplizna",Seeking Alpha,https://seekingalpha.com/news/4152948-amgen-stock-slips-following-phase-3-data-for-rocatinlimab-uplizna?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2324.0,9/25/2024 4:55:32 AM,Amgen's TEPEZZA Approved In Japan For Treatment Of Active Thyroid Eye Disease ,RTTNews,/news/stocks/amgen-s-tepezza-approved-in-japan-for-treatment-of-active-thyroid-eye-disease-1033795219
2325.0,9/25/2024 7:15:49 AM,Barclays Reaffirms Their Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-amgen-amgn-1033796249
2326.0,9/25/2024 9:36:43 AM,Amgen’s Mixed Clinical Outcomes Prompt Hold Rating Amidst Market Competition and Potential in Obesity Program,TipRanks,/news/stocks/amgen-s-mixed-clinical-outcomes-prompt-hold-rating-amidst-market-competition-and-potential-in-obesity-program-1033796697
2327.0,9/25/2024 9:48:26 AM,Amgen Drug Pipeline Update: Cautious Optimism Amidst Market Entry Challenges,TipRanks,/news/stocks/amgen-drug-pipeline-update-cautious-optimism-amidst-market-entry-challenges-1033796760
2328.0,9/25/2024 11:06:11 AM,Amgen’s Buy Rating Affirmed by Analyst Amid Potential of Uplizna and Strategic Horizon Acquisition,TipRanks,/news/stocks/amgen-s-buy-rating-affirmed-by-analyst-amid-potential-of-uplizna-and-strategic-horizon-acquisition-1033797387
2329.0,9/25/2024 11:15:09 AM,TD Cowen Sticks to Its Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/td-cowen-sticks-to-its-buy-rating-for-amgen-amgn-1033797438
2330.0,9/25/2024 11:27:02 AM,Piper Sandler Sticks to Their Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/piper-sandler-sticks-to-their-buy-rating-for-amgen-amgn-1033797493
2331.0,9/25/2024 11:56:31 AM,Truist Financial Keeps Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-amgen-amgn-1033797531
2332.0,9/25/2024 12:26:51 PM,Buy Rating Affirmed on Amgen: Uplizna Success and Promising AMG133 Obesity Data Outweigh OX40’s Modest Results,TipRanks,/news/stocks/buy-rating-affirmed-on-amgen-uplizna-success-and-promising-amg133-obesity-data-outweigh-ox40-s-modest-results-1033797725
2333.0,9/25/2024 1:26:04 PM,Neutral Hold on Amgen: Balancing Uplizna’s Market Potential Against Rocatinlimab’s Competitive Challenges,TipRanks,/news/stocks/neutral-hold-on-amgen-balancing-uplizna-s-market-potential-against-rocatinlimab-s-competitive-challenges-1033797959
2334.0,9/25/2024 2:26:03 PM,Hold Rating on Amgen Amid Concerns Over Rocatinlimab and Uplizna Trial Results,TipRanks,/news/stocks/hold-rating-on-amgen-amid-concerns-over-rocatinlimab-and-uplizna-trial-results-1033798089
2335.0,9/25/2024 2:26:09 PM,Robert W. Baird Remains a Sell on Amgen (AMGN),TipRanks,/news/stocks/robert-w-baird-remains-a-sell-on-amgen-amgn-1033798088
2336.0,9/25/2024 5:06:51 PM,"BioAge, obesity drug developer, upsizes proposed IPO",Seeking Alpha,https://seekingalpha.com/news/4153310-bioage-obesity-drug-developer-upsizes-proposed-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2337.0,9/25/2024 6:29:49 PM,Amgen stock slides 5% as analysts weigh in on drug study results,Seeking Alpha,https://seekingalpha.com/news/4153393-amgen-stock-slides-as-analysts-weigh-in-on-drug-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2338.0,9/26/2024 10:47:08 AM,RBC Capital Sticks to Its Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/rbc-capital-sticks-to-its-buy-rating-for-amgen-amgn-1033800870
2339.0,9/26/2024 4:35:56 PM,BioAge stock rallies 29% following upsized $198M IPO,Seeking Alpha,https://seekingalpha.com/news/4153819-bioage-stock-rallies-following-upsized-198m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2340.0,9/27/2024 1:36:44 PM,"Cantor highly bullish on Amgen obesity drug, starts coverage at overweight",Seeking Alpha,https://seekingalpha.com/news/4154101-cantor-highly-bullish-on-amgen-obesity-drug-starts-coverage-at-overweight?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2341.0,9/28/2024 1:37:00 PM,"Notable analyst calls this week: Microsoft, Starbucks and GM among top picks",Seeking Alpha,https://seekingalpha.com/news/4154123-notable-analyst-calls-this-week-microsoft-starbucks-and-gm-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2342.0,9/28/2024 5:06:10 PM,Here are the Medicare Part D drugs expected to face 2025 price negotiations,Seeking Alpha,https://seekingalpha.com/news/4154318-these-medicare-drugs-set-to-face-2025-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2343.0,9/29/2024 4:12:57 PM,"Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales",Seeking Alpha,https://seekingalpha.com/news/4154326-novo-nordisk-ozempic-regeneron-sanofi-dupixent-advance-top-drug-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2344.0,9/30/2024 12:59:37 PM,Biotech Stocks Facing FDA Decision In October 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2024-1033806960
2345.0,9/30/2024 3:25:11 PM,Roche sees Carmot obesity drugs' potential peak sales at $3.6B+: report,Seeking Alpha,https://seekingalpha.com/news/4154563-roche-sees-carmot-obesity-drugs-potential-peak-sales-at-4b-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2346.0,10/1/2024 2:22:33 PM,Lilly looking to test Zepbound as health maintenance drug: report,Seeking Alpha,https://seekingalpha.com/news/4155026-lilly-looking-to-test-zepbound-as-health-maintenance-drug-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2347.0,10/3/2024 12:02:11 PM,U.S. tweaks 2025 Medicare price negotiation process,Seeking Alpha,https://seekingalpha.com/news/4155891-us-tweaks-2025-medicare-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2348.0,10/3/2024 12:16:19 PM,Buy Rating Affirmed: Amgen’s Strategic Advancements in Obesity Drug Pipeline,TipRanks,/news/stocks/buy-rating-affirmed-amgen-s-strategic-advancements-in-obesity-drug-pipeline-1033818912
2349.0,10/4/2024 9:30:48 AM,Robust Portfolio and Strategic Growth Initiatives Justify Buy Rating for Amgen with a $310 Target Price,TipRanks,/news/stocks/robust-portfolio-and-strategic-growth-initiatives-justify-buy-rating-for-amgen-with-a-310-target-price-1033821129
2350.0,10/7/2024 2:15:17 AM,Barclays Keeps Their Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/barclays-keeps-their-hold-rating-on-amgen-amgn-1033823284
2351.0,10/8/2024 2:49:43 PM,"TEVA applications for Prolia biosimilar accepted by FDA, EMA",Seeking Alpha,https://seekingalpha.com/news/4157037-teva-applications-for-prolia-biosimilar-accepted-by-fda-ema?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2352.0,10/8/2024 6:03:33 PM,Harris home health care benefit likely funded through Medicare drug negotiations savings,Seeking Alpha,https://seekingalpha.com/news/4157079-harris-home-health-care-benefit-could-funded-through-medicare-drug-negotiations-savings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2353.0,10/8/2024 7:05:55 PM,Zenas started at buy by four banks on lead drug potential,Seeking Alpha,https://seekingalpha.com/news/4157089-zenas-started-at-buy-by-four-banks-on-lead-drug-potential?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2354.0,10/10/2024 12:10:16 PM,"Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Company (TAK), Amgen (AMGN) and Halozyme (HALO)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-takeda-pharmaceutical-company-tak-amgen-amgn-and-halozyme-halo-1033836242
2355.0,10/10/2024 4:47:34 PM,Alvotech application for Prolia/Xgeva biosimilar accepted by EMA,Seeking Alpha,https://seekingalpha.com/news/4157642-alvotech-application-for-proliaxgeva-biosimilar-accepted-by-ema?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2356.0,10/11/2024 12:35:40 PM,Morgan Stanley Keeps Their Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/morgan-stanley-keeps-their-hold-rating-on-amgen-amgn-1033839285
2357.0,10/14/2024 11:50:08 AM,Amgen downgraded at Truist on MariTide prospects for obesity,Seeking Alpha,https://seekingalpha.com/news/4158161-amgen-downgraded-truist-maritide-prospects-obesity?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2358.0,10/14/2024 8:35:08 PM,Jefferies Remains a Buy on Amgen (AMGN),TipRanks,/news/stocks/jefferies-remains-a-buy-on-amgen-amgn-1033844225
2359.0,10/15/2024 9:27:30 AM,Buy Rating for Amgen: Strong Growth Prospects Driven by Strategic Acquisitions and Promising Drug Pipeline,TipRanks,/news/stocks/buy-rating-for-amgen-strong-growth-prospects-driven-by-strategic-acquisitions-and-promising-drug-pipeline-1033846641
2360.0,10/15/2024 2:49:58 PM,Amgen Reports Positive Phase 3 Data For Uplizna In Generalized Myasthenia Gravis ,RTTNews,/news/stocks/amgen-reports-positive-phase-3-data-for-uplizna-in-generalized-myasthenia-gravis-1033846664
2361.0,10/16/2024 8:45:44 AM,Cautious Optimism: Amgen’s Uplizna Shows Promise but Limited Immediate Impact on Valuation,TipRanks,/news/stocks/cautious-optimism-amgen-s-uplizna-shows-promise-but-limited-immediate-impact-on-valuation-1033851023
2362.0,10/16/2024 9:25:21 AM,Amgen’s Growth Potential Driven by MariTide’s Phase 2 Obesity Study and Favorable Risk-Reward Scenario,TipRanks,/news/stocks/amgen-s-growth-potential-driven-by-maritide-s-phase-2-obesity-study-and-favorable-risk-reward-scenario-1033851212
2363.0,10/16/2024 9:05:09 PM,"Lilly, Gilead, Amgen started at outperform by Bernstein",Seeking Alpha,https://seekingalpha.com/news/4167588-lilly-gilead-amgen-started-at-outperform-by-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2364.0,10/17/2024 7:30:03 PM,"Consumer, labor groups urge FTC to block Catalent sale to Novo Holdings - report",Seeking Alpha,https://seekingalpha.com/news/4172071-consumer-labor-groups-urge-ftc-to-block-catalent-sale-to-novo-nordisk-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2365.0,10/19/2024 1:37:00 PM,"Notable analyst calls this week: Etsy, Zoom and Enphase among top picks",Seeking Alpha,https://seekingalpha.com/news/4175781-notable-analyst-calls-this-week-etsy-zoom-and-enphase-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2366.0,10/21/2024 10:55:25 AM,Amgen’s Growth Potential Affirmed: Buy Rating with Increased Price Target to $383,TipRanks,/news/stocks/amgen-s-growth-potential-affirmed-buy-rating-with-increased-price-target-to-383-1033864807
2367.0,10/21/2024 11:39:35 AM,Amgen price target raised to $383 from $381 at TD Cowen,TipRanks,/news/stocks/amgen-price-target-raised-to-383-from-381-at-td-cowen-1033865110
2368.0,10/21/2024 8:35:13 PM,Cautious Outlook for Amgen’s MariTide: Awaiting Key Differentiation Data,TipRanks,/news/stocks/cautious-outlook-for-amgen-s-maritide-awaiting-key-differentiation-data-1033866777
2369.0,10/21/2024 8:35:44 PM,Morgan Stanley names Amgen ‘catalyst-driven idea’ into Phase 2 MariTide data,TipRanks,/news/stocks/morgan-stanley-names-amgen-catalyst-driven-idea-into-phase-2-maritide-data-1033866771
2370.0,10/22/2024 4:39:47 PM,Regeneron drops after court rejects request for temporary injunction for Eylea generic,Seeking Alpha,https://seekingalpha.com/news/4191238-regeneron-drops-after-court-rejects-request-for-temporary-injunction-for-eylea-generic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2371.0,10/22/2024 5:25:18 PM,RBC would buy Regeneron on weakness with biosimilar Eylea priced in,TipRanks,/news/stocks/rbc-would-buy-regeneron-on-weakness-with-biosimilar-eylea-priced-in-1033873241
2372.0,10/22/2024 7:05:17 PM,"Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-050-from-1-200-at-wells-fargo-1033873548
2373.0,10/22/2024 7:30:16 PM,"Amgen to launch U.S. Eylea biosimilar, Reuters reports",TipRanks,/news/stocks/amgen-to-launch-u-s-eylea-biosimilar-reuters-reports-1033873540
2374.0,10/23/2024 6:46:17 AM,Buy Rating on Amgen: Strategic Positioning and Pavblu’s Market Potential,TipRanks,/news/stocks/buy-rating-on-amgen-strategic-positioning-and-pavblu-s-market-potential-1033877218
2375.0,10/23/2024 9:10:37 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Sangamo Biosciences (SGMO) and Disc Medicine (IRON)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-sangamo-biosciences-sgmo-and-disc-medicine-iron-1033877921
2376.0,10/23/2024 11:39:22 AM,Amgen (AMGN) Receives a Buy from Piper Sandler,TipRanks,/news/stocks/amgen-amgn-receives-a-buy-from-piper-sandler-1033879432
2377.0,10/23/2024 4:35:10 PM,Amgen put volume heavy and directionally bearish,TipRanks,/news/stocks/amgen-put-volume-heavy-and-directionally-bearish-1033880890
2378.0,10/25/2024 12:06:15 PM,Amgen (AMGN) Gets a Buy from Oppenheimer,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-oppenheimer-1033893827
2379.0,10/25/2024 8:04:06 PM,Amgen declares $2.25 dividend,Seeking Alpha,https://seekingalpha.com/news/4207145-amgen-declares-2_25-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2380.0,10/28/2024 4:23:31 AM,"Earnings week ahead: MSFT, AMZN, AAPL, META, GOOG, AMD, PFE, F, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4205996-earnings-week-ahead-msft-amzn-aapl-meta-goog-amd-pfe-f-mcd-sbux-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2381.0,10/28/2024 10:48:16 AM,RBC Capital Keeps Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/rbc-capital-keeps-their-buy-rating-on-amgen-amgn-1033901910
2382.0,10/29/2024 12:20:32 PM,"Analysts Offer Insights on Healthcare Companies: Humana (HUM), Encompass Health (EHC) and Amgen (AMGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-humana-hum-encompass-health-ehc-and-amgen-amgn-1033910421
2383.0,10/29/2024 6:39:33 PM,Amgen Q3 2024 Earnings Preview: All eyes on obesity candidate data,Seeking Alpha,https://seekingalpha.com/news/4220327-amgen-q3-2024-earnings-preview-all-eyes-on-obesity-candidate-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2384.0,10/30/2024 4:39:55 PM,FDA accepts Organon BLA for Prolia/Xgeva biosimilar,Seeking Alpha,https://seekingalpha.com/news/4224746-fda-accepts-organon-bla-for-proliaxgeva-biosimilar?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2385.0,10/30/2024 5:58:22 PM,What’s behind AbbVie's Q3 revenue beat?,Seeking Alpha,https://seekingalpha.com/news/4225082-reasons-behind-abbvie-q-3-revenue-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2386.0,10/30/2024 6:01:30 PM,Notable companies reporting after market close,TipRanks,/news/stocks/notable-companies-reporting-after-market-close-1033921036
2387.0,10/30/2024 8:03:35 PM,"Amgen Non-GAAP EPS of $5.58 beats by $0.47, revenue of $8.5B in-line",Seeking Alpha,https://seekingalpha.com/news/4225786-amgen-non-gaap-eps-of-5_58-beats-0_47-revenue-of-8_5b-in-line?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2388.0,10/30/2024 8:18:32 PM,"Amgen in charts: Prolia, XGEVA sales gain, while Enbrel continues to wind down in Q3",Seeking Alpha,https://seekingalpha.com/news/4225800-amgen-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2389.0,10/30/2024 9:09:50 PM,"Amgen Inc. Q3 Profit Increases, Beats Estimates ",RTTNews,/news/stocks/amgen-inc-q3-profit-increases-beats-estimates-1033920594
2390.0,10/30/2024 9:40:21 PM,Amgen updates 2024 guidance with revenue and EPS ranges including consensus,Seeking Alpha,https://seekingalpha.com/news/4226154-amgen-updates-2024-guidance-with-revenue-and-eps-ranges-including-consensus?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2391.0,10/31/2024 2:11:38 AM,Amgen’s Steady Financial Performance and Pipeline Developments Justify Hold Rating,TipRanks,/news/stocks/amgen-s-steady-financial-performance-and-pipeline-developments-justify-hold-rating-1033922284
2392.0,10/31/2024 3:55:48 AM,Strong Buy Rating for Amgen Amidst Impressive Growth and Promising Pipeline Developments,TipRanks,/news/stocks/strong-buy-rating-for-amgen-amidst-impressive-growth-and-promising-pipeline-developments-1033925068
2393.0,10/31/2024 4:19:03 AM,Amgen’s Q3 2024: Strong Sales and Strategic Growth,TipRanks,/news/stocks/amgen-s-q3-2024-strong-sales-and-strategic-growth-1033925326
2394.0,10/31/2024 8:40:52 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Organon (OGN) and DaVita (DVA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-organon-ogn-and-davita-dva-1033927179
2395.0,10/31/2024 11:02:49 AM,Piper Sandler Gives a Buy Rating to Amgen (AMGN),TipRanks,/news/stocks/piper-sandler-gives-a-buy-rating-to-amgen-amgn-1033928721
2396.0,10/31/2024 11:04:37 AM,Cantor Fitzgerald Gives a Buy Rating to Amgen (AMGN),TipRanks,/news/stocks/cantor-fitzgerald-gives-a-buy-rating-to-amgen-amgn-1033928696
2397.0,10/31/2024 12:10:20 PM,Amgen (AMGN) Gets a Buy from Oppenheimer,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-oppenheimer-1033929517
2398.0,10/31/2024 1:02:44 PM,Amgen (AMGN) Gets a Buy from Evercore ISI,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-evercore-isi-1033930063
2399.0,10/31/2024 2:05:33 PM,Amgen price target lowered to $326 from $335 at UBS,TipRanks,/news/stocks/amgen-price-target-lowered-to-326-from-335-at-ubs-1033930680
2400.0,11/1/2024 10:00:49 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), IDEAYA Biosciences (IDYA) and MiMedx Group (MDXG)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-ideaya-biosciences-idya-and-mimedx-group-mdxg-1033936523
2401.0,11/6/2024 8:17:19 PM,SA Asks: How will the U.S. election results impact healthcare stocks?,Seeking Alpha,https://seekingalpha.com/news/4257322-sa-asks-how-will-the-us-election-results-impact-healthcare-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2402.0,11/7/2024 8:56:07 PM,"Coherus stock rallies 19% on Q3 earnings, Udenyca production update",Seeking Alpha,https://seekingalpha.com/news/4262709-coherus-stock-rallies-on-q3-earnings-udenyca-production-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2403.0,11/7/2024 11:35:19 PM,Collegium Pharmaceutical appoints Vikram Karnani as CEO,TipRanks,/news/stocks/collegium-pharmaceutical-appoints-vikram-karnani-as-ceo-1033975151
2404.0,11/8/2024 10:10:25 AM,"Amgen, AstraZeneca announce top-line results from WAYPOINT trial",TipRanks,/news/stocks/amgen-astrazeneca-announce-top-line-results-from-waypoint-trial-1033981756
2405.0,11/8/2024 11:38:45 AM,"Amgen, AstraZeneca post Phase 3 win for nasal polyps therapy",Seeking Alpha,https://seekingalpha.com/news/4264964-amgen-astra-zeneca-post-phase-3-win-for-nasal-polyps-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2406.0,11/12/2024 7:30:14 PM,"Amgen MariTide bone mineral density loss data ‘leaked,’ says Cantor Fitzgerald",TipRanks,/news/stocks/amgen-maritide-bone-mineral-density-loss-data-leaked-says-cantor-fitzgerald-1034002668
2407.0,11/12/2024 8:20:09 PM,"Amgen’s AMG-133 Phase 1 bone data ‘seems non-issue,’ says Jefferies",TipRanks,/news/stocks/amgen-s-amg-133-phase-1-bone-data-seems-non-issue-says-jefferies-1034002772
2408.0,11/12/2024 8:32:02 PM,Amgen slips as Cantor cites safety concerns linked to obesity candidate,Seeking Alpha,https://seekingalpha.com/news/4281785-amgen-stock-slips-amid-risk-obesity-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2409.0,11/13/2024 10:10:55 AM,Amgen issues statement regarding MariTide Phase 1 data,TipRanks,/news/stocks/amgen-issues-statement-regarding-maritide-phase-1-data-1034007851
2410.0,11/13/2024 11:39:43 AM,Amgen rebounds after denying bone safety concerns linked to obesity drug,Seeking Alpha,https://seekingalpha.com/news/4283906-amgen-stock-gains-mari-tide-concerns-addressed?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2411.0,11/13/2024 12:29:04 PM,Truist Financial Issues a Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/truist-financial-issues-a-hold-rating-on-amgen-amgn-1034009514
2412.0,11/13/2024 1:08:25 PM,TD Cowen Keeps Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/td-cowen-keeps-their-buy-rating-on-amgen-amgn-1034009712
2413.0,11/13/2024 1:17:20 PM,Amgen Says No Link Between MariTide And Changes In Bone Mineral Density ,RTTNews,/news/stocks/amgen-says-no-link-between-maritide-and-changes-in-bone-mineral-density-1034007570
2414.0,11/13/2024 1:20:29 PM,"Analysts’ Top Healthcare Picks: Korro Bio (KRRO), Paragon 28 (FNA)",TipRanks,/news/stocks/analysts-top-healthcare-picks-korro-bio-krro-paragon-28-fna-1034009888
2415.0,11/13/2024 1:20:33 PM,Piper Sandler Sticks to Its Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/piper-sandler-sticks-to-its-buy-rating-for-amgen-amgn-1034009886
2416.0,11/13/2024 2:12:00 PM,"4 stocks to watch on Wednesday: AMGN, CSCO and more",Seeking Alpha,https://seekingalpha.com/news/4284726-4-stocks-to-watch-on-wednesday-amgn-csco-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2417.0,11/13/2024 9:16:43 PM,Amgen initiated with a Neutral at Citi,TipRanks,/news/stocks/amgen-initiated-with-a-neutral-at-citi-1034011800
2418.0,11/14/2024 1:01:45 PM,Evercore ISI Remains a Buy on Amgen (AMGN),TipRanks,/news/stocks/evercore-isi-remains-a-buy-on-amgen-amgn-1034019141
2419.0,11/14/2024 1:02:05 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Shattuck Labs (STTK) and Astria Therapeutics (ATXS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-shattuck-labs-sttk-and-astria-therapeutics-atxs-1034019137
2420.0,11/14/2024 2:45:32 PM,"American upgraded, Regeneron initiated: Wall Street’s top analyst calls",TipRanks,/news/stocks/american-upgraded-regeneron-initiated-wall-street-s-top-analyst-calls-1034019984
2421.0,11/14/2024 6:25:10 PM,Amgen call volume above normal and directionally bullish,TipRanks,/news/stocks/amgen-call-volume-above-normal-and-directionally-bullish-1034020675
2422.0,11/14/2024 7:26:46 PM,"Gilead, Vertex initiated as new big biotech buys at Citi",Seeking Alpha,https://seekingalpha.com/news/4291773-gilead-vertex-initiated-new-big-biotech-buys-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2423.0,11/14/2024 9:12:40 PM,Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases,TipRanks,/news/stocks/amgen-s-uplizna-shows-potential-efficacy-in-rare-inflammatory-diseases-1034021199
2424.0,11/14/2024 9:16:42 PM,Amgen initiated with a Peer Perform at Wolfe Research,TipRanks,/news/stocks/amgen-initiated-with-a-peer-perform-at-wolfe-research-1034021180
2425.0,11/14/2024 11:55:11 PM,Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs,TipRanks,/news/stocks/wolfe-research-starts-amgen-at-peer-perform-given-approaching-patent-cliffs-1034021596
2426.0,11/15/2024 7:29:29 PM,U.S. Pharma is largely immune from 'MAHA' impact: Wolfe,Seeking Alpha,https://seekingalpha.com/news/4296178-us-pharma-largely-immune-from-maha-impact-wolfe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2427.0,11/15/2024 7:30:36 PM,"Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS",Seeking Alpha,https://seekingalpha.com/news/4296140-large-pharmas-biotechs-down-industries-grapple-with-rfk-jr-hhs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2428.0,11/20/2024 11:20:24 AM,Cautious Hold Rating on Amgen’s MariTide Amid Safety and Efficacy Concerns,TipRanks,/news/stocks/cautious-hold-rating-on-amgen-s-maritide-amid-safety-and-efficacy-concerns-1034042329
2429.0,11/20/2024 11:20:32 AM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Eledon Pharmaceuticals (ELDN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-eledon-pharmaceuticals-eldn-1034042327
2430.0,11/20/2024 9:05:45 PM,Amgen appoints Howard Chang as SVP of Research and Chief Scientific Officer,TipRanks,/news/stocks/amgen-appoints-howard-chang-as-svp-of-research-and-chief-scientific-officer-1034045077
2431.0,11/21/2024 1:15:56 PM,Jefferies Sticks to Their Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/jefferies-sticks-to-their-buy-rating-for-amgen-amgn-1034050220
2432.0,11/21/2024 6:45:46 PM,Optimism over global healthcare sector rises: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4318258-optimism-over-global-healthcare-sector-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2433.0,11/22/2024 12:05:54 PM,Evan Seigerman’s Buy Rating on Amgen Driven by Positive MariTide Outlook and Undervaluation,TipRanks,/news/stocks/evan-seigerman-s-buy-rating-on-amgen-driven-by-positive-maritide-outlook-and-undervaluation-1034055433
2434.0,11/22/2024 3:20:09 PM,Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735,Seeking Alpha,https://seekingalpha.com/news/4321443-viking-therapeuticsanewbuyat-b-rileyonleadobesityasset-vk-2735?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2435.0,11/23/2024 2:25:05 AM,"Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC",Seeking Alpha,https://seekingalpha.com/news/4323803-trump-picks-surgeon-makary-to-head-fda-rep-dave-weldon-to-lead-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2436.0,11/24/2024 12:05:06 PM,"Eli Lilly, others to buy after RFK-inspired drop, Barron’s says",TipRanks,/news/stocks/eli-lilly-others-to-buy-after-rfk-inspired-drop-barron-s-says-1034057659
2437.0,11/26/2024 11:30:59 AM,"Biden administration proposes expanded obesity drug coverage under Medicare, Medicaid",Seeking Alpha,https://seekingalpha.com/news/4334040-biden-administration-proposes-expanded-obesity-drug-coverage-under-medicare-medicaid?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2438.0,11/26/2024 12:10:55 PM,Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study,TipRanks,/news/stocks/amgen-s-maritide-shows-up-to-20-average-weight-loss-in-phase-2-study-1034066594
2439.0,11/26/2024 12:18:47 PM,Amgen posts mid-stage data for weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4334405-amgen-stock-slips-on-data-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2440.0,11/26/2024 12:25:33 PM,Amgen down 4% after reporting MariTide weight loss study results,TipRanks,/news/stocks/amgen-down-4-after-reporting-maritide-weight-loss-study-results-1034066691
2441.0,11/26/2024 1:55:16 PM,Morning Movers: Dick’s Sporting jumps and Kohl’s sinks following earnings,TipRanks,/news/stocks/morning-movers-dick-s-sporting-jumps-and-kohl-s-sinks-following-earnings-1034067198
2442.0,11/26/2024 1:56:00 PM,"4 stocks to watch on Tuesday: AMGN, BBY and more",Seeking Alpha,https://seekingalpha.com/news/4335211-4-stocks-to-watch-on-tuesday-amgn-bby-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2443.0,11/26/2024 1:57:04 PM,Amgen Says Its Weight Loss Drug Candidate MariTide Reduced Weight  Up To 20 Percent In Phase 2 Study ,RTTNews,/news/stocks/amgen-says-its-weight-loss-drug-candidate-maritide-reduced-weight-up-to-20-percent-in-phase-2-study-1034065496
2444.0,11/26/2024 2:20:33 PM,"Amgen’s MariTide only differentiation seems to be dosing frequency, says Leerink",TipRanks,/news/stocks/amgen-s-maritide-only-differentiation-seems-to-be-dosing-frequency-says-leerink-1034067414
2445.0,11/26/2024 2:20:51 PM,"Amgen weight loss data ‘underwhelms,’ says Deutsche Bank",TipRanks,/news/stocks/amgen-weight-loss-data-underwhelms-says-deutsche-bank-1034067412
2446.0,11/26/2024 2:25:09 PM,Amgen’s Hold Rating Maintained Amid MariTide Trial Shortfalls and Uncertainty in Dosing Strategy,TipRanks,/news/stocks/amgen-s-hold-rating-maintained-amid-maritide-trial-shortfalls-and-uncertainty-in-dosing-strategy-1034067411
2447.0,11/26/2024 3:13:10 PM,"Biggest stock movers Tuesday: PSTX, ARWR, KSS, ALEC, AMGN, EMBC, and more",Seeking Alpha,https://seekingalpha.com/news/4333610-biggest-stock-movers-tuesday-pstx-smtc-alec-lesl-wwd-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2448.0,11/26/2024 3:40:24 PM,Weight loss drugmakers in spotlight as White House proposes coverage,TipRanks,/news/stocks/weight-loss-drugmakers-in-spotlight-as-white-house-proposes-coverage-1034067621
2449.0,11/26/2024 4:40:10 PM,"Viking’s VK2735 outpacing Amgen’s MariTide, says H.C. Wainwright",TipRanks,/news/stocks/viking-s-vk2735-outpacing-amgen-s-maritide-says-h-c-wainwright-1034067769
2450.0,11/26/2024 5:16:39 PM,Amgen decline on MariTide data could be due to lack of more details,Seeking Alpha,https://seekingalpha.com/news/4336219-amgen-decline-maritide-data-could-due-lack-more-details?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2451.0,11/27/2024 6:15:55 AM,Amgen’s MariTide: Hold Rating Amid Efficacy and Safety Concerns in Obesity Treatment,TipRanks,/news/stocks/amgen-s-maritide-hold-rating-amid-efficacy-and-safety-concerns-in-obesity-treatment-1034070097
2452.0,11/27/2024 7:35:53 AM,Amgen’s MariTide Phase 2 Success Drives Buy Rating Amid Promising Obesity Treatment Prospects,TipRanks,/news/stocks/amgen-s-maritide-phase-2-success-drives-buy-rating-amid-promising-obesity-treatment-prospects-1034070436
2453.0,11/27/2024 10:25:59 AM,Amgen’s Stock Outlook: Balancing Maritide’s Weight Loss Data Concerns and Diabetes Treatment Potential,TipRanks,/news/stocks/amgen-s-stock-outlook-balancing-maritide-s-weight-loss-data-concerns-and-diabetes-treatment-potential-1034071153
2454.0,11/27/2024 10:27:01 AM,"Amgen’s MariTide Faces Competitive Pressure and Market Challenges, Leading to ‘Hold’ Rating",TipRanks,/news/stocks/amgen-s-maritide-faces-competitive-pressure-and-market-challenges-leading-to-hold-rating-1034071147
2455.0,11/27/2024 11:15:56 AM,Hold Rating on Amgen’s Maritide Amid Uncertainties in Efficacy and Tolerability,TipRanks,/news/stocks/hold-rating-on-amgen-s-maritide-amid-uncertainties-in-efficacy-and-tolerability-1034071504
2456.0,11/27/2024 11:23:42 AM,Trump taps Jay Bhattacharya to lead National Institutes of Health,Seeking Alpha,https://seekingalpha.com/news/4338432-trump-taps-jay-bhattacharya-to-lead-national-institutes-of-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2457.0,11/27/2024 11:40:09 AM,Amgen price target lowered to $330 from $360 at RBC Capital,TipRanks,/news/stocks/amgen-price-target-lowered-to-330-from-360-at-rbc-capital-1034071548
2458.0,11/27/2024 12:16:27 PM,Evan Seigerman Recommends Buy on Amgen Due to Promising MariTide Trial Results and Strategic Growth Moves,TipRanks,/news/stocks/evan-seigerman-recommends-buy-on-amgen-due-to-promising-maritide-trial-results-and-strategic-growth-moves-1034072174
2459.0,11/27/2024 12:18:52 PM,Truist Financial Sticks to Their Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/truist-financial-sticks-to-their-hold-rating-for-amgen-amgn-1034072153
2460.0,11/27/2024 12:35:23 PM,TD Cowen Sticks to Their Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/td-cowen-sticks-to-their-buy-rating-for-amgen-amgn-1034072259
2461.0,12/2/2024 10:45:45 AM,Amgen removed from US Conviction List at Goldman Sachs,TipRanks,/news/stocks/amgen-removed-from-us-conviction-list-at-goldman-sachs-1034085904
2462.0,12/2/2024 12:25:40 PM,TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/td-cowen-reaffirms-their-buy-rating-on-amgen-amgn-1034086863
2463.0,12/2/2024 12:56:01 PM,Evercore ISI Sticks to Its Buy Rating for Amgen (AMGN),TipRanks,/news/stocks/evercore-isi-sticks-to-its-buy-rating-for-amgen-amgn-1034087087
,12/5/2024 2:06:54 PM,Amgen announces $1B manufacturing expansion in North Carolina,TipRanks,/news/stocks/amgen-announces-1b-manufacturing-expansion-in-north-carolina-1034103237
,12/5/2024 3:27:06 PM,Amgen To Invest Addl. $1 Bln For Second Drug Substance Manufacturing Facility In North Carolina ,RTTNews,/news/stocks/amgen-to-invest-addl-1-bln-for-second-drug-substance-manufacturing-facility-in-north-carolina-1034101969
,12/5/2024 3:58:30 PM,Amgen to spend $1B on second NC manufacturing plant,Seeking Alpha,https://seekingalpha.com/news/4366590-amgen-to-spend-1b-on-second-nc-manufacturing-plant?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/6/2024 10:44:19 PM,BioAge stock craters 70% on obesity drug study halt (update),Seeking Alpha,https://seekingalpha.com/news/4372757-bioage-stock-craters-on-obesity-drug-study-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/7/2024 4:20:27 PM,Amgen's Phase 3 Study: BLINCYTO Plus Chemotherapy Improves Survival In Pediatric B-ALL Patients ,RTTNews,/news/stocks/amgen-s-phase-3-study-blincyto-plus-chemotherapy-improves-survival-in-pediatric-b-all-patients-1034110422
,12/10/2024 12:00:21 PM,Amgen reinstated with an Underperform at BofA,TipRanks,/news/stocks/amgen-reinstated-with-an-underperform-at-bofa-1034119720
,12/10/2024 9:44:45 PM,Amgen raises quarterly dividend by 5.8% to  $2.38/share,Seeking Alpha,https://seekingalpha.com/news/4384408-amgen-raises-quarterly-dividend-by-58-to-238share?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/11/2024 12:46:36 PM,Oppenheimer Remains a Buy on Amgen (AMGN),TipRanks,/news/stocks/oppenheimer-remains-a-buy-on-amgen-amgn-1034125524
,12/17/2024 2:55:27 PM,Viridian Therapeutics price target raised to $47 from $44 at RBC Capital,TipRanks,/news/stocks/viridian-therapeutics-price-target-raised-to-47-from-44-at-rbc-capital-1034147501
,12/18/2024 12:19:45 PM,Merck enters obesity drug race in pact with Chinese pharma Hansoh,Seeking Alpha,https://seekingalpha.com/news/4387598-merck-enters-obesity-drug-race-in-pact-with-hansoh?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/18/2024 2:51:03 PM,FDA approves Celltrion's biosimilar of J&J's Stelara,Seeking Alpha,https://seekingalpha.com/news/4387650-fda-approves-celltrion-biosimilar-of-stelara?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/18/2024 3:49:06 PM,Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers,Seeking Alpha,https://seekingalpha.com/news/4387714-merck-hansoh-deal-hurts-obesity-drug-developers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/18/2024 7:02:38 PM,"BioAge, Novartis team up to discover age-related disease targets",Seeking Alpha,https://seekingalpha.com/news/4387789-bioage-novartis-team-up-to-discover-age-related-disease-targets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 10:05:24 AM,"Caterpillar, Epam among additions to Jefferies Franchise Picks list",TipRanks,/news/stocks/caterpillar-epam-among-additions-to-jefferies-franchise-picks-list-1034161351
,12/20/2024 11:31:34 AM,"Novo Nordisk crashes after data for next gen obesity drug, Eli Lilly spikes",Seeking Alpha,https://seekingalpha.com/news/4389022-novo-nordisk-stock-crashes-cagrisema-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 12:30:43 PM,"Novo obesity data positive for Eli Lilly and Amgen, says UBS",TipRanks,/news/stocks/novo-obesity-data-positive-for-eli-lilly-and-amgen-says-ubs-1034162520
,12/20/2024 3:18:36 PM,Why is Novo Nordisk crashing after data for next-gen weight loss drug?,Seeking Alpha,https://seekingalpha.com/news/4389278-novo-nordisk-stock-down-lilly-up-cagrisema-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/22/2024 9:12:14 PM,SA Asks: Which Big Pharmas are likely to announce big M&A deals?,Seeking Alpha,https://seekingalpha.com/news/4389614-sa-asks-which-big-pharmas-are-likely-to-announce-big-m-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/26/2024 6:26:49 PM,Top dividend picks for 2025 according to Seeking Alpha’s Quant metrics,Seeking Alpha,https://seekingalpha.com/news/4391026-top-dividend-picks-for-2025-according-to-seeking-alphas-quant-metrics?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/31/2024 2:20:45 PM,Amgen’s tarlatamab approved by MHRA for small cell lung cancer,TipRanks,/news/stocks/amgen-s-tarlatamab-approved-by-mhra-for-small-cell-lung-cancer-1034183414
,12/31/2024 3:22:02 PM,Amgen gets U.K. approval for tarlatamab for small cell lung cancer,Seeking Alpha,https://seekingalpha.com/news/4391716-amgen-gets-u_k_-approval-for-tarlatamab-for-small-cell-lung-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/2/2025 11:30:25 AM,Amgen price target lowered to $310 from $344 at Piper Sandler,TipRanks,/news/stocks/amgen-price-target-lowered-to-310-from-344-at-piper-sandler-1034186820
,1/3/2025 4:21:15 PM,Viking Therapeutics among potential buyout candidates: Oppenheimer,Seeking Alpha,https://seekingalpha.com/news/4392377-viking-stock-among-buyout-targets-oppenheimer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/6/2025 5:35:12 PM,Amgen put volume heavy and directionally bearish,TipRanks,/news/stocks/amgen-put-volume-heavy-and-directionally-bearish-1034196792
,1/6/2025 5:52:14 PM,"FDA issues first draft guidance on use of AI in drug, medical device development",Seeking Alpha,https://seekingalpha.com/news/4392790-fda-issues-first-draft-guidance-use-ai-drug-medical-device-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/7/2025 1:52:05 PM,Amgen price target lowered to $324 from $330 at RBC Capital,TipRanks,/news/stocks/amgen-price-target-lowered-to-324-from-330-at-rbc-capital-1034201415
,1/7/2025 4:53:02 PM,FDA issues draft guidance on developing weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4393123-fda-issues-draft-guidance-developing-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/8/2025 1:10:26 AM,Amgen price target lowered to $298 from $333 at Truist,TipRanks,/news/stocks/amgen-price-target-lowered-to-298-from-333-at-truist-1034202828
,1/8/2025 1:15:17 AM,Truist Financial Sticks to Its Hold Rating for Amgen (AMGN),TipRanks,/news/stocks/truist-financial-sticks-to-its-hold-rating-for-amgen-amgn-1034202854
,1/8/2025 3:19:24 PM,Merck downgraded by Truist to hold over growth concerns,Seeking Alpha,https://seekingalpha.com/news/4393442-merck-downgraded-by-truist-to-hold-over-growth-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/10/2025 11:40:09 AM,Amgen (AMGN) Receives a Hold from Wells Fargo,TipRanks,/news/stocks/amgen-amgn-receives-a-hold-from-wells-fargo-1034214467
,1/10/2025 2:45:40 PM,"Regeneron price target lowered to $950 from $1,000 at Oppenheimer",TipRanks,/news/stocks/regeneron-price-target-lowered-to-950-from-1-000-at-oppenheimer-1034216027
,1/11/2025 3:40:17 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-rhythm-pharmaceuticals-rytm-and-lyell-immunopharma-lyel-1034217252
,1/14/2025 12:47:18 PM,Amgen’s Strategic Shift and Strong Pipeline Drive Buy Rating,TipRanks,/news/stocks/amgen-s-strategic-shift-and-strong-pipeline-drive-buy-rating-1034226380
,1/15/2025 12:45:44 PM,Truist Financial Releases a Hold Rating on Amgen (AMGN),TipRanks,/news/stocks/truist-financial-releases-a-hold-rating-on-amgen-amgn-1034231396
,1/15/2025 1:16:41 PM,Jefferies Remains a Buy on Amgen (AMGN),TipRanks,/news/stocks/jefferies-remains-a-buy-on-amgen-amgn-1034231553
,1/16/2025 4:27:08 PM,AbbVie keeps Humira lead as biosimilar entry nears two-year mark,Seeking Alpha,https://seekingalpha.com/news/4395783-abbvie-retains-humira-market-share-biosimilars?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 11:46:07 AM,Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN),TipRanks,/news/stocks/piper-sandler-reaffirms-their-buy-rating-on-amgen-amgn-1034240196
,1/17/2025 1:19:18 PM,Wegovy included as Medicare lists 15 drugs selected for next pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4396094-wegovy-latest-medicare-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 1:20:48 PM,"Ozempic, Xtandi among next 15 drugs selected for U.S. price talks",TipRanks,/news/stocks/ozempic-xtandi-among-next-15-drugs-selected-for-u-s-price-talks-1034240882
,1/17/2025 2:05:35 PM,Amgen announces FDA approval of Lumakras in combination with Vectibix,TipRanks,/news/stocks/amgen-announces-fda-approval-of-lumakras-in-combination-with-vectibix-1034241108
,1/17/2025 4:05:48 PM,Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment ,RTTNews,/news/stocks/amgen-s-lumakras-vectibix-combo-gets-fda-approval-for-metastatic-colorectal-cancer-treatment-1034240504
,1/17/2025 4:58:51 PM,"Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting",Seeking Alpha,https://seekingalpha.com/news/4396192-pharma-lobby-slams-ira-pbms-as-medicare-lists-15-more-drugs-for-price-setting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/17/2025 7:54:43 PM,Argenx cut to Sell at Deutsche Bank on valuation,Seeking Alpha,https://seekingalpha.com/news/4396303-argenx-stock-cut-sell-deutsche-bank?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/21/2025 6:45:36 PM,"Amgen 2025 guidance could miss estimates, says Wells Fargo",TipRanks,/news/stocks/amgen-2025-guidance-could-miss-estimates-says-wells-fargo-1034251580
,1/23/2025 11:40:23 AM,"Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Arrowhead Pharmaceuticals (ARWR)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-abbott-laboratories-abt-arrowhead-pharmaceuticals-arwr-1034259971
,1/23/2025 11:07:44 PM,Allurion stock soars 70% on weight-loss therapy update,Seeking Alpha,https://seekingalpha.com/news/4398176-allurion-stock-soars-on-weight-loss-therapy-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/24/2025 11:57:28 AM,Amgen (AMGN) Receives a Buy from RBC Capital,TipRanks,/news/stocks/amgen-amgn-receives-a-buy-from-rbc-capital-1034266143
,1/24/2025 9:05:17 PM,"Janux Therapeutics names Zachariah McIver, D.O., Ph.D. as Chief Medical Officer",TipRanks,/news/stocks/janux-therapeutics-names-zachariah-mciver-d-o-ph-d-as-chief-medical-officer-1034268004
,1/28/2025 11:36:59 AM,Amgen price target lowered to $295 from $310 at Citi,TipRanks,/news/stocks/amgen-price-target-lowered-to-295-from-310-at-citi-1034277150
,1/28/2025 8:15:30 PM,Novo Nordisk's Ozempic gets FDA approval for kidney disease,Seeking Alpha,https://seekingalpha.com/news/4399631-novo-nordisk-ozempic-gets-fda-approval-for-kidney-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/29/2025 6:55:13 PM,"RFK Jr. comments contradict anti-vaccine legacy, says Truist",TipRanks,/news/stocks/rfk-jr-comments-contradict-anti-vaccine-legacy-says-truist-1034284331
,1/29/2025 7:30:50 PM,CMS aiming for more transparency in drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4400241-cms-aiming-for-more-transparency-in-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/30/2025 11:50:40 AM,"Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Exact Sciences (EXAS) and Amgen (AMGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-lexicon-pharmaceuticals-lxrx-exact-sciences-exas-and-amgen-amgn-1034288624
,1/30/2025 12:56:27 PM,Amgen’s Sell Rating: Declining EPS and Overvalued Stock Amid Modest Revenue Growth,TipRanks,/news/stocks/amgen-s-sell-rating-declining-eps-and-overvalued-stock-amid-modest-revenue-growth-1034289238
,1/31/2025 6:08:16 PM,Metsera sees stock rally 54% following $275M IPO,Seeking Alpha,https://seekingalpha.com/news/4401417-metsera-sees-stock-rally-54-following-275m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/31/2025 8:00:55 PM,"Catalyst Watch: Tariff drama, OPEC+, Alphabet and Amazon earnings, Lennar spinoff",Seeking Alpha,https://seekingalpha.com/news/4401505-catalyst-watch-tariff-drama-opec-alphabet-and-amazon-earnings-lennar-spinoff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/1/2025 12:53:24 PM,Are healthcare stocks on the rebound?,Seeking Alpha,https://seekingalpha.com/news/4401695-are-healthcare-stocks-rebound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/2/2025 1:00:00 PM,"Earnings week ahead: PLTR, AMZN, GOOG, AMD, LLY, PEP, F, PFE, MRK, PYPL and more",Seeking Alpha,https://seekingalpha.com/news/4401431-earnings-week-ahead-pltr-amzn-goog-amd-lly-pep-f-pfe-mrk-pypl-qcom-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/3/2025 5:10:43 PM,Amgen Q4 Earnings Preview: Street expects revenue to rise more than 8%,Seeking Alpha,https://seekingalpha.com/news/4402086-amgen-q4-earnings-preview-street-expects-revenue-to-rise-more-than-8?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/3/2025 5:30:39 PM,SA Asks: What's the most attractive weight-loss stock right now?,Seeking Alpha,https://seekingalpha.com/news/4401656-sa-asks-whats-the-most-attractive-weight-loss-stock-right-now?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 3:00:00 PM,Here are the major earnings after the close today,Seeking Alpha,https://seekingalpha.com/news/4401938-here-are-the-major-earnings-after-the-close-today?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 6:45:33 PM,Notable companies reporting after market close,TipRanks,/news/stocks/notable-companies-reporting-after-market-close-1034310844
,2/4/2025 8:05:25 PM,Amgen options imply 3.9% move in share price post-earnings,TipRanks,/news/stocks/amgen-options-imply-3-9-move-in-share-price-post-earnings-1034310985
,2/4/2025 9:02:30 PM,"Amgen Non-GAAP EPS of $5.31 beats by $0.23, revenue of $9.1B beats by $230M",Seeking Alpha,https://seekingalpha.com/news/4403051-amgen-non-gaap-eps-of-5_31-beats-by-0_23-revenue-of-9_1b-beats-by-230m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 9:05:56 PM,Amgen sees FY25 CapEx ~$2.3B,TipRanks,/news/stocks/amgen-sees-fy25-capex-~-2-3b-1034311164
,2/4/2025 9:06:11 PM,"Amgen sees FY25 adjusted EPS $20.00-$21.20, consensus $20.82",TipRanks,/news/stocks/amgen-sees-fy25-adjusted-eps-20-00--21-20-consensus-20-82-1034311162
,2/4/2025 9:06:39 PM,"Amgen reports Q4 adjusted EPS $5.31, consensus $5.08",TipRanks,/news/stocks/amgen-reports-q4-adjusted-eps-5-31-consensus-5-08-1034311158
,2/4/2025 9:18:20 PM,Amgen in charts: Enbrel sales rise most sequentially among major products in Q4,Seeking Alpha,https://seekingalpha.com/news/4403056-amgen-in-charts-enbrel-sales-rise-most-sequentially-among-major-products-in-q4?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 9:31:09 PM,Amgen CEO says ‘investing heavily in our rapidly advancing pipeline’,TipRanks,/news/stocks/amgen-ceo-says-investing-heavily-in-our-rapidly-advancing-pipeline-1034311448
,2/4/2025 9:31:16 PM,"Amgen down 2% after earnings, clinical hold on obesity study",TipRanks,/news/stocks/amgen-down-2-after-earnings-clinical-hold-on-obesity-study-1034311447
,2/4/2025 9:31:37 PM,Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA,TipRanks,/news/stocks/amgen-says-phase-1-amg-513-obesity-study-placed-on-clinical-hold-by-fda-1034311444
,2/4/2025 10:04:59 PM,"Amgen Inc. Q4 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/amgen-inc-q4-profit-decreases-but-beats-estimates-1034311074
,2/4/2025 10:18:52 PM,"Amgen sets 2025 revenue, EPS guidance ranges that include consensus",Seeking Alpha,https://seekingalpha.com/news/4403151-amgen-sets-2025-revenue-eps-guidance-ranges-that-include-consensus?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 10:58:34 PM,AMGN Earnings: Amgen Slips on Soft EPS Guidance,TipRanks,/news/stocks/amgn-earnings-amgen-slips-on-soft-eps-guidance-1034311766
,2/5/2025 12:00:36 AM,Closing Bell Movers: Alphabet down over 7% after Q4 results,TipRanks,/news/stocks/closing-bell-movers-alphabet-down-over-7-after-q4-results-1034311796
,2/5/2025 12:01:42 AM,Closing Bell Movers: Alphabet down over 7% after Q4 results,TipRanks,/news/stocks/closing-bell-movers-alphabet-down-over-7-after-q4-results-1034311795
,2/5/2025 11:00:46 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Amgen (AMGN) and IQVIA Holdings (IQV)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-transmedics-group-tmdx-amgen-amgn-and-iqvia-holdings-iqv-1034314509
,2/5/2025 11:38:03 AM,Amgen (AMGN) Gets a Buy from RBC Capital,TipRanks,/news/stocks/amgen-amgn-gets-a-buy-from-rbc-capital-1034314703
,2/5/2025 11:40:07 AM,"Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Premier (PINC) and Amgen (AMGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cvrx-cvrx-premier-pinc-and-amgen-amgn-1034314683
,2/5/2025 12:17:01 PM,Amgen (AMGN) Receives a Hold from Truist Financial,TipRanks,/news/stocks/amgen-amgn-receives-a-hold-from-truist-financial-1034315107
,2/5/2025 1:25:29 PM,Regeneron price target raised to $575 from $565 at BofA,TipRanks,/news/stocks/regeneron-price-target-raised-to-575-from-565-at-bofa-1034315530
,2/5/2025 2:30:15 PM,Amgen price target raised to $328 from $322 at Morgan Stanley,TipRanks,/news/stocks/amgen-price-target-raised-to-328-from-322-at-morgan-stanley-1034316037
,2/5/2025 3:27:25 PM,Amgen early-stage obesity asset placed on clinical hold,Seeking Alpha,https://seekingalpha.com/news/4403541-amgen-early-stage-obesity-asset-placed-clinical-hold?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/5/2025 8:40:12 PM,Amgen upgraded to Buy from Hold at Erste Group,TipRanks,/news/stocks/amgen-upgraded-to-buy-from-hold-at-erste-group-1034317566
,2/6/2025 12:11:08 PM,Amgen price target raised to $275 from $256 at BofA,TipRanks,/news/stocks/amgen-price-target-raised-to-275-from-256-at-bofa-1034321962
